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t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced in the detection,
anagement, or prevention of disease states. Rigorous and
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesxpert analysis of the available data documenting the abso-
ute and relative benefits and risks of those procedures and
herapies can produce helpful guidelines that improve the
ffectiveness of care, optimize patient outcomes, and favor-
bly affect the overall cost of care by focusing resources on
he most effective strategies.
The American College of Cardiology (ACC) and the
merican Heart Association (AHA) have jointly engaged
n the production of such guidelines in the area of cardio-
ascular disease since 1980. This effort is directed by the
CC/AHA Task Force on Practice Guidelines, whose
harge is to develop, update, or revise practice guidelines for
mportant cardiovascular diseases and procedures. Writing
ommittees are charged with the task of performing an
ssessment of the evidence and acting as an independent
roup of authors to develop and update written recommen-
ations for clinical practice.
Experts in the subject under consideration are selected
rom both organizations to examine subject-specific data
nd write guidelines. The process includes additional rep-
esentatives from other medical practitioner and specialty
roups where appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers, co-
orbidities, and issues of patient preference that might
nfluence the choice of particular tests or therapies are
onsidered, as well as frequency of follow-up. When avail-
ble, information from studies on cost will be considered;
owever, review of data on efficacy and clinical outcomes
ill be the primary basis for preparing recommendation in
hese guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflicts of interest that might arise as a result of an
utside relationship or personal interest of a member of the
riting committee. Specifically, all members of the writing
ommittee and peer reviewers of the document are asked to
rovide disclosure statements of all such relationships that
ight be perceived as real or potential conflicts of interest.
riting committee members are also strongly encouraged
o declare a previous relationship with industry that might
e perceived as relevant to guideline development. If a
riting committee member develops a new relationship
ith industry during his or her tenure, he or she is required
o notify guideline staff in writing. The continued partici-
ation of the writing committee member will be reviewed.
hese statements are reviewed by the parent task force,
eported orally to all members of the writing panel at each
eeting, and updated and reviewed by the writing commit-
ee as changes occur. Please refer to the methodology
anual for the ACC/AHA guideline writing committees
or further description and the relationships with industry
olicy, available on ACC and AHA World Wide Web sites
http://www.acc.org/clinical/manual/manual_introltr.htm ind http://circ.ahajournals.org/manual). See Appendix 1 for a
ist of writing committee member relationships with industry
nd Appendix 2 for a listing of peer reviewer relationships with
ndustry that are pertinent to this guideline.
These practice guidelines are intended to assist healthcare
roviders in clinical decision making by describing a range
f generally acceptable approaches for the diagnosis, man-
gement, and prevention of specific diseases or conditions.
hese guidelines attempt to define practices that meet the
eeds of most patients in most circumstances. These guide-
ine recommendations reflect a consensus of expert opinion
fter a thorough review of the available, current scientific
vidence and are intended to improve patient care. If these
uidelines are used as the basis for regulatory/payer deci-
ions, the ultimate goal is quality of care and serving the
atient’s best interests. The ultimate judgment regarding
are of a particular patient must be made by the healthcare
rovider and patient in light of all of the circumstances
resented by that patient. There are circumstances in which
eviations from these guidelines are appropriate.
The “ACC/AHA 2006 Guideline for the Management
f Patients With Valvular Heart Disease” was approved for
ublication by the ACC Foundation (ACCF) board of
rustees in May 2006 and the AHA Science Advisory and
oordinating Committee in May 2006. The executive
ummary and recommendations are published in the August
, 2006 issue of the Journal of the American College of
ardiology and the August 1, 2006 issue of Circulation. The
ull-text guideline is e-published in the same issues of each
ournal and is posted on the World Wide Web sites of the
CC (www.acc.org) and the AHA (www.american-
eart.org). The guidelines will be reviewed annually by the
CC/AHA Task Force on Practice Guidelines and will be
onsidered current unless they are updated, revised, or
unsetted and withdrawn from distribution. Copies of the
ull text and the executive summary are available from both
rganizations.
Sidney C. Smith, Jr., MD, FACC, FAHA,
Chair, ACC/AHA Task Force on Practice Guidelines
. INTRODUCTION
.1. Organization of the Committee and Evidence Review
he ACC and the AHA have long been involved in the
oint development of practice guidelines designed to assist
ealthcare providers in the management of selected cardio-
ascular disorders or the selection of certain cardiovascular
rocedures. The determination of the disorders or proce-
ures to develop guidelines for is based on several factors,
ncluding importance to healthcare providers and whether
here are sufficient data from which to derive accepted
uidelines. One important category of cardiac disorders that
ffect a large number of patients who require diagnostic
rocedures and decisions regarding long-term management
s valvular heart disease.
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ACC/AHA Practice Guidelines August 1, 2006:e1–148During the past 2 decades, major advances have occurred in
iagnostic techniques, the understanding of natural history,
nd interventional cardiology and surgical procedures for pa-
ients with valvular heart disease. These advances have resulted
n enhanced diagnosis, more scientific selection of patients for
urgery or catheter-based intervention versus medical manage-
ent, and increased survival of patients with these disorders.
he information base from which to make clinical manage-
ent decisions has greatly expanded in recent years, yet in
any situations, management issues remain controversial or
ncertain. Unlike many other forms of cardiovascular disease,
here is a scarcity of large-scale multicenter trials addressing the
iagnosis and treatment of patients with valvular disease from
hich to derive definitive conclusions, and the information
vailable in the literature represents primarily the experiences
eported by single institutions in relatively small numbers of
atients.
The 1998 Committee on Management of Patients With
alvular Heart Disease reviewed and compiled this informa-
ion base and made recommendations for diagnostic testing,
reatment, and physical activity. For topics for which there was
n absence of multiple randomized, controlled trials, the
referred basis for medical decision making in clinical practice
evidence-based medicine), the committee’s recommendations
ere based on data derived from single randomized trials or
onrandomized studies or were based on a consensus
pinion of experts. The current writing committee was
harged with revising the guidelines published in 1998. The
ommittee reviewed pertinent publications, including ab-
tracts, through a computerized search of the English
iterature since 1998 and performed a manual search of final
rticles. Special attention was devoted to identification of
andomized trials published since the original document. A
omplete listing of all publications covering the treatment of
alvular heart disease is beyond the scope of this document;
he document includes those reports that the committee
elieves represent the most comprehensive or convincing
ata that are necessary to support its conclusions. However,
vidence tables were updated to reflect major advances over
his time period. Inaccuracies or inconsistencies present in
he original publication were identified and corrected when
ossible. Recommendations provided in this document are
ased primarily on published data. Because randomized
rials are unavailable in many facets of valvular heart disease
reatment, observational studies and, in some areas, expert
pinions form the basis for recommendations that are offered.
All of the recommendations in this guideline revision
ere converted from the tabular format used in the 1998
uideline to a listing of recommendations that has been
ritten in full sentences to express a complete thought, such
hat a recommendation, even if separated and presented
part from the rest of the document, would still convey the
ull intent of the recommendation. It is hoped that this will
ncrease the readers’ comprehension of the guidelines. Also,
he level of evidence, either A, B, or C, for each recom-
endation is now provided. eClassification of recommendations and level of evidence
re expressed in the ACC/AHA format as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure or treat-
ment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
• Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
• Class IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective and in some cases may be harmful.
In addition, the weight of evidence in support of the
ecommendation is listed as follows:
Level of Evidence A: Data derived from multiple
randomized clinical trials.
Level of Evidence B: Data derived from a single
randomized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of ex-
perts, case studies, or standard-of-care.
The schema for classification of recommendations and
evel of evidence is summarized in Figure 1, which also
llustrates how the grading system provides an estimate of
he size of the treatment effect and an estimate of the
ertainty of the treatment effect.
Writing committee membership consisted of cardiovas-
ular disease specialists and representatives of the cardiac
urgery and cardiac anesthesiology fields; both the academic
nd private practice sectors were represented. The Society of
ardiovascular Anesthesiologists assigned an official repre-
entative to the writing committee.
This document was reviewed by 2 official reviewers
ominated by the ACC; 2 official reviewers nominated by
he AHA; 1 official reviewer from the ACC/AHA Task
orce on Practice Guidelines; reviewers nominated by the
ociety of Cardiovascular Anesthesiologists, the Society for
ardiovascular Angiography and Interventions, and the
ociety of Thoracic Surgeons (STS); and individual content
eviewers, including members of the ACCF Cardiac Cath-
terization and Intervention Committee, ACCF Cardiovas-
ular Imaging Committee, ACCF Cardiovascular Surgery
ommittee, AHA Endocarditis Committee, AHA Cardiac
linical Imaging Committee, AHA Cardiovascular Inter-
ention and Imaging Committee, and AHA Cerebrovascu-
ar Imaging and Intervention Committee.
.2. Scope of the Document
he guidelines attempt to deal with general issues of
reatment of patients with heart valve disorders, such as
valuation of patients with heart murmurs, prevention and
Figure 1. Applying classification of recommendations and level of evidence. *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender,
age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation
is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical
consensus that a particular test or therapy is useful or effective. †In 2003 the ACC/AHA Task Force on Practice Guidelines recently provided a list of suggested phrases to use when writing
recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart
from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension
of the guidelines and will allow queries at the individual recommendation level. e7
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ACC/AHA Practice Guidelines August 1, 2006:e1–148reatment of endocarditis, management of valve disease in
regnancy, and treatment of patients with concomitant
oronary artery disease (CAD), as well as more specialized
ssues that pertain to specific valve lesions. The guidelines
ocus primarily on valvular heart disease in the adult, with a
eparate section dealing with specific recommendations for
alve disorders in adolescents and young adults. The diag-
osis and management of infants and young children with
ongenital valvular abnormalities are significantly different
rom those of the adolescent or adult and are beyond the
cope of these guidelines.
This task force report overlaps with several previously
ublished ACC/AHA guidelines about cardiac imaging and
iagnostic testing, including the guidelines for the clinical
se of cardiac radionuclide imaging (1), the clinical appli-
ation of echocardiography (2), exercise testing (3), and
ercutaneous coronary intervention (4). Although these
uidelines are not intended to include detailed information
overed in previous guidelines on the use of imaging and
iagnostic testing, an essential component of this report is
he discussion of indications for these tests in the evaluation
nd treatment of patients with valvular heart disease.
The committee emphasizes the fact that many factors
ltimately determine the most appropriate treatment of
ndividual patients with valvular heart disease within a given
ommunity. These include the availability of diagnostic
quipment and expert diagnosticians, the expertise of inter-
entional cardiologists and surgeons, and notably, the
ishes of well-informed patients. Therefore, deviation from
hese guidelines may be appropriate in some circumstances.
hese guidelines are written with the assumption that a
iagnostic test can be performed and interpreted with skill
evels consistent with previously reported ACC training and
ompetency statements and ACC/AHA guidelines, that
nterventional cardiological and surgical procedures can be
erformed by highly trained practitioners within acceptable
afety standards, and that the resources necessary to perform
hese diagnostic procedures and provide this care are readily
vailable. This is not true in all geographic areas, which
urther underscores the committee’s position that its recom-
endations are guidelines and not rigid requirements.
. GENERAL PRINCIPLES
.1. Evaluation of the Patient With a Cardiac Murmur
.1.1. Introduction
ardiac auscultation remains the most widely used method
f screening for valvular heart disease. The production of
urmurs is due to 3 main factors:
high blood flow rate through normal or abnormal orifices
forward flow through a narrowed or irregular orifice into
a dilated vessel or chamber
backward or regurgitant flow through an incompetent
valveften, more than 1 of these factors is operative (5–7).
A heart murmur may have no pathological significance or
ay be an important clue to the presence of valvular,
ongenital, or other structural abnormalities of the heart (8).
ost systolic heart murmurs do not signify cardiac disease,
nd many are related to physiological increases in blood flow
elocity (9). In other instances, a heart murmur may be an
mportant clue to the diagnosis of undetected cardiac disease
e.g., valvular aortic stenosis [AS]) that may be important
ven when asymptomatic or that may define the reason for
ardiac symptoms. In these situations, various noninvasive
r invasive cardiac tests may be necessary to establish a firm
iagnosis and form the basis for rational treatment of an
nderlying disorder. Echocardiography is particularly useful
n this regard, as discussed in the “ACC/AHA/ASE 2003
uidelines for the Clinical Application of Echocardiogra-
hy” (2). Diastolic murmurs virtually always represent
athological conditions and require further cardiac evalua-
ion, as do most continuous murmurs. Continuous “inno-
ent” murmurs include venous hums and mammary souffles.
The traditional auscultation method of assessing cardiac
urmurs has been based on their timing in the cardiac cycle,
onfiguration, location and radiation, pitch, intensity
grades 1 through 6), and duration (5–9). The configuration
f a murmur may be crescendo, decrescendo, crescendo-
ecrescendo (diamond-shaped), or plateau. The precise
imes of onset and cessation of a murmur associated with
ardiac pathology depend on the period of time in the
ardiac cycle in which a physiologically important pressure
ifference between 2 chambers occurs (5–9). A classification
f cardiac murmurs is listed in Table 1.
.1.2. Classification of Murmurs
olosystolic (pansystolic) murmurs are generated when there
s flow between chambers that have widely different pressures
hroughout systole, such as the left ventricle and either the left
trium or right ventricle. With an abnormal regurgitant orifice,
he pressure gradient and regurgitant jet begin early in con-
raction and last until relaxation is almost complete.
Midsystolic (systolic ejection) murmurs, often crescendo-
ecrescendo in configuration, occur when blood is ejected
cross the aortic or pulmonic outflow tracts. The murmurs start
hortly after S1, when the ventricular pressure rises sufficiently
able 1. Classification of Cardiac Murmurs
1. Systolic murmurs
a. Holosystolic (pansystolic) murmurs
b. Midsystolic (systolic ejection) murmurs
c. Early systolic murmurs
d. Mid to late systolic murmurs
2. Diastolic murmurs
a. Early high-pitched diastolic murmurs
b. Middiastolic murmurs
c. Presystolic murmurs3. Continuous murmurs
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineso open the semilunar valve. As ejection increases, the murmur
s augmented, and as ejection declines, it diminishes.
In the presence of normal semilunar valves, this murmur
ay be caused by an increased flow rate such as that which
ccurs with elevated cardiac output (e.g., pregnancy, thyro-
oxicosis, anemia, and arteriovenous fistula), ejection of
lood into a dilated vessel beyond the valve, or increased
ransmission of sound through a thin chest wall. Most
nnocent murmurs that occur in children and young adults
re midsystolic and originate either from the aortic or
ulmonic outflow tracts. Valvular, supravalvular, or subval-
ular obstruction (stenosis) of either ventricle may also cause
midsystolic murmur, the intensity of which depends in
art on the velocity of blood flow across the narrowed area.
idsystolic murmurs also occur in certain patients with
unctional mitral regurgitation (MR) or, less frequently,
ricuspid regurgitation (TR). Echocardiography is often
ecessary to separate a prominent and exaggerated (grade 3)
enign midsystolic murmur from one due to valvular AS.
Early systolic murmurs are less common; they begin with
he first sound and end in midsystole. An early systolic
urmur is often due to TR that occurs in the absence of
ulmonary hypertension, but it also occurs in patients with
cute MR. In large ventricular septal defects with pulmo-
ary hypertension and small muscular ventricular septal
efects, the shunting at the end of systole may be insignif-
cant, with the murmur limited to early and midsystole.
Late systolic murmurs are soft or moderately loud, high-
itched murmurs at the left ventricular (LV) apex that start
ell after ejection and end before or at S2. They are often due
o apical tethering and malcoaptation of the mitral leaflets due
o anatomic and functional changes of the annulus and ven-
ricle. Late systolic murmurs in patients with midsystolic clicks
esult from late systolic regurgitation due to prolapse of the
itral leaflet(s) into the left atrium. Such late systolic murmurs
an also occur in the absence of clicks.
Early diastolic murmurs begin with or shortly after S2,
hen the associated ventricular pressure drops sufficiently
elow that in the aorta or pulmonary artery. High-pitched
urmurs of aortic regurgitation (AR) or pulmonic regurgi-
ation due to pulmonary hypertension are generally decre-
cendo, consistent with the rapid decline in volume or rate
f regurgitation during diastole. The diastolic murmur of
ulmonic regurgitation without pulmonary hypertension is
ow to medium pitched, and the onset of this murmur is
lightly delayed because regurgitant flow is minimal at
ulmonic valve closure, when the reverse pressure gradient
esponsible for the regurgitation is minimal. Such murmurs
re common late after repair of tetralogy of Fallot.
Middiastolic murmurs usually originate from the mitral
nd tricuspid valves, occur early during ventricular filling,
nd are due to a relative disproportion between valve orifice
ize and diastolic blood flow volume. Although they are
sually due to mitral or tricuspid stenosis, middiastolic
urmurs may also be due to increased diastolic blood flowcross the mitral or tricuspid valve when such valves are oeverely regurgitant, across the normal mitral valve (MV) in
atients with ventricular septal defect or patent ductus
rteriosus, and across the normal tricuspid valve in patients
ith atrial septal defect. In severe, chronic AR, a low-
itched, rumbling diastolic murmur (Austin-Flint murmur)
s often present at the LV apex; it may be either middiastolic
r presystolic. An opening snap is absent in isolated AR.
Presystolic murmurs begin during the period of ventric-
lar filling that follows atrial contraction and therefore occur
n sinus rhythm. They are usually due to mitral or tricuspid
tenosis. A right or left atrial myxoma may cause either
iddiastolic or presystolic murmurs similar to tricuspid or
itral stenosis (MS).
Continuous murmurs arise from high- to low-pressure
hunts that persist through the end of systole and the
eginning of diastole. Thus, they begin in systole, peak near
2, and continue into all or part of diastole. There are many
auses of continuous murmurs, but they are uncommon in
atients with valvular heart disease (5–9).
.1.2.1. Dynamic Cardiac Auscultation
ttentive cardiac auscultation during dynamic changes in
ardiac hemodynamics often enables the observer to deduce
he correct origin and significance of a cardiac murmur
10–13). Changes in the intensity of heart murmurs during
arious maneuvers are indicated in Table 2.
.1.2.2. Other Physical Findings
he presence of other physical findings, either cardiac or
oncardiac, may provide important clues to the significance of
cardiac murmur and the need for further testing (Fig. 2). For
xample, a right heart murmur in early to midsystole at the
ower left sternal border likely represents TR without pulmo-
ary hypertension in an injection drug user who presents with
ever, petechiae, Osler’s nodes, and Janeway lesions.
Associated cardiac findings frequently provide important
nformation about cardiac murmurs. Fixed splitting of the
econd heart sound during inspiration and expiration in a
atient with a grade 2/6 midsystolic murmur in the pul-
onic area and left sternal border should suggest the
ossibility of an atrial septal defect. A soft or absent A2 or
eversed splitting of S2 may denote severe AS. An early
ortic systolic ejection sound heard during inspiration and
xpiration suggests a bicuspid aortic valve, whereas an
jection sound heard only in the pulmonic area and at the
eft sternal border during expiration usually denotes pul-
onic valve stenosis. LV dilatation on precordial palpation
nd bibasilar pulmonary rales favor the diagnosis of severe,
hronic MR in a patient with a grade 2/6 holosystolic
urmur at the cardiac apex. A slow-rising, diminished
rterial pulse suggests severe AS in a patient with a grade
/6 midsystolic murmur at the second right intercostal
pace. The typical parvus et tardus pulse may be absent in
he elderly, even in those with severe AS, secondary to the
ffects of aging on the vasculature. Pulsus parvus may also
ccur with severely reduced cardiac output from any cause.
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ACC/AHA Practice Guidelines August 1, 2006:e1–148actors that aid in the differential diagnosis of LV outflow
ract obstruction are listed in Table 3 (14). Examination of
he jugular venous wave forms may provide additional or
orroborative information. For example, regurgitant cv
aves are indicative of TR and are often present without an
udible murmur.
able 2. Interventions Used to Alter the Intensity of Cardiac Mu
espiration
Right-sided murmurs generally increase with inspiration. Left-sided mu
alsalva maneuver
Most murmurs decrease in length and intensity. Two exceptions are th
MVP, which becomes longer and often louder. After release of the Val
left-sided murmurs.
xercise
Murmurs caused by blood flow across normal or obstructed valves (e.g.
exercise. Murmurs of MR, VSD, and AR also increase with handgrip e
ositional changes
With standing, most murmurs diminish, 2 exceptions being the murmu
often is intensified. With brisk squatting, most murmurs become loude
raising usually produces the same results as brisk squatting.
ostventricular premature beat or atrial fibrillation
Murmurs originating at normal or stenotic semilunar valves increase in
cycle length in AF. By contrast, systolic murmurs due to atrioventricula
or become shorter (MVP).
harmacological interventions
During the initial relative hypotension after amyl nitrite inhalation, mu
because of increased stroke volume. During the later tachycardia phase,
thus distinguish the murmur of the Austin-Flint phenomenon from tha
control).
ransient arterial occlusion
Transient external compression of both arms by bilateral cuff inflation t
MR, VSD, and AR but not murmurs due to other causes.
F indicates atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; HCM, h
alve prolapse; PS, pulmonic stenosis; VPB, ventricular premature beat; and VSD, vFigure 2. Strategy for evaluating heart murmurs. *If an electrocardiogram or ches.1.2.3. Associated Symptoms
n important consideration in the patient with a cardiac
urmur is the presence or absence of symptoms (15) (Fig.
). For example, symptoms of syncope, angina pectoris, or
eart failure in a patient with a midsystolic murmur will
s
s usually are louder during expiration.
olic murmur of HCM, which usually becomes much louder, and that of
right-sided murmurs tend to return to baseline intensity earlier than
nd MS) become louder with both isotonic and isometric (handgrip)
e.
CM, which becomes louder, and that of MVP, which lengthens and
those of HCM and MVP usually soften and may disappear. Passive leg
sity during the cardiac cycle after a VPB or in the beat after a long
e regurgitation do not change, diminish (papillary muscle dysfunction),
of MR, VSD, and AR decrease, whereas murmurs of AS increase
urs of MS and right-sided lesions also increase. This intervention may
S. The response in MVP often is biphasic (softer then louder than
mm Hg greater than peak systolic pressure augments the murmurs of
ophic cardiomyopathy; MR, mitral regurgitation; MS, mitral stenosis; MVP, mitral
lar septal defect.rmur
rmur
e syst
salva,
, PS a
xercis
r of H
r, but
inten
r valv
rmurs
murm
t of M
o 20t X-ray has been obtained and is abnormal, echocardiography is indicated.
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinessually result in a more aggressive diagnostic approach than
n a patient with a similar midsystolic murmur who has
one of these symptoms. An echocardiogram to rule in or
ule out the presence of significant AS should be obtained.
history of thromboembolism will also usually result in a
ore extensive workup. In patients with cardiac murmurs
nd clinical findings suggestive of endocarditis, echocardi-
graphy is indicated (2).
Conversely, many asymptomatic children and young
dults with grade 2/6 midsystolic murmurs and no other
ardiac physical findings need no further workup after the
nitial history and physical examination (Fig. 2). A partic-
larly important group is the large number of asymptomatic
lder patients, many with systemic hypertension, who have
idsystolic murmurs, usually of grade 1 or 2 intensity,
elated to sclerotic aortic valve leaflets; flow into tortuous,
oncompliant great vessels; or a combination of these
ndings. Such murmurs must be distinguished from those
aused by more significant degrees of aortic valve thicken-
ng, calcification, and reduced excursion that result in milder
r greater degrees of valvular AS. The absence of LV
ypertrophy on the electrocardiogram (ECG) may be reas-
uring, but echocardiography is frequently necessary. Aortic
clerosis can be defined by focal areas of increased echoge-
icity and thickening of the leaflets without restriction of
otion and a peak velocity of less than 2.0 m per second.
he recognition of aortic valve sclerosis may prompt the
nitiation of more aggressive programs of coronary heart
isease prevention. In patients with AS, it is difficult to
ssess the rate and severity of disease progression on the
asis of auscultatory findings alone.
.1.3. Electrocardiography and Chest Roentgenography
lthough echocardiography usually provides more specific
nd often quantitative information about the significance of
heart murmur and may be the only test needed, the ECG
nd chest X-ray are readily available and may have been
btained previously. The absence of ventricular hypertro-
hy, atrial enlargement, arrhythmias, conduction abnormal-
able 3. Factors That Differentiate the Various Causes of Left V
Factor Valvular
alve calcification Common after age 40 y
ilated ascending aorta Common after age 40 y
P after VPB Increased
alsalva effect on SM Decreased
urmur of AR Common after age 40 y
ourth heart sound
(S4)
If severe
aradoxical splitting Sometimes*
jection click Most (unless valve calcified)
aximal thrill and
murmur
2nd RIS
arotid pulse Normal to anacrotic* (parvus et tardus)
Depends on severity. Modified with permission from Marriott HJL. Bedside cardia
AR indicates aortic regurgitation; HCM, hypertrophic cardiomyopathy; LIS, left i
PB, ventricular premature beat.ties, prior myocardial infarction, and evidence of activeschemia on the ECG provides useful negative information
t a relatively low cost. Abnormal ECG findings in a patient
ith a heart murmur, such as ventricular hypertrophy or a
rior infarction, should lead to a more extensive evaluation
hat includes echocardiography (Fig. 2).
Posteroanterior and lateral chest roentgenograms often
ield qualitative information on cardiac chamber size, pul-
onary blood flow, pulmonary and systemic venous pres-
ure, and cardiac calcification in patients with cardiac
urmurs. When abnormal findings are present on chest
-ray, echocardiography should be performed (Fig. 2). A
ormal chest X-ray and ECG are likely in asymptomatic
atients with isolated midsystolic murmurs, particularly in
ounger age groups, when the murmur is grade 2 or less in
ntensity and heard along the left sternal border (16–18).
outine ECG and chest radiography are not recommended
n this setting.
.1.4. Echocardiography
lass I
. Echocardiography is recommended for asymptomatic
patients with diastolic murmurs, continuous mur-
murs, holosystolic murmurs, late systolic murmurs,
murmurs associated with ejection clicks or murmurs
that radiate to the neck or back. (Level of Evidence: C)
. Echocardiography is recommended for patients with
heart murmurs and symptoms or signs of heart
failure, myocardial ischemia/infarction, syncope,
thromboembolism, infective endocarditis, or other
clinical evidence of structural heart disease. (Level of
Evidence: C)
. Echocardiography is recommended for asymptomatic
patients who have grade 3 or louder midpeaking
systolic murmurs. (Level of Evidence: C)
lass IIa
. Echocardiography can be useful for the evaluation of
asymptomatic patients with murmurs associated with
cular Outflow Tract Obstruction
ravalvular Discrete Subvalvular Obstructive HCM
No No
re Rare Rare
reased Increased Decreased
creased Decreased Increased
re Sometimes No
common Uncommon Common
No Rather common*
No Uncommon or none
RIS 2nd RIS 4th LIS
equal Normal to anacrotic Brisk, jerky, systolic rebound
nosis. Philadelphia, PA: Lippincott; 1993:116.
stal space; PP, pulse pressure; RIS, right intercostal space; SM, systolic murmur; andentri
Sup
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ACC/AHA Practice Guidelines August 1, 2006:e1–148associated with an abnormal ECG or chest X-ray.
(Level of Evidence: C)
. Echocardiography can be useful for patients whose
symptoms and/or signs are likely noncardiac in origin
but in whom a cardiac basis cannot be excluded by
standard evaluation. (Level of Evidence: C)
lass III
Echocardiography is not recommended for patients
who have a grade 2 or softer midsystolic murmur
identified as innocent or functional by an experienced
observer. (Level of Evidence: C)
Echocardiography with color flow and spectral Doppler
valuation is an important noninvasive method for assessing
he significance of cardiac murmurs. Information regarding
alve morphology and function, chamber size, wall thick-
ess, ventricular function, pulmonary and hepatic vein flow,
nd estimates of pulmonary artery pressures can be readily
ntegrated.
Although echocardiography can provide important informa-
ion, such testing is not necessary for all patients with cardiac
urmurs and usually adds little but expense in the evaluation
f asymptomatic younger patients with short grade 1 to 2
idsystolic murmurs and otherwise normal physical findings.
t the other end of the spectrum are patients with heart
urmurs for whom transthoracic echocardiography proves
nadequate. Depending on the specific clinical circumstances,
ransesophageal echocardiography, cardiac magnetic reso-
ance, or cardiac catheterization may be indicated for better
haracterization of the valvular lesion.
It is important to note that Doppler ultrasound devices
re very sensitive and may detect trace or mild valvular
egurgitation through structurally normal tricuspid and
ulmonic valves in a large percentage of young, healthy
ubjects and through normal left-sided valves (particularly
he MV) in a variable but lower percentage of patients
16,19–22).
General recommendations for performing echocardiog-
aphy in patients with heart murmurs are provided. Of
ourse, individual exceptions to these indications may exist.
.1.5. Cardiac Catheterization
ardiac catheterization can provide important information
bout the presence and severity of valvular obstruction,
alvular regurgitation, and intracardiac shunting. It is not
ecessary in most patients with cardiac murmurs and
ormal or diagnostic echocardiograms, but it provides
dditional information for some patients in whom there is a
iscrepancy between the echocardiographic and clinical
ndings. Indications for cardiac catheterization for hemo-
ynamic assessment of specific valve lesions are given in
ection 3, “Specific Valve Lesions,” in these guidelines.
pecific indications for coronary angiography to screen for
he presence of CAD are given in Section 10.2. i.1.6. Exercise Testing
xercise testing can provide valuable information in patients
ith valvular heart disease, especially in those whose symp-
oms are difficult to assess. It can be combined with
chocardiography, radionuclide angiography, and cardiac
atheterization. It has a proven track record of safety, even
mong asymptomatic patients with severe AS. Exercise
esting has generally been underutilized in this patient
opulation and should constitute an important component
f the evaluation process.
.1.7. Approach to the Patient
he evaluation of the patient with a heart murmur may vary
reatly depending on many of the considerations discussed
bove (23,24). These include the timing of the murmur in the
ardiac cycle, its location and radiation, and its response to
arious physiological maneuvers (Table 2). Also of importance
s the presence or absence of cardiac and noncardiac symptoms
nd other findings on physical examination that suggest the
urmur is clinically significant (Fig. 2).
Patients with diastolic or continuous heart murmurs not
ue to a cervical venous hum or a mammary souffle during
regnancy are candidates for echocardiography. If the re-
ults of echocardiography indicate significant heart disease,
urther evaluation may be indicated. An echocardiographic
xamination is also recommended for patients with apical or
eft sternal edge holosystolic or late systolic murmurs, for
atients with midsystolic murmurs of grade 3 or greater
ntensity, and for patients with softer systolic murmurs in
hom dynamic cardiac auscultation suggests a definite
iagnosis (e.g., hypertrophic cardiomyopathy).
Echocardiography is also recommended for patients in
hom the intensity of a systolic murmur increases during
he Valsalva maneuver, becomes louder when the patient
ssumes the upright position, and decreases in intensity
hen the patient squats. These responses suggest the
iagnosis of either hypertrophic obstructive cardiomyopathy
r MV prolapse (MVP). Additionally, further assessment is
ndicated when a systolic murmur increases in intensity
uring transient arterial occlusion, becomes louder during
ustained handgrip exercise, or does not increase in intensity
ither in the cardiac cycle that follows a premature ventric-
lar contraction or after a long R-R interval in patients with
trial fibrillation. The diagnosis of MR or ventricular septal
efect in these circumstances is likely.
In many patients with grade 1 or 2 midsystolic murmurs,
n extensive workup is not necessary. This is particularly
rue for children and young adults who are asymptomatic,
ave an otherwise normal cardiac examination, and have no
ther physical findings associated with cardiac disease.
However, echocardiography is indicated in certain pa-
ients with grade 1 or 2 midsystolic murmurs, including
atients with symptoms or signs consistent with infective
ndocarditis, thromboembolism, heart failure, myocardial
schemia/infarction, or syncope. Echocardiography also
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinessually provides an accurate diagnosis in patients with other
bnormal physical findings, including widely split second
eart sounds, systolic ejection sounds, and specific changes
n intensity of the systolic murmur during certain physio-
ogical maneuvers (Table 2).
Although echocardiography is an important test for
atients with a moderate to high likelihood of a clinically
mportant cardiac murmur, it must be re-emphasized that
rivial, minimal, or physiological valvular regurgitation,
specially affecting the mitral, tricuspid, or pulmonic valves,
s detected by color flow imaging techniques in many
therwise normal patients, including many patients who
ave no heart murmur at all (16,19–22). This observation
ust be considered when the results of echocardiography
re used to guide decisions in asymptomatic patients in
hom echocardiography was used to assess the significance
f an isolated murmur.
Very few data address the cost-effectiveness of various
pproaches to the patient undergoing medical evaluation of
cardiac murmur. Optimal auscultation by well-trained
xaminers who can recognize an insignificant midsystolic
urmur with confidence (by dynamic cardiac auscultation
s indicated) results in less frequent use of expensive
dditional testing to define murmurs that do not indicate
ardiac pathology.
Characteristics of innocent murmurs in asymptomatic
dults that have no functional significance include the
ollowing:
grade 1 to 2 intensity at the left sternal border
a systolic ejection pattern
normal intensity and splitting of the second heart sound
no other abnormal sounds or murmurs
no evidence of ventricular hypertrophy or dilatation and
the absence of increased murmur intensity with the
Valsalva maneuver or with standing from a squatting
position (12).
Such murmurs are especially common in high-output
tates such as anemia and pregnancy (25,26). When the
haracteristic features of individual murmurs are consid-
red together with information obtained from the history
nd physical examination, the correct diagnosis can
sually be established (24). In patients with ambiguous
linical findings, the echocardiogram can often provide a
efinite diagnosis, rendering a chest X-ray and/or ECG
nnecessary.
In the evaluation of heart murmurs, the purposes of
chocardiography are to
define the primary lesion in terms of cause and severity
define hemodynamics
define coexisting abnormalities
detect secondary lesions
evaluate cardiac chamber size and function
establish a reference point for future comparisons
re-evaluate the patient after an intervention.Throughout these guidelines, treatment recommenda-
ions will often derive from specific echocardiographic
easurements of LV size and systolic function. Accuracy
nd reproducibility are critical, particularly when applied to
urgical recommendations for asymptomatic patients with
R or AR. Serial measurements over time, or reassessment
ith a different imaging technology (radionuclide ventricu-
ography or cardiac magnetic resonance), are often helpful
or counseling individual patients. Lastly, although hand-
eld echocardiography can be used for screening purposes, it
s important to note that its accuracy is highly dependent on
he experience of the user. The precise role of handheld
chocardiography for the assessment of patients with valvu-
ar heart disease has not been elucidated.
As valuable as echocardiography may be, the basic car-
iovascular physical examination is still the most appropri-
te method of screening for cardiac disease and will establish
any clinical diagnoses. Echocardiography should not re-
lace the cardiovascular examination but can be useful in
etermining the cause and severity of valvular lesions,
articularly in older and/or symptomatic patients.
.2. Valve Disease Severity Table
lassification of the severity of valve disease in adults is
isted in Table 4 (27). The classification for regurgitant
esions is adapted from the recommendations of the Amer-
can Society of Echocardiography (27). For full recommen-
ations of the American Society of Echocardiography,
lease refer to the original document. Subsequent sections
f the current guidelines refer to the criteria in Table 4 (27)
o define severe valvular stenosis or regurgitation.
.3. Endocarditis and Rheumatic Fever Prophylaxis
he following information is based on recommendations
ade by the AHA in 1997 (28). These recommendations
re currently under revision and subject to change. Recom-
endations for prophylaxis against and treatment of non-
alvular cardiac device–related infections have been pub-
ished previously (29).
.3.1. Endocarditis Prophylaxis
lass I
rophylaxis against infective endocarditis is recom-
ended for the following patients:
Patients with prosthetic heart valves and patients with
a history of infective endocarditis. (Level of Evi-
dence: C)
Patients who have complex cyanotic congenital heart
disease (e.g., single-ventricle states, transposition of
the great arteries, tetralogy of Fallot). (Level of Evi-
dence: C)
Patients with surgically constructed systemic-
pulmonary shunts or conduits. (Level of Evidence: C)
Patients with congenital cardiac valve malformations,
particularly those with bicuspid aortic valves, and
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. Left-sided valve disease
Indicator
Aortic Stenosis
Mild Moderate Severe
et velocity (m per second) Less than 3.0 3.0–4.0 Greater than 4.0
ean gradient (mm Hg)* Less than 25 25–40 Greater than 40
alve area (cm2) Greater than 1.5 1.0–1.5 Less than 1.0
alve area index (cm2 per m2) Less than 0.6
Mitral Stenosis
Mild Moderate Severe
ean gradient (mm Hg)* Less than 5 5–10 Greater than 10
ulmonary artery systolic pressure
(mm Hg)
Less than 30 30–50 Greater than 50
alve area (cm2) Greater than 1.5 1.0–1.5 Less than 1.0
Aortic Regurgitation
Mild Moderate Severe
ualitative
Angiographic grade 1 2 3–4
Color Doppler jet width Central jet, width less than 25%
of LVOT
Greater than mild but no signs of
severe AR
Central jet, width greater
than 65% LVOT
Doppler vena contracta width
(cm)
Less than 0.3 0.3–0.6 Greater than 0.6
uantitative (cath or echo)
Regurgitant volume (ml per beat) Less than 30 30–59 Greater than or equal to 60
Regurgitant fraction (%) Less than 30 30–49 Greater than or equal to 50
Regurgitant orifice area (cm2) Less than 0.10 0.10–0.29 Greater than or equal to
0.30
dditional essential criteria
Left ventricular size Increased
Mitral Regurgitation
Mild Moderate Severe
ualitative
Angiographic grade 1 2 3–4
Color Doppler jet area Small, central jet (less than 4 cm2
or less than 20% LA area)
Signs of MR greater than mild present
but no criteria for severe MR
Vena contracta width greater
than 0.7 cm with large
central MR jet (area
greater than 40% of LA
area) or with a wall-
impinging jet of any size,
swirling in LA
Doppler vena contracta width
(cm)
Less than 0.3 0.3–0.69 Greater than or equal to
0.70
uantitative (cath or echo)
Regurgitant volume (ml per beat) Less than 30 30–59 Greater than or equal to 60
Regurgitant fraction (%) Less than 30 30–49 Greater than or equal to 50
Regurgitant orifice area (cm2) Less than 0.20 0.2–0.39 Greater than or equal to
0.40
dditional essential criteria
Left atrial size Enlarged
Left ventricular size Enlarged
B. Right-sided valve disease Characteristic
evere tricuspid stenosis: Valve area less than 1.0 cm2
evere tricuspid regurgitation: Vena contracta width greater than 0.7 cm and systolic flow reversal in hepatic veins
evere pulmonic stenosis: Jet velocity greater than 4 m per second or maximum gradient greater than 60 mmHg
evere pulmonic regurgitation: Color jet fills outflow tract; dense continuous wave Doppler signal with a steep deceleration slope
Valve gradients are flow dependent and when used as estimates of severity of valve stenosis should be assessed with knowledge of cardiac output or forward flow across the valve.
odified from the Journal of the American Society of Echocardiography, 16, Zoghbi WA, Recommendations for evaluation of the severity of native valvular regurgitation withwo-dimensional and Doppler echocardiography, 777–802, Copyright 2003, with permission from American Society of Echocardiography (27).
AR indicates aortic regurgitation; cath, catheterization; echo, echocardiography; LA, left atrial/atruim; LVOT, left ventricular outflow tract; and MR, mitral regurgitation.
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinespatients with acquired valvular dysfunction (e.g.,
rheumatic heart disease). (Level of Evidence: C)
Patients who have undergone valve repair. (Level of
Evidence: C)
Patients who have hypertrophic cardiomyopathy when
there is latent or resting obstruction. (Level of Evi-
dence: C)
Patients with MVP and auscultatory evidence of val-
vular regurgitation and/or thickened leaflets on echo-
cardiography.* (Level of Evidence: C)
lass III
rophylaxis against infective endocarditis is not recom-
ended for the following patients:
Patients with isolated secundum atrial septal defect.
(Level of Evidence: C)
Patients 6 or more months after successful surgical or
percutaneous repair of atrial septal defect, ventricular
septal defect, or patent ductus arteriosus. (Level of
Evidence: C)
Patients with MVP without MR or thickened leaflets
on echocardiography.* (Level of Evidence: C)
Patients with physiological, functional, or innocent
heart murmurs, including patients with aortic valve
sclerosis as defined by focal areas of increased echo-
genicity and thickening of the leaflets without restric-
tion of motion and a peak velocity less than 2.0 m per
second. (Level of Evidence: C)
Patients with echocardiographic evidence of physio-
logic MR in the absence of a murmur and with
structurally normal valves. (Level of Evidence: C)
Patients with echocardiographic evidence of physio-
logical TR and/or pulmonary regurgitation in the
absence of a murmur and with structurally normal
valves. (Level of Evidence: C)
Patients with MVP without regurgitation require addi-
ional clinical judgment. Indications for antibiotic prophy-
axis in MVP are discussed in Section 3.5.2. Patients who do
ot have MR but who do have echocardiographic evidence of
hickening and/or redundancy of the valve leaflets, and
specially men 45 years of age or older, may be at increased
isk for infective endocarditis (30). Additionally, approxi-
ately one third of patients with MVP without MR at rest
ay have exercise-induced MR (31). Some patients may
xhibit MR at rest on one occasion and not on another. There
re no data available to address this latter issue, and at
resent, the decision must be left to clinical judgment, taking
nto account the nature of the invasive procedure, the
revious history of endocarditis, and the presence or absence
f valve thickening and/or redundancy.
Infective endocarditis is a serious illness associated with
ignificant morbidity and mortality. Its prevention by the
ppropriate administration of antibiotics before procedures
xpected to produce bacteremia merits serious consideration.
xperimental studies suggest that endothelial damage leads to dlatelet and fibrin deposition and the formation of a nonbac-
erial thrombotic endocardial lesion. In the presence of bacte-
emia, the organisms may adhere to these lesions and multiply
ithin the platelet-fibrin complex, leading to an infective
egetation (30,32). Valvular and congenital abnormalities,
specially those that result in abnormal high-velocity jet
treams, can damage the endothelial lining and predispose to
latelet aggregation and fibrin deposition at those sites, which
re thus at higher risk for bacterial colonization.
Several issues must be considered in generating recom-
endations for endocarditis prophylaxis (33). The rationale
or antimicrobial prophylaxis is based on the following:
Clinical experience documents endocarditis after
bacteremia.
Bacteremia by organisms known to produce endocarditis
follows various procedures, such as dental procedures,
endoscopy, and cystoscopy.
Antibiotics to which known offending organisms are
sensitive are available.
Antibiotics prevent Streptococcus viridans endocarditis
in experimental endocarditis.
Small clinical studies in humans suggest benefit from
prophylaxis against endocarditis (34,35).
The following evidence raises questions about the value of
rophylaxis:
Lack of any randomized, controlled clinical trials to support
the application of the results of animal studies to humans.
Clinical reports of failure of antibiotic prophylaxis against
endocarditis (33,36) or studies that appear to show that
prophylaxis is not protective (37).
The evidence that dental and other procedures cause
endocarditis is circumstantial. With the incidence of
bacteremia (positive blood culture) varying from 8%
(urethral catheterization) to as high as 94% (periodontal
surgery/extractions) (38), the actual incidence of endo-
carditis is low (10 to 60 cases per 1 million persons per
year) (33). Studies suggest that dental treatment alone is
not a risk factor for endocarditis (39,40).
In specific circumstances, such as prophylaxis for all cases of
MVP, the risk of death due to penicillin is estimated to be
greater than the risk of infective endocarditis (41,42).
In view of these issues, and until the AHA’s recommen-
ations have been revised, the committee continues to
ecommend that the risk of endocarditis in patients with
re-existing cardiac disorders be classified as relatively high,
oderate, or low, as determined primarily by the underlying
ardiac disorder (28).
Various dental and surgical procedures are associated with
arying degrees and frequencies of bacteremia. The frequency
f bacteremia is highest with dental and oral procedures,
ntermediate with procedures that involve the genitourinary
ract, and lowest with gastrointestinal procedures (33). Rec-
mmendations for endocarditis prophylaxis, as determined by
ental, surgical, and other procedures, are listed in Tables 5
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omplicating body piercing and tattoo application underscore
he changing nature of this disease.
The procedure—and thus, the portal of entry—
etermines the type of organisms involved in the resulting
acteremia and dictates the choice of antibiotic for prophy-
axis. Because streptococci are normal inhabitants of the oral
avity, the antibiotic prophylaxis regimen for dental and oral
rocedures is directed against these organisms. For genito-
rinary and lower gastrointestinal tract procedures, the
ntibiotic prophylactic regimen is designed primarily to
over enterococci.
.3.2. Rheumatic Fever Prophylaxis
.3.2.1. General Considerations
heumatic fever is an important cause of valvular heart disease.
n the United States (and Western Europe), cases of acute
Table 5. Endocarditis Prophylaxis for Nonden
A. Endocarditis prophylaxis recommended
Respiratory tract
● Tonsillectomy/adenoidectomy
● Surgical operations involving respiratory muco
● Bronchoscopy with rigid bronchoscope
Gastrointestinal tract (prophylaxis for high-risk pa
● Sclerotherapy for esophageal varies
● Esophageal stricture dilation
● Endoscopic retrograde cholangiography with b
● Biliary tract surgery
● Surgical operations involving intestinal mucosa
Genitourinary tract
● Prostatic surgery
● Cystoscopy
● Urethral dilation
B. Endocarditis prophylaxis not recommended
Respiratory tract
● Endotracheal intubation
● Bronchoscopy with a flexible bronchoscope wi
● Tympanostomy tube insertion
Gastrointestinal tract
● Transesophageal echocardiography*
● Endoscopy with or without gastrointestinal bi
Genitourinary tract
● Vaginal hysterectomy*
● Vaginal delivery*
● Caesarean section
● In uninfected tissue:
Urethral catheterization
Uterine dilation and curettage
Therapeutic abortion
Sterilization procedures
Insertion or removal of intrauterine devices
Other
● Cardiac catheterization, including balloon ang
● Implantation of cardiac pacemakers, implantab
● Incision or biopsy of surgically scrubbed skin
● Circumcision
*Prophylaxis is optional for high-risk patients. Reprinted w
Prevention of bacterial endocarditis: recommendations by thheumatic fever have been uncommon since the 1970s. How- bver, starting in 1987, an increase in cases has been observed
43,44). With the enhanced understanding of the causative
rganism, group A beta hemolytic streptococcus, its rheumato-
enicity is attributed to the prevalence of M-protein serotypes
f the offending organism. This finding has resulted in the
evelopment of kits that allow rapid detection of group A
treptococci with specificity greater than 95% and more rapid
dentification of their presence in upper respiratory infection.
ecause the test has a low sensitivity, a negative test requires
hroat culture confirmation (44). Prompt recognition and
reatment comprise primary rheumatic fever prevention. For
atients who have had a previous episode of rheumatic fever,
ontinuous antistreptococcal prophylaxis is indicated for sec-
ndary prevention.
.3.2.2. Primary Prevention
heumatic fever prevention and treatment guidelines have
ocedures
; optimal for moderate risk)
obstruction
without biopsy*
ty
fibrillators, and coronary stents
rmission from Dajani AS, Taubert KA, Wilson W, et al.
rican Heart Association. Circulation 1997;96:358–66 (28).tal Pr
sa
tients
iliary
th or
opsy*
ioplas
le de
ith pe
e Ameeen established previously by the AHA (Table 9) (45).
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lass I
Patients who have had rheumatic fever with or without
carditis (including patients with MS) should receive
prophylaxis for recurrent rheumatic fever. (Level of
Evidence: B)
Patients who have had an episode of rheumatic fever are
t high risk of developing recurrent episodes of acute
heumatic fever. Patients who develop carditis are especially
rone to similar episodes with subsequent attacks. Second-
ry prevention of rheumatic fever recurrence is thus of great
mportance. Continuous antimicrobial prophylaxis has been
hown to be effective. Anyone who has had rheumatic fever
ith or without carditis (including patients with MS)
hould receive prophylaxis for recurrent rheumatic fever.
he 1995 AHA guidelines for secondary prevention are shown
Table 6. Endocarditis Prophylaxis for Dental P
A. Endocarditis prophylaxis recommended
Dental extraction
Periodontal procedures, including surgery, scaling
Dental implant placement and reimplantation of a
Endodontic (root canal) instrumentation or surger
Subgingival placement of antibiotic fibers/strips
Initial placement of orthodontic bands but not bra
Intraligamentary local anesthetic injections*
Prophylactic cleaning of teeth or implants when b
B. Endocarditis prophylaxis not recommended
Restorative dentistry† (operative and prosthodonti
Local anesthetic injections (nonintraligamentary)*
Intracanal endodontic treatment; post placement a
Placement of rubber dams
Postoperative suture removal
Placement of removable prosthodontic/orthodonti
Taking of oral impressions
Fluoride treatments
Taking of oral radiographs
Orthodontic appliance adjustment
Shedding of primary teeth
*Intraligamentary injections are directed between the root an
†Includes filling cavities and replacement of missing teeth
antibiotic use may be indicated. Reprinted with permission
bacterial endocarditis: recommendations by the American H
able 7. Endocarditis Prophylaxis Regimens for Dental, Oral, Re
Situation Agent
tandard general prophylaxis Amoxicillin Ad
nable to take oral medication Ampicillin Ad
enicillin—allergic Clindamycin or Ad
Cephalexin or Ad
Cefadroxil† or Ad
Azithromycin or Ad
Clarithromycin Ad
enicillin—allergic and unable to take
oral medications
Clindamycin or
Cefazolin†
Ad
Ad
Total children’s dose should not exceed adult dose. †Cephalosporins should not be u
naphylaxis) to penicillins. Reprinted with permission from Dajani AS, Taubert KA,
eart Association. Circulation 1997;96:358–66 (28).
IM indicates intramuscular; IV, intravenous; and PO, by mouth.n Table 10, and the 1995 AHA guidelines for duration of
econdary prevention are shown in Table 11 (45).
. SPECIFIC VALVE LESIONS
.1. Aortic Stenosis
.1.1. Introduction
he most common cause of AS in adults is calcification of
normal trileaflet or congenital bicuspid valve (46–49).
his calcific disease progresses from the base of the cusps to
he leaflets, eventually causing a reduction in leaflet motion
nd effective valve area without commissural fusion. Calcific
S is an active disease process characterized by lipid
ccumulation, inflammation, and calcification, with many
imilarities to atherosclerosis (50–60). Rheumatic AS due
o fusion of the commissures with scarring and eventual
alcification of the cusps is less common and is invariably
dures
oot planning, probing, and recall maintenance
teeth
beyond the apex
g is anticipated
h/without retraction cord
ild up
iances
to deliver anesthetic agents to the periosteum of the bone.
elected circumstances, especially with significant bleeding,
Dajani AS, Taubert KA, Wilson W, et al. Prevention of
ssociation. Circulation 1997;96:358–66 (28).
tory Tract, or Esophageal Procedures
Regimen*
2.0 g; children: 50 mg per kg PO 1 h before procedure
2.0 g IM or IV; children: 50 mg per kg IM or IV within 30 min before
dure
600 mg; children: 20 mg per kg PO 1 h before procedure
2.0 g; children 50 mg per kg PO 1 h before procedure
2.0 g; children 50 mg per kg PO 1 h before procedure
500 mg; children 15 mg per kg PO 1 h before procedure
500 mg; children 15 mg per kg PO 1 h before procedure
600 mg; children 20 mg per kg IV within 30 min before procedure
1.0 g; children 25 mg per kg IM or IV within 30 min before procedure
individuals with immediate-type hypersensitivity reaction (urticaria, angioedema, or
n W, et al. Prevention of bacterial endocarditis: recommendations by the Americanroce
and r
vulsed
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he valve may also result in stenosis and is the more common
ause in young adults. The management of congenital AS in
dolescents and young adults is discussed in Section 6.1.
.1.1.1. Grading the Degree of Stenosis
lthough AS is best described as a disease continuum, and
here is no single value that defines severity, for these
uidelines, we graded AS severity on the basis of a variety of
emodynamic and natural history data (Table 4) (27,61),
sing definitions of aortic jet velocity, mean pressure gradi-
nt, and valve area as follows:
Mild (area 1.5 cm2, mean gradient less than 25 mm Hg,
or jet velocity less than 3.0 m per second)
able 8. Endocarditis Prophylaxis Regimens for Genitourinary/G
Situation Agent(s)*
igh-risk patients Ampicillin plus gentamicin A
C
igh-risk patients allergic to
ampicillin/amoxicillin
Vancomycin plus
gentamicin
A
oderate-risk patients Amoxicillin or ampicillin A
C
oderate-risk patients allergic to
ampicillin/amoxicillin
Vancomycin A
C
No second dose of vancomycin or gentamicin is recommended. †Total children’s do
ilson W, et al. Prevention of bacterial endocarditis: recommendations by the Ame
IM indicates intramuscular; IV, intravenous; and PO, by mouth.
able 9. Primary Prevention of Rheumatic Fever
Agent
enzathine penicillin G Patients 27 kg (60 lb
Patients greater than
r
enicillin V (phenoxymethyl penicillin) Children: 250 mg 2–
Adolescents and adu
or individuals allergic to penicillin
Erythromycin
Estolate 20–40 mg per kg per
(maximum 1 g per
r
Ethylsuccinate 40 mg per kg per da
(maximum 1 g per
r
Azithromycin 500 mg on first day,
next 4 days
eprinted with permission from Dajani A, Taubert K, Ferrieri P, et al. Treatment o
rofessionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the
ediatrics 1995;96:758–64, Copyright © 1995 by the AAP (45).Moderate (area 1.0 to 1.5 cm2, mean gradient 25 to 40
mm Hg, or jet velocity 3.0 to 4.0 m per second)
Severe (area less than 1.0 cm2, mean gradient greater
than 40 mm Hg, or jet velocity greater than 4.0 m per
second).
hen stenosis is severe and cardiac output is normal, the
ean transvalvular pressure gradient is generally greater
han 40 mm Hg. However, when cardiac output is low,
evere stenosis may be present with a lower transvalvular
radient and velocity, as discussed below. Some patients
ith severe AS remain asymptomatic, whereas others with
nly moderate stenosis develop symptoms. Therapeutic
ecisions, particularly those related to corrective surgery, are
ased largely on the presence or absence of symptoms.
intestinal (Excluding Esophageal) Procedures
Regimen†
: ampicillin 2.0 g IM/IV plus gentamicin 1.5 mg per kg (not to exceed
mg) within 30 min of starting the procedure. Six hours later, ampicillin
IM/IV or amoxicillin 1 g PO.
en: ampicillin 50 mg per kg IM or IV (not to exceed 2.0 g) plus
tamicin 1.5 mg per kg within 30 min of starting the procedure. Six
rs later, ampicillin 25 mg per kg IM/IV or amoxicillin 25 mg per kg
.
: vancomycin 1.0 g IV over 1–2 h plus gentamicin 1.5 mg per kg IV/
(not to exceed 120 mg). Complete injection/infusion within 30 min of
ting the procedure. Children: vancomycin 20 mg per kg IV over 1–2 h
gentamicin 1.5 mg per kg IV/IM. Complete injection/infusion within
in of starting the procedure.
: amoxicillin 2.0 g PO 1 h before procedure, or ampicillin 2.0 g IM/IV
in 30 min of starting the procedure.
en: amoxicillin 50 mg per kg PO 1 h before procedure, or ampicillin 50 mg
kg IM/IV within 30 min of starting the procedure.
: vancomycin 1.0 g IV over 1–2 h. Complete infusion within 30 min of
ting the procedure.
en: vancomycin 20 mg per kg IV over 1–2 h. Complete infusion within
in of starting the procedure.
ld not exceed adult dose. Reprinted with permission from Dajani AS, Taubert KA,
Heart Association. Circulation 1997;96:358–66 (28).
e Mode Duration
ess: 600 000 U Intramuscular Once
g (60 lb): 1 200 000 U
es daily Oral 10 d
0 mg 2–3 times daily
Oral 10 d
2–4 times daily
times daily Oral 10 d
g per day for the Oral 5 d
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineshus, the absolute valve area (or transvalvular pressure
radient) is not the primary determinant of the need for
ortic valve replacement (AVR).
.1.2. Pathophysiology
n adults with AS, the obstruction develops gradually—
sually over decades. During this time, the left ventricle
dapts to the systolic pressure overload through a hypertro-
hic process that results in increased LV wall thickness,
hile a normal chamber volume is maintained (62–64). The
esulting increase in relative wall thickness is usually enough
o counter the high intracavitary systolic pressure, and as a
esult, LV systolic wall stress (afterload) remains within the
ange of normal. The inverse relation between systolic wall
tress and ejection fraction is maintained; as long as wall
tress is normal, the ejection fraction is preserved (65).
owever, if the hypertrophic process is inadequate and
elative wall thickness does not increase in proportion to
ressure, wall stress increases and the high afterload
auses a decrease in ejection fraction (65– 67). Depressed
ontractile state of the myocardium may also be respon-
ible for a low ejection fraction, and it is often difficult
linically to determine whether a low ejection fraction is
ue to depressed contractility or to excessive afterload
68). When low ejection fraction is caused by depressed
ontractility, corrective surgery will be less beneficial than
n patients with a low ejection fraction caused by high
fterload (69).
As a result of increased wall thickness, low volume/mass
atio, and diminished compliance of the chamber, LV
able 10. Secondary Prevention of Rheumatic Fever
Agent
enzathine penicillin G 1 200 000 U every 4
those with residual
r
enicillin V 250 mg twice daily
r
ulfadiazine 0.5 g once daily for p
patients
greater than 27 kg (6
or individuals allergic to penicillin
and sulfadiazine
Erythromycin 250 mg twice daily
High-risk patients include patients with residual rheumatic carditis and patients from ec
errieri P, et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic
awasaki Disease of the Council on Cardiovascular Disease in the Young, the America
able 11. Duration of Secondary Rheumatic Fever Prophylaxis
Category
heumatic fever with carditis and residual
heart disease (persistent valvular disease)
10 y or greater
heumatic fever with carditis but no residual
heart disease (no valvular disease)
10 y or well in
heumatic fever without carditis 5 y or until age
The committee’s interpretation of “lifelong” prophylaxis refers to patients who are
treptococcal infection, that is, teachers and day-care workers. Reprinted with permissi
nd prevention of rheumatic fever: a statement for health professionals. Committee on Rhe
isease in the Young, the American Heart Association. Pediatrics 1995;96:758–64, Copynd-diastolic pressure increases without chamber dilatation
70–72). Thus, increased end-diastolic pressure usually
eflects diastolic dysfunction rather than systolic dysfunction
r failure (73). A forceful atrial contraction that contributes
o an elevated end-diastolic pressure plays an important role
n ventricular filling without increasing mean left atrial or
ulmonary venous pressure (74). Loss of atrial contraction
uch as that which occurs with atrial fibrillation is often
ollowed by serious clinical deterioration.
The development of concentric hypertrophy appears to
e an appropriate and beneficial adaptation to compen-
ate for high intracavitary pressures. Unfortunately, this
daptation often carries adverse consequences. The hy-
ertrophied heart may have reduced coronary blood flow
er gram of muscle and also exhibit a limited coronary
asodilator reserve, even in the absence of epicardial
AD (75–77). The hemodynamic stress of exercise or
achycardia can produce a maldistribution of coronary
lood flow and subendocardial ischemia, which can
ontribute to systolic or diastolic dysfunction of the left
entricle. Hypertrophied hearts also exhibit an increased
ensitivity to ischemic injury, with larger infarcts and
igher mortality rates than are seen in the absence of
ypertrophy (78 – 80). Another problem that is particu-
arly common in elderly patients, especially women, is an
xcessive or inappropriate degree of hypertrophy; wall
hickness is greater than necessary to counterbalance the
igh intracavitary pressures (81– 84). As a result, systolic
all stress is low and ejection fraction is high; such
Dose Mode
very 3 wk for high-risk* patients such as
tis)
Intramuscular
Oral
s 27 g (60 lb) or less; 1.0 g once daily for Oral
Oral
cally disadvantaged populations. Reprinted with permission from Dajani A, Taubert K,
a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and
t Association. Pediatrics 1995;96:758–64, Copyright © 1995 by the AAP (45).
Duration
last episode and at least until age 40 y; sometimes lifelong prophylaxis*
lthood, whichever is longer
, whichever is longer
gh risk and likely to come in contact with populations with a high prevalence of
m Dajani A, Taubert K, Ferrieri P, et al. Treatment of acute streptococcal pharyngitiswk (e
cardi
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0 lb)
onomisince
to adu
21 y
at hi
on froumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular
right © 1995 by the AAP (45).
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igh perioperative morbidity and mortality (81,83).
.1.3. Natural History
he natural history of AS in the adult consists of a
rolonged latent period during which morbidity and mor-
ality are very low. The rate of progression of the stenotic
esion has been estimated in a variety of invasive and
oninvasive studies (85). Once even moderate stenosis is
resent (jet velocity greater than 3.0 m per second) (Table 4)
27), the average rate of progression is an increase in jet
elocity of 0.3 m per second per year, an increase in mean
ressure gradient of 7 mm Hg per year, and a decrease in
alve area of 0.1 cm2 per year (86–96). However, there is
arked individual variability in the rate of hemodynamic
rogression. Although it appears that the progression of AS
an be more rapid in patients with degenerative calcific
isease than in those with congenital or rheumatic disease
96–98), it is not possible to predict the rate of progression
n an individual patient. For this reason, regular clinical
ollow-up is mandatory in all patients with asymptomatic
ild to moderate AS. In addition, progression to AS may
ccur in patients with aortic sclerosis, defined as valve
hickening without obstruction to ventricular outflow (99).
Aortic sclerosis, defined as irregular valve thickening with-
ut obstruction to LV outflow, is present in about 25% of
dults over 65 years of age and is associated with clinical factors
uch as age, sex, hypertension, smoking, serum low-density
ipoprotein and lipoprotein(a) levels, and diabetes mellitus
100). In the Cardiovascular Health Study, the presence of
ortic sclerosis on echocardiography in subjects without known
oronary disease was also associated with adverse clinical
utcome, with an approximately 50% increased risk of myo-
ardial infarction and cardiovascular death compared with
ubjects with a normal aortic valve (101). This has been
onfirmed in 2 additional studies (102,103). The association
etween aortic sclerosis and adverse cardiovascular outcomes
ersisted even when age, sex, known cardiovascular disease,
nd cardiovascular risk factors were taken into account. How-
ver, the mechanism of this association is unclear and is
nlikely to be related to valve hemodynamics. Studies are in
rogress to evaluate potential mechanisms of this association,
ncluding subclinical atherosclerosis, endothelial dysfunction,
nd systemic inflammation.
In most patients with severe AS, impaired platelet function
nd decreased levels of von Willebrand factor can be demon-
trated. The severity of the coagulation abnormality correlates
ith the severity of AS and resolves after valve replacement,
xcept when the prosthetic valve area is small for patient size
less than 0.8 cm2 per m2). This acquired von Willebrand
yndrome is associated with clinical bleeding, most often
pistaxis or ecchymoses, in approximately 20% of patients (104).
Eventually, symptoms of angina, syncope, or heart failure
evelop after a long latent period, and the outlook changes
ramatically. After the onset of symptoms, average survivals 2 to 3 years (105–111), with a high risk of sudden death.hus, the development of symptoms identifies a critical
oint in the natural history of AS. Management decisions
re based largely on these data; most clinicians treat asymp-
omatic patients conservatively, whereas corrective surgery is
enerally recommended in patients with symptoms thought
o be due to AS. It is important to emphasize that
ymptoms may be subtle and often are not elicited by the
hysician in taking a routine clinical history.
Sudden death is known to occur in patients with severe
S and, in older retrospective studies, has been reported to
ccur without prior symptoms (105,108,112,113). How-
ver, in prospective echocardiographic studies, sudden death
n previously asymptomatic patients is rare (61,96,109,114–
16). Therefore, although sudden death may occur in the
bsence of preceding symptoms in patients with AS
105,108,112,113,116), it is an uncommon event, estimated
t less than 1% per year when patients with known AS are
ollowed up prospectively.
.1.4. Management of the Asymptomatic Patient
symptomatic patients with AS have outcomes similar to
ge-matched normal adults. However, disease progression
ith symptom onset is common, as detailed in Table 12
61,96,109,114–118). In a prospective study of 123 asymp-
omatic adults with an initial jet velocity of at least 2.6 m per
econd, the rate of symptom development was 38% at 3
ears for the total group. However, clinical outcome was
trongly dependent on AS severity, with an event-free
urvival of 84% at 2 years in those with a jet velocity less
han 3 m per second compared with only 21% in those with
jet velocity more than 4 m per second (61,98). In another
tudy of 128 asymptomatic adults with an initial aortic jet
elocity of at least 4 m per second, event-free survival was
7% at 1 year and 33% at 4 years, with predictors of
utcome that included age and the degree of valve calcifi-
ation (96). A third study of patients with aortic jet
elocities greater than 4 m per second provided similar
esults, with 33% remaining asymptomatic without surgery
t 5 years (116). Therefore, patients with asymptomatic AS
equire frequent monitoring for development of symptoms
nd progressive disease.
.1.4.1. Echocardiography (Imaging, Spectral, and Color
oppler) in Aortic Stenosis
lass I
. Echocardiography is recommended for the diagnosis
and assessment of AS severity. (Level of Evidence: B)
. Echocardiography is recommended in patients with
AS for the assessment of LV wall thickness, size, and
function. (Level of Evidence: B)
. Echocardiography is recommended for re-evaluation
of patients with known AS and changing symptoms
or signs. (Level of Evidence: B)
. Echocardiography is recommended for the assess-
ment of changes in hemodynamic severity and LV
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesfunction in patients with known AS during preg-
nancy. (Level of Evidence: B)
. Transthoracic echocardiography is recommended for
re-evaluation of asymptomatic patients: every year for
severe AS; every 1 to 2 years for moderate AS; and
every 3 to 5 years for mild AS. (Level of Evidence: B)
Aortic stenosis typically is first suspected on the basis of the
nding of a systolic ejection murmur on cardiac auscultation;
owever, physical examination findings are specific but not
ensitive for the diagnosis of AS severity (119). The classic
ndings of a loud (grade 4/6), late-peaking systolic murmur
hat radiates to the carotids, a single or paradoxically split
econd heart sound (S2), and a delayed and diminished carotid
pstroke confirm the presence of severe AS. However, in the
lderly, the carotid upstroke may be normal because of the
ffects of aging on the vasculature, and the murmur may be soft
able 12. Clinical Outcomes in Prospective Studies of Asymptom
Study, Year
No. of
Patients
Severity of Aortic
Stenosis Age, y
elly et al., 1988
(109)
51 Vmax greater than
3.6 m per second
63  8
ellikka et al., 1990
(114)
113 Vmax 4.0 m per
second or greater
40–94
ennedy et al., 1991
(115)
66 AVA 0.7–1.2 cm2 67  10
tto et al., 1997
(61)
123 Vmax greater than
2.6 m per second
63  16
osenhek et al., 2000
(96)
128 Vmax greater than
4.0 m per second
60  18
mato et al., 2001
(117)
66 AVA 1.0 cm2 or
greater
18–80
(50  15)
as et al., 2005
(118)
125 AVA less than 1.4
cm2
56–74
(mean 65)
ellikka et al., 2005
(116)
622 Vmax 4.0 m per
second or greater
72  11
Positive exercise test indicates symptoms, abnormal ST-segment response, or abnor
AVA indicates aortic valve area; Ca2, aortic valve calcification; and Vmax, peak ir may radiate to the apex. The only physical examination inding that is reliable in excluding the possibility of severe AS
s a normally split second heart sound (119).
Echocardiography is indicated when there is a systolic
urmur that is grade 3/6 or greater, a single S2, or
ymptoms that might be due to AS. The 2-dimensional
2D) echocardiogram is valuable for evaluation of valve
natomy and function and determining the LV response to
ressure overload. In nearly all patients, the severity of the
tenotic lesion can be defined with Doppler echocardio-
raphic measurements of maximum jet velocity, mean
ransvalvular pressure gradient, and continuity equation
alve area, as discussed in the “ACC/AHA/ASE 2003
uidelines for the Clinical Application of Echocardiogra-
hy” (2). Doppler evaluation of AS severity requires atten-
ion to technical details, with the most common error being
nderestimation of disease severity due to a nonparallel
Aortic Stenosis in Adults
ean Follow-Up Group
Event-Free
Survival Withou
Symptoms
5 mo Overall 59% at 15 mo
mo Overall 86% at 1 y
62% at 2 y
mo Overall 59% at 4 y
 1.4 y Overall 93  5% at 1 y
62  8% at 3 y
26  10% at 5 y
Subgroups:
Vmax less than 3–4 m per
second
84  16% at 2 y
Vmax 3–4 m per second 66  13% at 2 y
Vmax greater than 3 m per
second
21  18% at 2 y
 18 mo Overall 67  5% at 1 y
56  55% at 2 y
33  5% at 4 y
Subgroups:
No or mild Ca2 75  9% at 4 y
Moderate-severe Ca2 20  5% at 4 y
 12 mo Overall 57% at 1 y
38% at 2 y
Subgroups:
AVA 0.7 cm2 or greater 72% at 2 y
AVA less than 0.7 cm2 21% at 2 y
Negative exercise test 85% at 2 y
Positive exercise test* 19% at 2 y
mo Overall 71% at 1 y
Subgroups:
AVA 1.2 cm2 or greater 100% at 1 y
AVA 0.8 cm2 or less 46% at 1 y
No symptoms on exercise test 89% at 1 y
Symptoms on exercise test 49% at 1 y
 4.0 y Overall 82% at 1 y
67% at 2 y
33% at 5 y
ood pressure response (less than 20-mm Hg increase) with exercise.
aneous velocity.atic
M
5–2
20
35
2.5
22
15
12
5.4ntercept angle between the ultrasound beam and high-
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ACC/AHA Practice Guidelines August 1, 2006:e1–148elocity jet through the narrowed valve. When measurement
f LV outflow tract diameter is problematic, the ratio of
utflow tract velocity to aortic jet velocity can be substituted
or valve area, because this ratio is, in effect, indexed for
ody size. A ratio of 0.9 to 1.0 is normal, with a ratio less
han 0.25 indicating severe stenosis. Echocardiography is
lso used to assess LV size and function, degree of hyper-
rophy, and presence of other associated valvular disease.
In some patients, it may be necessary to proceed with
ardiac catheterization and coronary angiography at the
ime of initial evaluation. For example, this is appropriate if
here is a discrepancy between clinical and echocardio-
raphic examinations or if symptoms might be due to CAD.
.1.4.2. Exercise Testing
lass IIb
Exercise testing in asymptomatic patients with AS may
be considered to elicit exercise-induced symptoms and
abnormal blood pressure responses. (Level of Evidence: B)
lass III
Exercise testing should not be performed in symptom-
atic patients with AS. (Level of Evidence: B)
Exercise testing in adults with AS has poor diagnostic
ccuracy for evaluation of concurrent CAD. Presumably,
his is due to the presence of an abnormal baseline ECG,
V hypertrophy, and limited coronary flow reserve. Elec-
rocardiographic ST depression during exercise occurs in
0% of adults with asymptomatic AS and has no known
rognostic significance.
Exercise testing should not be performed in symptomatic
atients owing to a high risk of complications. However, in
symptomatic patients, exercise testing is relatively safe and
ay provide information that is not uncovered during the
nitial clinical evaluation (61,117,118,120–124). When the
edical history is unclear, exercise testing can identify a
imited exercise capacity, abnormal blood pressure re-
ponses, or even exercise-induced symptoms (117,118,124).
n one series (117), patients manifesting symptoms, abnor-
al blood pressure (less than 20-mm Hg increase), or
T-segment abnormalities with exercise had a symptom-
ree survival at 2 years of only 19% compared with 85%
ymptom-free survival in those with none of these findings
ith exercise. Four patients died during the course of this
tudy (1.2% annual mortality rate); all had an aortic valve
rea less than 0.7cm2 and an abnormal exercise test. In
nother series (118), exercise testing brought out symptoms
n 29% of patients who where considered asymptomatic
efore testing; in these patients, spontaneous symptoms
eveloped in 51% over the next year compared with only
1% of patients who had no symptoms on exercise testing.
n abnormal hemodynamic response (e.g., hypotension or
ailure to increase blood pressure with exercise) in a patient
ith severe AS is considered a poor prognostic finding s117,125). Finally, in selected patients, the observations
ade during exercise may provide a basis for advice about
hysical activity. Exercise testing in asymptomatic patients
hould be performed only under the supervision of an
xperienced physician with close monitoring of blood pres-
ure and the ECG.
.1.4.3. Serial Evaluations
he frequency of follow-up visits to the physician depends
n the severity of the valvular stenosis and on the presence
f comorbid conditions. Recognizing that an optimal sched-
le for repeated medical examinations has not been defined,
any physicians perform an annual history and physical
xamination on patients with asymptomatic AS of any
egree. An essential component of each visit is patient
ducation about the expected disease course and symptoms
f AS. Periodic echocardiography may be appropriate as
iscussed below. Patients should be advised to promptly
eport the development of any change in exercise tolerance,
xertional chest discomfort, dyspnea, lightheadedness, or
yncope.
Serial echocardiography is an important part of an inte-
rated approach that includes a detailed history, physical
xamination, and, in some patients, a carefully monitored
xercise test. Because the rate of progression varies consid-
rably, clinicians often perform an annual echocardiogram
n patients known to have moderate to severe AS. Serial
chocardiograms are helpful for assessing changes in steno-
is severity, LV hypertrophy, and LV function. Therefore,
n patients with severe AS, an echocardiogram every year
ay be appropriate. In patients with moderate AS, serial
tudies performed every 1 to 2 years are satisfactory, and in
atients with mild AS, serial studies can be performed every
to 5 years. Echocardiograms should be performed more
requently if there is a change in signs or symptoms.
.1.4.4. Medical Therapy
ntibiotic prophylaxis is indicated in all patients with AS
or prevention of infective endocarditis and, in those with
heumatic AS, for prevention of recurrent rheumatic fever.
atients with associated systemic arterial hypertension
hould be treated cautiously with appropriate antihyperten-
ive agents. With these exceptions, there is no specific
edical therapy for patients who have not yet developed
ymptoms. Patients who develop symptoms require surgery,
ot medical therapy.
There are no medical treatments proven to prevent or
elay the disease process in the aortic valve leaflets. How-
ver, the association of AS with clinical factors similar to
hose associated with atherosclerosis and the mechanisms of
isease at the tissue level (50–60,99–103,126–129) have
ed to the hypothesis that intervention may be possible to
low or prevent disease progression in the valve leaflet
127,130). Specifically, the effect of lipid-lowering therapy
n progression of calcific AS has been examined in several
mall retrospective studies using echocardiography or car-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesiac computed tomography to measure disease severity
131–136), suggesting a benefit of statins. However, a
rospective, randomized, placebo-controlled trial in patients
ith calcific aortic valve disease failed to demonstrate a
enefit of atorvastatin in reducing the progression of aortic
alve stenosis over a 3-year period (137). It is noteworthy
hat the patients in this study had high levels of aortic valve
alcification by computed tomography and evidence of
oderate to severe AS at baseline, based on peak aortic
alve gradient (48 to 50 mm Hg), aortic valve area (1.02 to
.03 cm2), and peak jet velocity (3.39 to 3.45 m per second).
t is possible that the calcific process was too advanced in
hese patients to be reversed by short-term statin therapy.
hus, further trials in patients with less severe aortic valve
alcification, with longer follow-up periods, are needed. In
he meanwhile, evaluation and modification of cardiac risk
actors is important in patients with aortic valve disease to
revent concurrent CAD.
.1.4.5. Physical Activity and Exercise
ecommendations for physical activity are based on the
linical examination, with special emphasis on the hemody-
amic severity of the stenotic lesion. The severity can
sually be judged by Doppler echocardiography, but in
orderline cases, diagnostic cardiac catheterization may be
ecessary to accurately define the degree of stenosis.
Recommendations on participation in competitive sports
ave been published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
138). Physical activity is not restricted in asymptomatic
atients with mild AS; these patients can participate in
ompetitive sports. Patients with moderate to severe AS
hould avoid competitive sports that involve high dynamic
nd static muscular demands. Other forms of exercise can be
erformed safely, but it is advisable to evaluate such patients
ith an exercise test before they begin an exercise or athletic
rogram.
.1.5. Indications for Cardiac Catheterization
lass I
. Coronary angiography is recommended before AVR
in patients with AS at risk for CAD (see Section
10.2). (Level of Evidence: B)
. Cardiac catheterization for hemodynamic measure-
ments is recommended for assessment of severity of
AS in symptomatic patients when noninvasive tests
are inconclusive or when there is a discrepancy
between noninvasive tests and clinical findings re-
garding severity of AS. (Level of Evidence: C)
. Coronary angiography is recommended before AVR
in patients with AS for whom a pulmonary autograft
(Ross procedure) is contemplated and if the origin of
the coronary arteries was not identified by noninva-
sive technique. (Level of Evidence: C) ilass III
. Cardiac catheterization for hemodynamic measure-
ments is not recommended for the assessment of
severity of AS before AVR when noninvasive tests are
adequate and concordant with clinical findings.
(Level of Evidence: C)
. Cardiac catheterization for hemodynamic measure-
ments is not recommended for the assessment of LV
function and severity of AS in asymptomatic patients.
(Level of Evidence: C)
In patients with AS, the indications for cardiac catheter-
zation and angiography are essentially the same as in other
onditions, namely, to assess the coronary circulation and
onfirm or clarify the clinical diagnosis. In preparation for
VR, coronary angiography is indicated in patients sus-
ected of having CAD, as discussed in Section 10.2. If the
linical and echocardiographic data are typical of severe
solated AS, coronary angiography may be all that is needed
efore AVR. A complete left- and right-heart catheteriza-
ion may be necessary to assess the hemodynamic severity of
he AS if there is a discrepancy between clinical and
chocardiographic data.
The pressure gradient across a stenotic valve is related to
he valve orifice area and the transvalvular flow (139). Thus,
n the presence of depressed cardiac output, relatively low
ressure gradients may be obtained in patients with severe
S. On the other hand, during exercise or other high-flow
tates, significant pressure gradients can be measured in
inimally stenotic valves. For these reasons, complete
ssessment of AS requires
measurement of transvalvular flow
determination of the mean transvalvular pressure gradient
calculation of the effective valve area.
Attention to detail with accurate measurements of pres-
ure and flow is important, especially in patients with low
ardiac output or a low transvalvular pressure gradient.
.1.6. Low-Flow/Low-Gradient Aortic Stenosis
lass IIa
. Dobutamine stress echocardiography is reasonable to
evaluate patients with low-flow/low-gradient AS and
LV dysfunction. (Level of Evidence: B)
. Cardiac catheterization for hemodynamic measure-
ments with infusion of dobutamine can be useful for
evaluation of patients with low-flow/low-gradient AS
and LV dysfunction. (Level of Evidence: C)
Patients with severe AS and low cardiac output often
resent with a relatively low transvalvular pressure gradient
i.e., mean gradient less than 30 mm Hg). Such patients can
e difficult to distinguish from those with low cardiac output
nd only mild to moderate AS. In the former (true anatom-
cally severe AS), the stenotic lesion contributes to an
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ACC/AHA Practice Guidelines August 1, 2006:e1–148levated afterload, decreased ejection fraction, and low
troke volume. In the latter, primary contractile dysfunction
s responsible for the decreased ejection fraction and low
troke volume; the problem is further complicated by
educed valve opening forces that contribute to limited valve
obility and apparent stenosis. In both situations, the
ow-flow state and low-pressure gradient contribute to a
alculated effective valve area that can meet criteria for
evere AS. Alternate measures of AS severity have been
roposed as being less flow dependent than gradients or
alve area. These include valve resistance and stroke work
oss. However, all of these measures are flow dependent,
ave not been shown to predict clinical outcome, and have
ot gained widespread clinical use (140).
In selected patients with low-flow/low-gradient AS and
V dysfunction, it may be useful to determine the transval-
ular pressure gradient and to calculate valve area during a
aseline state and again during exercise or low-dose phar-
acological (i.e., dobutamine infusion) stress, with the goal
f determining whether stenosis is severe or only moderate
n severity (123,141–147). Such studies can be performed in
he echocardiography laboratory or in the cardiac catheter-
zation laboratory. This approach is based on the notion that
atients who do not have true anatomically severe stenosis
ill exhibit an increase in the valve area and little change in
radient during an increase in stroke volume (141,142).
hus, if a dobutamine infusion produces an increment in
troke volume and an increase in valve area greater than 0.2
m2 and little change in gradient, it is likely that baseline
valuation overestimated the severity of stenosis. In con-
rast, patients with severe AS will have a fixed valve area
ith an increase in stroke volume and an increase in
radient. These patients are likely to respond favorably to
urgery. Patients who fail to show an increase in stroke
olume with dobutamine (less than 20%), referred to as
lack of contractile reserve,” appear to have a very poor
rognosis with either medical or surgical therapy (2,148).
obutamine stress testing in patients with AS should be
erformed only in centers with experience in pharmacolog-
cal stress testing and with a cardiologist in attendance.
The clinical approach to the patient with low-output AS
elies on integration of multiple sources of data. In addition
o measurement of Doppler velocity, gradient, and valve
rea, the extent of valve calcification should be assessed.
evere calcification suggests that AVR may be beneficial.
hen transthoracic images are suboptimal, transesophageal
maging or fluoroscopy may be used to assess the degree of
alve calcification and orifice area. The risk of surgery and
atient comorbidities also are taken into account. Although
atients with low-output severe AS have a poor prognosis,
n those with contractile reserve, outcome is still better with
VR than with medical therapy (148). Some patients
ithout contractile reserve may also benefit from AVR, but
ecisions in these high-risk patients must be individualized
ecause there are no data indicating who will have a better
utcome with surgery. a.1.7. Indications for Aortic Valve Replacement
lass I
. AVR is indicated for symptomatic patients with
severe AS.* (Level of Evidence: B)
. AVR is indicated for patients with severe AS* under-
going coronary artery bypass graft surgery (CABG).
(Level of Evidence: C)
. AVR is indicated for patients with severe AS* under-
going surgery on the aorta or other heart valves.
(Level of Evidence: C)
. AVR is recommended for patients with severe AS* and
LV systolic dysfunction (ejection fraction less than
0.50). (Level of Evidence: C)
lass IIa
AVR is reasonable for patients with moderate AS*
undergoing CABG or surgery on the aorta or other
heart valves (see Section 3.7 on combined multiple
valve disease and Section 10.4 on AVR in patients
undergoing CABG). (Level of Evidence: B)
lass IIb
. AVR may be considered for asymptomatic patients
with severe AS* and abnormal response to exercise
(e.g., development of symptoms or asymptomatic
hypotension). (Level of Evidence: C)
. AVRmay be considered for adults with severe asymp-
tomatic AS* if there is a high likelihood of rapid
progression (age, calcification, and CAD) or if sur-
gery might be delayed at the time of symptom onset.
(Level of Evidence: C)
. AVR may be considered in patients undergoing
CABG who have mild AS* when there is evidence,
such as moderate to severe valve calcification, that
progression may be rapid. (Level of Evidence: C)
. AVR may be considered for asymptomatic patients
with extremely severe AS (aortic valve area less than
0.6 cm2, mean gradient greater than 60 mm Hg, and
jet velocity greater than 5.0 m per second) when the
patient’s expected operative mortality is 1.0% or less.
(Level of Evidence: C)
lass III
AVR is not useful for the prevention of sudden death
in asymptomatic patients with AS who have none of
the findings listed under the class IIa/IIb recommen-
dations. (Level of Evidence: B)
See Table 4 (27).
In adults with severe, symptomatic, calcific AS, AVR is
he only effective treatment. Younger patients with congen-
tal or rheumatic AS may be candidates for valvotomy (see
ection 6.1 under management of adolescents and young
dults). Although there is some lack of agreement about the
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesptimal timing of surgery in asymptomatic patients, it is
ossible to develop rational guidelines for most patients. A
roposed management strategy for patients with severe AS
s shown in Figure 3 (149). Particular consideration should
e given to the natural history of asymptomatic patients and
o operative risks and outcomes after surgery. See also
ection 7.2.
.1.7.1. Symptomatic Patients
n symptomatic patients with AS, AVR improves symptoms
nd improves survival (106,150–155). These salutary results
f surgery are partly dependent on LV function. The
utcome is similar in patients with normal LV function and
n those with moderate depression of contractile function.
he depressed ejection fraction in many patients in this
atter group is caused by excessive afterload (afterload
ismatch) (66), and LV function improves after AVR in
uch patients. If LV dysfunction is not caused by afterload
ismatch, survival is still improved, but improvement in LV
unction and resolution of symptoms might not be complete
fter AVR (150,154,156–158). Therefore, in the absence of
erious comorbid conditions, AVR is indicated in virtually
ll symptomatic patients with severe AS. Because of the risk
f sudden death, AVR should be performed promptly after
he onset of symptoms. Age is not a contraindication to
igure 3. Management strategy for patients with severe aortic stenosis. Pr
y age, symptoms, and coronary risk factors. Cardiac catheterization and ang
nd echocardiography. Modified from CM Otto. Valvular aortic stenosis: d
149). AVA indicates aortic valve area; BP, blood pressure; CABG, coronary art
max, maximal velocity across aortic valve by Doppler echocardiography.urgery, with several series showing outcomes similar to
ge-matched normal subjects in the very elderly. The
perative risks can be estimated with readily available and
ell-validated online risk calculators from the Society of
horacic Surgeons (www.sts.org) and the European System
or Cardiac Operative Risk Evaluation (www.euroscore.org)
159–161), as well as the risk calculator developed specifi-
ally for valvular heart surgery by Ambler et al (162).
.1.7.2. Asymptomatic Patients
any clinicians are reluctant to proceed with AVR in an
symptomatic patient (163), whereas others are concerned
bout caring for a patient with severe AS without surgery.
lthough AVR is associated with low perioperative mor-
idity and mortality in many centers, the average perioper-
tive mortality in the STS database is 3.0% to 4.0% for
solated AVR and 5.5% to 6.8% for AVR plus CABG
164,165). These rates are 33% higher in centers with low
olume than in centers with the highest surgical volume
166). A review of Medicare data (167), involving 684 US
ospitals and more than 142 000 patients, indicates that the
verage in-hospital mortality for AVR in patients over the
ge of 65 years is 8.8% (13.0% in low-volume centers and
.0% in high-volume centers). In addition, despite im-
roved longevity of current-generation bioprosthetic valves
ative coronary angiography should be performed routinely as determined
phy may also be helpful when there is discordance between clinical findings
severity and timing of intervention. J Am Coll Cardiol 2006;47:2141–51eoper
iogra
iseaseery bypass graft surgery; echo, echocardiography; LV, left ventricular; and
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ACC/AHA Practice Guidelines August 1, 2006:e1–148168,169), AVR in young patients subjects them to the risks
f structural valve deterioration of bioprostheses (168,170–
74) and the appreciable morbidity and mortality of me-
hanical valves (172,174–178). Thus, the combined risk of
urgery in older patients and the late complications of a
rosthesis in younger patients needs to be balanced against
he possibility of preventing sudden death, which, as noted
bove, occurs at a rate of less than 1.0% per year.
Despite these considerations, some difference of opinion
ersists among clinicians regarding the indications for AVR
n asymptomatic patients with severe AS, because the
robability of remaining free of cardiac symptoms without
urgery is less than 50% at 5 years (61,96,116). Some argue
hat irreversible myocardial depression or fibrosis might
evelop during a prolonged asymptomatic stage and that
his might preclude an optimal outcome. Such irreversibility
as not been proved, but this concept has been used to
upport early surgery (152,179). Still others attempt to
dentify patients who are at especially high risk of sudden
eath without surgery, although data supporting this ap-
roach are limited. Currently, there is general agreement
hat the risk of AVR exceeds any potential benefit in
atients with severe AS who are truly asymptomatic with
ormal LV systolic function. However, as improved valve
ubstitutes are developed and methods of valve replacement
ecome safer, the risk-benefit balance may change to favor
arlier intervention in AS.
Studies suggest that patients at risk of rapid disease
rogression and impending symptom onset can be identified
n the basis of clinical and echocardiographic parameters.
he rate of hemodynamic progression is faster in patients
ith asymptomatic severe (96) or mild to moderate (98) AS
hen patient age is over 50 years and severe valve calcifi-
ation or concurrent CAD is present. Adverse clinical
utcomes are more likely in patients with a more rapid rate
f hemodynamic progression, defined as an annual increase
n aortic jet velocity greater than 0.3 m per second per year
r a decrease in valve area greater than 0.1 cm2 per year
61,96). The presence of left ventricular hypertrophy by
CG and smaller aortic valve area by Doppler echocardi-
graphy predict the development of symptoms (61,116). In
ddition, serum levels of B-type natriuretic peptide may
rovide important prognostic information (180). In situa-
ions in which there is delay between symptom onset and
urgical intervention, patients are at high risk of adverse
utcomes during the waiting period. These higher-risk
atients might warrant more frequent echocardiography or
arlier consideration of valve replacement.
In the 1998 ACC/AHA Guidelines for the Management
f Patients with Valvular Heart Disease, consideration was
iven to performing AVR in patients with AS and severe
V hypertrophy and those with ventricular tachycardia
Class IIb). The current committee determined that there
as insufficient evidence to support those recommenda-
ions, which are not carried forward in the current
ocument. s.1.7.3. Patients Undergoing Coronary Artery Bypass or Other
ardiac Surgery
atients with severe AS, with or without symptoms, who
re undergoing CABG should undergo AVR at the time of
he revascularization procedure. Similarly, patients with
evere AS undergoing surgery on other valves (such as MV
epair) or the aortic root should also undergo AVR as part
f the surgical procedure. In patients with moderate AS, it
s generally accepted practice to perform AVR at the time of
ABG (181–185). Many clinicians also recommend AVR
or moderate AS at the time of MV or aortic root surgery
for further detail, see Section 3.7, “Multiple Valve Dis-
ase”). However, there are no data to support a policy of
VR for mild AS at the time of CABG, with the exception
f those patients with moderate to severe valvular calcifica-
ion (98,181,182,185–187). Recommendations for AVR at
he time of CABG are discussed in Section 10.4.
.1.8. Aortic Balloon Valvotomy
lass IIb
. Aortic balloon valvotomy might be reasonable as a
bridge to surgery in hemodynamically unstable adult
patients with AS who are at high risk for AVR. (Level
of Evidence: C)
. Aortic balloon valvotomy might be reasonable for
palliation in adult patients with AS in whom AVR
cannot be performed because of serious comorbid
conditions. (Level of Evidence: C)
lass III
Aortic balloon valvotomy is not recommended as an
alternative to AVR in adult patients with AS; certain
younger adults without valve calcification may be an
exception (see Section 6.1.3). (Level of Evidence: B)
Percutaneous balloon aortic valvotomy is a procedure
n which 1 or more balloons are placed across a stenotic
alve and inflated to decrease the severity of AS (188 –
90). This procedure has an important role in treating
dolescents and young adults with AS (see Section 6.1.)
ut a very limited role in older adults. The mechanism
nderlying relief of the stenotic lesion in older adults is
racture of calcific deposits within the valve leaflets and,
o a minor degree, stretching of the annulus and separa-
ion of the calcified or fused commissures (191–193).
mmediate hemodynamic results include a moderate
eduction in the transvalvular pressure gradient, but the
ostvalvotomy valve area rarely exceeds 1.0 cm2. Despite
he modest change in valve area, an early symptomatic
mprovement is usually seen. However, serious acute
omplications occur with a frequency greater than 10%
194 –200), and restenosis and clinical deterioration occur
ithin 6 to 12 months in most patients (195,200 –204).
herefore, in adults with AS, balloon valvotomy is not aubstitute for AVR (204 –207).
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesSome clinicians contend that despite the procedural
orbidity and mortality and limited long-term results,
alloon valvotomy can have a temporary role in the man-
gement of some symptomatic patients who are not initially
andidates for AVR (207). For example, patients with
evere AS and refractory pulmonary edema or cardiogenic
hock might benefit from aortic valvuloplasty as a “bridge”
o surgery; an improved hemodynamic state may reduce the
isks of surgery. However, most clinicians recommend
roceeding directly to AVR in these cases. The indications
or palliative valvotomy in patients in whom AVR cannot be
ecommended because of serious comorbid conditions are
ven less well established, with no data to suggest improved
ongevity, although some patients do report a decrease in
ymptoms. Most asymptomatic patients with severe AS
ho require urgent noncardiac surgery can undergo surgery
t a reasonably low risk with monitoring of anesthesia and
ttention to fluid balance (208–212). Balloon aortic valvot-
my is not recommended for these patients. If preoperative
orrection of AS is needed, they should be considered for
VR.
.1.9. Medical Therapy for the Inoperable Patient
omorbid conditions (e.g., malignancy) or, on occasion,
atient preferences might preclude AVR for severe AS.
nder such circumstances, there is no therapy that prolongs
ife, and only limited medical therapies are available to
lleviate symptoms. Patients with evidence of pulmonary
ongestion can benefit from cautious treatment with digi-
alis, diuretics, and angiotensin converting enzyme (ACE)
nhibitors. Indeed, a cautious reduction in central blood
olume and LV preload can be efficacious in some patients
ith heart failure symptoms. It should be recognized,
owever, that excessive preload reduction can depress car-
iac output and reduce systemic arterial pressure; patients
ith severe AS are especially subject to this untoward effect
ue to a small hypertrophied ventricle. In patients with
cute pulmonary edema due to AS, nitroprusside infusion
ay be used to reduce congestion and improve LV perfor-
ance. Such therapy should be performed in an intensive
are unit under the guidance of invasive hemodynamic
onitoring (213). Digitalis should be reserved for patients
ith depressed systolic function or atrial fibrillation. Atrial
brillation and other atrial arrhythmias have an adverse
ffect on atrial pump function and ventricular rate; if prompt
ardioversion is unsuccessful, pharmacological control of the
entricular rate is essential. If angina is the predominant
ymptom, cautious use of nitrates and beta blockers can
rovide relief. There is no specific medical therapy for
yncope unless it is caused by a bradyarrhythmia or tachy-
rrhythmia.
.1.10. Evaluation After Aortic Valve Replacement
onsidering the known complications of prosthetic aortic
alves (168,170–178,214), patients require periodic clinical
nd selected laboratory examinations after AVR. A com- alete history and physical examination should be performed
t least once a year. Indications for echocardiography are
iscussed in Section 9.3.
.1.11. Special Considerations in the Elderly
ecause there is no effective medical therapy and balloon
alvotomy is not an acceptable alternative to surgery, AVR
ust be considered in all elderly patients who have symp-
oms caused by AS. Valve replacement is technically possi-
le at any age (215), but the decision to proceed with such
urgery depends on many factors, including the patient’s
ishes and expectations. Older patients with symptoms due
o severe AS, normal coronary arteries, and preserved LV
unction can expect a better outcome than those with CAD
r LV dysfunction (110). Certainly advanced cancer and
ermanent neurological defects as a result of stroke or
ementia make cardiac surgery inappropriate. Decondi-
ioned and debilitated patients often do not return to an
ctive existence, and the presence of the other comorbid
isorders could have a major impact on outcome.
In addition to the confounding effects of CAD and the
otential for stroke, other considerations are peculiar to
lder patients. For example, a narrow LV outflow tract and
small aortic annulus sometimes present in elderly women
ould require enlargement of the annulus. Heavy calcifica-
ion of the valve, annulus, and aortic root may require
ebridement. Occasionally, a composite valve-aortic graft is
eeded. Likewise, excessive or inappropriate hypertrophy
ssociated with valvular stenosis can be a marker for peri-
perative morbidity and mortality (81,83). Preoperative
ecognition of elderly patients with marked LV hypertrophy
ollowed by appropriate perioperative management can
educe this morbidity and mortality substantially. There is
o perfect method for weighing all of the relevant factors
nd identifying specifically high- and low-risk elderly pa-
ients, but this risk can be estimated well in individual
atients (159–162,216). The decision to proceed with AVR
epends on an imprecise analysis that considers the balance
etween the potential for improved symptoms and survival
nd the morbidity and mortality of surgery (217–219).
.2. Aortic Regurgitation
.2.1. Etiology
here are a number of common causes of AR. These
nclude idiopathic dilatation of the aorta, congenital abnor-
alities of the aortic valve (most notably bicuspid valves),
alcific degeneration, rheumatic disease, infective endocar-
itis, systemic hypertension, myxomatous degeneration, dis-
ection of the ascending aorta, and Marfan syndrome. Less
ommon causes include traumatic injuries to the aortic
alve, ankylosing spondylitis, syphilitic aortitis, rheumatoid
rthritis, osteogenesis imperfecta, giant cell aortitis, Ehlers-
anlos syndrome, Reiter’s syndrome, discrete subaortic
tenosis, and ventricular septal defects with prolapse of an
ortic cusp. Recently, anorectic drugs have also been re-
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ACC/AHA Practice Guidelines August 1, 2006:e1–148orted to cause AR (see Section 3.9.). The majority of these
esions produce chronic AR with slow, insidious LV dilation
nd a prolonged asymptomatic phase (Table 4) (27). Other
esions, in particular infective endocarditis, aortic dissection,
nd trauma, more often produce acute severe AR, which can
esult in sudden catastrophic elevation of LV filling pres-
ures and reduction in cardiac output.
.2.2. Acute Aortic Regurgitation
.2.2.1. Pathophysiology
n acute severe AR, the sudden large regurgitant volume is
mposed on a left ventricle of normal size that has not had time
o accommodate the volume overload. With an abrupt increase
n end-diastolic volume, the ventricle operates on the steep
ortion of a normal diastolic pressure-volume relationship, and
V end-diastolic and left atrial pressures may increase rapidly
nd dramatically. The Frank-Starling mechanism is used, but
he inability of the ventricle to develop compensatory chamber
ilatation acutely results in a decrease in forward stroke
olume. Although tachycardia develops as a compensatory
echanism to maintain cardiac output, this is often insuffi-
ient. Hence, patients frequently present with pulmonary
dema or cardiogenic shock. Acute AR creates especially
arked hemodynamic changes in patients with pre-existing
ressure overload hypertrophy, in whom the small, noncom-
liant LV cavity is set on an even steeper diastolic pressure-
olume relationship and has reduced preload reserve. Examples
f this latter situation include aortic dissection in patients with
ystemic hypertension, infective endocarditis in patients with
re-existing AS, and acute regurgitation after balloon valvot-
my or surgical commissurotomy for congenital AS. Patients
ay also present with signs and symptoms of myocardial
schemia. As the LV end-diastolic pressure approaches the
iastolic aortic and coronary artery pressures, myocardial per-
usion pressure in the subendocardium is diminished. LV
ilation and thinning of the LV wall result in increased
fterload, and this combines with tachycardia to increase
yocardial oxygen demand. Therefore, ischemia and its con-
equences, including sudden death, occur commonly in acute
evere AR.
.2.2.2. Diagnosis
any of the characteristic physical findings of chronic AR
re modified or absent when valvular regurgitation is acute,
hich can lead to underestimation of its severity. LV size
ay be normal on physical examination, and cardiomegaly
ay be absent on chest X-ray. Pulse pressure may not be
ncreased because systolic pressure is reduced and the aortic
iastolic pressure equilibrates with the elevated LV diastolic
ressure. Because this diastolic pressure equilibration be-
ween aorta and ventricle can occur before the end of
iastole, the diastolic murmur may be short and/or soft and
herefore poorly heard. The elevated LV diastolic pressure
an close the MV prematurely, reducing the intensity of the
rst heart sound. An apical diastolic rumble can be present, eut it is usually brief and without presystolic accentuation.
achycardia is invariably present.
Echocardiography is indispensable in confirming the
resence and severity of the valvular regurgitation, deter-
ining its cause, estimating the degree of pulmonary
ypertension (if TR is present), and determining whether
here is rapid equilibration of aortic and LV diastolic
ressure. Evidence for rapid pressure equilibration includes
short AR diastolic half-time (less than 300 ms), a short
itral deceleration time (less than 150 ms), or premature
losure of the MV.
Acute AR caused by aortic root dissection is a surgical
mergency that requires particularly prompt identification and
anagement. Transesophageal echocardiography is indicated
hen aortic dissection is suspected (220–222). In some set-
ings, computed tomographic imaging or magnetic resonance
maging should be performed if this will lead to a more rapid
iagnosis than can be achieved by transesophageal echocardi-
graphy (220,221,223). Cardiac catheterization, aortography,
nd coronary angiography are rarely required, are associated
ith increased risk, and might delay urgent surgery unneces-
arily (221,224–227). Angiography should be considered only
hen the diagnosis cannot be determined by noninvasive
maging and when patients have known CAD, especially those
ith previous CABG (see Section 10.2).
.2.2.3. Treatment
eath due to pulmonary edema, ventricular arrhythmias,
lectromechanical dissociation, or circulatory collapse is
ommon in acute severe AR, even with intensive medical
anagement. Urgent surgical intervention is recommended.
itroprusside, and possibly inotropic agents such as dopa-
ine or dobutamine to augment forward flow and reduce
V end-diastolic pressure, may be helpful to manage the
atient temporarily before surgery. Intra-aortic balloon
ounterpulsation is contraindicated. Although beta blockers
re often used in treating aortic dissection, these agents
hould be used very cautiously, if at all, in the setting of
cute AR because they will block the compensatory tachy-
ardia. In patients with acute severe AR resulting from
nfective endocarditis, surgery should not be delayed, espe-
ially if there is hypotension, pulmonary edema, or evidence
f low output. In patients with mild acute AR, antibiotic
reatment may be all that is necessary if the patient is
emodynamically stable. Exceptions to this latter recom-
endation are discussed in Section 4.6.1.
.2.3. Chronic Aortic Regurgitation
.2.3.1. Pathophysiology
he left ventricle responds to the volume load of chronic
R with a series of compensatory mechanisms, including an
ncrease in end-diastolic volume, an increase in chamber
ompliance that accommodates the increased volume with-
ut an increase in filling pressures, and a combination of
ccentric and concentric hypertrophy. The greater diastolic
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesolume permits the ventricle to eject a large total stroke
olume to maintain forward stroke volume in the normal
ange. This is accomplished through rearrangement of
yocardial fibers with the addition of new sarcomeres and
evelopment of eccentric LV hypertrophy (228). As a result,
reload at the sarcomere level remains normal or near
ormal, and the ventricle retains its preload reserve. The
nhanced total stroke volume is achieved through normal
erformance of each contractile unit along the enlarged
ircumference (229). Thus, LV ejection performance is
ormal, and ejection phase indexes such as ejection fraction
nd fractional shortening remain in the normal range.
owever, the enlarged chamber size, with the associated
ncrease in systolic wall stress, also results in an increase in
V afterload and is a stimulus for further hypertrophy
228,230). Thus, AR represents a condition of combined
olume overload and pressure overload (231). As the disease
rogresses, recruitment of preload reserve and compensatory
ypertrophy permit the ventricle to maintain normal ejec-
ion performance despite the elevated afterload (232,233).
he majority of patients remain asymptomatic throughout
his compensated phase, which may last for decades. Vaso-
ilator therapy has the potential to reduce the hemodynamic
urden in such patients.
For purposes of the subsequent discussion, patients
ith normal LV systolic function will be defined as those
ith normal LV ejection fraction at rest. It is recognized
hat other indices of LV function may not be “normal” in
hronic severe AR and that the hemodynamic abnormal-
ties noted above may be considerable. It is also recog-
ized that the transition to LV systolic dysfunction
epresents a continuum and that there is no single
emodynamic measurement that represents the absolute
oundary between normal LV systolic function and LV
ystolic dysfunction.
In a large subset of patients, the balance between after-
oad excess, preload reserve, and hypertrophy cannot be
aintained indefinitely. Preload reserve may be exhausted
233), and/or the hypertrophic response may be inadequate
63), so that further increases in afterload result in a
eduction in ejection fraction, first into the low normal
ange and then below normal. Impaired myocardial contrac-
ility may also contribute to this process. Patients often
evelop dyspnea at this point in the natural history. In
ddition, diminished coronary flow reserve in the hypertro-
hied myocardium may result in exertional angina (234).
owever, this transition may be much more insidious, and
t is possible for patients to remain asymptomatic until
evere LV dysfunction has developed.
LV systolic dysfunction (defined as an ejection fraction
elow normal at rest) is initially a reversible phenomenon
elated predominantly to afterload excess, and full recov-
ry of LV size and function is possible with AVR
235–246). With time, during which the ventricle devel-
ps progressive chamber enlargement and a more spher-
cal geometry, depressed myocardial contractility pre- 1ominates over excessive loading as the cause of
rogressive systolic dysfunction. This can progress to the
xtent that the full benefit of surgical correction of the
egurgitant lesion, in terms of recovery of LV function
nd improved survival, can no longer be achieved
244,247–256).
A large number of studies have identified LV systolic
unction and end-systolic size as the most important determi-
ants of survival and postoperative LV function in patients
ndergoing AVR for chronic AR (235,237–267). Studies of
redictors of surgical outcome are listed in Table 13.
Among patients undergoing valve replacement for
hronic AR with preoperative LV systolic dysfunction
defined as an ejection fraction below normal at rest), several
actors are associated with worse functional and survival
esults after operation. These are listed in Table 14.
.2.3.2. Natural History
.2.3.2.1. ASYMPTOMATIC PATIENTS WITH NORMAL LEFT
ENTRICULAR FUNCTION. There are no truly large-scale
tudies evaluating the natural history of asymptomatic
atients in whom LV systolic function was known to be
ormal (as determined by invasive or noninvasive testing).
he current recommendations are derived from 9 published
eries (268–277) involving a total of 593 such patients
range, 27 to 104 patients/series) with a mean follow-up
eriod of 6.6 years (Table 15). This analysis is subject to the
sual limitations of comparisons of different clinical series
ith different patient selection factors and different end
oints. For example, 1 series (270) represents patients
eceiving placebo in a randomized drug trial (278) that
ncluded some patients with “early” New York Heart Asso-
iation (NYHA) functional class II symptoms (although
one had “limiting” symptoms), and another (272) repre-
ents patients receiving digoxin in a long-term study com-
aring the effects of nifedipine with digoxin. In 2 studies
274,276), LV function was not reported in all patients, and
t is unclear whether all had normal LV systolic function at
aseline. In another study (275), 20% of patients were not
symptomatic but had “early” NYHA functional class II
ymptoms, and the presence of these symptoms was a
ignificant predictor of death, LV dysfunction, or develop-
ent of more severe symptoms. Some patients in this latter
eries had evidence of LV systolic dysfunction (fractional
hortening as low as 18%).
The results of these 9 studies are summarized in Tables
5 and 16. The rate of progression to symptoms and/or LV
ystolic dysfunction averaged 4.3% per year. Sudden death
ccurred in 7 of the 593 patients, for an average mortality
ate of less than 0.2% per year. Seven of the 9 studies
eported the rate of development of asymptomatic LV
ysfunction, defined as an ejection fraction at rest below
ormal (269–273,275,276); 37 of a total of 535 patients
eveloped depressed systolic function at rest without symp-
oms during a mean 5.9-year follow-up period, a rate of
.2% per year.
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ACC/AHA Practice Guidelines August 1, 2006:e1–148able 13. Preoperative Predictors of Surgical Outcome in Aortic Regurgitation
Study, Year
Study
Design
No. of
Patients Outcome Assessed Findings
orman et al., 1980 (251) Retrospective 90 Survival High-risk group identified by preoperative angiographic
LV EF less than 0.50
enry et al., 1980 (257) Prospective 50 Survival High-risk group identified by preoperative
echocardiographic LV FS less than 0.25 and/or ESD
greater than 55 mm.
unha et al., 1980 (250) Retrospective 86 Survival High-risk group identified by preoperative
echocardiographic LV FS less than 0.30. Mortality
also significantly associated with preoperative ESD.
Among patients with FS less than 0.30, mortality
higher in NYHA FC III–IV than in FC I–II.
reves et al., 1981 (252) Retrospective 45 Survival High-risk group identified by preoperative angiographic
LV EF less than 0.45 and/or CI less than 2.5
L/mm. Among patients with EF less than 0.45,
mortality higher in NYHA FC III–IV than in
FC I–II.
umpuris et al., 1982 (258) Prospective 43 Survival, heart failure,
LV function
Persistent LV dilatation after AVR predicted by
preoperative echocardiographic LV ESD,
radius/thickness mean and end-systolic wall stress.
All deaths occurred in patients with persistent LV
dilatation.
aasch et al., 1983 (253) Prospective 32 Symptoms, LV
function
Persistent LV dilatation after AVR predicted by
echocardiographic LV ESD greater than 2.6 cm/m2
and radius/thickness ratio greater than 3.8. Trend
toward worse survival in patients with persistent
LV dilatation.
ioretti et al., 1983 (259) Retrospective 47 LV function Persistent LV dysfunction predicted by preoperative
EDD 75 mm or greater and/or ESD 55 mm or
greater.
tone et al., 1984 (260) Prospective 113 LV function Normal LV function after AVR predicted by
preoperative LV FS greater than 0.26, ESD less than
55 mm, and EDD less than 80 mm. No preoperative
variable predicted postoperative LV function.
onow et al., 1985, 1988 (254,245) Prospective 80 Survival, LV function Postoperative survival and LV function predicted by
preoperative LV EF, FS, and ESD. High-risk group
identified by subnormal EF at rest. Among patients
with subnormal EF, poor exercise tolerance and
prolonged duration of LV dysfunction identified the
group at highest risk.
aniel et al., 1985 (261) Retrospective 84 Survival, symptoms,
LV function
Outcome after AVR predicted by preoperative LV FS
and ESD. Survival at 2.5 years was 90.5% with FS
greater than 0.25 and ESD 55 mm or less but only
70% with ESD greater than 55 mm and FS 25% or
less.
ormier et al., 1986 (262) Prospective 73 Survival High-risk group identified by preoperative LV EF less
than 0.40 and ESD 55 mm or greater.
heiban et al., 1986 (263) Retrospective 84 Survival High-risk group identified by preoperative LV EF less
than 0.50 and ESD greater than 55 mm.
arabello et al., 1987 (243) Retrospective 14 LV function Postoperative LV EF predicted by preoperative ESD,
FS, EDD, and radius/thickness ratio.
aniguchi et al., 1987 (244) Retrospective 62 Survival High-risk group identified by preoperative ESV greater
than 200 ml/m2 and/or EF less than 0.40.
ichel et al., 1995 (256) Retrospective 286 LV function Postoperative LV dysfunction predicted by preoperative
LV EF, FS, ESD, and EDD.
lodas et al., 1996, 1997 (264,265) Retrospective 289 Survival High-risk group identified by symptom severity and
preoperative EF less than 0.50.
urina et al., 1998 (266) Retrospective 192 Survival High-risk group identified by symptom severity, low
EF, and elevated end-diastolic volume.
ornos et al., 2006 (267) Prospective 170 Survival High-risk identified by symptom severity, low EF and
elevated EDD and ESD.VR indicates aortic valve replacement; CI, cardiac index; EDD, end-diastolic dimension; EF, ejection fraction; ESD, end-systolic dimension; ESV, end-systolic volume; FC,
unctional class; FS, fractional shortening; LV, left ventricular; and NYHA, New York Heart Association.
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesDespite the low likelihood of patients developing asymp-
omatic LV dysfunction, it should also be emphasized that
ore than one fourth of patients who die or develop systolic
ysfunction do so before the onset of warning symptoms
269–271,275). Thus, thorough questioning of patients
egarding symptomatic status is not sufficient in the serial
valuation of asymptomatic patients; quantitative evaluation
f LV function is also indispensable. Moreover, patients at
isk of future symptoms, death, or LV dysfunction can also
e identified on the basis of noninvasive testing. Five of the
able 14. Factors Predictive of Reduced Postoperative Survival
nd Recovery of Left Ventricular Function in Patients With
ortic Regurgitation and Preoperative Left Ventricular Systolic
ysfunction
Severity of preoperative symptoms or reduced exercise tolerance
Severity of depression of left ventricular ejection fraction
Duration of preoperative left ventricular systolic dysfunction
able 15. Studies of the Natural History of Asymptomatic Patien
Study, Year
No. of
Patients
Mean
Follow-
Up, y
Progression
to Symptoms,
Death, or LV
Dysfunction,
Rate per y
(%)
onow et al., 1983, 1991
(268,271)
104 8.0 3.8
cognamiglio et al., 1986*
(269)
30 4.7 2.1
iemienczuk et al., 1989
(270)
50 3.7 4.0
cognamiglio et al., 1994*
(272)
74 6.0 5.7
ornos et al., 1995
(273)
101 4.6 3.0
shii et al., 1996
(274)
27 14.2 3.6
orer et al., 1998
(275)
104 7.3 6.2
arasoutchi et al., 2003
(276)
72 10 4.7
vangelista et al., 2005
(277)
31 7 3.6
verage 593 6.6 4.3
dash indicates that data were not available. *Two studies by the same authors inv
BP indicates blood pressure; EDD, end-diastolic dimension; EDV, end-diastolic volume;
unctional class; FS, fractional shortening; LV, left ventricular; NYHA, New York Heart Aatural history studies provide concordant information on
he variables associated with higher risk (270–272,275,276).
hese variables are age, LV end-systolic dimension (or
olume), LV end-diastolic dimension (or volume), and the
V ejection fraction during exercise. In 1 study (275), the
V ejection fraction during exercise was an independent risk
actor. However, the direction and magnitude of change in
jection fraction from rest to exercise is related not only to
yocardial contractility (279) but also to severity of volume
verload (271,278–280) and exercise-induced changes in
reload and peripheral resistance (280). In 2 multivariate
nalyses (271,276), only age and end-systolic dimension on
nitial study were independent predictors of outcome, as
ere the rate of increase in end-systolic dimension and
ecrease in resting ejection fraction during serial longitudi-
al studies (271). During a mean follow-up period of 8
ears, patients with initial end-systolic dimensions greater
ith Aortic Regurgitation
gression to
ymptomatic
Dysfunction
Mortality,
No. of
Patients Comments
Rate per
y (%)
0.5 2 Outcome predicted by LV ESD, EDD
change in EF with exercise, and rat
of change in ESD and EF at rest
with time
2.1 0 3 patients who developed asymptomat
LV dysfunction initially had lower
PAP/ESV ratios and trended towar
higher LV ESD and EDD and low
FS
0.5 0 Patients included those receiving
placebo and medical dropouts in a
randomized drug trial; included som
patients with NYHA FC II
symptoms; outcome predicted by L
ESV, EDV, change in EF with
exercise, and end-systolic wall stress
3.4 0 All patients received digoxin as part o
a randomized trial
1.3 0 Outcome predicted by pulse pressure,
LV ESD, EDD, and EF at least
— 0 Development of symptoms predicted
systolic BP, LV ESD, EDD, mass
index, and wall thickness. LV
function not reported in all patients
0.9 4 20% Of patients in NYHA FC II;
outcome predicted by initial FC II
symptoms, change in LV EF with
exercise, LV ESD, and LV FS
0.1 0 Development of symptoms predicted
LV ESD and EDD. LV function
not reported in all patients
— 1 Placebo control group in 7-year
vasodilator clinical trial
1.2 0.18% per y
eparate patient groups.ts W
Pro
As
LV
n
4
3
1
15
6
—
7
1
—
37
olved s
EF, ejection fraction; ESD, end-systolic dimension; ESV, end-systolic volume; FC,
ssociation; and PAP, pulmonary artery pressure.
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ACC/AHA Practice Guidelines August 1, 2006:e1–148han 50 mm had a likelihood of death, symptoms, and/or
V dysfunction of 19% per year. In those with end-systolic
imensions of 40 to 50 mm, the likelihood was 6% per year,
nd when the dimension was less than 40 mm, it was zero
271).
.2.3.2.2. ASYMPTOMATIC PATIENTS WITH DEPRESSED SYS-
OLIC FUNCTION. The limited data in asymptomatic patients
ith depressed LV ejection fraction indicate that the majority
evelop symptoms that warrant AVR within 2 to 3 years
281–283). The average rate of symptom onset in such patients
s greater than 25% per year (Table 16) (268–277,281–288).
.2.3.2.3. SYMPTOMATIC PATIENTS. There are no contem-
orary large-scale studies of the natural history of symptom-
tic patients with chronic AR, because the onset of angina
r significant dyspnea is usually an indication for valve
eplacement. The data developed in the presurgical era
ndicate that patients with dyspnea, angina, or overt heart
ailure have a poor outcome with medical therapy, analo-
ous to that of patients with symptomatic AS. Mortality
ates of greater than 10% per year have been reported in
atients with angina pectoris and greater than 20% per year
n those with heart failure (284–286). LV function was not
easured in these patients, so it is unclear whether symp-
omatic patients with normal ejection fractions have the
ame adverse outcome as symptomatic patients with LV
ysfunction; however, subsequent data indicate a poor
utcome for symptomatic patients with medical therapy,
ven among those with preserved LV systolic function
274,287,288).
.2.3.3. Diagnosis and Initial Evaluation
lass I
. Echocardiography is indicated to confirm the pres-
ence and severity of acute or chronic AR. (Level of
Evidence: B)
. Echocardiography is indicated for diagnosis and as-
sessment of the cause of chronic AR (including valve
morphology and aortic root size and morphology)
and for assessment of LV hypertrophy, dimension (or
volume), and systolic function. (Level of Evidence: B)
. Echocardiography is indicated in patients with an
enlarged aortic root to assess regurgitation and the
severity of aortic dilatation. (Level of Evidence: B)
. Echocardiography is indicated for the periodic re-
evaluation of LV size and function in asymptomatic
patients with severe AR. (Level of Evidence: B)
. Radionuclide angiography or magnetic resonance
imaging is indicated for the initial and serial assess-
ment of LV volume and function at rest in patients
with AR and suboptimal echocardiograms. (Level of
Evidence: B) v. Echocardiography is indicated to re-evaluate mild,
moderate, or severe AR in patients with new or
changing symptoms. (Level of Evidence: B)
lass IIa
. Exercise stress testing for chronic AR is reasonable
for assessment of functional capacity and symptom-
atic response in patients with a history of equivocal
symptoms. (Level of Evidence: B)
. Exercise stress testing for patients with chronic AR is
reasonable for the evaluation of symptoms and func-
tional capacity before participation in athletic activ-
ities. (Level of Evidence: C)
. Magnetic resonance imaging is reasonable for the
estimation of AR severity in patients with unsatisfac-
tory echocardiograms. (Level of Evidence: B)
lass IIb
Exercise stress testing in patients with radionuclide
angiography may be considered for assessment of LV
function in asymptomatic or symptomatic patients
with chronic AR. (Level of Evidence: B)
The diagnosis of chronic severe AR can usually be made
n the basis of the diastolic murmur, displaced LV impulse,
ide pulse pressure, and characteristic peripheral findings
hat reflect wide pulse pressure. A third heart sound is often
eard as a manifestation of the volume load and is not
ecessarily an indication of heart failure. An Austin-Flint
umble is a specific finding for severe AR (289,290). In
any patients with more mild to moderate AR, the physical
xamination will identify the regurgitant lesion but will be
ess accurate in determining its severity. When the diastolic
urmur of AR is louder in the third and fourth right
ntercostal spaces than in the third and fourth left intercostal
paces, the AR likely results from aortic root dilatation
ather than from a deformity of the leaflets alone (291). The
hest X-ray and ECG are helpful in evaluating overall heart
ize and rhythm, evidence of LV hypertrophy, and evidence
f conduction disorders.
Echocardiography is indicated
to confirm the diagnosis of AR if there is an equivocal
diagnosis based on physical examination
to assess the cause of AR and to assess valve morphology
to provide a semiquantitative estimate of the severity of
AR
to assess LV dimension, mass, and systolic function
to assess aortic root size.
In asymptomatic patients with preserved systolic func-
ion, these initial measurements represent the baseline
nformation with which future serial measurements can be
ompared. In addition to semiquantitative assessment of the
everity of AR by color flow jet area and width by Doppler
chocardiography, quantitative measurement of regurgitant
olume, regurgitant fraction, and regurgitant orifice area can
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinese performed in experienced laboratories (Table 4) (27).
ndirect measures of severity of AR are helpful, using the
ate of decline in regurgitant gradient measured by the slope
f diastolic flow velocity, the degree of reversal in pulse wave
elocity in the descending aorta, and the magnitude of LV
utflow tract velocity (2,292,293). Comparison of stroke
olumes at the aortic valve compared with another unin-
olved valve may provide a quantitative measurement of
egurgitant fraction (294), but this measurement is more
echnically demanding.
LV wall stress may also be estimated from blood pressure
nd echocardiographic measurements. However, such wall
tress measurements are difficult to reproduce, have meth-
dological and conceptual problems, and should not be used
or diagnosis or management decision making in clinical
ractice.
For purposes of the subsequent discussion of manage-
ent of patients with AR, severe AR is defined as clinical
nd Doppler evidence of severe regurgitation (Table 4) (27)
n addition to LV cavity dilatation. If the patient is
symptomatic and leads an active lifestyle and the echocar-
iogram is of good quality, no other testing is necessary. If
he patient has severe AR and is sedentary or has equivocal
ymptoms, exercise testing is helpful to assess functional
apacity, symptomatic responses, and hemodynamic effects
f exercise (Fig. 4). If the echocardiogram is of insufficient
uality to assess LV function, radionuclide angiography or
ardiac magnetic resonance should be used in asymptomatic
atients to measure LV ejection fraction at rest and estimate
V volumes. In patients who are symptomatic on initial
valuation, it is reasonable to proceed directly to transesoph-
geal echocardiography or cardiac catheterization and an-
iography if the echocardiogram is of insufficient quality to
ssess LV function or severity of AR.
The exercise ejection fraction and the change in ejection
raction from rest to exercise are often abnormal, even in
symptomatic patients (268,270 –272,275,283,295–303);
owever, these have not been proved to have independent
iagnostic or prognostic value when LV function at rest and
everity of LV volume overload by echocardiography are
lready known. One study that did identify the LV ejection
raction response to exercise as a predictor of symptomatic
eterioration or LV dysfunction (275) included many pa-
ients with NYHA functional class II symptoms, LV
ystolic dysfunction (fractional shortening as low as 18%),
Table 16. Natural History of Aortic Regurgita
Asymptomatic patients with normal LV systolic func
Progression to symptoms and/or LV dysfunction
Progression to asymptomatic LV dysfunction
Sudden death
Asymptomatic patients with LV dysfunction (281–2
Progression to cardiac symptoms
Symptomatic patients (284–288)
Mortality rate
LV indicates left ventricular.nd severe LV dilatation (end-diastolic and end-systolic Timensions as high as 87 and 65 mm, respectively). Hence,
he predictive nature of this response in asymptomatic
atients with normal LV systolic function and without
evere LV dilatation has not been fully demonstrated.
.2.3.4. Medical Therapy
lass I
Vasodilator therapy is indicated for chronic therapy
in patients with severe AR who have symptoms or LV
dysfunction when surgery is not recommended be-
cause of additional cardiac or noncardiac factors.
(Level of Evidence: B)
lass IIa
Vasodilator therapy is reasonable for short-term ther-
apy to improve the hemodynamic profile of patients
with severe heart failure symptoms and severe LV
dysfunction before proceeding with AVR. (Level of
Evidence: C)
lass IIb
Vasodilator therapy may be considered for long-term
therapy in asymptomatic patients with severe AR
who have LV dilatation but normal systolic function.
(Level of Evidence: B)
lass III
. Vasodilator therapy is not indicated for long-term
therapy in asymptomatic patients with mild to mod-
erate AR and normal LV systolic function. (Level of
Evidence: B)
. Vasodilator therapy is not indicated for long-term
therapy in asymptomatic patients with LV systolic
dysfunction who are otherwise candidates for AVR.
(Level of Evidence: C)
. Vasodilator therapy is not indicated for long-term
therapy in symptomatic patients with either normal
LV function or mild to moderate LV systolic dys-
function who are otherwise candidates for AVR.
(Level of Evidence: C)
Therapy with vasodilating agents is designed to improve
orward stroke volume and reduce regurgitant volume.
(268–277)
Less than 6% per y
Less than 3.5% per y
Less than 0.2% per y
Greater than 25% per y
Greater than 10% per ytion
tion
83)hese effects should translate into reductions in LV end-
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ACC/AHA Practice Guidelines August 1, 2006:e1–148iastolic volume, wall stress, and afterload, resulting in
reservation of LV systolic function and reduction in LV
ass. The acute administration of sodium nitroprusside,
ydralazine, nifedipine, or felodipine reduces peripheral
ascular resistance and results in an immediate augmenta-
ion in forward cardiac output and a decrease in regurgitant
olume (304–313). With nitroprusside and hydralazine,
hese acute hemodynamic changes lead to a consistent
eduction in end-diastolic volume and an increase in ejec-
ion fraction (304–306,312). This is an inconsistent finding
ith a single oral dose of nifedipine (308–311). Reduced
nd-diastolic volume and increased ejection fraction have
lso been observed in small numbers of patients receiving
ong-term oral therapy with hydralazine and nifedipine for
igure 4. Management strategy for patients with chronic severe aortic regu
etermined by age, symptoms, and coronary risk factors. Cardiac catheteri
linical findings and echocardiography. “Stable” refers to stable echocardiog
adionuclide ventriculography (RVG) or magnetic resonance imaging (MR
nd systolic function. AVR indicates aortic valve replacement; DD, end-d
imension.eriods of 1 to 2 years (278,314); with nifedipine, these pffects are associated with a reduction in LV mass (272,314).
ess consistent results have been reported with ACE
nhibitors, depending on the degree of reduction in arterial
ressure and end-diastolic volume (315–317). Reduced
lood pressure with enalapril and quinapril has been asso-
iated with decreases in end-diastolic volume and mass but
o change in ejection fraction (316,317).
There are 3 potential uses of vasodilating agents in
hronic AR. It should be emphasized that these criteria
pply only to patients with severe AR. The first is long-term
reatment of patients with severe AR who have symptoms
nd/or LV dysfunction who are considered poor candidates
or surgery because of additional cardiac or noncardiac
actors. The second is improvement in the hemodynamic
tion. Preoperative coronary angiography should be performed routinely as
and angiography may also be helpful when there is discordance between
c measurements. In some centers, serial follow-up may be performed with
ther than echocardiography (Echo) to assess left ventricular (LV) volume
c dimension; EF, ejection fraction; eval, evaluation; and SD, end-systolicrgita
zation
raphi
I) ra
iastolirofile of patients with severe heart failure symptoms and
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesevere LV dysfunction with short-term vasodilator therapy
efore proceeding with AVR. In such patients, vasodilating
gents with negative inotropic effects should be avoided.
he third is prolongation of the compensated phase of
symptomatic patients who have volume-loaded left ventri-
les but normal systolic function.
Whether this latter effect can be achieved has been
nvestigated in only 2 studies. The first study compared
ong-acting nifedipine versus digoxin in a prospective ran-
omized trial (272). Over a 6-year period, fewer patients
andomized to nifedipine required AVR because of symp-
oms or development of LV dysfunction (ejection fraction
ess than 0.50). This study enrolled a relatively small
umber of patients (143 patients); there were relatively few
nd points (20 patients in the digoxin group and 6 in the
ifedipine group underwent AVR); and there was no
lacebo control group. A more recent study compared
lacebo, long-acting nifedipine, and enalapril in 95 consec-
tive patients, who were followed for 7 years (277). Neither
ifedipine nor enalapril reduced the development of symp-
oms or LV dysfunction warranting AVR compared with
lacebo. Moreover, neither drug significantly altered LV
imension, ejection fraction, or mass over the course of time
ompared with placebo. Thus, definitive recommendations
egarding the indications for long-acting nifedipine or ACE
nhibitors cannot be made at this time.
If vasodilator therapy is used, the goal is to reduce systolic
lood pressure, and drug dosage should be increased until
here is a measurable decrease in systolic blood pressure or
he patient develops side effects. It is rarely possible to
ecrease systolic blood pressure to normal because of the
ncreased LV stroke volume, and drug dosage should not be
ncreased excessively in an attempt to achieve this goal.
asodilator therapy is of unknown benefit and is not
ndicated in patients with normal blood pressure or normal
V cavity size.
Vasodilator therapy is not recommended for asymptom-
tic patients with mild or moderate AR and normal LV
unction in the absence of systemic hypertension, because
hese patients have an excellent outcome with no therapy. In
atients with severe AR, vasodilator therapy is not an
lternative to surgery in asymptomatic or symptomatic
atients with LV systolic dysfunction; such patients should
e considered surgical candidates rather than candidates for
ong-term medical therapy unless AVR is not recommended
ecause of additional cardiac or noncardiac factors. Whether
ymptomatic patients who have preserved systolic function
an be treated safely with aggressive medical management
nd whether aggressive medical management is as good or
etter than AVR have not been determined. It is recom-
ended that symptomatic patients undergo surgery rather
han long-term medical therapy.
There is scant information about long-term therapy with
rugs other than vasodilators in asymptomatic patients with
evere AR and normal LV function. Thus, there are no data
o support the long-term use of digoxin, diuretics, nitrates, sr positive inotropic agents in asymptomatic patients and no
ata with regard to any drug in patients with mild or
oderate AR.
.2.3.5. Physical Activity and Exercise
here are no data suggesting that exercise, particularly
trenuous periodic exercise, will contribute to or accelerate
he progression of LV dysfunction in AR. Asymptomatic
atients with normal LV systolic function may participate in
ll forms of normal daily physical activity, including mild
orms of exercise and in some cases competitive athletics.
sometric exercise should be avoided. Recommendations
egarding participation in competitive athletics were pub-
ished by the Task Force on Acquired Valvular Heart
isease of the 36th Bethesda Conference (138). Before
articipation in athletics, exercise testing to at least the level
f exercise required by the proposed activity is recom-
ended so that the patient’s tolerance for this degree of
xercise can be evaluated. This does not necessarily evaluate
he long-term effects of strenuous exercise, which are
nknown.
.2.3.6. Serial Testing
he aim of serial evaluation of asymptomatic patients
ith chronic AR is to detect the onset of symptoms and
bjectively assess changes in LV size and function that
an occur in the absence of symptoms. In general, the
tability and chronicity of the regurgitant lesion and the
V response to volume load need to be established when
he patient first presents to the physician, especially if AR
s moderate to severe. If the chronic nature of the lesion
s uncertain and the patient does not present initially with
ne of the indications for surgery, repeat physical exam-
nation and echocardiography should be performed
ithin 2 to 3 months after the initial evaluation to ensure
hat a subacute process with rapid progression is not
nder way. Once the chronicity and stability of the
rocess has been established, the frequency of clinical
e-evaluation and repeat noninvasive testing depends on
he severity of the valvular regurgitation, the degree of
V dilatation, the level of systolic function, and whether
revious serial studies have revealed progressive changes
n LV size or function (Fig. 4). In most patients, serial
esting during the long-term follow-up period should
nclude a detailed history, physical examination, and
chocardiography. Serial chest X-rays and ECGs have
ess value but are helpful in selected patients.
Asymptomatic patients with mild AR, little or no LV
ilatation, and normal LV systolic function can be seen on
yearly basis, with instructions to alert the physician if
ymptoms develop in the interim. Yearly echocardiography
s not necessary unless there is clinical evidence that regur-
itation has worsened. Routine echocardiography can be
erformed every 2 to 3 years in such patients.
Asymptomatic patients with normal systolic function butevere AR and significant LV dilatation (end-diastolic
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ACC/AHA Practice Guidelines August 1, 2006:e1–148imension greater than 60 mm) require more frequent and
areful re-evaluation, with a history and physical examina-
ion every 6 months and echocardiography every 6 to 12
onths, depending on the severity of dilatation and stability
f measurements. If patients are stable, echocardiographic
easurements are not required more frequently than every
2 months. In patients with more advanced LV dilatation
end-diastolic dimension greater than 70 mm or end-
ystolic dimension greater than 50 mm), for whom the risk
f developing symptoms or LV dysfunction ranges between
0% and 20% per year (271,272), it is reasonable to perform
erial echocardiograms as frequently as every 4 to 6 months.
erial chest X-rays and ECGs have less value but are helpful
n selected patients.
Chronic AR may develop from disease processes that
nvolve the proximal ascending aorta. In patients with aortic
oot dilatation, serial echocardiograms are indicated to
valuate aortic root size, as well as LV size and function.
his is discussed in Section 3.2.4.
Repeat echocardiograms are also recommended when
he patient has onset of symptoms, there is an equivocal
istory of changing symptoms or changing exercise tol-
rance, or there are clinical findings that suggest wors-
ning regurgitation or progressive LV dilatation. Patients
ith echocardiographic evidence of progressive ventricu-
ar dilatation or declining systolic function have a greater
ikelihood of developing symptoms or LV dysfunction
271) and should have more frequent follow-up exami-
ations (every 6 months) than those with stable LV
unction.
In some centers with expertise in nuclear cardiology,
erial radionuclide ventriculograms to assess LV volume and
unction at rest may be an accurate and cost-effective
lternative to serial echocardiograms. However, there is no
ustification for routine serial testing with both an echocar-
iogram and a radionuclide ventriculogram. Serial radionu-
lide ventriculograms are also recommended in patients
ith suboptimal echocardiograms, patients with suggestive
ut not definite echocardiographic evidence of LV systolic
ysfunction, and patients for whom there is discordance
etween clinical assessment and echocardiographic data. In
enters with specific expertise in cardiac magnetic resonance
maging, serial magnetic resonance imaging may be per-
ormed in place of radionuclide angiography for the indica-
ions listed above. In addition to accurate assessment of LV
olume, mass, wall thickness, and systolic function (318–
22), cardiac magnetic resonance imaging may be used to
uantify the severity of valvular regurgitation (323–327).
Serial exercise testing is also not recommended routinely
n asymptomatic patients with preserved systolic function;
owever, exercise testing may be invaluable to assess func-
ional capacity and symptomatic responses in patients with
quivocal changes in symptomatic status. Serial exercise
maging studies to assess LV functional reserve are not
ndicated in asymptomatic patients or those in whom
ymptoms develop. h.2.3.7. Indications for Cardiac Catheterization
lass I
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is indicated for
assessment of severity of regurgitation, LV function,
or aortic root size when noninvasive tests are incon-
clusive or discordant with clinical findings in patients
with AR. (Level of Evidence: B)
. Coronary angiography is indicated before AVR in
patients at risk for CAD. (Level of Evidence: C)
lass III
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is not indicated for
assessment of LV function, aortic root size, or sever-
ity of regurgitation before AVR when noninvasive
tests are adequate and concordant with clinical find-
ings and coronary angiography is not needed. (Level
of Evidence: C)
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is not indicated for
assessment of LV function and severity of regurgita-
tion in asymptomatic patients when noninvasive tests
are adequate. (Level of Evidence: C)
Cardiac catheterization is not required in patients with
hronic AR unless there are questions about the severity of
R, hemodynamic abnormalities, or LV systolic dysfunc-
ion that persist despite physical examination and noninva-
ive testing, or unless AVR is contemplated and there is a
eed to assess coronary anatomy. The indications for
oronary arteriography are discussed in Section 10.2. In
ome patients undergoing left-heart catheterization for cor-
nary angiography, additional aortic root angiography and
emodynamic measurements may provide useful supple-
entary data.
Hemodynamic and angiographic assessment of the sever-
ty of AR and LV function may be necessary in some
atients being considered for surgery when there are con-
icting data between clinical assessment and noninvasive
ests. Less commonly, asymptomatic patients who are not
eing considered for surgery may also require invasive
easurement of hemodynamics and/or determination of
everity of AR when this information cannot be obtained
ccurately from noninvasive tests.
Hemodynamic measurements during exercise are occa-
ionally helpful for determining the effect of AR on LV
unction or making decisions regarding medical or surgical
herapy. In selected patients with severe AR, borderline or
ormal LV systolic function, and LV chamber enlargement
hat is approaching the threshold for surgery (defined
elow), measurement of cardiac output and LV filling
ressures at rest and during exercise with a right-heart
atheter may be valuable for identifying patients with severe
emodynamic abnormalities in whom surgery is warranted.
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August 1, 2006:e1–148 ACC/AHA Practice Guidelines.2.3.8. Indications for Aortic Valve Replacement or Aortic
alve Repair
he majority of patients with severe AR requiring surgery
ndergo valve replacement (see Section 7.2.). However, in
everal surgical centers, there is increasing experience in
erforming aortic valve repair in selected patients (see
ection 7.2.6.). In the discussion that follows, the term
AVR” applies to both aortic valve replacement and aortic
alve repair, with the understanding that aortic valve repair
hould be considered only in those surgical centers that have
eveloped the appropriate technical expertise, gained expe-
ience in patient selection, and demonstrated outcomes
quivalent to those of valve replacement. The indications for
alve replacement and repair do not differ.
In patients with pure, chronic AR, AVR should be
onsidered only if AR is severe (Table 4) (27). Patients with
nly mild AR are not candidates for AVR, and if such
atients have symptoms or LV dysfunction, other causes
hould be considered, such as CAD, hypertension, or
ardiomyopathic processes. If the severity of AR is uncertain
fter a review of clinical and echocardiographic data, addi-
ional information may be needed, such as invasive hemo-
ynamic and angiographic data. The following discussion
pplies only to those patients with pure, severe AR.
lass I
. AVR is indicated for symptomatic patients with
severe AR irrespective of LV systolic function. (Level
of Evidence: B)
. AVR is indicated for asymptomatic patients with
chronic severe AR and LV systolic dysfunction (ejec-
tion fraction 0.50 or less) at rest. (Level of Evidence:
B)
. AVR is indicated for patients with chronic severe AR
while undergoing CABG or surgery on the aorta or
other heart valves. (Level of Evidence: C)
lass IIa
AVR is reasonable for asymptomatic patients with
severe AR with normal LV systolic function (ejection
fraction greater than 0.50) but with severe LV dila-
tation (end-diastolic dimension greater than 75 mm
or end-systolic dimension greater than 55 mm).*
(Level of Evidence: B)
lass IIb
. AVR may be considered in patients with moderate
AR while undergoing surgery on the ascending aorta.
(Level of Evidence: C)
. AVR may be considered in patients with moderate
AR while undergoing CABG. (Level of Evidence: C)
. AVR may be considered for asymptomatic patients
with severe AR and normal LV systolic function at
rest (ejection fraction greater than 0.50) when the
degree of LV dilatation exceeds an end-diastolic mdimension of 70 mm or end-systolic dimension of
50 mm, when there is evidence of progressive LV
dilatation, declining exercise tolerance, or abnor-
mal hemodynamic responses to exercise.* (Level of
Evidence: C)
lass III
AVR is not indicated for asymptomatic patients with
mild, moderate, or severe AR and normal LV systolic
function at rest (ejection fraction greater than 0.50)
when degree of dilatation is not moderate or severe
(end-diastolic dimension less than 70 mm, end-
systolic dimension less than 50 mm).* (Level of
Evidence: B)
Consider lower threshold values for patients of small stature
f either gender.
.2.3.8.1. SYMPTOMATIC PATIENTS WITH NORMAL LEFT
ENTRICULAR SYSTOLIC FUNCTION. AVR is indicated in
atients with normal LV systolic function (defined as
jection fraction greater than 0.50 at rest) who have NYHA
unctional class III or IV symptoms. Patients with Canadian
eart Association functional class II to IV angina pectoris
hould also be considered for surgery. In many patients with
YHA functional class II dyspnea, the cause of symptoms
s often unclear, and clinical judgment is required. Patients
ith well-compensated AR often have chronic mild dys-
nea or fatigue, and it may be difficult to differentiate the
ffects of deconditioning or aging from true cardiac symp-
oms. In such patients, exercise testing may be valuable. If
he cause of these mild symptoms is uncertain and they are
ot severe enough to interfere with the patient’s lifestyle, a
eriod of observation may be reasonable. However, new
nset of mild dyspnea has different implications in severe
R, especially in patients with increasing LV chamber size
r evidence of declining LV systolic function into the low
ormal range. Thus, even if patients have not achieved the
hreshold values of LV size and function recommended for
urgery in asymptomatic patients, development of mild
ymptoms is an indication for AVR in a patient who is
earing these values.
.2.3.8.2. SYMPTOMATIC PATIENTS WITH LEFT VENTRICU-
AR DYSFUNCTION. Patients with NYHA functional class
I, III, or IV symptoms and with mild to moderate LV
ystolic dysfunction (ejection fraction 0.25 to 0.50) should
ndergo AVR. Patients with NYHA functional class IV
ymptoms have worse postoperative survival rates and lower
ikelihood of recovery of systolic function than patients with
ess severe symptoms (245,250,252,254), but AVR will
mprove ventricular loading conditions and expedite subse-
uent management of LV dysfunction (238).
Severely symptomatic patients (NYHA functional class
V) with advanced LV dysfunction (ejection fraction less
han 0.25 and/or end-systolic dimension greater than 60
m) present difficult management issues. Some patients
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ACC/AHA Practice Guidelines August 1, 2006:e1–148ill manifest meaningful recovery of LV function after
VR, but many will have developed irreversible myocardial
hanges. The mortality associated with valve replacement
pproaches 10%, and postoperative mortality over the sub-
equent few years is high. Valve replacement should be
onsidered more strongly in patients with NYHA func-
ional class II and III symptoms, especially if
symptoms and evidence of LV dysfunction are of recent
onset;
intensive short-term therapy with vasodilators and di-
uretics results in symptomatic improvement;
intravenous positive inotropic agents result in substantial
improvement in hemodynamics or systolic function.
However, even in patients with NYHA functional class
V symptoms and ejection fraction less than 0.25, the high
isks associated with AVR and subsequent medical manage-
ent of LV dysfunction are usually a better alternative than
he higher risks of long-term medical management alone
328).
.2.3.8.3. ASYMPTOMATIC PATIENTS. AVR in asymptom-
tic patients remains a controversial topic, but it is generally
greed (233,329–335) that AVR is indicated in patients
ith LV systolic dysfunction. As noted previously, for the
urposes of these guidelines, LV systolic dysfunction is
efined as an ejection fraction below normal at rest. The
ower limit of normal will be assumed to be 0.50, with the
ealization that this lower limit is technique dependent and
ay vary among institutions. The committee also realizes
hat there may be variability in any given measurement of
V dimension or ejection fraction. Therefore, the commit-
ee recommends that 2 consecutive measurements be ob-
ained before one proceeds with a decision to recommend
urgery in the asymptomatic patient. These consecutive
easurements could be obtained with the same test re-
eated in a short time period (such as a second echocardio-
ram after an initial echocardiogram) or with a separate,
ndependent test (e.g., radionuclide ventriculography, mag-
etic resonance imaging, or contrast left ventriculography
fter an initial echocardiogram).
AVR is also recommended in patients with severe LV
ilatation (end-diastolic dimension greater than 75 mm or
nd-systolic dimension greater than 55 mm), even if ejec-
ion fraction is normal. The majority of patients with this
egree of dilatation will have already developed systolic
ysfunction because of afterload mismatch and will thus be
andidates for valve replacement on the basis of the de-
ressed ejection fraction. The elevated end-systolic dimen-
ion in this regard is often a surrogate for systolic dysfunc-
ion. The relatively small number of asymptomatic patients
ith preserved ejection fraction despite severe increases in
nd-systolic and end-diastolic chamber size should be con-
idered for surgery, because they appear to represent a
igh-risk group with an increased incidence of sudden death
271,336), and the results of valve replacement in such matients have thus far been excellent (264). In contrast,
ostoperative mortality is considerable once patients with
evere LV dilatation develop symptoms or LV systolic
ysfunction (264). The recommendations regarding the risk
f sudden death and postoperative outcome with severe LV
ilatation were based on reports of sudden death in 2 of 3
atients with an LV end-diastolic dimension greater than
0 mm (271) and 2 patients with an LV end-diastolic
olume index greater than 200 ml/m2 (336). It should be
ecognized, however, that LV end-diastolic dimension,
hether examined as a continuous or as a dichotomous
ariable (less than 80 vs. greater than 80 mm), has not been
ound to be predictive of postoperative survival or LV
unction, whereas ejection fraction is predictive. Conserva-
ively managed patients with an end-diastolic dimension
xceeding 70 mm likewise exhibit a favorable clinical out-
ome (276). These data do not strongly support the use of
xtreme LV enlargement as an indication for AVR, unless
ardiac symptoms or systolic dysfunction is present (337).
owever, the committee recommends surgery before the
eft ventricle achieves an extreme degree of dilatation and
ecommends AVR for patients with LV end-diastolic di-
ension greater than 75 mm.
Anthropometric normalization of LV end-diastolic di-
ension (or volume) should be considered, but unfortu-
ately, there is lack of agreement as to whether or not
ormalization based on body surface area or body mass
ndex is predictive of outcome (288,338). Normalization of
nd-diastolic dimension for body surface area tends to mask
he diagnosis of LV enlargement, especially in patients who
re overweight (339). The use of height and a consideration
f gender are likely to be more appropriate than body
urface area (340).
Patients with severe AR in whom the degree of LV
ilatation has not reached but is approaching these thresh-
ld values (e.g., LV end-diastolic dimension of 70 to 75 mm
r end-systolic dimension of 50 to 55 mm) should be
ollowed with frequent echocardiograms every 4 to 6
onths, as noted previously (Fig. 4). In addition, AVR may
e considered in such patients if there is evidence of
eclining exercise tolerance or abnormal hemodynamic
esponses to exercise, for example, an increase in pulmonary
rtery wedge pressure greater than 25 mm Hg with exercise.
Several patient subgroups develop LV systolic dysfunc-
ion with less marked LV dilatation than observed in the
ajority of patients with uncomplicated AR. These include
atients with long-standing hypertension in whom the
ressure-overloaded ventricle has reduced compliance and a
imited potential to increase its chamber size; patients with
oncomitant CAD, in whom myocardial ischemia may
evelop with increasing myocardial wall stress, resulting in
V dysfunction; and patients with concomitant MS, in
hom the left ventricle will not dilate to the same extent as
n patients with pure AR (341). In such patients, it is
articularly important that LV ejection fraction and not
erely systolic dimension be monitored. Women also tend
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineso develop symptoms and LV dysfunction with less LV
ilatation than men (338); this appears to be related to body
ize, because these differences are not apparent when LV
imensions are corrected for body surface area. Hence, LV
imensions alone may be misleading in small patients of
ither gender, and the threshold values of end-diastolic and
nd-systolic dimension recommended above for AVR in
symptomatic patients (75 and 55 mm, respectively) may
eed to be reduced in such patients. There are no data with
hich to derive guidelines for LV dimensions corrected for
ody size, and clinical judgment is required.
A decrease in ejection fraction during exercise should not
e used as the only indication for AVR in asymptomatic
atients with normal LV systolic function at rest, because
he exercise ejection fraction response is multifactorial, and
he strength of evidence is limited. The ejection fraction
esponse to exercise has not proved to have independent
rognostic value in patients undergoing surgery (254). The
hange in ejection fraction with exercise is a relatively
onspecific response related to both severity of volume load
271,296,300,301) and exercise-induced changes in preload
nd peripheral resistance (280) that develop early in the
atural history of AR. AVR should also not be recom-
ended in asymptomatic patients with normal systolic
unction merely because of evidence of LV dilatation as long
s the dilatation is not severe (end-diastolic dimension less
han 75 mm or end-systolic dimension less than 55 mm).
Patients who demonstrate progression of LV dilatation or
rogressive decline in ejection fraction on serial studies
epresent a higher-risk group who require careful monitor-
ng (271), but such patients often reach a new steady state
nd may do well for extended periods of time. Hence, AVR
s not recommended until the threshold values noted above
re reached or symptoms or LV systolic dysfunction de-
elop. However, prompt referral to AVR once patients
evelop symptoms, subnormal ejection fraction, or progres-
ive LV dilatation results in significantly better postopera-
ive survival than if AVR is delayed until symptoms or LV
ystolic function becomes more severe (254,265,267).
The surgical options for treating AR are expanding, with
rowing experience in aortic homografts, pulmonary au-
ografts, unstented tissue valves, and aortic valve repair. If
hese techniques are ultimately shown to improve long-term
urvival or reduce postoperative valve complications, it is
onceivable that the thresholds for recommending AVR
ay be reduced. Until such data are available, the indica-
ions for surgery for AR should not vary with the operative
echnique to be used.
.2.4. Concomitant Aortic Root Disease
n addition to causing acute AR, diseases of the proximal
orta may also contribute to chronic AR. Dilatation of the
scending aorta is among the most common causes of
solated AR (342). In such patients, the valvular regurgita-
ion may be less important in decision making than the
rimary disease of the aorta, such as Marfan syndrome, pissection, or chronic dilatation of the aortic root related to
ypertension or a bicuspid aortic valve (see Section 3.3). In
uch patients, if the AR is mild or the left ventricle is only
ildly dilated, management should focus on treating the
nderlying aortic root disease. In many patients, however,
R may be severe and associated with severe LV dilatation
r systolic dysfunction, in which case decisions regarding
edical therapy and timing of the operation must consider
oth conditions. In general, AVR and aortic root recon-
truction are indicated in patients with disease of the aortic
oot or proximal aorta and AR of any severity when the
egree of dilatation of the aorta or aortic root reaches or
xceeds 5.0 cm by echocardiography (343). However, some
ave recommended surgery at a lower level of dilatation (4.5
m) or based on a rate of increase of 0.5 cm per year or
reater in surgical centers with established expertise in
epair of the aortic root and ascending aorta (344). Aortic
oot and ascending aorta dilation in patients with bicuspid
ortic valves is discussed in greater detail in Section 3.3.
.2.5. Evaluation of Patients After Aortic Valve Re-
lacement
fter AVR, close follow-up is necessary during the early
nd long-term postoperative course to evaluate prosthetic
alve function and assess LV function, as discussed in
ections 9.3. to 9.3.3. An echocardiogram should be per-
ormed soon after surgery to assess the results of surgery on
V size and function and to serve as a baseline against
hich subsequent echocardiograms may be compared. This
ould be performed either before hospital discharge or
referably at the first outpatient re-evaluation. Within the
rst few weeks of surgery, there is little change in LV
ystolic function, and ejection fraction may even deteriorate
ompared with preoperative values because of the reduced
reload (345), even though ejection fraction may increase
ver the subsequent several months. Thus, persistent or
ore severe systolic dysfunction early after AVR is a poor
redictor of subsequent improvement in LV function in
atients with preoperative LV dysfunction. A better predic-
or of subsequent LV systolic function is the reduction in
V end-diastolic dimension, which declines significantly
ithin the first week or 2 after AVR (240,245,346). This is
n excellent marker of the functional success of valve
eplacement, because 80% of the overall reduction in end-
iastolic dimension observed during the long-term postop-
rative course occurs within the first 10 to 14 days after
VR (240,245,346), and the magnitude of reduction in
nd-diastolic dimension after surgery correlates with the
agnitude of increase in ejection fraction (245).
After the initial postoperative re-evaluation, the patient
hould be seen and examined again at 6 and 12 months and
hen on a yearly basis if the clinical course is uncomplicated. If
he patient is asymptomatic, the early postoperative echocar-
iogram demonstrates substantial reduction in LV end-
iastolic dimension, and LV systolic function is normal, serial
ostoperative echocardiograms after the initial early postoper-
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ACC/AHA Practice Guidelines August 1, 2006:e1–148tive study are usually not indicated. However, repeat echocar-
iography is warranted at any point at which there is evidence
f a new murmur, questions of prosthetic valve integrity, or
oncerns about LV function. Patients with persistent LV
ilatation on the initial postoperative echocardiogram should
e treated as would any other patient with symptomatic or
symptomatic LV dysfunction, including treatment with ACE
nhibitors and beta-adrenergic blocking agents. In such pa-
ients, repeat echocardiography to assess LV size and systolic
unction is warranted at the 6- and 12-month re-evaluations. If
V dysfunction persists beyond this time frame, repeat echo-
ardiograms should be performed as clinically indicated. Man-
gement of patients after AVR is discussed in greater detail in
ection 9.3.
.2.6. Special Considerations in the Elderly
he vast majority of elderly patients with aortic valve disease
ave AS or combined AS and AR, and pure AR is
ncommon (347). Elderly patients with AR generally fare
ess well than patients who are young or middle-aged.
atients older than 75 years are more likely to develop
ymptoms or LV dysfunction at earlier stages of LV
ilatation, have more persistent ventricular dysfunction and
eart failure symptoms after surgery, and have worse post-
perative survival rates than their younger counterparts.
any such patients have concomitant CAD, which must be
onsidered in the evaluation of symptoms, LV dysfunction,
nd indications for surgery. Because the goal of therapy is to
mprove the quality of life rather than longevity, symptoms
re the most important guide to determining whether or not
VR should be performed. Nonetheless, asymptomatic or
ildly symptomatic patients who develop LV dysfunction
as defined previously) should be considered for AVR if the
isks of surgery are balanced in otherwise healthy patients
gainst the expected improvement in long-term outcome.
.3. Bicuspid Aortic Valve With Dilated Ascending Aorta
lass I
. Patients with known bicuspid aortic valves should
undergo an initial transthoracic echocardiogram to
assess the diameters of the aortic root and ascending
aorta. (Level of Evidence: B)
. Cardiac magnetic resonance imaging or cardiac com-
puted tomography is indicated in patients with bicus-
pid aortic valves when morphology of the aortic root
or ascending aorta cannot be assessed accurately by
echocardiography. (Level of Evidence: C)
. Patients with bicuspid aortic valves and dilatation of
the aortic root or ascending aorta (diameter greater
than 4.0 cm*) should undergo serial evaluation of
aortic root/ascending aorta size and morphology by
echocardiography, cardiac magnetic resonance, or
computed tomography on a yearly basis. (Level of
Evidence: C) i. Surgery to repair the aortic root or replace the
ascending aorta is indicated in patients with bicuspid
aortic valves if the diameter of the aortic root or
ascending aorta is greater than 5.0 cm* or if the rate
of increase in diameter is 0.5 cm per year or more.
(Level of Evidence: C)
. In patients with bicuspid valves undergoing AVR
because of severe AS or AR (see Sections 3.1.7 and
3.2.3.8), repair of the aortic root or replacement of
the ascending aorta is indicated if the diameter of the
aortic root or ascending aorta is greater than 4.5 cm.*
(Level of Evidence: C)
lass IIa
. It is reasonable to give beta-adrenergic blocking
agents to patients with bicuspid valves and dilated
aortic roots (diameter greater than 4.0 cm*) who are
not candidates for surgical correction and who do not
have moderate to severe AR. (Level of Evidence: C)
. Cardiac magnetic resonance imaging or cardiac com-
puted tomography is reasonable in patients with
bicuspid aortic valves when aortic root dilatation is
detected by echocardiography to further quantify
severity of dilatation and involvement of the ascend-
ing aorta. (Level of Evidence: B)
Consider lower threshold values for patients of small stature
f either gender.
There is growing awareness that many patients with
icuspid aortic valves have disorders of vascular connective
issue, involving loss of elastic tissue (348,349), which may
esult in dilatation of the aortic root or ascending aorta even
n the absence of hemodynamically significant AS or AR
350–353). Aortic root or ascending aortic dilatation can
rogress with time in this condition (354). These patients
ave a risk of aortic dissection that is related to the severity
f dilatation (349,355–357). Recommendations for athletic
articipation in patients with bicuspid valve disease and
ssociated dilatation of the aortic root or ascending aorta
rom the 36th Bethesda Conference (138) are based on
imited data but with the understanding that aortic dissec-
ion can occur in some patients with aortic root or ascending
orta diameters less than 50 mm (344,356,358). Therapy
ith beta-adrenergic blocking agents might be effective in
lowing the progression of aortic dilatation, but the available
ata have been developed in patients with Marfan syndrome
359) and not in patients with bicuspid aortic valves.
Echocardiography remains the primary imaging technique
or identifying those patients in whom the aortic root or
scending aorta is enlarged. In many cases, echocardiography,
ncluding transesophageal imaging, provides all of the neces-
ary information required to make management decisions.
ore accurate quantification of the diameter of the aortic root
nd ascending aorta, as well as full assessment of the degree of
nlargement, can be obtained with cardiac magnetic resonance
maging or computed tomography. These techniques also
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesllow for an accurate depiction of the size and contour of the
orta in its arch, descending thoracic, and abdominal segments.
hen the findings on transthoracic echocardiography relative
o the aortic root and ascending aorta are concordant with
hose of either cardiac magnetic resonance or computed tomo-
raphic imaging, then transthoracic echocardiography can be
sed for annual surveillance. The dimensions of the aortic root
nd ascending aorta show considerable variability in normal
opulations. Regression formulas and nomograms have been
eveloped for adolescents and adults that account for age and
ody surface area (360). An upper limit of 2.1 cm per m2 has
een established at the level of the aortic sinuses. Dilatation is
onsidered an increase in diameter above the norm for age and
ody surface area, and an aneurysm has been defined as a 50%
ncrease over the normal diameter (361).
Surgery to repair the aortic root or replace the ascending
orta has been recommended for those patients with greatly
nlarged aortic roots or ascending aortas (344,349,357,358).
n recommending elective surgery for this condition, a
umber of factors must be considered, including the pa-
ient’s age, the relative size of the aorta and aortic root, the
tructure and function of the aortic valve, and the experience
f the surgical team. Aortic valve-sparing operations are
easible in most patients with dilatation of the aortic root or
scending aorta who do not have significant AR or aortic
alve calcification (362–364). It is recommended that pa-
ients with bicuspid valves should undergo elective repair of
he aortic root or replacement of the ascending aorta if the
iameter of these structures exceeds 5.0 cm. Such surgery
hould be performed by a surgical team with established
xpertise in these procedures. Others have recommended a
alue of 2.5 cm per m2 or greater as the indication for
urgery (365). If patients with bicuspid valves and associated
ortic root enlargement undergo AVR because of severe AS
r AR (Sections 3.1.7. and 3.2.3.8.), it is recommended that
epair of the aortic root or replacement of the ascending
orta be performed if the diameter of these structures is
reater than 4.5 cm (366).
.4. Mitral Stenosis
.4.1. Pathophysiology and Natural History
S is an obstruction to LV inflow at the level of the MV as a
esult of a structural abnormality of the MV apparatus, which
revents proper opening during diastolic filling of the left
entricle. The predominant cause of MS is rheumatic carditis.
solated MS occurs in 40% of all patients presenting with
heumatic heart disease, and a history of rheumatic fever can be
licited from approximately 60% of patients presenting with
ure MS (367,368). The ratio of women to men presenting
ith isolated MS is 2:1 (367–369). Congenital malfor-
ation of the MV occurs rarely and is observed mainly in
nfants and children (370). Acquired causes of MV
bstruction, other than rheumatic heart disease, are rare.
hese include left atrial myxoma, ball valve thrombus,
ucopolysaccharidosis, and severe annular calcification. sIn patients with MS due to rheumatic fever, the patho-
ogical process causes leaflet thickening and calcification,
ommissural fusion, chordal fusion, or a combination of
hese processes (370,371). The result is a funnel-shaped
itral apparatus in which the orifice of the mitral opening
s decreased in size. Interchordal fusion obliterates the
econdary orifices, and commissural fusion narrows the
rincipal orifice (370,371).
The normal MV area is 4.0 to 5.0 cm2. Narrowing of the
alve area to less than 2.5 cm2 typically occurs before the
evelopment of symptoms (139). With a reduction in valve
rea by the rheumatic process, blood can flow from the left
trium to the left ventricle only if propelled by a pressure
radient. This diastolic transmitral gradient is the funda-
ental expression of MS (372) and results in elevation of
eft atrial pressure, which is reflected back into the pulmo-
ary venous circulation. Decreased pulmonary venous com-
liance that results in part from an increased pulmonary
ndothelin-1 spillover rate may also contribute to increased
ulmonary venous pressure (373). Increased pressure and
istension of the pulmonary veins and capillaries can lead to
ulmonary edema as pulmonary venous pressure exceeds
hat of plasma oncotic pressure. In patients with chronic
V obstruction, however, even when it is severe and
ulmonary venous pressure is very high, pulmonary edema
ay not occur owing to a marked decrease in pulmonary
icrovascular permeability. The pulmonary arterioles may
eact with vasoconstriction, intimal hyperplasia, and medial
ypertrophy, which lead to pulmonary arterial hypertension.
An MV area greater than 1.5 cm2 usually does not
roduce symptoms at rest (374). However, if there is an
ncrease in transmitral flow or a decrease in the diastolic
lling period, there will be a rise in left atrial pressure and
evelopment of symptoms. From hydraulic considerations,
t any given orifice size, the transmitral gradient is a
unction of the square of the transvalvular flow rate and is
ependent on the diastolic filling period (139). Thus, the
rst symptoms of dyspnea in patients with mild MS are
sually precipitated by exercise, emotional stress, infection,
regnancy, or atrial fibrillation with a rapid ventricular
esponse (374). As the obstruction across the MV increases,
ecreasing effort tolerance occurs.
As the severity of stenosis increases, cardiac output becomes
ubnormal at rest (374) and fails to increase during exercise
375). The degree of pulmonary vascular disease is also an
mportant determinant of symptoms in patients with MS
373,374,376). A second obstruction to flow develops from
ncreased pulmonary arteriolar resistance (376,377), which may
rotect the lungs from pulmonary edema (376,377). In some
atients, an additional reversible obstruction develops at the
evel of the pulmonary veins (378,379). The low cardiac output
nd increased pulmonary arteriolar resistance, which results
rom functional and structural changes (alveolar basement
embrane thickening, adaptation of neuroreceptors, increased
ymphatic drainage, and increased transpulmonary endothelin
pillover rate), contribute to the ability of a patient with severe
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ime (374,376,377).
The natural history of patients with untreated MS has
een defined from studies in the 1950s and 1960s (367–
69). Mitral stenosis is a continuous, progressive, lifelong
isease, usually consisting of a slow, stable course in the
arly years followed by a progressive acceleration later in life
367–369,380). In developed countries, there is a long latent
eriod of 20 to 40 years from the occurrence of rheumatic
ever to the onset of symptoms. Once symptoms develop,
here is another period of almost a decade before symptoms
ecome disabling (367). Overall, the 10-year survival of
ntreated patients presenting with MS is 50% to 60%,
epending on symptoms at presentation (368,369). In the
symptomatic or minimally symptomatic patient, survival is
reater than 80% at 10 years, with 60% of patients having no
rogression of symptoms (368,369,380). However, once
ignificant limiting symptoms occur, there is a dismal 0% to
5% 10-year survival rate (367–369,380,381). Once there is
evere pulmonary hypertension, mean survival drops to less
han 3 years (382). The mortality of untreated patients with
S is due to progressive pulmonary and systemic conges-
ion in 60% to 70%, systemic embolism in 20% to 30%,
ulmonary embolism in 10%, and infection in 1% to 5%
369,370). In North America and Europe, this classic
istory of MS has been replaced by an even milder delayed
ourse with the decline in incidence of rheumatic fever
380,383). The mean age of presentation is now in the fifth
o sixth decade (380,383); more than one third of patients
ndergoing valvotomy are older than 65 years (384). In
ome geographic areas, MS progresses more rapidly, pre-
umably due to either a more severe rheumatic insult or
epeated episodes of rheumatic carditis due to new strepto-
occal infections, resulting in severe symptomatic MS in the
ate teens and early 20s (380). Serial hemodynamic and
oppler-echocardiographic studies have reported annual
oss of MV area ranging from 0.09 to 0.32 cm2 (385,386).
Although MS is best described as a disease continuum,
nd there is no single value that defines severity, for these
uidelines, MS severity is based on a variety of hemody-
amic and natural history data (Table 4) (27) using mean
radient, pulmonary artery systolic pressure, and valve area
s follows: mild (area greater than 1.5 cm2, mean gradient
ess than 5 mm Hg, or pulmonary artery systolic pressure
ess than 30 mm Hg), moderate (area 1.0 to 1.5 cm2, mean
radient 5 to 10 mm Hg, or pulmonary artery systolic
ressure 30 to 50 mm Hg), and severe (area less than 1.0
m2, mean gradient greater than 10 mm Hg, or pulmonary
rtery systolic pressure greater than 50 mm Hg).
.4.2. Indications for Echocardiography in Mitral
tenosis
lass I
. Echocardiography should be performed in patients
for the diagnosis of MS, assessment of hemodynamic iseverity (mean gradient, MV area, and pulmonary
artery pressure), assessment of concomitant valvular
lesions, and assessment of valve morphology (to
determine suitability for percutaneous mitral balloon
valvotomy). (Level of Evidence: B)
. Echocardiography should be performed for re-
evaluation in patients with known MS and changing
symptoms or signs. (Level of Evidence: B)
. Echocardiography should be performed for assess-
ment of the hemodynamic response of the mean
gradient and pulmonary artery pressure by exercise
Doppler echocardiography in patients with MS when
there is a discrepancy between resting Doppler echo-
cardiographic findings, clinical findings, symptoms,
and signs. (Level of Evidence: C)
. Transesophageal echocardiography in MS should be
performed to assess the presence or absence of left
atrial thrombus and to further evaluate the severity of
MR in patients considered for percutaneous mitral
balloon valvotomy. (Level of Evidence: C)
. Transesophageal echocardiography in MS should be
performed to evaluate MV morphology and hemody-
namics in patients when transthoracic echocardiogra-
phy provides suboptimal data. (Level of Evidence: C)
lass IIa
Echocardiography is reasonable in the re-evaluation
of asymptomatic patients with MS and stable clinical
findings to assess pulmonary artery pressure (for
those with severe MS, every year; moderate MS,
every 1 to 2 years; and mild MS, every 3 to 5 years).
(Level of Evidence: C)
lass III
Transesophageal echocardiography in the patient
with MS is not indicated for routine evaluation of
MV morphology and hemodynamics when complete
transthoracic echocardiographic data are satisfactory.
(Level of Evidence: C)
The diagnosis of MS should be made on the basis of the
istory, physical examination, chest X-ray, and ECG (Fig.
). Patients may present with no symptoms but have an
bnormal physical examination (380,383). Although some
atients may present with fatigue, dyspnea, or frank pulmo-
ary edema, in others, the initial manifestation of MS is the
nset of atrial fibrillation or an embolic event (367). Rarely,
atients may present with hemoptysis, hoarseness, or dys-
hagia. The characteristic auscultatory findings of rheu-
atic MS are accentuated first heart sound (S1), opening
nap (OS), low-pitched middiastolic rumble, and a presys-
olic murmur. These findings, however, may also be present
n patients with nonrheumatic MV obstruction (e.g., left
trial myxoma) and may be absent with severe pulmonary
ypertension, low cardiac output, and a heavily calcifiedmmobile MV. A shorter A2-OS interval and longer dura-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesion of diastolic rumble indicates more severe MS. An
2-OS interval of less than 0.08 seconds implies severe MS
387). Physical findings of pulmonary hypertension, such as
loud P2 or right ventricular (RV) heave, also suggest severe
S.
The diagnostic tool of choice in the evaluation of a
atient with MS is 2D and Doppler echocardiography
388–393). Echocardiography is able to identify restricted
iastolic opening of the MV leaflets due to “doming” of the
igure 5. Management strategy for patients with mitral stenosis. *The wri
itral valve area (MVA) and that the mean transmitral gradients, pulmonar
hould also be taken into consideration. †There is controversy as to whe
ulmonary hypertension (pulmonary artery pressure greater than 60 mm H
alve replacement to prevent right ventricular failure. ‡Assuming no other c
hest X-ray; ECG, electrocardiogram; echo, echocardiography; LA, left anterior leaflet and immobility of the posterior leaflet v388,390,392,393). Other entities that can simulate the
linical features of rheumatic MS, such as left atrial myx-
ma, mucopolysaccharidosis, nonrheumatic calcific MS, cor
riatriatum, and a parachute MV, can be readily identified
y 2D echocardiography. Planimetry of the orifice area may
e possible from the short-axis view. Two-dimensional
chocardiography can be used to assess the morphological
ppearance of the MV apparatus, including leaflet mobility
nd flexibility, leaflet thickness, leaflet calcification, subval-
ommittee recognizes that there may be variability in the measurement of
ry wedge pressure (PAWP), and pulmonary artery systolic pressure (PASP)
atients with severe mitral stenosis (MVA less than 1.0 cm2) and severe
hould undergo percutaneous mitral balloon valvotomy (PMBV) or mitral
or pulmonary hypertension is present. AF indicates atrial fibrillation; CXR,
R, mitral regurgitation; and 2D, 2-dimensional.ting c
y arte
ther p
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ause fular fusion, and the appearance of commissures (391,394–
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ACC/AHA Practice Guidelines August 1, 2006:e1–14898). These features may be important when one considers
he timing and type of intervention to be performed
394–400). Patients with mobile noncalcified leaflets, no
ommissural calcification, and little subvalvular fusion may
e candidates for either balloon catheter or surgical com-
issurotomy/valvotomy (394 –399). There are several
ethods used to assess suitability for valvotomy, including a
ilkins score (Table 17) (400), an echocardiographic
rouping (based on valve flexibility, subvalvular fusion, and
eaflet calcification) (397), and the absence or presence of
ommissural calcium (398). Chamber size and function and
ther structural valvular, myocardial, or pericardial abnor-
alities can be assessed with the 2D echocardiographic
tudy.
Doppler echocardiography can be used to assess the
emodynamic severity of the obstruction (389,391,401).
he mean transmitral gradient can be accurately and repro-
ucibly measured from the continuous-wave Doppler signal
cross the MV with the modified Bernoulli equation
391,401). The MV area can be noninvasively derived from
oppler echocardiography with either the diastolic pressure
alf-time method (401–404) or the continuity equation
402). The half-time method may be inaccurate in patients
ith abnormalities of left atrial or LV compliance, those
ith associated AR, and those who have had mitral valvot-
my (403,404). Doppler echocardiography may also be used
o estimate pulmonary artery systolic pressure from the TR
elocity signal (405) and to assess severity of concomitant
R or AR. Formal hemodynamic exercise testing can be
one noninvasively with either a supine bicycle or upright
readmill with Doppler recordings of transmitral and tricus-
id velocities (406–409). This allows measurement of both
he transmitral gradient (407–409) and pulmonary artery
ystolic pressure (406,408) at rest and with exercise (410).
he criteria for the assessment of the severity of MS are
ummarized in Table 4 (27). These criteria are applicable
hen the heart rate is between 60 and 90 bpm.
In all patients with MS, an initial clinical history, physical
xamination, ECG, and chest X-ray should be performed.
D and Doppler echocardiography should also be per-
able 17. Determinants of the Echocardiographic Mitral Valve S
rade Mobility Subvalvular Thicken
1 Highly mobile valve with only
leaflet tips restricted
Minimal thickening just b
mitral leaflets
2 Leaflet mid and base portions
have normal mobility
Thickening of chordal stru
extending up to one thi
chordal length
3 Valve continues to move
forward in diastole, mainly
from the base
Thickening extending to t
third of the chords
4 No or minimal forward
movement of the leaflets in
diastole
Extensive thickening and
shortening of all chorda
structures extending dow
the papillary muscles
eprinted with permission from Wilkins GT, Weyman AE, Abascal VM, Bloc
chocardiographic variables related to outcome and the mechanism of dilatation. Brormed to confirm the diagnosis of MS and rule out other iauses of MV obstruction and concomitant problems that
ould require further therapy, that is, myocardial or other
alvular heart disease. The morphology of the MV appara-
us and suitability for valvotomy should be assessed. The
everity of MS should be determined using both the mean
ransmitral gradient and valve area from the Doppler echo-
ardiogram, and pulmonary artery pressure should be esti-
ated when possible. A transesophageal echocardiogram is
ot required unless a question about diagnosis remains after
ransthoracic echocardiography.
In the asymptomatic patient who has documented mild
S (valve area greater than 1.5 cm2 and mean gradient less
han 5 mm Hg), no further investigations are needed on the
nitial workup (Fig. 5). These patients usually remain stable
or years (368,369,380). If there is more significant MS, a
ecision to proceed further should be based on the suitabil-
ty of the patient for mitral valvotomy. In patients with
liable, noncalcified valves with no or little subvalvular
usion, no calcification in the commissures, and no left atrial
hrombus, percutaneous mitral valvotomy can be performed
ith a low complication rate and may be indicated if
ymptoms develop. Because of the slowly progressive course
f MS, patients may remain “asymptomatic” with severe
tenosis merely by readjusting their lifestyles to a more
edentary level. Elevated pulmonary vascular resistance
nd/or low cardiac output may also play an adaptive role in
reventing congestive symptoms from occurring in patients
ith severe MS (374,376,377). Elevation of pulmonary
ascular resistance is an important physiological event in
S (377), and the level of pulmonary pressure is an
ndicator of the overall hemodynamic consequence. Patients
ith moderate pulmonary hypertension at rest (pulmonary
rtery systolic pressure greater than 50 mm Hg) and pliable
V leaflets may be considered for percutaneous mitral
alvotomy even if they deny symptoms. In patients who lead
sedentary lifestyle, a hemodynamic exercise test with
oppler echocardiography is useful (406–409). Objective
imitation of exercise tolerance with a rise in transmitral
radient greater than 15 mm Hg and a rise in pulmonary
rtery systolic pressure greater than 60 mm Hg may be an
Thickening Calcification
the Leaflets near normal in thickness
(4 to 5 mm)
A single area of increased
echo brightness
s
the
Midleaflets normal, considerable
thickening of margins (5 to 8
mm)
Scattered areas of
brightness confined to
leaflet margins
tal Thickening extending through
the entire leaflet (5 to 8 mm)
Brightness extending into
the midportion of the
leaflets
Considerable thickening of all
leaflet tissue (greater than 8 to
10 mm)
Extensive brightness
throughout much of
the leaflet tissue
Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of
J 1988;60:299–308 (400).core
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesgy is suitable. There is a subset of asymptomatic patients
ith severe MS (valve area less than 1.0 cm2) and severe
ulmonary hypertension (pulmonary artery systolic pressure
reater than 75% of systemic pressure either at rest or with
xercise). If these patients do not have a valve morphology
avorable for percutaneous mitral balloon valvotomy or
urgical valve repair, it is controversial whether MV replace-
ent should be performed in the absence of symptoms to
revent RV failure, but surgery is generally recommended in
uch patients. However, the patient (and the family) should
e involved in the decision regarding intervention.
.4.3. Medical Therapy
.4.3.1. Medical Therapy: General
n the patient with MS, the major problem is mechanical
bstruction to inflow at the level of the MV, and no medical
herapy will specifically relieve the fixed obstruction. The
eft ventricle is protected from a volume or pressure over-
oad, and thus, no specific medical therapy is required in the
symptomatic patient in normal sinus rhythm who has mild
S. Because rheumatic fever is the primary cause of MS,
rophylaxis against rheumatic fever is recommended. Infec-
ive endocarditis is uncommon but does occur in isolated
S (368,369), and appropriate endocarditis prophylaxis is
lso recommended.
In the patient who has more than a mild degree of MS,
ounseling on avoidance of unusual physical stresses is
dvised. Increased flow and a shortening of the diastolic
lling period by tachycardia increase left atrial pressure
gainst an obstructed MV. Agents with negative chrono-
ropic properties, such as beta blockers or heart rate–
egulating calcium channel blockers, may be of benefit in
atients in sinus rhythm who have exertional symptoms if
hese symptoms occur with high heart rates (411,412). The
reater efficacy of a beta blocker compared with a heart
ate–regulating calcium channel blocker has been reported
413). Some patients with MS have increased bronchial
eactivity that may improve with inhaled corticosteroids
414). Salt restriction and intermittent administration of a
iuretic are useful if there is evidence of pulmonary vascular
ongestion. Digitalis does not benefit patients with MS in
inus rhythm unless there is LV or RV dysfunction (415).
Although MS is a slowly progressive condition, acute
ulmonary edema can occur suddenly in asymptomatic
atients with severe MS, especially with the onset of rapid
trial fibrillation, and this can be rapidly fatal. Thus,
atients should be counseled to seek medical attention
mmediately if they experience a sudden marked increase in
hortness of breath.
.4.3.2. Medical Therapy: Atrial Fibrillation
atients with MS are prone to developing atrial arrhyth-
ias, particularly atrial fibrillation and atrial flutter. Thirty
o forty percent of patients with symptomatic MS develop
trial fibrillation (367,368). Structural changes from the Mressure and volume overload alter the electrophysiological
roperties of the left atrium (380), and the rheumatic
rocess itself may lead to fibrosis of the internodal and
nteratrial tracts and damage to the sinoatrial node. There
ay be significant hemodynamic consequences resulting
rom the acute development of atrial fibrillation, primarily
rom the rapid ventricular rate, which shortens the diastolic
lling period and causes elevation of left atrial pressure.
trial fibrillation occurs more commonly in older patients
367) and is associated with a poorer prognosis, with a
0-year survival rate of 25% compared with 46% in patients
ho remain in sinus rhythm (369). The risk of arterial
mbolization, especially stroke, is significantly increased in
atients with atrial fibrillation (367,368,416–418).
Treatment of an acute episode of rapid atrial fibrillation
onsists of anticoagulation with heparin and control of the
eart rate response. Intravenous digoxin, heart rate–
egulating calcium channel blockers, or beta blockers should
e used to control ventricular response by slowing conduc-
ion through the atrioventricular node. Intravenous or oral
miodarone can also be used when beta blockers or heart
ate-regulating calcium channel blockers cannot be used. If
here is hemodynamic instability, electrical cardioversion
hould be undertaken urgently, with intravenous heparin
efore, during, and after the procedure. In selected patients,
hemical cardioversion may also be attempted. Patients who
ave been in atrial fibrillation longer than 24 to 48 h
ithout anticoagulation are at an increased risk for embolic
vents after cardioversion, but embolization may occur with
ess than 24 h of atrial fibrillation. The decision to proceed
ith elective cardioversion is dependent on multiple factors,
ncluding duration of atrial fibrillation, hemodynamic re-
ponse to the onset of atrial fibrillation, a documented
istory of prior episodes of atrial fibrillation, and a history of
rior embolic events. If the decision has been made to
roceed with elective cardioversion in a patient who has had
ocumented atrial fibrillation for longer than 24 to 48 h and
ho has not been on long-term anticoagulation, 1 of 2
pproaches is recommended based on data from patients
ith nonrheumatic atrial fibrillation. The first is anticoag-
lation with warfarin for more than 3 weeks, followed by
lective cardioversion (419). The second is anticoagulation
ith heparin and transesophageal echocardiography to look
or left atrial thrombus. In the absence of left atrial throm-
us, cardioversion is performed with intravenous heparin
efore, during, and after the procedure (420). It is important
o continue long-term anticoagulation after cardioversion.
Recurrent paroxysmal atrial fibrillation may be treated for
aintenance of sinus rhythm in selected patients with class
C antiarrhythmic drugs (in conjunction with negative
romotropic agent) or class III antiarrhythmic drugs; how-
ver, eventually, the atrial fibrillation becomes resistant to
revention or cardioversion (376), and control of ventricular
esponse becomes the mainstay of therapy. Digoxin slows
he heart rate response in patients with atrial fibrillation andS (415). However, heart rate–regulating calcium channel
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ACC/AHA Practice Guidelines August 1, 2006:e1–148lockers or beta blockers are more effective for preventing
xercise-induced increases in heart rate. Patients with either
aroxysmal or sustained atrial fibrillation should be treated
ith long-term anticoagulation with warfarin to prevent
mbolic events if they do not have a strong contraindication
o anticoagulation (417,421). It is controversial whether
ercutaneous mitral valvotomy should be performed in
atients with new-onset atrial fibrillation and moderate to
evere MS who are otherwise asymptomatic.
Successful percutaneous balloon mitral commissurotomy
ay not prevent the development of atrial fibrillation.
dvanced age and left atrial dimension appear to be the
mportant predictors of development of atrial fibrillation
422).
.4.3.3. Medical Therapy: Prevention of Systemic
mbolization
lass I
. Anticoagulation is indicated in patients with MS and
atrial fibrillation (paroxysmal, persistent, or perma-
nent). (Level of Evidence: B)
. Anticoagulation is indicated in patients with MS and
a prior embolic event, even in sinus rhythm. (Level of
Evidence: B)
. Anticoagulation is indicated in patients with MS
with left atrial thrombus. (Level of Evidence: B)
lass IIb
. Anticoagulation may be considered for asymptomatic
patients with severe MS and left atrial dimension
greater than or equal to 55 mm by echocardiography.*
(Level of Evidence: B)
. Anticoagulation may be considered for patients with
severe MS, an enlarged left atrium, and spontaneous
contrast on echocardiography. (Level of Evidence: C)
This recommendation is based on a grade C level of evidence
iven by the American College of Chest Physicians Fourth
onsensus Conference on Antithrombotic Therapy (423).
Systemic embolization may occur in 10% to 20% of
atients with MS (367,368,416). The risk of embolization is
elated to age and the presence of atrial fibrillation
367,368,416–418). One third of embolic events occur
ithin 1 month of the onset of atrial fibrillation, and two
hirds occur within 1 year. The frequency of embolic events
oes not seem to be related to the severity of MS, cardiac
utput, size of the left atrium, or even the presence or
bsence of heart failure symptoms (368,417,424). An em-
olic event may thus be the initial manifestation of MS
367). In patients who have experienced an embolic event,
he frequency of recurrence is as high as 15 to 40 events per
00 patient-months (417–421).
There are no randomized trials examining the efficacy ofnticoagulation in preventing embolic events specifically in satients with MS. Retrospective studies have shown a 4- to
5-fold decrease in the incidence of embolic events with
nticoagulation in these patients (417,421). This benefit
pplies to both systemic and pulmonary embolism. Most
rials involved patients who had 1 embolus before the onset
f anticoagulation therapy (421). However, large random-
zed trials have demonstrated a significant reduction in
mbolic events by treatment with anticoagulation in subsets
f patients with atrial fibrillation not associated with MS
425,426). In these randomized trials, the subset of patients
ho benefited most from anticoagulation were those with
he highest risk of embolic events (353,354). Patients with
S at the highest risk for future embolic events are those
ith prior embolic events and those with paroxysmal or
ersistent atrial fibrillation (367,368,416–418,421). Parox-
smal atrial fibrillation may be difficult to detect; ambulatory
CG monitoring is valuable in patients with palpitations.
here are no data to support the concept that oral antico-
gulation is beneficial in patients with MS who have not
ad atrial fibrillation or an embolic event. It is controversial
hether patients without atrial fibrillation or an embolic
vent who might be at higher risk for future embolic events
i.e., those with severe MS or an enlarged left atrium)
hould be considered for long-term warfarin therapy
423,427).
Although embolic events are thought to originate from
eft atrial thrombi (417,418), the presence or absence of a
eft atrial thrombus does not appear to correlate with
mbolic events (367,418). Left atrial thrombi are found
uring surgery in 15% to 20% of patients with prior embolic
vents and a similar number of patients without embolic
vents (367,416). However, in clinical practice, anticoagu-
ation is frequently used if obvious left atrial thrombi are
etected.
It has been suggested that surgical commissurotomy
educes the incidence of future embolic events (381). There
re no randomized trial data to support this hypothesis, and
he retrospective studies that have been reported were
erformed before the availability of standardized anticoag-
lation regimens. Other retrospective studies have con-
luded that surgery does not decrease the incidence of
ystemic emboli (380,428,429). One prospective study has
eported decreased risk for arterial embolism after mitral
ommissurotomy (430).
.4.4. Recommendations Regarding Physical Activity
nd Exercise
any patients with mild MS will remain asymptomatic
ven with strenuous exercise. In more severe MS, exercise
an cause sudden marked increases in pulmonary venous
ressure from the increase in heart rate and cardiac output,
t times resulting in pulmonary edema (375,376). The
ong-term effects of repeated exertion-related increases in
ulmonary venous and pulmonary artery pressures on the
ung or right ventricle remain unknown. MS rarely causes
udden death (367–369). These factors must be considered
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineshen recommending physical activity and exercise for the
atient with MS.
In the majority of patients with MS, recommendations
or exercise are symptom limited. Patients should be en-
ouraged to pursue a low-level aerobic exercise program for
aintenance of cardiovascular fitness. Exertional symptoms
f dyspnea are the limiting factors in terms of exercise
olerance. However, there is a subset of asymptomatic
atients who wish to participate in competitive athletics
ho may deny symptoms. The 36th Bethesda Conference
n Recommendations for Determining Eligibility for Com-
etition in Athletes with Cardiovascular Abnormalities
ublished guidelines for patients with MS who wish to
ngage in competitive athletics (138).
.4.5. Serial Testing
erial follow-up testing of a patient with MS should be
ased on whether the results of a test will dictate either a
hange in therapy or a recommendation for a procedure.
atients with MS usually have years without symptoms
efore the onset of deterioration (367,380). All patients
hould be informed that any change in symptoms warrants
e-evaluation. In the asymptomatic patient, yearly re-
valuation is recommended (Fig. 5). At the time of the
early evaluation, a history, physical examination, chest
-ray, and ECG should be obtained. Physical examination
s useful to assess the progression of the severity of MS. A
hortening of the A2-OS interval, longer duration of the
iddiastolic murmur, and the presence of findings of
ulmonary hypertension indicates more severe MS. An
chocardiogram is not recommended yearly unless there is a
hange in clinical status or the patient has severe MS.
mbulatory ECG monitoring (Holter or event recorder) to
etect paroxysmal atrial fibrillation is indicated in patients
ith palpitations.
.4.6. Evaluation of the Symptomatic Patient
atients who develop symptoms should undergo evaluation
ith a history, physical examination, ECG, chest X-ray, and
chocardiogram (Figs. 6 and 7). Two-dimensional and
oppler echocardiography is indicated to evaluate MV
orphology, MV hemodynamics, and pulmonary artery
ressure. Patients with NYHA functional class II symptoms
nd moderate or severe MS (MV area less than or equal to
.5 cm2 or mean gradient greater than 5 mm Hg) may be
onsidered for mitral balloon valvotomy if they have suitable
V morphology and no left atrial thrombi. Patients who
ave NYHA functional class III or IV symptoms and
vidence of severe MS have a poor prognosis if left un-
reated (367–369) and should be considered for intervention
ith either balloon valvotomy or surgery.
A subset of patients have significant limiting symptoms,
et clinical and Doppler echocardiographic evaluation do
ot indicate moderate or severe MS. In such patients,
ormal exercise testing or dobutamine stress may be useful to
ifferentiate symptoms due to MS from other causes of gymptoms. Exercise tolerance, heart rate and blood pressure
esponse, transmitral gradient, and pulmonary artery pres-
ure can be obtained at rest and during exercise. This can
sually be accomplished with either supine bicycle or up-
ight exercise testing with Doppler recording of TR and
ransmitral velocities (406–409). Right- and left-heart
atheterization with exercise may be helpful and occasion-
lly necessary (431). Patients who are symptomatic with a
ignificant elevation of pulmonary artery pressure (greater
han 60 mm Hg), mean transmitral gradient (greater than
5 mm Hg), or pulmonary artery wedge pressure (greater
han 25 mm Hg) during exercise (375,407–409,432,433)
ave hemodynamically significant MS and should be con-
idered for further intervention. Alternatively, patients who
o not manifest elevation in either pulmonary artery, pul-
onary artery wedge, or transmitral pressures coincident
ith development of exertional symptoms most likely would
ot benefit from intervention on the MV.
.4.7. Indications for Invasive Hemodynamic Evaluation
lass I
. Cardiac catheterization for hemodynamic evaluation
should be performed for assessment of severity of MS
when noninvasive tests are inconclusive or when
there is discrepancy between noninvasive tests and
clinical findings regarding severity of MS. (Level of
Evidence: C)
. Catheterization for hemodynamic evaluation includ-
ing left ventriculography (to evaluate severity of MR)
for patients with MS is indicated when there is a
discrepancy between the Doppler-derived mean gra-
dient and valve area. (Level of Evidence: C)
lass IIa
. Cardiac catheterization is reasonable to assess the
hemodynamic response of pulmonary artery and left
atrial pressures to exercise when clinical symptoms
and resting hemodynamics are discordant. (Level of
Evidence: C)
. Cardiac catheterization is reasonable in patients with
MS to assess the cause of severe pulmonary arterial
hypertension when out of proportion to severity of
MS as determined by noninvasive testing. (Level of
Evidence: C)
lass III
Diagnostic cardiac catheterization is not recom-
mended to assess the MV hemodynamics when 2D
and Doppler echocardiographic data are concordant
with clinical findings. (Level of Evidence: C)
Hemodynamic measurements by cardiac catheterization can
e used to determine the severity of MS. Direct measurements
f left atrial and LV pressure determine the transmitral
radient, which is the fundamental expression of severity of
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ACC/AHA Practice Guidelines August 1, 2006:e1–148S (372). Because the severity of obstruction is dependent on
oth flow and gradient (376), the hydraulic Gorlin equation
as been used in the catheterization laboratory to derive a
alculated valve area (139). Pulmonary artery pressure and
ulmonary vascular resistance can be measured to determine
he effect of MS on the pulmonary circulation.
With the advent of Doppler echocardiography, cardiac
atheterization is no longer required for assessment of
emodynamics in the majority of patients with isolated MS.
eliable measurements of the transmitral gradient may be
btained with the modified Bernoulli equation (389,391).
he potential problems of angle dependence, pressure
ecovery, proximal acceleration, and inadequate velocity
ignals that occur in the evaluation of other valve lesions are
ot present with MS. There is often overestimation of the
igure 6. Management strategy for patients with mitral stenosis and mild sym
f mitral valve area (MVA) and that the mean transmitral gradient, pulmona
hould also be taken into consideration. †There is controversy as to whether p
ypertension (PH; PASP greater than 60 to 80 mm Hg) should undergo perc
revent right ventricular failure. CXR indicates chest X-ray; ECG, electrocard
ean mitral valve pressure gradient; NYHA, New York Heart Association; Pransmitral gradient when catheterization is performed with vulmonary artery wedge pressure as a substitute for left atrial
ressure, even after correction for phase delay. Thus, the
ransmitral gradient derived by Doppler echocardiography
ay be more accurate than that obtained by cardiac cathe-
erization with pulmonary artery wedge pressure (434).
MV area is derived from either the half-time method or
he continuity equation by Doppler echocardiography.
hese measurements correlate well in most instances with
alve areas from cardiac catheterization (401,402). The
oppler half-time method may be inaccurate if there are
hanges in compliance of the left atrium or left ventricle
402,403), especially after mitral balloon valvotomy, or if
here is concomitant AR. There are limitations to MV area
alculations derived from catheter hemodynamic measure-
ents, because the Gorlin equation may not be valid under
. *The committee recognizes that there may be variability in the measurement
ry wedge pressure (PAWP), and pulmonary artery systolic pressure (PASP)
s with severe mitral stenosis (MVA less than 1.0 cm2) and severe pulmonary
ous mitral balloon valvotomy (PMBV) or mitral valve replacement (MVR) to
m; echo, echocardiography; LA, left atrial; MR, mitral regurgitation; MVG,
pulmonary artery pressure; and 2D, 2-dimensional.ptoms
ry arte
atient
utane
iograarying hemodynamic conditions, and the empirical coeffi-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesient of discharge may be inaccurate with different orifice
hapes (379,404). Calculation of valve area by catheteriza-
ion is also dependent on measurement of transmitral
radient and cardiac output. Gradients may be inaccurate
hen pulmonary artery wedge pressure is used, as may
ardiac output derived by the thermodilution method.
hen there is concomitant MR, measures of forward flow
y thermodilution or the Fick method will result in under-
stimation of the MV area, as discussed in Section 3.7.2.2.2.
igure 7. Management strategy for patients with mitral stenosis and mode
ariability in the measurement of mitral valve area (MVA) and that the
ulmonary artery systolic pressure (PASP) should also be taken into con
orphology should undergo percutaneous mitral balloon valvotomy (PM
lectrocardiography; echo, echocardiography; LA, left atrial; MR, mitral
eplacement; NYHA, New York Heart Association; and 2D, 2-dimensionhus, there may be inaccuracies with both Doppler and Datheter-derived valve areas, and a single valve area should
ot be the sole measure of MS severity. Estimates of the
everity of MS should be based on all data, including
ransmitral gradient, MV area, pulmonary artery wedge
ressure, and pulmonary artery pressure.
In most instances, Doppler measurements of transmitral
radient, valve area, and pulmonary pressure will correlate
ell with each other. Catheterization is indicated to assess
emodynamics when there is a discrepancy between
o severe symptoms. *The writing committee recognizes that there may be
n transmitral gradient, pulmonary artery wedge pressure (PAWP), and
ation. †It is controversial as to which patients with less favorable valve
rather than mitral valve surgery (see text). CXR, chest X-ray; ECG,
gitation; MVG, mean mitral valve pressure gradient; MVR, mitral valverate t
mea
sider
BV)
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ACC/AHA Practice Guidelines August 1, 2006:e1–148ymptomatic patient. Absolute left- and right-side pressure
easurements should be obtained by catheterization when
here is elevation of pulmonary artery pressure out of
roportion to mean gradient and valve area. Invasive hemo-
ynamic evaluation is also necessary to assess the severity
nd the hemodynamic cause of increased pulmonary vascu-
ar resistance, because pulmonary vasodilator therapy may be
f benefit in such patients. Catheterization including left
entriculography (to evaluate the severity of MR) is indi-
ated when there is a discrepancy between the Doppler-
erived mean gradient and valve area. Aortic root angiog-
aphy may be necessary to evaluate severity of AR. If
ymptoms appear to be out of proportion to noninvasive
ssessment of resting hemodynamics, right- and left-heart
atheterization with exercise may be useful. Transseptal
atheterization may rarely be required for direct measure-
ent of left atrial pressure if there is doubt about the
ccuracy of pulmonary artery wedge pressure. Coronary
ngiography may be required in selected patients who may
eed intervention (see Section 10.2.).
.4.8. Indications for Percutaneous Mitral Balloon
alvotomy
lass I
. Percutaneous mitral balloon valvotomy is effective
for symptomatic patients (NYHA functional class II,
III, or IV), with moderate or severe MS* and valve
morphology favorable for percutaneous mitral bal-
loon valvotomy in the absence of left atrial thrombus
or moderate to severe MR. (Level of Evidence: A)
. Percutaneous mitral balloon valvotomy is effective
for asymptomatic patients with moderate or severe
MS* and valve morphology that is favorable for
percutaneous mitral balloon valvotomy who have
pulmonary hypertension (pulmonary artery systolic
pressure greater than 50 mm Hg at rest or greater
than 60 mm Hg with exercise) in the absence of left
atrial thrombus or moderate to severe MR. (Level of
Evidence: C)
lass IIa
Percutaneous mitral balloon valvotomy is reasonable
for patients with moderate or severe MS* who have a
nonpliable calcified valve, are in NYHA functional
class III–IV, and are either not candidates for surgery
or are at high risk for surgery. (Level of Evidence: C)
lass IIb
. Percutaneous mitral balloon valvotomy may be con-
sidered for asymptomatic patients with moderate or
severe MS* and valve morphology favorable for per-
cutaneous mitral balloon valvotomy who have new
onset of atrial fibrillation in the absence of left atrial
thrombus or moderate to severe MR. (Level of Evi-
dence: C) b. Percutaneous mitral balloon valvotomy may be con-
sidered for symptomatic patients (NYHA functional
class II, III, or IV) with MV area greater than 1.5 cm2
if there is evidence of hemodynamically significant
MS based on pulmonary artery systolic pressure
greater than 60 mm Hg, pulmonary artery wedge
pressure of 25 mmHg or more, or mean MV gradient
greater than 15 mm Hg during exercise. (Level of
Evidence: C)
. Percutaneous mitral balloon valvotomy may be con-
sidered as an alternative to surgery for patients with
moderate or severe MS who have a nonpliable calci-
fied valve and are in NYHA class III–IV. (Level of
Evidence: C)
lass III
. Percutaneous mitral balloon valvotomy is not indicated
for patients with mild MS. (Level of Evidence: C)
. Percutaneous mitral balloon valvotomy should not be
performed in patients with moderate to severe MR or
left atrial thrombus. (Level of Evidence: C)
See Table 4 (27).
The concept of mitral commissurotomy was first pro-
osed by Brunton in 1902, and the first successful surgical
itral commissurotomy was performed in the 1920s. By the
ate 1940s and 1950s, both transatrial and transventricular
losed surgical commissurotomy were accepted clinical pro-
edures. With the development of cardiopulmonary bypass,
pen mitral commissurotomy and replacement of the MV
ecame the surgical procedures of choice for the treatment
f MS. Percutaneous mitral balloon valvotomy emerged in
he mid 1980s. This procedure, in which 1 or more large
alloons is inflated across the MV by a catheter-based
pproach, has become the preferred procedure in selected
atients compared with surgical approaches.
The mechanism of improvement from surgical commis-
urotomy or percutaneous valvotomy is related to the
uccessful opening of commissures that were fused by the
heumatic process. This results in a decrease in gradient and
n increase in the calculated MV area, with resulting
mprovement in clinical symptomatology. The extent of
emodynamic and clinical improvement is dependent on
he magnitude of decrease of transmitral gradient and
ncrease in valve area. Patients with pliable, noncalcified
alves and minimal fusion of the subvalvular apparatus
chieve the best immediate and long-term results when a
ubstantial increase in the valve area can be achieved.
Closed surgical commissurotomy with either a transatrial
r transventricular approach was popularized in the 1950s
nd 1960s. Early and long-term postoperative follow-up
tudies showed that patients had a significant improvement
n symptoms and survival compared with those treated
edically (435–437). Closed commissurotomy remains the
urgical technique of choice in many developing countries,
ut open commissurotomy is the accepted surgical proce-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesure in most institutions in the United States (438–441),
ecause it allows direct inspection of the MV apparatus and,
nder direct vision, division of the commissures, splitting of
used chordae tendineae and papillary muscles, and debride-
ent of calcium deposits. Amputation of the left atrial ap-
endage is recommended to reduce the likelihood of postop-
rative thromboembolic events (442). The results of the
peration are dependent on the morphology of the MV
pparatus and the surgeon’s skill and experience. In patients
ith marked deformity of the MV apparatus, a decision for
V replacement can be made at the time of operation. The
isk of surgery is between 1% and 3%, depending on the
oncomitant medical status of the patient (439–441). Al-
hough there is an inherent bias in the large reported surgical
eries, the 5-year reoperation rate is 4% to 7%, and the 5-year
omplication-free survival rate ranges from 80% to 90%.
Percutaneous mitral balloon valvotomy was first per-
ormed in the early 1980s and became a clinically approved
echnique in 1994. In the past decade, there have been
ajor advances in techniques and equipment, as well as
hanges in patient selection. A double-balloon technique
as the initial procedure used by most investigators. Today,
n hourglass-shaped single balloon (Inoue balloon) is used
y most centers performing the technique. Percutaneous
echanical mitral commissurotomy with a metallic valvo-
ome has been introduced, and the results appear to be
imilar. The advantage of this technique is that multiple
ses of the metallic device after sterilization are feasible and
educe the cost of treatment (443); however, it is not widely
vailable, and there is limited experience with this tech-
ique. The balloon valvotomy procedure itself is technically
hallenging and involves a steep learning curve. There is a
igher success rate and lower complication rate in experi-
nced, high-volume centers (444). Thus, the results of the
rocedure are highly dependent on the experience of the
perators involved, which must be considered when making
ecommendations for proceeding with this technique.
The immediate results of percutaneous mitral valvotomy
re similar to those of mitral commissurotomy (444–453).
he mean valve area usually doubles (from 1.0 to 2.0 cm2),
ith a 50% to 60% reduction in transmitral gradient.
verall, 80% to 95% of patients may have a successful
rocedure, which is defined as a MV area greater than 1.5
m2 and a decrease in left atrial pressure to less than 18 mm
g in the absence of complications. The most common
cute complications reported in large series include severe
R, which occurs in 2% to 10%, and a residual atrial septal
efect. A large atrial septal defect (greater than 1.5:1
eft-to-right shunt) occurs in fewer than 12% of patients
ith the double-balloon technique and fewer than 5% with
he Inoue balloon technique. Smaller atrial septal defects
ay be detected by transesophageal echocardiography in
arger numbers of patients. Less frequent complications
nclude perforation of the left ventricle (0.5% to 4.0%),
mbolic events (0.5% to 3%), and myocardial infarction
0.3% to 0.5%). The mortality rate with balloon valvotomy ln larger series has ranged from 1% to 2% (444–447,453);
owever, with increasing experience with the procedure,
ercutaneous mitral valvotomy can be done in selected
atients with a mortality rate of less than 1% (448).
imultaneous echocardiography may be useful in directing
alloon placement and assessing hemodynamics.
Follow-up information after percutaneous balloon valvot-
my is limited. Event-free survival (freedom from death, repeat
alvotomy, or MV replacement) overall is 50% to 65% over 3
o 7 years, with an event-free survival of 80% to 90% in patients
ith favorable MV morphology (398,446,448–455). More
han 90% of patients free of events remain in NYHA
unctional class I or II after percutaneous mitral valvotomy.
andomized trials have compared percutaneous balloon
alvotomy with both closed and open surgical commissur-
tomy (456–461). These trials, summarized in Table 18,
onsisted primarily of younger patients (aged 10 to 30 years)
ith pliable MV leaflets. There was no significant difference
n acute hemodynamic results or complication rate between
ercutaneous mitral valvotomy and surgery, and early
ollow-up data indicate no difference in hemodynamics,
linical improvement, or exercise time. However, longer-
erm follow-up studies at 3 to 7 years (459,460) indicate
ore favorable hemodynamic and symptomatic results with
ercutaneous balloon valvotomy than with closed commis-
urotomy. Of the 2 studies that compared percutaneous
alloon valvotomy with open commissurotomy, one re-
orted equivalent results (460), and the other showed more
avorable results with open commissurotomy (461). This
atter study included older patients with higher MV scores.
The immediate results, acute complications, and
ollow-up results of percutaneous balloon valvotomy are
ependent on multiple factors. It is of utmost importance
hat this procedure be performed in centers with skilled and
xperienced operators. Other factors include age, NYHA
unctional class, stenosis severity, LV end-diastolic pressure,
ardiac output, and pulmonary artery wedge pressure
446,448,449,453). The underlying MV morphology is the
actor of greatest importance in determining outcome (394–
00,446,449,450,453,454,462), and immediate postval-
otomy hemodynamics are predictive of long-term clin-
cal outcome (448,450,453). Patients with valvular
alcification, thickened fibrotic leaflets with decreased
obility, and subvalvular fusion have a higher incidence
f acute complications and a higher rate of recurrent
tenosis on follow-up (Table 19). Because the success of
he procedure is dependent on the ability to split fused
ommissures, the presence of marked fusion and severe
alcification of commissures is associated with an in-
reased complication rate and higher incidence of recur-
ent symptoms (396 –398). Alternatively, in patients with
oncalcified pliable valves, mild subvalvular fusion, and
o calcium in the commissures, the procedure can be
erformed with a high success rate (greater than 90%),ow complication rate (less than 3%), and sustained
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ACC/AHA Practice Guidelines August 1, 2006:e1–148mprovement in 80% to 90% over a 3- to 7-year follow-up
eriod (397,398,400,446,448,450,453,454).
Relative contraindications to percutaneous balloon val-
otomy include the presence of a left atrial thrombus and
ignificant (3 to 4) MR. Transesophageal echocardiog-
aphy is recommended before the procedure to determine
he presence of left atrial thrombus, specifically examining
he left atrial appendage. If a thrombus is found, 3 months
f anticoagulation with warfarin may result in resolution of
he thrombus. A prognostic model for predicting the
esolution of left atrial thrombi in candidates for percuta-
eous mitral commissurotomy has been suggested. Com-
ined clinical functional class and echocardiographic left
trial thrombus are predictive of the outcome of oral
nticoagulation for thrombus resolution (463).
In centers with skilled, experienced operators, percutane-
us balloon valvotomy should be considered the initial
rocedure of choice for symptomatic patients with moderate
o severe MS who have a favorable valve morphology in the
bsence of significant MR or left atrial thrombus. Echocar-
iographic parameters that can predict the risks of develop-
ng severe MR after percutaneous mitral valvotomy by the
noue technique have been reported (464), and the overall
chocardiographic assessment (397,398,400) identifies pa-
ients with less favorable long-term outcome (Tables 17 and
9). In asymptomatic patients with a favorable valve mor-
hology, percutaneous mitral valvotomy may be considered
f there is evidence of a hemodynamic effect on left atrial
ressure or pulmonary circulation (pulmonary artery systolic
ressure greater than 50 mm Hg at rest or greater than 60
m Hg with exercise); the strength of evidence for this
ecommendation is low because there are no data comparing
he results of percutaneous balloon valvotomy and those of
edical therapy in such asymptomatic patients. It is con-
roversial whether severely symptomatic patients with less
avorable valve morphology should undergo this catheter-
ased procedure (465) (Fig. 7; Table 19). Although there is
higher acute complication rate and a lower event-free
urvival rate (approximately 50% at 5 years in these patients
ompared with 80% to 90% in patients with favorable valve
orphology), this must be weighed against the average
n-hospital mortality of surgical MV replacement of 6%
164,165), which is as high as 16% in low-volume centers
166), and the expected long-term outcome. In many cases,
V replacement is preferable for patients with severe
alvular calcification and deformity.
Patients who are being considered for an intervention
hould undergo evaluation with a history, physical exami-
ation, and 2D and Doppler echocardiographic examina-
ion. The appearance and mobility of the MV apparatus and
ommissures should be evaluated by 2D echocardiography,
nd the transmitral gradient, MV area, and pulmonary
rtery pressure should be obtained from the Doppler exam-
nation. If there is a discrepancy between symptoms and
emodynamics, a formal hemodynamic exercise test may beperformed. Patients thought to be candidates for percuta-Ta
b
P
at
T
u
A
ro
R
ey
B
en
C
o
A
d C
n
e
e
p
p
t
t
s
p
g
n
M
p
e
T
v
e
l
c
w
s
(
3
C
1
2
C
C
T
C
P
D
I
C
P
A
c
alve re
b
e53JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:e1–148 ACC/AHA Practice Guidelineseous mitral valvotomy should undergo transesophageal
chocardiography to rule out left atrial thrombus and to
xamine the severity of MR. If a left atrial thrombus is
resent, a repeat transesophageal echocardiogram can be
erformed after several months of anticoagulation. Percu-
aneous mitral balloon valvotomy may be safely performed if
here has been resolution of the thrombus. If there is a
uspicion that the severity of MR is 3 or 4 based on the
hysical examination or echocardiogram, a left ventriculo-
ram should be performed. Mitral balloon valvotomy should
ot be performed in patients who have grade 3 or 4
R. Percutaneous mitral balloon valvotomy should be
erformed only by skilled operators at institutions with
xtensive experience in performing the technique (444,447).
hus, the decision to proceed with percutaneous balloon
alvotomy or surgical commissurotomy is dependent on the
xperience of the operator and institution. Because of the
ess invasive nature of percutaneous balloon valvotomy
ompared with surgical intervention, appropriate patients
ithout symptoms or those with NYHA functional class II
ymptoms may be considered for catheter-based therapy
Figs. 5 and 6).
.4.9. Indications for Surgery for Mitral Stenosis
lass I
. MV surgery (repair if possible) is indicated in pa-
able 19. Echocardiographic Prediction of Outcome of Percutan
Author, Year
Mean
Follow-Up,
mo Echo Criteria
No. of
Patients
ohen et al., 1992
(446)
36  20 Score less than or
equal to 8
84
Score greater
than 8
52
alacios et al., 1995
(454)
20  12 Score less than or
equal to 8
211
Score greater
than 8
116
ean et al., 1996
(449)
38  16 Score less than or
equal to 8
272
Score 8 to 12 306
Score greater
than 12
24
ung et al., 1996*
(397)
32  18 Group 1 87
Group 2 311
Group 3 130
annan et al., 1997
(398)
22  10 Com Ca 120
Com Ca 29
alacios et al., 2002
(453)
50  44 Score greater
than 8
278
Score less than 8 601
dash indicates that data were not available. Echocardiography (Echo) score based on
hordal fusion, and valve calcification in Iung et al. (397).
Com Ca indicates commissural calcification; FC, functional class; MVR, mitral v
alloon valvotomy.tients with symptomatic (NYHA functional classIII–IV) moderate or severe MS* when 1) percutane-
ous mitral balloon valvotomy is unavailable, 2) per-
cutaneous mitral balloon valvotomy is contraindi-
cated because of left atrial thrombus despite
anticoagulation or because concomitant moderate to
severe MR is present, or 3) the valve morphology is
not favorable for percutaneous mitral balloon valvot-
omy in a patient with acceptable operative risk. (Level
of Evidence: B)
. Symptomatic patients with moderate to severe MS*
who also have moderate to severe MR should receive
MV replacement, unless valve repair is possible at the
time of surgery. (Level of Evidence: C)
lass IIa
MV replacement is reasonable for patients with se-
vere MS* and severe pulmonary hypertension (pul-
monary artery systolic pressure greater than 60) with
NYHA functional class I–II symptoms who are not
considered candidates for percutaneous mitral bal-
loon valvotomy or surgical MV repair. (Level of
Evidence: C)
lass IIb
MV repair may be considered for asymptomatic pa-
tients with moderate or severe MS* who have had
Mitral Balloon Valvotomy
, y Survival
Survival Free
of Events Events
— 68% at 5 y Death, MVR, repeat PMBV
— 28% at 5 y
14 98% at 4 y 98% at 4 y Death, MVR, NYHA FC
III–IV symptoms
11 39% at 4 y 39% at 4 y
13 95% at 4 y — Death
15 83% at 4 y —
15 24% at 4 y —
— 89% at 3 y Death, MVR, repeat PMBV,
FC III–IV symptoms
13 — 78% at 3 y
— 65% at 3 y
— 86% at 3 y Death, MVR, repeat PMBV
— 40% at 3 y
14 82% at 12 y 38% at 12 y Death, MVR, repeat PMBV
14 57% at 12 y 22% at 12 y
g system of Wilkins et al. (400). *Echocardiographic group based on valve flexibility,
placement; NYHA, New York Heart Association; and PMBV, percutaneous mitraleous
Age
—
—
48 
64 
49 
58 
58 
46 
—
—
63 
51 
scorinrecurrent embolic events while receiving adequate
C1
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vorable for repair. (Level of Evidence: C)
lass III
. MV repair for MS is not indicated for patients with
mild MS. (Level of Evidence: C)
. Closed commissurotomy should not be performed in
patients undergoing MV repair; open commissurot-
omy is the preferred approach. (Level of Evidence: C)
See Table 4 (27).
MV replacement is an accepted surgical procedure for
atients with severe MS who are not candidates for surgical
ommissurotomy or percutaneous mitral valvotomy. The
erioperative mortality of MV replacement is dependent on
ultiple factors, including functional status, age, LV func-
ion, cardiac output, concomitant medical problems, and
oncomitant CAD. In the young, healthy person, MV
eplacement can be performed with a risk of less than 5%;
owever, in the older patient with concomitant medical
roblems or pulmonary hypertension at systemic levels, the
erioperative mortality of MV replacement may be as high
s 10% to 20% (166,167). MV replacement with preserva-
ion of subvalvular apparatus aids in maintaining LV func-
ion (466), but this can be particularly difficult in patients
ith rheumatic MS. Alternative approaches to ventricular
reservation exist, such as artificial chordal reconstruction
efore MV replacement (467,468). Complications of MV
eplacement include valve thrombosis, valve dehiscence,
alve infection, valve malfunction, and embolic events.
hese are discussed in Section 7.3. There is also the known
isk of long-term anticoagulation in patients receiving
echanical prostheses.
If there is significant calcification, fibrosis, and subvalvu-
ar fusion of the MV apparatus, commissurotomy or percu-
aneous balloon valvotomy is less likely to be successful, and
V replacement will be necessary. Given the risk of MV
eplacement and the potential long-term complications of a
rosthetic valve, there are stricter indications for MV
peration in these patients with calcified fibrotic valves. In
he patient with NYHA functional class III symptoms due
o severe MS or combined MS/MR, MV replacement
esults in excellent symptomatic improvement. Postpone-
ent of surgery until the patient reaches the functional class
V symptomatic state should be avoided, because operative
ortality is high and the long-term outcome is suboptimal.
owever, if the patient presents in NYHA functional class
V heart failure, surgery should not be denied, because the
utlook without surgical intervention is grave. It is
ontroversial whether asymptomatic or mildly symptom-
tic patients with severe MS (valve area less than 1 cm2)
nd severe pulmonary hypertension (pulmonary artery
ystolic pressure greater than 60 to 80 mm Hg) should
ndergo MV replacement to prevent RV failure, but
urgery is generally recommended in such patients. It is recognized that patients with such severe pulmonary
ypertension are rarely asymptomatic.
.4.10. Management of Patients After Valvotomy or
ommissurotomy
ymptomatic improvement occurs almost immediately after
uccessful percutaneous balloon valvotomy or surgical com-
issurotomy, although objective measurement of maximum
xygen consumption may continue to improve over several
onths postoperatively owing to slowly progressive im-
rovement in skeletal muscle metabolism (469). Hemody-
amic measurements before and after either percutaneous
alvotomy or surgical commissurotomy have confirmed a
ecrease in left atrial pressure, pulmonary artery pressure,
nd pulmonary arteriolar resistance and an improvement in
ardiac output (470–473). In patients with significant right
eart failure after catheter-based or surgical relief of MV
bstruction, inhaled nitric oxide, intravenous prostacyclin,
r an endothelin antagonist may be useful in reducing
ulmonary vascular resistance and pulmonary hypertension
474). Gradual regression of pulmonary hypertension over
onths has been demonstrated (470–472).
Recurrent symptoms after successful surgical commissur-
tomy have been reported to occur in as many as 60% of
atients after 9 years (405,435,475); however, recurrent
tenosis accounts for symptoms in fewer than 20% of
atients (475). In patients with an adequate initial result,
rogressive MR and development of other valvular or
oronary problems are more frequently responsible for
ecurrent symptoms (475). Thus, in patients presenting
ith symptoms late after commissurotomy, a comprehen-
ive evaluation is required to look for other causes. Patients
ndergoing percutaneous mitral valvotomy with an unfavor-
ble MV morphology have a higher incidence of recurrent
ymptoms at 1- to 2-year follow-up due to either an initial
nadequate result or restenosis (476).
The management of patients after successful percutane-
us balloon valvotomy or surgical commissurotomy is sim-
lar to that of the asymptomatic patient with MS. A baseline
chocardiogram should be performed after the procedure to
btain a baseline measurement of postoperative hemody-
amics and to exclude significant complications such as
R, LV dysfunction, or atrial septal defect (in the case of
ercutaneous valvotomy). This echocardiogram should be
erformed at least 72 h after the procedure, because acute
hanges in atrial and ventricular compliance immediately
fter the procedure affect the reliability of the half-time in
alculation of valve area (402,403). Patients with severe MR
r a large atrial septal defect should be considered for early
urgery; however, the majority of small left-to-right shunts
t the atrial level will close spontaneously over the course of
months. In patients with a history of atrial fibrillation,
arfarin should be restarted 1 to 2 days after the procedure.
A history, physical examination, chest X-ray, and ECG
hould be obtained at yearly intervals in the patient who
emains asymptomatic or minimally symptomatic. Prophylaxis
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesgainst infective endocarditis (Section 2.3.1) and recurrence of
heumatic fever (Section 2.3.2.3; Table 11) (45) should be
ollowed. If the patient is in atrial fibrillation or has a history of
trial fibrillation, anticoagulation is recommended, as would be
he case for all patients with MS. With recurrent symptoms,
xtensive 2D and Doppler echocardiography should be per-
ormed to evaluate the MV hemodynamics and pulmonary
rtery pressure and to rule out significant MR or a left-to-right
hunt. As with all patients with MS, exercise hemodynamics
ay be indicated in the patient with a discrepancy in clinical
nd hemodynamic findings.
Repeat percutaneous balloon valvotomy can be per-
ormed in the patient in whom there is restenosis after
ither a prior surgical commissurotomy or a balloon
alvotomy (378,477). The results of these procedures are
dequate in many patients but may be less satisfactory
han the overall results of initial valvotomy, because there
s usually more valve deformity, calcification, and fibrosis
han with the initial procedure (395,477,478). MV re-
lacement should be considered in those patients with
ecurrent severe symptoms and severe deformity of the
itral apparatus.
.4.11. Special Considerations
.4.11.1. Pregnant Patients
S often affects young women who are in their childbear-
ng years. The increased intravascular volume, increased
ardiac output, and tachycardia associated with pregnancy
ay raise complex issues in the patient with MS and are
eviewed in Section 5.5.1. Percutaneous mitral valvuloplasty
an be performed with few or no complications to the
other or the fetus and excellent clinical and hemodynamic
esults (479).
.4.11.2. Older Patients
n increasing number of older patients now present with
ymptomatic MS, most likely due to a change in the natural
istory of the disease (383,384). Older patients are more
ikely to have heavy calcification and fibrosis of the MV
eaflets, with significant subvalvular fusion. In patients older
han 65 years, the success rate of percutaneous valvotomy is
ower (less than 50%) than in prior reports of younger
atients. Procedural mortality is 3%, and there is an in-
reased risk of complications, including pericardial tampon-
de in 5% and thromboembolism in 3%; however, in
elected patients with favorable valve morphology, the
rocedure may be done safely with good intermediate-term
esults (384). The long-term clinical improvement is con-
iderably less and mortality is higher in older than younger
atients (480).
.5. Mitral Valve Prolapse
.5.1. Pathophysiology and Natural History
VP refers to a systolic billowing of 1 or both mitral leaflets
nto the left atrium with or without MR. Utilizing current tchocardiographic criteria for diagnosing MVP (valve pro-
apse of 2 mm or more above the mitral annulus in the
ong-axis parasternal view and other views [481]), the
revalence of this entity is 1% to 2.5% of the population
482). MVP occurs as a clinical entity with or without
hickening (5 mm or greater, measured during diastasis) and
ith or without MR.
Primary MVP can be familial or nonfamilial. There is
nterchordal hooding due to leaflet redundancy that includes
oth the rough and clear zones of the involved leaflets (483).
he basic microscopic feature of primary MVP is marked
roliferation of the spongiosa, the delicate myxomatous
onnective tissue between the atrialis (a thick layer of
ollagen and elastic tissue that forms the atrial aspect of the
eaflet) and the fibrosa or ventricularis (dense layer of
ollagen that forms the basic support of the leaflet). Myx-
matous proliferation of the acid mucopolysaccharide–
ontaining spongiosa tissue causes focal interruption of the
brosa. Secondary effects of the primary MVP syndrome
nclude fibrosis of the surface of the MV leaflets, thinning
nd/or elongation of the chordae tendineae, and ventricular
riction lesions. Fibrin deposits often form at the MV–left
trial angle.
Familial MVP is transmitted as an autosomal trait
484,485), and several chromosomal loci have been identi-
ed (486–488). Primary MVP occurs with increased fre-
uency in patients with Marfan syndrome and other con-
ective tissue diseases (483,489 – 491). It has been
peculated that the primary MVP syndrome represents a
eneralized disease of connective tissue. The increased
ncidence of MVP in Von Willebrand’s disease and other
oagulopathies, primary hypomastia, and various connective
issue diseases has been used to support the concept that
ncreased incidence of MVP is a result of defective embry-
genesis of cell lines of mesenchymal origin (492). Thoracic
keletal abnormalities such as straight thoracic spine and
ectus excavatum are commonly associated with MVP.
The auscultatory findings in MVP, when present, may
onsist of a click or multiple clicks that move within systole
ith changes in LV dimensions and/or a late systolic or
olosystolic murmur of MR. There may be left atrial
ilatation and LV enlargement, depending on the presence
nd severity of MR. Involvement of other valves may occur.
ricuspid valve prolapse may occur in 40% of patients with
VP (485). Pulmonic and aortic valve prolapses occur in
% to 10% of patients with MVP (483). There is an
ncreased incidence of associated secundum atrial septal
efect and/or left-sided atrioventricular bypass tracts and
upraventricular arrhythmias.
The natural history of asymptomatic MVP is heteroge-
eous and can vary from benign and normal life expectancy
o adverse with significant morbidity or mortality. The
pectrum of MR ranges from absent to severe. The most
requent predictor of cardiovascular mortality is moderate to
evere MR and, less frequently, an LV ejection fraction less
han 0.50 (493). Echocardiographic evidence of thickened
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ACC/AHA Practice Guidelines August 1, 2006:e1–148V leaflets (5 mm or greater) is also a predictor of
omplications related to MVP (Table 20) (494–499). In
ost patients, the MVP syndrome is associated with a
enign prognosis (500,501). The age-adjusted survival rate
or both men and women with MVP is similar to that of
ndividuals without this entity (485).
The gradual progression of MR in patients with MVP
ay result in the progressive dilatation of the left atrium and
entricle. Left atrial dilatation may result in atrial fibrilla-
ion, and moderate to severe MR may eventually result in
V dysfunction and congestive heart failure (502). Pulmo-
ary hypertension may occur, with associated RV dysfunc-
ion. In some patients, after an initially prolonged asymp-
omatic interval, the entire process may enter an accelerated
hase as a result of left atrial and ventricular dysfunction and
trial fibrillation. In some instances, spontaneous rupture of
V chordae will occur (502). Infective endocarditis is a
erious complication of MVP, which is the leading predis-
osing cardiovascular diagnosis in most series of patients
eported with endocarditis (490,502,503). Because the ab-
olute incidence of endocarditis is extremely low for the
ntire population with MVP, there is much controversy
bout the risk of endocarditis in MVP (504).
Fibrin emboli are responsible in patients with visual
ymptoms consistent with involvement of the ophthalmic or
osterior cerebral circulation (505). Several studies have
ndicated an increased likelihood of cerebrovascular acci-
ents in patients under age 45 years who have MVP beyond
hat would have been expected in a similar population
ithout MVP (506).
Sudden death is a rare complication of MVP, occurring
n fewer than 2% of known cases during long-term
ollow-up (495,500 –511), with annual mortality rates
ess than 1% per year. The likely cause is a ventricular
achyarrhythmia, given the finding of increased incidence
f complex ventricular ectopy on ambulatory ECG re-
able 20. Use of Echocardiography for Risk Stratification in Mit
Study, Year
No. of
Patients Features Exa
handraratna et al., 1984 (494) 86 MV leaflets greater
ishimura et al., 1985 (495) 237 MV leaflet 5 mm or
LVID 60 mm or gr
arks et al., 1989 (496) 456 MV leaflet 5 mm or
akamoto et al., 1991 (497) 142 MV leaflet 3 mm or
redundant, low ec
abuty et al., 1994 (498) 58 Undefined MV thic
uppiroli et al., 1994 (499) 119 MV leaflet greater t
eprinted from the ACC/AHA/ASE 2004 Guidelines for the Clinical Application
LVID indicates left ventricular internal diameter; MR, mitral regurgitation; MV,
rolapse. 1 indicates increase.ordings in patients with MVP who had sudden death a512,513). Although infrequent, the highest incidence of
udden death has been reported in the familial form of
VP; some patients have also been noted to have QT
rolongation (502,514).
.5.2. Evaluation and Management of the Asymptom-
tic Patient
lass I
Echocardiography is indicated for the diagnosis of
MVP and assessment of MR, leaflet morphology, and
ventricular compensation in asymptomatic patients
with physical signs of MVP. (Level of Evidence: B)
lass IIa
. Echocardiography can effectively exclude MVP in
asymptomatic patients who have been diagnosed
without clinical evidence to support the diagnosis.
(Level of Evidence: C)
. Echocardiography can be effective for risk stratifica-
tion in asymptomatic patients with physical signs of
MVP or known MVP. (Level of Evidence: C)
lass III
. Echocardiography is not indicated to exclude MVP in
asymptomatic patients with ill-defined symptoms in
the absence of a constellation of clinical symptoms or
physical findings suggestive of MVP or a positive
family history. (Level of Evidence: B)
. Routine repetition of echocardiography is not indi-
cated for the asymptomatic patient who has MVP
and no MR or MVP and mild MR with no changes
in clinical signs or symptoms. (Level of Evidence: C)
The primary diagnostic evaluation of the patient with
VP is the physical examination (502,515). The principal
alve (MV) Prolapse
d Outcome p <
5 mm 1 Cardiovascular abnormalities (60% vs. 6%;
Marfan syndrome, TVP, MR, dilated
ascending aorta)
0.001
ter 1 Sum of sudden death, endocarditis, and
cerebral embolus
0.02
1 MVR (26% vs. 3.1%) 0.001
ter 1 Endocarditis (3.5% vs. 0%) 0.02
1 Moderate-severe MR (11.9% vs. 0%) 0.001
1 MVR (6.6% vs. 0.7%) 0.02
1 Stroke (7.5% vs. 5.8%) NS
ter,
stiny
1 Ruptured chordae (48% vs. 5%)
g No relation to complex ventricular
arrhythmias
NS
mm 1 Complex ventricular arrhythmias 0.001
ocardiography.
valve; MVR, mitral valve replacement; NS, not significant; and TVP, tricuspid valveral V
mine
than
grea
eater
grea
grea
ho de
kenin
han 5
of Echuscultatory feature of this syndrome is the midsystolic click,
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineshigh-pitched sound of short duration. One or more clicks
ay vary considerably in intensity and timing in systole
ccording to LV loading conditions and contractility. Clicks
esult from sudden tensing of the MV apparatus as the leaflets
rolapse into the left atrium during systole. The midsystolic
lick may be followed by a late systolic murmur that is usually
edium to high-pitched and loudest at the cardiac apex.
ccasionally the murmur has a musical or honking quality.
he character and intensity of the murmur also vary under
ertain conditions, from brief and almost inaudible to holosys-
olic and loud. Dynamic auscultation is often useful for
stablishing the diagnosis of MVP syndrome (515). Changes
n LV end-diastolic volume result in changes in the timing of
he midsystolic click(s) and murmur. When end-diastolic
olume is decreased (such as with standing), MVP occurs
arlier in systole and the click-murmur complex occurs shortly
fter the first heart sound. In contrast, any maneuver that
ugments the volume of blood in the ventricle reduces myo-
ardial contractility or increases LV afterload (such as squat-
ing) lengthens the time from onset of systole to occurrence of
VP and the click-murmur complex moves toward the
econd heart sound. MVP can be present in the absence of
hese classic auscultatory findings and the clicks may be
ntermittent and variable.
Although the ECG may provide some information in
atients with MVP, it is often normal. Nonspecific ST-T
ave changes, T-wave inversions, prominent Q waves,
nd prolongation of the QT interval also occur. Contin-
ous ambulatory ECG recordings or event monitors may
e useful for documenting arrhythmias in patients with
alpitations. They are not indicated as a routine test for
symptomatic patients. Most of the arrhythmias detected
re not life threatening and patients often complain of
alpitations when the ambulatory ECG recording shows
o abnormality.
Two-dimensional and Doppler echocardiography is the
ost useful noninvasive test for defining MVP. Valve
rolapse of 2 mm or more above the mitral annulus in the
ong-axis parasternal view and other views, and especially
hen the leaflet coaptation occurs on the atrial side of the
nnular plane, indicates a high likelihood of MVP. There is
isagreement concerning the reliability of echocardio-
raphic appearance of anterior leaflet billowing when ob-
erved only in the apical 4-chamber view (496,516). Leaflet
hickness of 5 mm or more indicates abnormal leaflet
hickness and its added presence makes MVP even more
ertain. Leaflet redundancy is often associated with an
nlarged mitral annulus and elongated chordae tendineae
502). The absence or presence of MR is an important
onsideration and MVP is more likely when MR is detected
s a high velocity eccentric jet in late systole (517).
Reassurance is a major part of the management of
atients with MVP. Patients with mild or no symptoms and
ndings of milder forms of prolapse should be reassured of
he benign prognosis. A normal lifestyle and regular exercise
s encouraged (502, 515).Antibiotic prophylaxis, for the prevention of endocarditis
uring procedures associated with bacteremia, is recom-
ended for most patients with a definite diagnosis of MVP,
articularly if there is associated MR (518). The committee
ecommends that patients without MR but who have leaflet
hickening, elongated chordae, left atrial enlargement or LV
ilatation should receive endocarditis prophylaxis (494–
99) (see Section 2.3.1).
.5.3. Evaluation and Management of the Symptomatic
atient
lass I
. Aspirin therapy (75 to 325 mg per day) is recom-
mended for symptomatic patients with MVP who
experience cerebral transient ischemic attacks. (Level
of Evidence: C)
. In patients with MVP and atrial fibrillation, warfarin
therapy is recommended for patients aged greater
than 65 or those with hypertension, MR murmur, or
a history of heart failure. (Level of Evidence: C)
. Aspirin therapy (75 to 325 mg per day) is recom-
mended for patients with MVP and atrial fibrillation
who are less than 65 years old and have no history of
MR, hypertension, or heart failure. (Level of Evi-
dence: C)
. In patients with MVP and a history of stroke,
warfarin therapy is recommended for patients with
MR, atrial fibrillation or left atrial thrombus. (Level
of Evidence: C)
lass IIa
. In patients with MVP and a history of stroke, who do
not have MR, atrial fibrillation or left artrial throm-
bus, warfarin therapy is reasonable for patients with
echocardiographic evidence of thickening (5mm or
greater) and/or redundancy of the valve leaflets.
(Level of Evidence: C)
. In patients with MVP and a history of stroke, aspirin
therapy is reasonable for patients who do not have
MR, atrial fibrillation, left atrial thrombus, or echo-
cardiographic evidence of thickening (5 mm or
greater) or redundancy of the valve leaflets. (Level of
Evidence: C)
. Warfarin therapy is reasonable for patients with
MVP with transient ischemic attacks despite aspirin
therapy. (Level of Evidence: C)
. Aspirin therapy (75 to 325 mg per day) can be
beneficial for patients with MVP and a history of
stroke who have contraindications to anticoagulants.
(Level of Evidence: B)
lass IIb
Aspirin therapy (75 to 325 mg per day) may be
considered for patients in sinus rhythm with echo-
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Evidence: C)
Some patients consult their physicians about 1 or more of
he common symptoms that occur with this syndrome:
alpitations, often reported at a time when continuous
mbulatory ECG recordings show no arrhythmias; atypical
hest pain that rarely resembles classic angina pectoris;
yspnea and fatigue, when objective exercise testing often
ails to show any impairment in exercise tolerance; and
europsychiatric complaints, with many patients having
anic attacks and similar syndromes (502). Bankier and
ittman report that a significant number of patients with
goraphobia also have MVP; that 45% of patients with
anic disorder have MVP; and that significant predictors for
alpitations in these patients are depression, poor self-rated
ealth, alcohol intoxication in women, and heavy coffee
rinking and physical inactivity in men (519).
Transient cerebral ischemic episodes occur with increased
ncidence in patients with MVP, and some patients develop
troke syndromes. Reports of amaurosis fugax, homonymous
eld loss, and retinal artery occlusion have been described;
ccasionally, the visual loss persists (506,520–522).
The roles of cardiac auscultation and echocardiography in
he assessment of symptomatic patients with MVP are the
ame as for patients without symptoms. The indications for
ntibiotic prophylaxis to prevent endocarditis are also un-
hanged.
Patients with MVP and palpitations associated with mild
achyarrhythmias or increased adrenergic symptoms and
hose with chest pain, anxiety, or fatigue often respond to
herapy with beta blockers (523). In many cases, however,
he cessation of stimulants such as caffeine, alcohol, and
igarettes may be sufficient to control symptoms. In patients
ith recurrent palpitations, continuous or event-activated
mbulatory ECG recordings may reveal the presence or
bsence of arrhythmias at the time of symptoms and
ndicate appropriate treatment of existing arrhythmias. The
ndications for electrophysiological testing are similar to
hose in the general population (e.g., aborted sudden death,
ecurrent syncope of unknown cause, and symptomatic or
ustained ventricular tachycardia) (524).
Orthostatic symptoms due to postural hypotension and
achycardia are best treated with volume expansion, prefer-
bly by liberalizing fluid and salt intake. Mineralocorticoid
herapy or clonidine may be needed in severe cases, and it
ay be beneficial to have the patient wear support stockings.
Daily aspirin therapy (75 to 325 mg per day) is recom-
ended for MVP patients with documented transient focal
eurological events who are in sinus rhythm with no atrial
hrombi. Such patients also should avoid cigarettes and oral
ontraceptives. The American Stroke Association guidelines
524a) recommend aspirin for patients with MVP who have
xperienced an ischemic stroke (class IIa, level of evidence
), based on the evidence of efficacy of antiplatelet agentsor general stroke patients. No randomized trials have lddressed the efficacy of selected antithrombotic therapies
or the specific subgroup of stroke patients with MVP. In
he current guidelines, the committee recommends aspirin
or those post-stroke patients with MVP who have no
vidence of MR, atrial fibrillation, left atrial thrombus, or
chocardiographic evidence of thickening (5 mm or greater)
r redundancy of the valve leaflets. However, long-term
nticoagulation therapy with warfarin is recommended
class I) for post-stroke patients with MVP who have MR,
trial fibrillation, or left atrial thrombus. In the absence of
hese indications, warfarin is also recommended (class IIa)
n post-stroke patients with MVP who have echocardio-
raphic evidence of thickening (5 mm or greater) or redun-
ancy of the valve leaflets and in MVP patients who
xperience recurrent transient ischemic attacks while taking
spirin. In each of these situations, the international nor-
alized ratio (INR) should be maintained between 2.0 and
.0). In MVP patients with atrial fibrillation, warfarin
herapy is indicated in patients aged greater than 65 years
nd in those with MR, hypertension, or a history of heart
ailure (INR 2.0 to 3.0). Aspirin therapy is satisfactory in
atients with atrial fibrillation who are younger than 65
ears old, have no MR, and have no history of hypertension
r heart failure (525,526). Daily aspirin therapy is often
ecommended for patients with high-risk echocardiographic
haracteristics.
A normal lifestyle and regular exercise are encouraged for
ost patients with MVP, especially those who are asymp-
omatic (511,526). Whether exercise-induced ischemia de-
elops in some patients with MVP remains controversial
527,528). Restriction from competitive sports is recom-
ended when moderate LV enlargement, LV dysfunction,
ncontrolled tachyarrhythmias, long-QT interval, unex-
lained syncope, prior resuscitation from cardiac arrest, or
ortic root enlargement is present individually or in combi-
ation (502). A familial occurrence of MVP should be
xplained to the patient and is particularly important in
hose with associated disease who are at greater risk for
omplications. There is no contraindication to pregnancy
ased on the diagnosis of MVP alone.
Asymptomatic patients with MVP and no significant
R can be evaluated clinically every 3 to 5 years. Serial
chocardiography is not necessary in most patients and is
ecommended only in patients who have high-risk charac-
eristics on the initial echocardiogram and in those who
evelop symptoms consistent with cardiovascular disease or
ho have a change in physical findings that suggests
evelopment of significant MR. Patients who have high-
isk characteristics, including those with moderate to severe
R, should be followed up once a year.
Patients with severe MR with symptoms or impaired LV
ystolic function require cardiac catheterization and evalua-
ion for MV surgery (see Section 3.6.4.2). The thickened,
edundant MV can often be repaired rather than replaced
ith a low operative mortality and excellent short- andong-term results (529,530). Follow-up studies also suggest
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han with prosthetic valves.
.5.4. Surgical Considerations
anagement of MVP may require valve surgery, particu-
arly in those patients who develop a flail mitral leaflet due
o rupture of chordae tendineae or their marked elongation.
ost such valves can be repaired successfully by surgeons
xperienced in MV repair, especially when the posterior
eaflet of the MV is predominantly affected. MV repair for
R due to MVP is associated with excellent long-term
urvival and remains superior to MV replacement beyond 10
ears and up to 20 years after surgery (529,530). Anterior
eaflet MV repair is associated with a higher risk for
eoperation than posterior leaflet repair. As noted in Section
.6.4.2, cardiologists are strongly encouraged to refer pa-
ients who are candidates for complex MV repair to surgical
enters experienced in performing MV repair. Residual MR
s associated with a higher risk for reoperation (530).
ymptoms of heart failure, severity of MR, presence or
bsence of atrial fibrillation, LV systolic function, LV
nd-diastolic and end-systolic volumes, and pulmonary
rtery pressure (rest and exercise) all influence the decision
o recommend MV surgery. Recommendations for surgery
n patients with MVP and MR are the same as for those
ith other forms of nonischemic severe MR. For further
etail, please review Section 7.3. on MV surgery.
.6. Mitral Regurgitation
.6.1. Etiology
he common causes of organic MR include MVP syn-
rome, rheumatic heart disease, CAD, infective endocardi-
is, certain drugs, and collagen vascular disease. MR may
lso occur secondary to a dilated annulus from dilatation of
he left ventricle. In some cases, such as ruptured chordae
endineae, ruptured papillary muscle, or infective endocar-
itis, MR may be acute and severe. Alternatively, MR may
orsen gradually over a prolonged period of time. These 2
nds of the spectrum have quite different clinical presenta-
ions.
.6.2. Acute Severe Mitral Regurgitation
.6.2.1. Pathophysiology
n acute severe MR, a sudden volume overload is imposed
n the left atrium and left ventricle. Acute volume overload
ncreases LV preload, allowing for a modest increase in total
V stroke volume (531). However, in the absence of
ompensatory eccentric hypertrophy (which has had no time
o develop), forward stroke volume and cardiac output are
educed. At the same time, the unprepared left atrium and
eft ventricle cannot accommodate the regurgitant volume,
hich causes large v waves in the left atrium and results in
ulmonary congestion. In this phase of the disease, the
atient has both reduced forward output (even shock) and
imultaneous pulmonary congestion. In severe MR, the iemodynamic overload often cannot be tolerated, and MV
epair or replacement must often be performed urgently.
.6.2.2. Diagnosis
he patient with acute severe MR is almost always severely
ymptomatic. Physical examination of the precordium may
e misleading, because a normal-sized left ventricle does not
roduce a hyperdynamic apical impulse. The systolic mur-
ur of MR may not be holosystolic and may even be absent.
third heart sound or early diastolic flow rumble may be
he only abnormal physical finding present. Transthoracic
chocardiography may demonstrate the disruption of the
V and help provide semiquantitative information on
esion severity; however, transthoracic echocardiography
ay underestimate lesion severity by inadequate imaging of
he color flow jet. Thus, if there is hyperdynamic systolic
unction of the left ventricle on a transthoracic echocardio-
ram in a patient with acute heart failure, the suspicion of
evere MR should be raised. Because transesophageal echo-
ardiography can more accurately assess the color flow jet
532), transesophageal imaging should be performed if MV
orphology and regurgitant severity are still in question
fter transthoracic echocardiography. Transesophageal
chocardiography is also helpful in demonstrating the ana-
omic cause of acute severe MR and directing successful
urgical repair.
In the hemodynamically stable patient, if CAD is sus-
ected or there are risk factors for CAD (see Section 10.2),
oronary arteriography is necessary before surgery because
yocardial revascularization should be performed during
V surgery in those patients with concomitant CAD
533,534).
.6.2.3. Medical Therapy
n acute severe MR, medical therapy has a limited role and
s aimed primarily to stabilize hemodynamics in preparation
or surgery. The goal of nonsurgical therapy is to diminish
he amount of MR, in turn increasing forward output and
educing pulmonary congestion. In the normotensive pa-
ient, administration of nitroprusside may effectively accom-
lish all 3 goals. Nitroprusside increases forward output not
nly by preferentially increasing aortic flow but also by
artially restoring MV competence as LV size diminishes
535,536). In the patient rendered hypotensive because of a
evere reduction in forward output, nitroprusside should not
e administered alone, but combination therapy with an
notropic agent (such as dobutamine) and nitroprusside is of
enefit in some patients. In such patients, aortic balloon
ounterpulsation increases forward output and mean arterial
ressure while diminishing regurgitant volume and LV
lling pressure and can be used to stabilize the patient while
hey are prepared for surgery. If infective endocarditis is the
ause of acute MR, identification and treatment of the
nfectious organism are essential.
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.6.3.1. Pathophysiology and Natural History
atients with mild to moderate MR may remain asymp-
omatic with little or no hemodynamic compromise for
any years; however, MR from a primary MV abnormality
ends to progress over time with an increase in volume
verload due to an increase in the effective orifice area.
rogression of the MR is variable and determined by
rogression of lesions or mitral annulus size (537).
Once the MR has become severe, there has been time for
evelopment of eccentric cardiac hypertrophy in which new
arcomeres are laid down in series, which increases the
ength of individual myocardial fibers (228,531). The result-
ng increase in LV end-diastolic volume is compensatory
ecause it permits an increase in total stroke volume, which
llows for restoration of forward cardiac output (538). At
he same time, the increase in LV and left atrial size allows
ccommodation of the regurgitant volume at a lower filling
ressure, and the symptoms of pulmonary congestion abate.
n this phase of compensated MR, the patient may be
ntirely asymptomatic, even during vigorous exercise. It
hould be noted that in the compensatory phase, augmented
reload and reduced or normal afterload (provided by the
nloading of the left ventricle into the left atrium) facilitate
V ejection, which results in a large total stroke volume and
normal forward stroke volume.
The compensated phase of MR is variable but may last
or many years. However, the prolonged burden of volume
verload may eventually result in LV dysfunction. In this
hase, contractile dysfunction impairs ejection, and end-
ystolic volume increases. There may be further LV
ilatation and increased LV filling pressure. These he-
odynamic events result in reduced forward output and
ulmonary congestion. However, the still favorable load-
ng conditions often maintain ejection fraction in the low
ormal range (0.50 to 0.60) despite the presence of
ignificant muscle dysfunction (531,539,540). Correction
f MR should be performed before the advanced phases
f LV decompensation.
Numerous studies indicate that patients with chronic
evere MR have a high likelihood of developing symptoms
r LV dysfunction over the course of 6 to 10 years
518,526,541,542). However, the incidence of sudden death
n asymptomatic patients with normal LV function varies
idely among these studies.
The natural history of severe MR due to a flail posterior
eaflet has been documented (518). At 10 years, 90% of
atients are dead or require MV operation. The mortality
ate in patients with severe MR caused by flail leaflets is 6%
o 7% per year. However, patients at risk of death are
redominantly those with LV ejection fractions less than
.60 or with NYHA functional class III–IV symptoms, and
ess so those who are asymptomatic and have normal LV
unction (518,543). Severe symptoms also predict a poor
utcome after MV repair or replacement (543)..6.3.2. Diagnosis
n evaluating the patient with chronic MR, the history is
nvaluable. A well-established estimation of baseline exer-
ise tolerance is important in gauging the subtle onset of
ymptoms at subsequent evaluations. Physical examination
hould demonstrate displacement of the LV apical impulse,
hich indicates that MR is severe and chronic, producing
ardiac enlargement. A third heart sound or early diastolic
ow rumble is usually present and does not necessarily
ndicate LV dysfunction. Findings consistent with pulmo-
ary hypertension are worrisome because they indicate
dvanced disease with worsened prognosis (544). An ECG
nd chest X-ray are useful in establishing rhythm and for
ssessment of the pulmonary vascularity and pulmonary
ongestion.
.6.3.3. Indications for Transthoracic Echocardiography
lass I
. Transthoracic echocardiography is indicated for
baseline evaluation of LV size and function, RV and
left atrial size, pulmonary artery pressure, and sever-
ity of MR (Table 4) in any patient suspected of
having MR. (Level of Evidence: C)
. Transthoracic echocardiography is indicated for de-
lineation of the mechanism of MR. (Level of Evi-
dence: B)
. Transthoracic echocardiography is indicated for an-
nual or semiannual surveillance of LV function (es-
timated by ejection fraction and end-systolic dimen-
sion) in asymptomatic patients with moderate to
severe MR. (Level of Evidence: C)
. Transthoracic echocardiography is indicated in pa-
tients with MR to evaluate the MV apparatus and LV
function after a change in signs or symptoms. (Level
of Evidence: C)
. Transthoracic echocardiography is indicated to eval-
uate LV size and function and MV hemodynamics in
the initial evaluation after MV replacement or MV
repair. (Level of Evidence: C)
lass IIa
Exercise Doppler echocardiography is reasonable in
asymptomatic patients with severe MR to assess
exercise tolerance and the effects of exercise on
pulmonary artery pressure and MR severity. (Level of
Evidence: C)
lass III
Transthoracic echocardiography is not indicated for
routine follow-up evaluation of asymptomatic pa-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinestients with mild MR and normal LV size and systolic
function. (Level of Evidence: C)
An initial comprehensive 2D, Doppler echocardiogram is
ndispensable in the management of the patient with MR.
he echocardiogram provides a baseline estimation of LV
nd left atrial size, an estimation of LV ejection fraction,
nd approximation of the severity of regurgitation (2).
uantification of the severity of MR (Table 4) (27) is
trongly recommended (27,541,545,546). In the majority of
atients, an estimate of pulmonary artery pressure can be
btained from the TR peak velocity (547). Changes from
hese baseline values are subsequently used to guide the
iming of MV surgery. The blood pressure at the time of
ach study should be documented, because the afterload on
he ventricle will affect the measured severity of the MR.
The initial transthoracic echocardiogram should disclose
he anatomic cause of the MR. A central color flow jet of
R with a structurally normal MV apparatus suggests the
resence of functional MR, which may be due to annular
ilatation from LV dilatation or tethering of the posterior
eaflet because of regional LV dysfunction in patients with
schemic heart disease. An eccentric color flow jet of MR
ith abnormalities of the MV apparatus indicates organic
R. In patients with organic MR, the echocardiogram
hould assess the presence of calcium in the annulus or
eaflets, the redundancy of the valve leaflets, and the MV
eaflet involved (anterior leaflet, posterior leaflet, or bileaf-
et). These factors will help determine the feasibility of valve
epair if surgery is contemplated. The system proposed by
arpentier (548) allows the echocardiographer to focus on
he anatomic and physiologic characteristics of the valve
hat aid the surgeon in planning the repair. The valve
ysfunction is described on the basis of the motion of the
ree edge of the leaflet relative to the plane of the annulus:
ype I, normal; type II, increased, as in MVP; type IIIA,
estricted during systole and diastole, and type IIIB, re-
tricted during systole.
The diagnosis of severe MR should be made by correlat-
ng the findings on physical examination with the findings
rom a comprehensive 2D, Doppler echocardiogram. Mul-
iple parameters from the Doppler examination should be
sed to diagnose severe MR (Table 4) (27), including the
olor flow jet width and area, the intensity of the
ontinuous-wave Doppler signal, the pulmonary venous
ow contour, the peak early mitral inflow velocity, and
uantitative measures of effective orifice area and regurgita-
ion volume (2). In addition, there should be enlargement of
he left ventricle and left atrium in chronic severe MR.
bnormalities of the MV apparatus are often present if
here is severe MR, but ischemic left ventricle dysfunction
ay also result in severe MR. If a discrepancy is present, or
f the patient has poor windows on transthoracic echocar-
iography, then further evaluation of the severity of MR is
equired, including cardiac catheterization, magnetic reso-
ance imaging, or transesophageal echocardiography. w.6.3.4. Indications for Transesophageal Echocardiography
See also Section 8.1.4.)
lass I
. Preoperative or intraoperative transesophageal echo-
cardiography is indicated to establish the anatomic
basis for severe MR in patients in whom surgery is
recommended to assess feasibility of repair and to
guide repair. (Level of Evidence: B)
. Transesophageal echocardiography is indicated for
evaluation of MR patients in whom transthoracic
echocardiography provides nondiagnostic informa-
tion regarding severity of MR, mechanism of MR,
and/or status of LV function. (Level of Evidence: B)
lass IIa
Preoperative transesophageal echocardiography is
reasonable in asymptomatic patients with severe MR
who are considered for surgery to assess feasibility of
repair. (Level of Evidence: C)
lass III
Transesophageal echocardiography is not indicated
for routine follow-up or surveillance of asymptomatic
patients with native valve MR. (Level of Evidence: C)
.6.3.5. Serial Testing
he aim of serial follow-up of the patient with MR is to
ubjectively assess changes in symptomatic status and ob-
ectively assess changes in LV function and exercise toler-
nce that can occur in the absence of symptoms. Asymp-
omatic patients with mild MR and no evidence of LV
nlargement, LV dysfunction, or pulmonary hypertension
an be followed on a yearly basis with instructions to alert
he physician if symptoms develop in the interim. Yearly
chocardiography is not necessary unless there is clinical
vidence that MR has worsened. In patients with moderate
R, clinical evaluation including echocardiography should
e performed annually and sooner if symptoms occur.
Asymptomatic patients with severe MR should be fol-
owed up with history, physical examination, and echocar-
iography every 6 to 12 months to assess symptoms or
ransition to asymptomatic LV dysfunction. Exercise stress
esting may be used to add objective evidence regarding
ymptoms and changes in exercise tolerance. Exercise test-
ng is especially important if a good history of the patient’s
xercise capacity cannot be obtained. Measurement of
ulmonary artery pressure and assessment of severity of MR
uring exercise may be helpful.
Interpretation of LV ejection fraction in the patient with
R is made difficult because the loading conditions present
n MR facilitate ejection and increase ejection fraction, the
tandard guide to LV function. Nonetheless, several studies
ave indicated that the preoperative ejection fraction is an
mportant predictor of postoperative survival in patients
ith chronic MR (539,544,549–551). Ejection fraction in a
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ACC/AHA Practice Guidelines August 1, 2006:e1–148atient with MR with normal LV function is usually greater
han or equal to 0.60. Consistent with this concept, post-
perative ventricular function is lower and survival is re-
uced in patients with a preoperative ejection fraction less
han 0.60 compared with patients with higher ejection
ractions (550,551).
Alternatively or in concert, echocardiographic LV end-
ystolic dimension (or volume) can be used in the timing of
V surgery. End-systolic dimension, which may be less
oad dependent than ejection fraction (552), should be less
han 40 mm preoperatively to ensure normal postoperative
V function (538,551–553). If patients become symptom-
tic, they should undergo MV surgery even if LV function
s normal.
.6.3.6. Guidelines for Physical Activity and Exercise
ecommendations regarding participation in competitive
thletics were published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
138). Asymptomatic patients with MR of any severity who
re in sinus rhythm and who have normal LV and left atrial
imensions and normal pulmonary artery pressure may
xercise without restriction (138). However, those with
efinite LV enlargement (greater than or equal to 60 mm),
ulmonary hypertension, or any degree of LV systolic
ysfunction at rest should not participate in any competitive
ports.
.6.3.7. Medical Therapy
n the asymptomatic patient with chronic MR, there is no
enerally accepted medical therapy. Although intuitively,
he use of vasodilators may appear to be logical for the
ame reasons that they are effective in acute MR, there
re no large, long-term studies to indicate that they are
eneficial. Furthermore, because MR with normal ejec-
ion fraction is a disease in which afterload is not
ncreased (230,538,554,555), drugs that reduce afterload
ight produce a physiological state of chronic low afterload
ith which there is very little experience. There has not
een a consistent improvement in LV volumes and severity
f MR in the small studies that have examined the effect of
CE inhibitors (312,556–558). The beneficial effect seen
n some studies may be more related to blockade of tissue
ngiotensin rather than the vasodilatory effect of the drug
559). Thus, in the absence of systemic hypertension, there
s no known indication for the use of vasodilating drugs or
CE inhibitors in asymptomatic patients with MR and
reserved LV function.
However, in patients with functional or ischemic MR
resulting from dilated or ischemic cardiomyopathy), there
s reason to believe that preload reduction may be beneficial
535). If LV systolic dysfunction is present, primary treat-
ent of the LV systolic dysfunction with drugs such as
CE inhibitors or beta blockers (particularly carvedilol) and
iventricular pacing have all been shown to reduce the
everity of functional MR (560–563). eIn patients with MR who develop symptoms but have
reserved LV function, surgery is the most appropriate
herapy. If atrial fibrillation develops, heart rate should be
ontrolled with rate-lowering calcium channel blockers,
eta blockers, digoxin, or, rarely, amiodarone. In patients
ith severe MR and chronic atrial fibrillation, a Maze
rocedure may be added to an MV repair (see Section
.6.4.2.4), because this will reduce the risk of postoperative
troke. Although the risk of embolism with the combination
f MR and atrial fibrillation was formerly considered similar
o that of MS and atrial fibrillation, subsequent studies
uggest that embolic risk may be less in MR (564,565).
onetheless, it is recommended that the INR be main-
ained at 2 to 3 in this population.
.6.3.8. Indications for Cardiac Catheterization
lass I
. Left ventriculography and hemodynamic measure-
ments are indicated when noninvasive tests are in-
conclusive regarding severity of MR, LV function, or
the need for surgery. (Level of Evidence: C)
. Hemodynamic measurements are indicated when
pulmonary artery pressure is out of proportion to the
severity of MR as assessed by noninvasive testing.
(Level of Evidence: C)
. Left ventriculography and hemodynamic measure-
ments are indicated when there is a discrepancy
between clinical and noninvasive findings regarding
severity of MR. (Level of Evidence: C)
. Coronary angiography is indicated before MV repair
or MV replacement in patients at risk for CAD.
(Level of Evidence: C)
lass III
Left ventriculography and hemodynamic measurements
are not indicated in patients with MR in whom valve
surgery is not contemplated. (Level of Evidence: C)
Cardiac catheterization, with or without exercise, is
ecessary when there is a discrepancy between clinical and
oninvasive findings. Catheterization is also performed
hen surgery is contemplated in cases in which there is still
ome doubt about the severity of MR after noninvasive
esting or when there is a need to assess extent and severity
f CAD preoperatively. In patients with MR who have risk
actors for CAD (e.g., advanced age, hypercholesterolemia,
r hypertension) or when there is a suspicion that MR is
schemic in origin (either because of known myocardial
nfarction or suspected ischemia), coronary angiography
hould be performed before surgery.
Patients should usually not undergo valve surgery unless
he degree of MR is severe. If there is a discrepancy
egarding the severity of MR between the physical exami-
ation or elements of the comprehensive 2D, Doppler
xamination, then transesophageal echocardiography, mag-
n
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesetic resonance imaging, or left ventriculography should be
erformed. Although the standard semiquantitative ap-
roach to determining the severity of MR from ventricu-
ography has its own limitations (566), ventriculography
oes provide an additional method to assess LV dilatation
nd function and gauge the severity of MR. Exercise
emodynamics may provide additional information that is
elpful in decision making.
During the catheterization procedure, a right-heart cath-
terization should be performed if the severity of MR is
ncertain to obtain right-sided pressures to quantify the
ncrease in left atrial pressure (pulmonary artery wedge
ressure) and pulmonary artery pressure. The presence or
bsence of a large v wave has little diagnostic impact when
ombined with data from the rest of the catheterization
567).
.6.4. Indications for Surgery
.6.4.1. Types of Surgery
hree different MV operations are currently used for cor-
ection of MR: 1) MV repair; 2) MV replacement with
reservation of part or all of the mitral apparatus; and 3)
V replacement with removal of the mitral apparatus. Each
rocedure has its advantages and disadvantages, and there-
ore, the indications for each procedure are somewhat
ifferent.
In most cases, MV repair is the operation of choice when
he valve is suitable for repair and appropriate surgical skill
nd expertise are available. This procedure preserves the
atient’s native valve without a prosthesis and therefore
voids the risk of chronic anticoagulation (except in patients
n atrial fibrillation) or prosthetic valve failure late after
urgery. Additionally, preservation of the mitral apparatus
eads to better postoperative LV function and survival than
n cases in which the apparatus is disrupted (545,568–573).
mproved postoperative function occurs with repair because
he mitral apparatus is an integral part of the left ventricle
hat is essential for maintenance of normal shape, volume,
nd function of the left ventricle (574). However, MV repair
s technically more demanding than MV replacement, may
equire longer extracorporeal circulation time, and may
ccasionally fail. Valve morphology and surgical expertise
re of critical importance for the success of valve repair (see
elow).
The reoperation rate after MV repair is similar to the
eoperation rate after MV replacement (530). There is a 7%
o 10% reoperation rate at 10 years in patients undergoing
V repair, usually for severe recurrent MR (530,575–578).
pproximately 70% of the recurrent MR is thought to be
ue to the initial procedure and 30% to progressive valve
isease (575). The reoperation rate is lower in those patients
ho had the initial operation for posterior leaflet abnormal-
ties than in those who had bileaflet or anterior leaflet
bnormalities (518,577).The advantage of MV replacement with preservation of
he chordal apparatus is that this operation ensures postop-
rative MV competence, preserves LV function, and en-
ances postoperative survival compared with MV replace-
ent, in which the apparatus is disrupted (570,579–582).
he disadvantage is the use of a prosthetic valve, with the
isks of deterioration inherent in tissue valves or the need for
nticoagulation inherent in mechanical valves.
MV replacement in which the MV apparatus is resected
hould almost never be performed. It should only be
erformed in those circumstances in which the native valve
nd apparatus are so distorted by the preoperative pathology
rheumatic disease, for example) that the mitral apparatus
annot be spared. As noted previously (Section 3.4.9),
rtificial chordal reconstruction does extend the opportuni-
ies for repair in some such patients with rheumatic MR
467,468).
The advantages of MV repair make it applicable across
he full spectrum of MR, including the 2 extremes of the
pectrum. Valve repair might be possible in patients with
ar-advanced symptomatic MR and depressed LV function
ecause it preserves LV function at the preoperative level
572); MV replacement with disruption of the apparatus in
uch patients could lead to worsened or even fatal LV
ysfunction after surgery. At the other extreme, in the
elatively asymptomatic patient with well-preserved LV
unction, repair of a severely regurgitant valve might be
ontemplated to avoid the onset of ventricular dysfunction
rom longstanding volume overload (583). However, failed
V repair would result in the need for a prosthetic valve;
his would represent a clear complication, because it would
mpose the risks of a prosthesis on a patient who did not
reviously require it. Hence, “prophylactic” surgery in an
symptomatic patient with MR and normal LV function
equires a high likelihood of successful repair.
.6.4.2. Indications for Mitral Valve Operation
lass I
. MV surgery is recommended for the symptomatic
patient with acute severe MR.* (Level of Evidence: B)
. MV surgery is beneficial for patients with chronic
severe MR* and NYHA functional class II, III, or IV
symptoms in the absence of severe LV dysfunction
(severe LV dysfunction is defined as ejection fraction
less than 0.30) and/or end-systolic dimension greater
than 55 mm. (Level of Evidence: B)
. MV surgery is beneficial for asymptomatic patients
with chronic severe MR* and mild to moderate LV
dysfunction, ejection fraction 0.30 to 0.60, and/or
end-systolic dimension greater than or equal to 40
mm. (Level of Evidence: B)
. MV repair is recommended over MV replacement in
the majority of patients with severe chronic MR* who
require surgery, and patients should be referred to
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ACC/AHA Practice Guidelines August 1, 2006:e1–148surgical centers experienced in MV repair. (Level of
Evidence: C)
lass IIa
. MV repair is reasonable in experienced surgical cen-
ters for asymptomatic patients with chronic severe
MR* with preserved LV function (ejection fraction
greater than 0.60 and end-systolic dimension less
than 40 mm) in whom the likelihood of successful
repair without residual MR is greater than 90%.
(Level of Evidence: B)
. MV surgery is reasonable for asymptomatic patients
with chronic severe MR,* preserved LV function, and
new onset of atrial fibrillation. (Level of Evidence: C)
. MV surgery is reasonable for asymptomatic patients
with chronic severe MR,* preserved LV function, and
pulmonary hypertension (pulmonary artery systolic
pressure greater than 50 mm Hg at rest or greater
than 60 mm Hg with exercise). (Level of Evidence: C)
. MV surgery is reasonable for patients with chronic
severe MR* due to a primary abnormality of the
mitral apparatus and NYHA functional class III–IV
symptoms and severe LV dysfunction (ejection frac-
tion less than 0.30 and/or end-systolic dimension
greater than 55 mm) in whom MV repair is highly
likely. (Level of Evidence: C)
lass IIb
MV repair may be considered for patients with
chronic severe secondary MR* due to severe LV
dysfunction (ejection fraction less than 0.30) who
have persistent NYHA functional class III-IV symp-
toms despite optimal therapy for heart failure, in-
cluding biventricular pacing. (Level of Evidence: C)
lass III
. MV surgery is not indicated for asymptomatic pa-
tients with MR and preserved LV function (ejection
fraction greater than 0.60 and end-systolic dimension
less than 40 mm) in whom significant doubt about
the feasibility of repair exists. (Level of Evidence: C)
. Isolated MV surgery is not indicated for patients with
mild or moderate MR. (Level of Evidence: C)
See Table 4 (27).
In many cases, the type of operation, MV repair versus
eplacement, is important in timing surgery. In fact, al-
hough the type of surgery to be performed is never actually
stablished until the operation, many situations lend them-
elves to preoperative prediction of the operation that can be
erformed. This prediction is based on the skill and expe-
ience of the surgeon in performing repair and on the
ocation and type of MV disease that caused the MR.
onrheumatic posterior leaflet prolapse due to degenerative
V disease or a ruptured chordae tendineae can usually be aepaired using a resection of the portion of the valve and an
nnuloplasty (584,585). Involvement of the anterior leaflet
r both anterior and posterior leaflets diminishes the
ikelihood of repair because the operation requires other
nterventions, such as chordal shortening, chordal trans-
er, and innovative anatomic repairs (586 –591). Conse-
uently, the skill and experience of the surgeon are
robably the most important determinants of the even-
ual operation that will be performed. In general, rheu-
atic involvement of the MV and calcification of the MV
eaflets or annulus diminish the likelihood of repair, even
n experienced hands (592).
The number of patients undergoing MV repair for MR
as increased steadily over the past decade in the United
tates and Canada in relation to the number undergoing
V replacement. However, among isolated MV procedures
eported in the STS National Cardiac Database from 1999
o 2000 (593), the frequency of repair was only 35.7% (3027
f a total of 8486 procedures), which suggests that MV
epair is underutilized. The STS National Database also
ndicates an operative mortality rate of under 2% in patients
ndergoing isolated MV repair in 2004, which compares
avorably to the greater than 6% operative mortality rate for
atients undergoing isolated MV replacement (165). Con-
idering the beneficial effect of MV repair on survival and
V function, cardiologists are strongly encouraged to refer
atients who are candidates for MV repair to surgical
enters experienced in performing MV repair.
.6.4.2.1. SYMPTOMATIC PATIENTS WITH NORMAL LEFT
ENTRICULAR FUNCTION. Patients with symptoms of con-
estive heart failure despite normal LV function on echo-
ardiography (ejection fraction greater than 0.60 and end-
ystolic dimension less than 40 mm) require surgery.
urgery should be performed in patients with mild symp-
oms and severe MR (Fig. 8), especially if it appears that
V repair rather than replacement can be performed. The
easibility of repair is dependent on several factors, including
alve anatomy and surgical expertise. Successful surgical
epair improves symptoms, preserves LV function, and
voids the problems of a prosthetic valve. When repair is not
easible, MV replacement with chordal preservation should
elieve symptoms and maintain LV function.
.6.4.2.2. ASYMPTOMATIC OR SYMPTOMATIC PATIENTS
ITH LEFT VENTRICULAR DYSFUNCTION. Preoperative
ariables that are predictive of postoperative survival, symp-
omatic improvement, and postoperative LV function are
ummarized in Table 21 (538,539,544,549–552). The tim-
ng of surgery for asymptomatic patients is controversial, but
ost would now agree that MV surgery is indicated with
he appearance of echocardiographic indicators of LV dys-
unction. These include LV ejection fraction less than or
qual to 0.60 and/or LV end-systolic dimension greater
han or equal to 40 mm (Fig. 8). Surgery performed at this
ime will likely prevent further deterioration in LV function
nd improve longevity. This is true whether repair or
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineseplacement is performed (551), although repair is clearly
referred. It must be emphasized that, unlike with the
iming of AVR for AR, LV ejection fraction should not be
llowed to fall into the lower limit of the normal range in
atients with chronic MR (551,594–596). The data regard-
ng postoperative survival are much stronger with LV
jection fraction than with end-systolic dimension
544,549–551), whereas both ejection fraction and end-
ystolic dimension strongly influence postoperative LV
unction and heart failure (538,539,544,551,552). MV sur-
ery should also be recommended for symptomatic patients
igure 8. Management strategy for patients with chronic severe mitral regu
ith normal left ventricular (LV) function if performed by an experienced
F indicates atrial fibrillation; Echo, echocardiography; EF, ejection fractio
itral valve replacement.ith evidence of LV systolic dysfunction (ejection fraction cess than or equal to 0.60, and/or end-systolic dimension
reater than or equal to 40 mm).
Determining the surgical candidacy of the symptomatic
atient with MR and far-advanced LV dysfunction is a
ommon clinical dilemma. The question that often arises is
hether the patient with MR has such advanced LV
ysfunction that he or she is no longer a candidate for
urgery. Often such cases present difficulty in distinguishing
rimary cardiomyopathy with secondary MR from primary
R with secondary myocardial dysfunction. In the latter
ase, if MV repair appears likely, surgery should still be
ion. *Mitral valve (MV) repair may be performed in asymptomatic patients
al team and if the likelihood of successful MV repair is greater than 90%.
D, end-systolic dimension; eval, evaluation; HT, hypertension; and MVR,rgitat
surgic
n; ESontemplated (Fig. 8). Even though such a patient is likely
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ACC/AHA Practice Guidelines August 1, 2006:e1–148o have persistent LV dysfunction, surgery is likely to
mprove symptoms and prevent further deterioration of LV
unction (328). If MV replacement is necessary in such
atients, it should be performed only if the chordal appa-
atus can be preserved. The modification of MV geometry
y an “undersized” annular ring in patients with severe LV
ysfunction and significant functional MR may be beneficial
n a subset of patients with primary myocardial disease
597–602), although the impact on outcomes compared
ith aggressive medical therapy, including beta blockers and
ardiac resynchronization therapy (560–563), has not been
tudied in a prospective randomized trial.
.6.4.2.3. ASYMPTOMATIC PATIENTS WITH NORMAL LEFT
ENTRICULAR FUNCTION. As noted previously, repair of a
everely regurgitant valve may be contemplated in an
symptomatic patient with severe MR and normal LV
unction to preserve LV size and function and prevent the
equelae of chronic severe MR (541). Although there are no
andomized data with which to recommend this approach
o all patients, the committee recognizes that some experi-
nced centers are moving in this direction for patients for
hom the likelihood of successful repair is high. Natural
istory studies indicate uniformly that asymptomatic pa-
ients with severe MR and normal LV function have a high
ikelihood of developing symptoms and/or LV dysfunction
arranting operation over the course of 6 to 10 years
518,526,541,542). Two recent studies have also addressed
he risk of sudden death (541,542) in asymptomatic patients
ith severe MR and normal LV function. In a long-term
etrospective study in which severity of MR was quantified
y Doppler echocardiography (541), 198 patients with an
ffective orifice area greater than 40 mm2 had a 4% per year
able 21. Preoperative Predictors of Surgical Outcome in Mitral
Study, Year
Study
Design
Type of
Surgery
No. of
Patients
chuler et al.,
1979 (539)
Retrospective MVR 20
hillips et al.,
1981 (549)
Retrospective MVR 105
ile et al.,
1984 (538)
Prospective MVR 16
rawford et al.,
1990 (544)
Prospective MVR 48
isenbaugh et al.,
1994 (552)
Registry MVR
MVR-CP
26
35
nriquez-Sarano et al.,
1994 (550)
Retrospective MVR
MV repair
214
195
nriquez-Sarano et al.,
1994 (551)
Retrospective MVR
MV repair
104
162
P indicates chordal sparing procedure; echo, echocardiographic; EDD, end-diastolic
S, fractional shortening; LA, left atrial; LV, left ventricular; MV, mitral valve; MVisk of cardiac death during a mean follow-up period of 2.7 aears. However, in the second study of 132 patients fol-
owed up prospectively for 5 years, during which the
ndications for surgery were symptoms, development of LV
ysfunction (ejection fraction less than 0.60), LV dilatation
LV end-systolic dimension greater than 45 mm), atrial
brillation, or pulmonary hypertension, there was only 1
ardiac death in an asymptomatic patient, but this patient
ad refused surgery which was indicated by development of
V dilation (542).
MV repair is often recommended in hemodynamically
table patients with newly acquired severe MR, such as
ight occur with ruptured chordae. Surgery is also recom-
ended in an asymptomatic patient with chronic MR with
ecent onset of atrial fibrillation in whom there is a high
ikelihood of successful valve repair (see below).
Surgery for asymptomatic patients with severe MR and
ormal LV function should only be considered if there is a
reater than 90% likelihood of successful valve repair in a
enter experienced in this procedure. As noted above,
ardiologists are strongly encouraged to refer patients who
re candidates for MV repair to surgical centers experienced
n performing MV repair.
.6.4.2.4. ATRIAL FIBRILLATION. Atrial fibrillation is a
ommon, potentially morbid arrhythmia associated with
R. In patients with MR due to MVP, there is a high risk
f development of atrial fibrillation. The development of
trial fibrillation is independently associated with a high risk
f cardiac death or heart failure (603). Preoperative atrial
brillation is an independent predictor of reduced long-
erm survival after MV surgery for chronic MR (551,603–
05). The persistence of atrial fibrillation after MV surgery
an lead to thromboembolism and partially nullifies an
rgitation
tcome Assessed Findings
function 12 Patients with average LV EF 0.70 had normal
postoperative EF; 4 patients with average EF
0.58 had postoperative EF 0.25
ival EF less than 0.50 predicted poor survival
rt failure, LV
nction
LV ESD index greater than 2.6 cm per m2 (45
mm) and LV FS less than 0.32 predicted poor
outcome
ival, LV function LV EF less than 0.50 predicted reduced survival;
ESV less than 50 ml per m2 predicted
persistent LV dilatation
ival, LV function ESD, EDD, and FS predicted poor survival and
LV function; only ESD significant in
multivariate analysis
ival LV EF 0.60 or less predicted poor survival
whether MVR or CP was performed; EF
estimated by echo FS or visual analysis
function EF, ESD, LV diameter/thickness ratio, and end-
systolic wall stress predicted outcome; EF
estimated by echo FS or visual analysis
sion; EF, ejection fraction; ESD, end-systolic dimension; ESV, end-systolic volume;
tral valve replacement; and PAWP, pulmonary artery wedge pressure.Regu
Ou
LV
Surv
Hea
fu
Surv
Surv
Surv
LVdvantage of mitral repair by requiring anticoagulation
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August 1, 2006:e1–148 ACC/AHA Practice Guidelines605). Predictors of the persistence of atrial fibrillation after
uccessful valve surgery are the presence of atrial fibrillation
or greater than 1 year and left atrial size greater than 50 mm
606). In 1 study, an even shorter duration of preoperative
trial fibrillation (3 months) was a predictor of persistent
trial fibrillation after MV repair (607); persistent atrial
brillation after surgery occurred in 80% of patients with
reoperative atrial fibrillation greater than or equal to 3
onths but in no patient with preoperative atrial fibrillation
ess than 3 months. Although patients who develop atrial
brillation also usually manifest other symptomatic or
unctional changes that would warrant MV operation, many
linicians would consider the recent onset of atrial fibrilla-
ion to be an indication in and of itself for surgery, if there
s a high likelihood of valve repair (Fig. 8) (582,607). In
atients presenting for MV operation with chronic atrial
brillation, a concomitant Maze procedure may prevent
uture thromboembolic events by restoring normal sinus
hythm (608–614). The decision to proceed with a Maze
rocedure should be based on the age and health of the
atient, as well as the surgical expertise, because this
rocedure may add to the morbidity of the operation.
.6.5. Ischemic Mitral Regurgitation
he outlook for the patient with ischemic MR is substan-
ially worse than that for regurgitation from other causes
533,615). A worse prognosis accrues from the fact that
schemic MR is usually caused by LV dysfunction resulting
rom myocardial infarction. Furthermore, the MV itself is
sually anatomically normal, and MR is secondary to
apillary muscle displacement and tethering of the mitral
eaflet(s). The mechanism of MR in chronic ischemic
isease is local LV remodeling (apical and posterior dis-
lacement of papillary muscles), which leads to excess
alvular tenting and loss of systolic annular contraction
616–623). The indication for MV operation in the patient
ho undergoes CABG with mild to moderate MR is still
nclear, but there are data to indicate benefit of MV repair
n such patients (624–627). Patients with ischemic heart
isease who have MR have a worse prognosis than those
ho do not have MR (628–631). CABG alone may
mprove LV function and reduce ischemic MR in selected
atients (629,632), especially those with transient severe
R due to ischemia, in whom myocardial revascularization
an eliminate episodes of severe MR. However, CABG
lone is usually insufficient and leaves many patients with
ignificant residual MR, and these patients would benefit
rom concomitant MV repair at the time of the CABG
623–627,633–642). Mitral annuloplasty alone with a
ownsized annuloplasty ring is often effective at relieving
R (637,638,641).
In severe MR secondary to acute myocardial infarction,
ypotension and pulmonary edema often occur. Severe MR
ccurs in 6% to 7% of patients with cardiogenic shock (643).
he cause of the MR should be established, because the
R may be due to a ruptured papillary muscle, papillary huscle displacement with leaflet tethering, or annular dila-
ation from severe LV dilatation. Those patients with an
cute rupture of the papillary muscle should undergo surgery
n an emergency basis, with either valve repair or MV
eplacement (644). In those patients with papillary muscle
ysfunction, treatment should initially consist of hemody-
amic stabilization, usually with insertion of an intra-aortic
alloon pump. Surgery should be considered for those
atients who do not improve with aggressive medical
herapy. Correction of acute severe ischemic MR usually
equires valve surgery in addition to revascularization. The
est operation for ischemic MR is controversial (645,646),
ut MV repair with an annuloplasty ring is the best
pproach in most instances (624,627,633–642).
.6.6. Evaluation of Patients After Mitral Valve Re-
lacement or Repair
fter MV surgery, follow-up is necessary to detect late
urgical failure and assess LV function, as discussed in
ection 9.3. For patients in whom a bioprosthesis has been
nserted, the specter of eventual deterioration is always
resent and must be anticipated. If a mechanical valve has
een inserted, anticoagulation is required, and chronic
urveillance of prothrombin time and INR is necessary.
fter valve repair, follow-up to assess the effectiveness of the
epair is indicated early, especially because most repair
ailures are detected soon after surgery.
.6.7. Special Considerations in the Elderly
lderly patients with MR fare more poorly with valve
urgery than do their counterparts with AS. In general,
perative mortality increases and survival is reduced in
atients older than 75 years of age, especially if MV
eplacement must be performed or if the patient has
oncomitant CAD or other valve lesions (164,167,545,647–
50). Operative mortality in the elderly is low in experi-
nced centers (651), but the overall operative mortality for
V replacement in this age group in the United States
xceeds 14% (167,649,650) and is particularly high (greater
han 20%) in low-volume centers (167). Although the risks
re reduced if MV repair is performed rather than MV
eplacement, the majority of patients in this age group
equire concomitant CABG (650). The average operative
isk for combined MV repair plus CABG in the United
tates is 8% (165), which will undoubtedly be higher in the
lder population. These risks are worth taking in patients
ith significant symptoms. However, under most circum-
tances, asymptomatic patients or patients with mild symp-
oms should be treated medically.
.7. Multiple Valve Disease
.7.1. Introduction
emarkably few data exist to objectively guide the manage-
ent of mixed valve disease. The large number of combinedemodynamic disturbances (and their varied severity) yields
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ew data exist for any specific category. Hence, each case
ust be considered individually, and management must be
ased on understanding the potential derangements in
emodynamics and LV function and the probable benefit of
edical versus surgical therapy. Other than recommending
valuation with physical examination, echocardiography,
nd cardiac catheterization as clinically indicated for patient
valuation and management, the committee has developed
o specific recommendations in this section.
.7.2. Mixed Single Valve Disease
.7.2.1. Pathophysiology
n mixed mitral or aortic valve disease, 1 lesion usually
redominates over the other, and the pathophysiology
esembles that of the pure dominant lesion. Thus, for the
atient with mixed AS and AR in whom stenosis predom-
nates, the pathophysiology and management resemble that
f pure AS. The left ventricle develops concentric hyper-
rophy rather than dilatation. The timing of AVR is based
n symptomatic status. However, if the attendant regurgi-
ation is more than mild, it complicates the pathophysiology
y placing the concentrically hypertrophied and noncom-
liant left ventricle on a steeper portion of its diastolic
ressure-volume curve, in turn causing pulmonary conges-
ion. The effect is that neither lesion by itself might be
onsidered severe enough to warrant surgery, but both
ogether produce substantial hemodynamic compromise
hat necessitates intervention.
In patients with severe AR and mild AS, the high total
troke volume due to extensive regurgitation may produce a
ubstantial transvalvular gradient. Because the transvalvular
radient varies with the square of the transvalvular flow
139), a high gradient in predominant AR may be predi-
ated primarily on excess transvalvular flow rather than on a
everely compromised orifice area.
In mixed mitral disease, predominant MS produces a left
entricle of normal volume, whereas in predominant MR,
hamber dilatation occurs. A substantial transvalvular gra-
ient may exist in regurgitation-predominant disease be-
ause of high transvalvular flow, but, as in mixed aortic valve
isease with predominant regurgitation, the gradient does
ot represent severe orifice stenosis.
.7.2.2. Diagnosis
.7.2.2.1. TWO-DIMENSIONAL AND DOPPLER ECHOCARDIO-
RAPHIC STUDIES. As noted above, chamber geometry is
mportant in assessing the dominant lesion (stenotic versus
egurgitant), which in turn is important in management.
or instance, a small left ventricle is inconsistent with
hronic severe regurgitation. Doppler interrogation of the
ortic valve and MVs with mixed disease should provide a
eliable estimate of the transvalvular mean gradient; how-
ver, there may be a significant discrepancy between the
oppler-derived maximum instantaneous gradient and latheter peak gradient with mixed aortic valve disease.
xercise hemodynamics derived by Doppler echocardiogra-
hy have been helpful in managing mixed valve disease. MV
rea can be measured accurately by the half-time method in
ixed MS/MR. Aortic valve area would be measured
naccurately at the time of cardiac catheterization in mixed
S/AR if cardiac output were measured by either thermodi-
ution or the Fick method. The valve area can be measured
ore accurately by the continuity equation from Doppler
chocardiography in mixed AS/AR; however, the continuity
quation calculation of valve area may not be completely
ndependent of flow (652). Although these valve area
easurements by Doppler echocardiography are more ac-
urate than those obtained at cardiac catheterization, in
eneral, the confusing nature of mixed valve disease makes
ardiac catheterization necessary to obtain additional hemo-
ynamic information in most patients.
.7.2.2.2. CARDIAC CATHETERIZATION. Catheterization is
ften necessary to fully assess hemodynamics. The diag-
osis of “moderate” mixed disease is frequently made on
he basis of noninvasive tests alone. This term suggests
hat the valve disease is not severe enough to mandate
urgery. However, as noted previously, the nondominant
esion may exacerbate the pathophysiology of the domi-
ant lesion and produce symptoms. In this context, a
omplete hemodynamic evaluation that includes exercise
emodynamics may be important. For example, resting
emodynamics in mixed mitral disease might show a
ransmitral gradient of 5 mm Hg, a valve area of 1.5 cm2,
nd 2 MR, with a resting pulmonary artery wedge
ressure of 15 mm Hg. However, with exercise, the
edge pressure can increase dramatically, identifying a
emodynamic cause for the patient’s symptoms and
uggesting that mechanical correction will be of benefit.
any cases of mixed valve disease require hemodynamic
xercise testing to delineate proper assessment (653).
Hemodynamic estimation of valve area requires deter-
ination of total valve flow and transvalvular gradient.
he presence of valvular regurgitation in a primarily
tenotic valve causes forward cardiac output to underes-
imate total valve flow, which is the sum of forward plus
egurgitant flow. Thus, if standard measures of forward
ardiac output (e.g., thermodilution or Fick method) are
sed to calculate valve area, the area will be underesti-
ated. One approach to this problem is to use total
troke volume (angiographic end-diastolic volume minus
nd-systolic volume) in place of forward stroke volume
Fick or thermodilution cardiac output/heart rate) in the
orlin formula. Although this approach is logically valid,
t has not been clinically tested or vetted against a “gold
tandard.” Furthermore, angiographic stroke volume is
ependent on accurate calculation of cardiac volumes,
hich can be difficult in the very large and/or sphericaleft ventricles encountered in valvular regurgitation (654).
I
p
3
U
s
T
t
A
p
n
d
m
e
w
l
fi
m
o
r
3
3
W
c
t
o
M
o
fi
T
c
p
c
l
r
p
r
e
3
M
i
h
b
a
w
b
d
o
s
t
p
p
3
g
3
W
h
w
a
n
M
t
g
c
r
t
r
3
O
w
c
t
m
e
v
3
I
v
s
s
t
a
p
f
m
t
s
b
i
t
c
t
v
s
T
b
(
3
g
3
A
e69JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:e1–148 ACC/AHA Practice Guidelinesn general, the utility of this approach is limited. Doppler
ressure half-time may be very useful in this situation.
.7.2.3. Management
nlike the management of a severe pure valve lesion,
olid guidelines for mixed disease are difficult to establish.
he most logical approach is to surgically correct disease
hat produces more than mild symptoms or, in the case of
S-dominant aortic valve disease, to operate in the
resence of even mild symptoms. In regurgitant domi-
ant lesions, surgery can be delayed until symptoms
evelop or asymptomatic LV dysfunction (as gauged by
arkers used in pure regurgitant disease) becomes appar-
nt. The use of vasodilators to forestall surgery in patients
ith asymptomatic mixed disease is untested. Anticoagu-
ants should be used in mixed mitral disease if atrial
brillation is present. In mixed mitral disease with
oderate or severe (3 to 4) regurgitation, percutane-
us mitral balloon valvotomy is contraindicated because
egurgitation may worsen.
.7.3. CombinedMitral Stenosis and Aortic Regurgitation
.7.3.1. Pathophysiology
hen both AR and MS coexist, severe MS usually
oexists with mild AR with pathophysiology similar to
hat of isolated MS. However, the coexistent AR is
ccasionally severe. The combination of coexistent severe
S and severe AR may present confusing pathophysiol-
gy and often leads to misdiagnosis. MS restricts LV
lling, blunting the impact of AR on LV volume (341).
hus, even severe AR may fail to cause a hyperdynamic
irculation, so that typical signs of AR are absent during
hysical examination. Likewise, echocardiographic LV
avitary dimensions may be only mildly enlarged. Dopp-
er half-time measurements of MV area may be inaccu-
ate in the presence of significant AR. The picture
resented by this complex combination of lesions usually
equires all diagnostic modalities, including cardiac cath-
terization, for resolution.
.7.3.2. Management
echanical correction of both lesions is eventually necessary
n most patients. Development of symptoms or pulmonary
ypertension is the usual indication for intervention. Com-
ined aortic valve and MV replacement is a reasonable
pproach, but when correction is anticipated in patients
ith predominant MS, balloon mitral valvotomy followed
y AVR may be performed. This obviates the need for
ouble-valve replacement, which has a higher risk of peri-
perative mortality and postoperative complications than
ingle-valve replacement (165). In most cases, it is advisable
o perform mitral valvotomy first and then monitor the
atient for symptomatic improvement. If symptoms disap-
ear, correction of AR can be delayed. A.7.4. Combined Mitral Stenosis and Tricuspid Regur-
itation
.7.4.1. Pathophysiology
hen TR coexists with MS, some elements of pulmonary
ypertension are also usually present. Thus, the issue arises
hether TR will or will not improve when MS is corrected
nd pulmonary artery pressure decreases (655). Unfortu-
ately, the status of the tricuspid valve after correction of
S is difficult to predict. In general, if pulmonary hyper-
ension is severe and the tricuspid valve anatomy is not
rossly distorted, improvement in TR can be expected after
orrection of MS (656). On the other hand, if there is severe
heumatic deformity of the tricuspid valve, dilatation of the
ricuspid annulus, or severe TR, competence is likely to be
estored only by surgery.
.7.4.2. Diagnosis
nce TR is suspected by physical examination to coexist
ith MS, both can be further evaluated by Doppler echo-
ardiographic studies. The presence of TR almost guaran-
ees that an estimation of pulmonary artery pressure can be
ade by Doppler interrogation of the tricuspid valve. An
valuation of the anatomy of both the mitral and tricuspid
alves can be made.
.7.4.3. Management
f the MV anatomy is favorable for percutaneous balloon
alvotomy and there is concomitant pulmonary hyperten-
ion, valvotomy should be performed regardless of symptom
tatus. After successful mitral valvotomy, pulmonary hyper-
ension and TR almost always diminish (656).
If MV surgery is performed, concomitant tricuspid
nnuloplasty should be considered, especially if there are
reoperative signs or symptoms of right-sided heart
ailure, rather than risking severe persistent TR, which
ay necessitate a second operation (657). If intraopera-
ive assessment suggests that TR is functional without
ignificant dilatation of the tricuspid annulus, it may not
e necessary to perform an annuloplasty. However, there
s growing evidence that TR associated with dilatation of
he tricuspid annulus should be repaired (658,659). Tri-
uspid dilatation is an ongoing process that may progress
o severe TR if untreated. Annuloplasty of the tricuspid
alve based on tricuspid dilatation improves functional
tatus independent of the degree of TR (658). Residual
R after tricuspid annuloplasty is determined principally
y the degree of preoperative tricuspid leaflet tethering
660).
.7.5. Combined Mitral Regurgitation and Aortic Re-
urgitation
.7.5.1. Pathophysiology
s noted in the previous discussions of isolated MR and
R, these are 2 very different diseases with different
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iming of surgery. Thus, in the patient with double-valve
egurgitation, proper management becomes problematic.
he most straightforward approach is the same as for mixed
ingle-valve disease, that is, to determine which lesion is
ominant and to treat primarily according to that lesion.
lthough both lesions produce LV dilatation, AR will
roduce modest systemic systolic hypertension and a mild
ncrease in LV wall thickness.
.7.5.2. Diagnosis and Therapy
oppler echocardiographic interrogation shows bivalve re-
urgitation and an enlarged left ventricle. 2D echocardiog-
aphy is usually performed to assess the severity of AR and
R, LV size and function, left atrial size, pulmonary artery
ressure, and feasibility of MV repair. When surgery is
equired, AVR plus MV repair is the preferred strategy
hen MV repair is possible (661).
.7.6. Combined Mitral Stenosis and Aortic Stenosis
.7.6.1. Pathophysiology
ombined stenotic disease is almost always secondary to
heumatic heart disease. Obstruction of flow at the MV
iminishes aortic valve flow as well. Thus, the problem of
valuating aortic valve severity in a low-flow/low-gradient
ituation often exists.
.7.6.2. Diagnosis and Therapy
n patients with significant AS and MS, the physical
ndings of AS generally dominate, and those of MS may be
verlooked, whereas the symptoms are usually those of MS.
oninvasive evaluation should be performed with 2D and
oppler echocardiographic studies to evaluate the severity
f AS and MS, paying special attention to suitability for
itral balloon valvotomy in symptomatic patients, and to
ssess ventricular size and function. If the degree of AS
ppears to be mild and the MV is acceptable for balloon
alvotomy, this should be attempted first. If mitral balloon
alvotomy is successful, the aortic valve should then be
e-evaluated.
.7.7. Combined Aortic Stenosis and Mitral Regurgita-
ion
.7.7.1. Pathophysiology
ombined AS and MR often develop secondary to rheu-
atic heart disease. However, congenital AS and MVP may
ccur in combination in younger patients, as may degener-
tive AS and MR in the elderly. If severe, AS will worsen
he degree of MR. In addition, MR may cause difficulty in
ssessing the severity of AS because of reduced forward
ow. MR will also enhance LV ejection performance,
hereby masking the early development of LV systolic
ysfunction caused by AS. Development of atrial fibrillation
nd loss of atrial systole may further reduce forward output oecause of impaired filling of the hypertrophied left
entricle.
.7.7.2. Diagnosis and Therapy
oninvasive evaluation should be performed with 2D and
oppler echocardiography to evaluate the severity of both
S and MR. Attention should be paid to LV size, wall
hickness, and function; left atrial size; right-heart function;
nd pulmonary artery pressure. Particular attention should
e paid to MV morphology in patients with these combined
esions. Patients with severe AS and severe MR (with
bnormal MV morphology) with symptoms, LV dysfunc-
ion, or pulmonary hypertension should undergo combined
VR and MV replacement or MV repair. AVR plus MV
epair is the preferred strategy when MV repair is possible
661). However, in patients with severe AS and lesser
egrees of MR, the severity of MR may improve greatly
fter isolated AVR, particularly when there is normal MV
orphology. Intraoperative transesophageal echocardiogra-
hy and, if necessary, visual inspection of the MV should be
erformed at the time of AVR to determine whether
dditional MV surgery is warranted in these patients.
In patients with mild to moderate AS and severe MR in
hom surgery on the MV is indicated because of symptoms,
V dysfunction, or pulmonary hypertension, preoperative
ssessment of the severity of AS may be difficult because of
educed forward stroke volume. If the mean aortic valve
radient is greater than 30 mm Hg, AVR should be
erformed. In patients with less severe aortic valve gradi-
nts, inspection of the aortic valve and its degree of opening
n 2D or transesophageal echocardiography and visual
nspection by the surgeon may be important in determining
he need for concomitant AVR.
.8. Tricuspid Valve Disease
.8.1. Pathophysiology
ricuspid valve dysfunction can occur with normal or
bnormal valves. When normal tricuspid valves develop
ysfunction, the resulting hemodynamic abnormality is
lmost always pure regurgitation. This occurs with elevation
f RV systolic and/or diastolic pressure, RV cavity enlarge-
ent, and tricuspid annular dilatation (662,663); RV sys-
olic hypertension occurs in MS, pulmonic valve stenosis,
nd the various causes of pulmonary hypertension. RV
iastolic hypertension occurs in dilated cardiomyopathy, RV
nfarction, and RV failure of any cause (662,663).
acemaker-induced severe TR is rare but may require
ntervention.
Abnormalities of the tricuspid valve leading to TR can occur
ith rheumatic valvulitis, infective endocarditis, carcinoid,
heumatoid arthritis, radiation therapy, trauma (such as re-
eated endomyocardial biopsies), Marfan syndrome, tricuspid
alve prolapse, tricuspid annular dilatation, or congenital dis-
rders such as Ebstein’s anomaly (663) or a cleft tricuspid valve
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ay also cause TR (see Section 3.9).
Tricuspid stenosis is most commonly rheumatic in origin.
n very rare occasions, infective endocarditis (with large
ulky vegetations), congenital abnormalities, carcinoid,
abry’s disease, Whipple’s disease, or previous methysergide
herapy may be implicated (664). Right atrial mass lesions
epresent a nonvalvular cause of obstruction to the tricuspid
rifice and may also over time destroy the leaflets and cause
egurgitation. Rheumatic tricuspid involvement usually re-
ults in both stenosis and regurgitation.
.8.2. Diagnosis
he clinical features of tricuspid stenosis include a giant a
ave and diminished rate of y descent in the jugular venous
ulse, a tricuspid opening snap, and a murmur that is
resystolic as well as middiastolic and that increases on
nspiration (665). Because chronic rheumatic valve disease is
he most common cause of tricuspid stenosis, there is
sually associated mitral and/or aortic disease, and the
linical findings include those associated with the other 2
alves, especially the MV.
The clinical features of TR include abnormal systolic c
nd v waves in the jugular venous pulse, a lower left
arasternal systolic murmur (holosystolic or less than holo-
ystolic, depending on the severity of hemodynamic de-
angement) that may increase on inspiration (Carvallo’s
ign), a middiastolic murmur in severe regurgitation, and
ystolic hepatic pulsation. In rare instances, severe TR may
roduce systolic propulsion of the eyeballs (666), pulsatile
aricose veins (667), or a venous systolic thrill and murmur
n the neck (668). Other associated clinical features are
elated to the cause of TR. Moderate or severe TR may be
resent without the classic clinical features.
Echocardiography is valuable in assessing tricuspid valve
tructure and motion, measuring annular size, and identi-
ying other cardiac abnormalities that might influence tri-
uspid valve function. Doppler echocardiography permits
stimation of the severity of TR (669), RV systolic pressure,
nd the tricuspid valve diastolic gradient. Although echo-
ardiography is a valuable diagnostic tool, it should be
ointed out that clinically insignificant TR is detected by
olor Doppler imaging in many normal persons (16,19–22).
his is not an indication for either routine follow-up or
rophylaxis against bacterial endocarditis. Clinical correla-
ion and judgment must accompany the echocardiographic
esults. Systolic pulmonary artery pressures greater than 55
m Hg are likely to cause TR with anatomically normal
ricuspid valves, whereas TR occurring with systolic pulmo-
ary artery pressures less than 40 mm Hg is likely to reflect
structural abnormality of the valve apparatus. Systolic
ulmonary artery pressure estimation combined with infor-
ation about annular circumference will further improvehe accuracy of clinical assessment (662). r.8.3. Management
lass I
Tricuspid valve repair is beneficial for severe TR in
patients with MV disease requiring MV surgery.
(Level of Evidence: B)
lass IIa
. Tricuspid valve replacement or annuloplasty is rea-
sonable for severe primary TR when symptomatic.
(Level of Evidence: C)
. Tricuspid valve replacement is reasonable for severe
TR secondary to diseased/abnormal tricuspid valve
leaflets not amenable to annuloplasty or repair. (Level
of Evidence: C)
lass IIb
Tricuspid annuloplasty may be considered for less
than severe TR in patients undergoing MV surgery
when there is pulmonary hypertension or tricuspid
annular dilatation. (Level of Evidence: C)
lass III
. Tricuspid valve replacement or annuloplasty is not
indicated in asymptomatic patients with TR whose
pulmonary artery systolic pressure is less than 60 mm
Hg in the presence of a normal MV. (Level of
Evidence: C)
. Tricuspid valve replacement or annuloplasty is not
indicated in patients with mild primary TR. (Level of
Evidence: C)
The patient’s clinical status and the cause of the tricuspid
alve abnormality usually determine the appropriate thera-
eutic strategy. Medical and/or surgical management may
e required. For example, in the patient with severe MS and
ulmonary hypertension with resulting RV dilatation and
R, relief of MS and the resulting decrease in pulmonary
rtery pressure may result in substantial diminution of the
egree of TR. The timing of surgical intervention for TR
emains controversial, as do the surgical techniques. To
ome extent, this controversy has diminished since the
dvent of 2D and Doppler echocardiography for preopera-
ive diagnosis and assessment. Intraoperative transesopha-
eal Doppler echocardiography allows refinement of annu-
oplasty techniques to optimize outcome (670–672). At
resent, surgery on the tricuspid valve for TR occurs
ommonly at the time of MV surgery. As noted in Section
.7.4.3, TR associated with dilatation of the tricuspid
nnulus should be repaired (658,659), because tricuspid
ilatation is an ongoing process that may progress to severe
R if left untreated.
Tricuspid valve balloon valvotomy has been advocated for
ricuspid stenosis of various causes (673–675). However,
evere TR is a common consequence of this procedure, and
esults are poor when severe TR develops.
l
s
c
T
r
c
m
m
b
t
i
d
e
n
3
I
d
u
m
p
t
m
s
a
t
m
t
s
t
g
s
r
r
r
M
w
a
c
t
t
s
v
r
(
o
D
a
d
a
r
w
(
T
(
c
t
5
i
t
d
c
a
p
(
t
T
n
n
a
o
n
P
d
s
h
e
b
l
3
M
i
r
p
o
a
v
t
t
m
a
t
c
l
i
n
p
p
c
t
a
p
p
d
c
e72 Bonow et al. JACC Vol. 48, No. 3, 2006
ACC/AHA Practice Guidelines August 1, 2006:e1–148Patients with severe TR of any cause have a poor
ong-term outcome because of RV dysfunction and/or
ystemic venous congestion (676). Tricuspid valve and
hordal reconstruction can be attempted in some cases of
R resulting from endocarditis and trauma (677–679). In
ecent years, annuloplasty has become an established surgi-
al approach to significant TR (657–660,680–684).
When the valve leaflets themselves are diseased, abnor-
al, or destroyed, valve replacement with a low-profile
echanical valve or bioprosthesis is often necessary (685). A
iological prosthesis is preferred because of the high rate of
hromboembolic complications with mechanical prostheses
n the tricuspid position. In patients with associated con-
uction defects, insertion of a permanent epicardial pacing
lectrode at the time of valve replacement can avoid the later
eed to pass a transvenous lead across the prosthetic valve.
.9. Drug-Related Valvular Heart Disease
n addition to the common causes of the valvular lesions
escribed in the preceding sections, there are a number of
ncommon causes related to systemic diseases (e.g., rheu-
atoid arthritis, systemic lupus erythematosus, anti-
hospholipid antibody syndrome, and ankylosing spondyli-
is), drugs (e.g., ergotamine, methysergide, anorexiant
edications, and pergolide), and toxins. It is beyond the
cope of these guidelines to discuss the specific pathology
nd natural history of valve disease stemming from each of
hese many causes. In general, the evaluation and manage-
ent strategies for patients with valve disease related to
hese disorders are directed both toward the underlying
ystemic process when appropriate and to the diagnosis and
reatment of the associated valvular disease according to the
uidelines developed for each of the valve lesions as de-
cribed in Section 3.
The sympathomimetic appetite-suppressant drug fenflu-
amine and its pure d-enantiomer, dexfenfluramine, were
emoved from the market in September 1997 after several
eports of unusual left-sided valvular heart disease (AR and
R) linked to these agents (686–690). These medications,
hen used alone or in combination with the noradrenergic
gent phentermine, had been previously implicated as a
ause of pulmonary hypertension, even when used for less
han 1 month (691–693). The echocardiographic and his-
opathological findings reported were similar to those de-
cribed in patients with carcinoid or ergotamine-induced
alvular heart disease (694–699). The fibroproliferative
esponse appears to be mediated via the 5-HT2B receptor
700). Subsequent reports have estimated a lower prevalence
f anorexiant drug–related valvulopathy meeting Food and
rug Administration (FDA) criteria and have identified
ge, dose, and duration of exposure as risk factors for its
evelopment (701–706). In the meta-analysis by Sachdev
nd colleagues, the pooled prevalence of qualifying valvular
egurgitation among patients treated for more than 90 days
as 12.0% compared with 5.9% for the unexposed groupodds ratio 2.2, 95% confidence interval 1.7–2.7) (707). Fhis increase was primarily the result of mild or greater AR
exposed 9.6% and unexposed 4.5%, odds ratio 2.5, 95%
onfidence interval 1.9–3.3). The prevalence among pa-
ients exposed for less than 90 days was 6.8% compared with
.8% for unexposed patients (odds ratio 1.4, 95% confidence
nterval 0.8–2.4) (707). Isolated reports have implied that
he valvular disease associated with combination- or single-
rug therapy does not progress and may improve after
essation of treatment (708,709). Concomitant therapy with
selective serotonin reuptake inhibitor for depression or
anic disorder does not appear to confer incremental risk
703). Fewer patients are now presenting for initial evalua-
ion since the drugs were removed from the market in 1997.
o date, an excess prevalence of valvular heart disease has
ot been reported for sibutramine, a serotonin and norepi-
ephrine reuptake inhibitor, or for phentermine when used
s monotherapy for obesity (710,711). The lipase inhibitor
rlistat is not known to produce valvular disease. There are
ow several reports of a carcinoid-like valvulopathy in
arkinson’s disease patients treated with pergolide, a
opamine-receptor agonist (712–714). A history of expo-
ure to any of the ergotamine-like agents briefly reviewed
ere should prompt a careful cardiovascular examination,
chocardiography when indicated, and treatment as would
e dictated by the nature and severity of the heart valve
esion(s).
.10. Radiation Heart Disease
ediastinal radiation may produce cardiac valve abnormal-
ties that usually become evident at least 5 years after the
adiation injury. The assessment and treatment of these
atients can be difficult in part because these valve lesions
ccur within a context of multiple cardiac and noncardiac
bnormalities produced by radiation. Radiation-induced
alvular lesions are based on calcification of valve leaflets and
he fibrous skeleton of the heart. Mixed aortic valve disease
hat combines stenosis and insufficiency is the most com-
on lesion, but MR and TR may also occur. Nonvalvular
spects of radiation-induced heart disease include a restric-
ive cardiomyopathy, aortic and great vessel calcification,
oronary artery stenoses including ostial lesions and diffuse
esions, pericardial constriction, and conduction abnormal-
ties. Noncardiac abnormalities such as skin and sternal
ecrosis, recurrent pleural effusions, and radiation-induced
ulmonary dysfunction can also play a role in the overall
icture.
Valve dysfunction is often part of a presenting picture of
ongestive heart failure and dyspnea, but the relative con-
ributions of valve dysfunction and restrictive cardiomyop-
thy may be difficult to separate. In addition, recurrent
leural effusions are often prominent, and radiation-induced
ulmonary dysfunction can occur. Thus, for these patients,
yspnea is a multifactorial problem.
For patients with radiation heart disease, surgery for any
ardiac lesion should be approached with caution (715).
irst, symptom relief secondary to valve surgery may be
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesncomplete because the restrictive cardiomyopathy may
imit improvement of congestive heart failure symptoms,
nd pulmonary dysfunction may contribute to ongoing
ymptoms of dyspnea. Second, surgical risks are increased
or patients with radiation heart disease both from cardiac
isease and noncardiac conditions, such as aortic calcifica-
ion and skin necrosis. Thus, logic dictates that patients be
ignificantly symptomatic before undergoing surgery or have
ubstantial jeopardy from severe coronary artery lesions.
hird, reoperation for a patient with mediastinal radiation is
n extremely difficult issue, because the radiation injury
ppears to be ongoing after a primary operation, creating
evere mediastinal adhesions and an increased risk of reop-
ration (715). The most common indication for surgery for
atients with radiation heart disease is CAD, a common
ause of late mortality after mediastinal radiation. During
oronary artery surgery, even moderately dysfunctional aor-
ic valves should be replaced to avoid the dangers of early
eoperation in the future (716). Aortic and aortic root
alcification can make even primary surgery for AVR
ifficult, and the lack of aortic root enlargement may limit
he size of a prosthesis that can be implanted. Overall,
adiation heart disease constitutes one of the most difficult
anagement problems in acquired heart disease, and pa-
ients with this condition should be evaluated in centers
ith experience in its management (717).
. EVALUATION AND MANAGEMENT OF INFECTIVE
NDOCARDITIS
lass I
Patients at risk for infective endocarditis who have
unexplained fever for more than 48 h should have at
least 2 sets of blood cultures obtained from different
sites. (Level of Evidence: B)
lass III
Patients with known valve disease or a valve prosthe-
sis should not receive antibiotics before blood cul-
tures are obtained for unexplained fever. (Level of
Evidence: C)
Infective endocarditis may be suspected in a patient with
cardiac murmur suggestive of organic valvular or congen-
tal heart disease or in a patient with a prosthetic heart valve
y the presence of fever, anemia, hematuria, and physical
ndings such as petechiae, Osler’s nodes, Janeway lesions,
oth spots, splenomegaly, and splinter hemorrhages. A
efinitive diagnosis may be made with positive blood
ultures and/or characteristic echocardiographic findings.
he diagnosis of infective endocarditis is often imprecise,
ecause bacteremia can occur without endocardial infection,
nd endocarditis can occur with negative blood cultures,
specially if a patient has received antibiotics for minor
ndiagnosed febrile illness (30). The role of echocardiogra- ohy has emerged with visualization of vegetation by trans-
horacic echocardiography in approximately 60% to 75% of
atients and by transesophageal echocardiography in more
han 95% of patients (718).
Criteria for the diagnosis of infective endocarditis were
roposed by Van Reyn et al. (719) based on the combina-
ion of blood cultures, clinical signs, and symptoms. Durack
t al proposed a new set of diagnostic criteria that placed
chocardiographic findings of endocardial lesions on an
qual footing as positive blood cultures (720). The Duke
riteria designated a patient as “definite,” “rejected,” or
possible” with regard to the likelihood of infective endo-
arditis. Because the designation of “possible” infective
ndocarditis seemed overly broad based on 1 minor criterion
f the patient did not meet requirements for “rejected” (721),
more recent modification of the Duke criteria has been
eveloped with the intent to improve diagnostic specificity
ithout sacrificing sensitivity (722). These modified Duke
riteria are shown in Table 22, which defines major and
inor criteria, and in Table 23, which uses the diagnostic
lassifications of definite, possible, or rejected.
The diagnosis of infective endocarditis in a patient with a
athological murmur or a valvular prosthesis and unex-
lained fever lasting more than 72 h should include an
ssessment for vascular and immunologic phenomena, 3 to
sets of blood cultures, and a transthoracic echocardiogram.
hen the echocardiogram is technically inadequate, is
ondiagnostic, or is negative for infective endocarditis,
ransesophageal echocardiography should be obtained.
.1. Antimicrobial Therapy
ntimicrobial therapy in endocarditis is guided by identifi-
ation of the causative organism. The majority (80%) of
ases of endocarditis are due to streptococcal and staphylo-
occal organisms. The latter species is also the most fre-
uent organism in endocarditis resulting from intravenous
rug abuse. Eighty percent of tricuspid valve infection is by
taphylococcus aureus. This organism is also a frequent cause
f infective endocarditis in patients with insulin-dependent
iabetes mellitus. With prosthetic valve endocarditis, a wide
pectrum of organisms can be responsible within the first
ear of operation. However, in “early” prosthetic valve
ndocarditis, usually defined as endocarditis during the first
months after surgery, Staphylococcus epidermidis is the
redominant offending organism. Late-onset prosthetic
alve endocarditis follows the profile of native valve endo-
arditis, that is, streptococci (viridans) and staphylococci. En-
erococcus faecalis and E. faecium account for 90% of entero-
occal endocarditis, which is usually associated with
alignancy or manipulation of the genitourinary or gastro-
ntestinal tract. Gram-positive and Gram-negative bacilli
re relatively uncommon causes of endocarditis. In recent
ears, the HACEK group of organisms (Haemophilus, Ac-
inobacillus, Cardiobacterium, Eikenella, and Kingella species)
as become an important cause of endocarditis. These
rganisms cause large vegetations (greater than 1 cm),
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hould be considered along with fungal endocarditis when
arge vegetations are noted. Fungi, especially Candida, are
mportant causes of endocarditis in patients with prosthetic
alves, compromised immune systems, and intravenous drug
buse. Several of the AHA recommendations for antimi-
robial regimens, updated in 2005, are given in Tables 24
hrough 29 (723). Complete treatment regimens for resis-
ant organisms are provided in that statement from the
HA which can be found at http://www.american-
eart.org/presenter.jhtml?identifier2158 (723).
able 22. Definition of Terms Used in the Proposed Modified D
ajor criteria
Blood culture positive for IE
Typical microorganisms consistent with IE from 2 separate blood cu
Viridans streptococci, Streptococcus bovis, HACEK group, Staphylococ
Community-acquired enterococci in the absence of a primary focus;
Microorganisms consistent with IE from persistently positive blood c
At least 2 positive cultures of blood samples drawn more than 12
All of 3 or a majority of greater than 4 separate cultures of blood
Single positive blood culture for Coxiella burnetti or anti-phase 1
Evidence of endocardial involvement
Echocardiogram positive for IE (TEE recommended in patients with p
IE [paravalvular abscess]; TTE as first test in other patients), defin
Oscillating intracardiac mass on valve or supporting structures, in the
alternative anatomic explanation; or
Abscess; or
New partial dehiscence of prosthetic valve
New valvular regurgitation (worsening or changing of pre-existing mur
inor criteria
Predisposition, predisposing heart condition, or injection drug use
Fever, temperature greater than 38°C
Vascular phenomena, major arterial emboli, septic pulmonary infarcts, m
Janeway’s lesions
Immunologic phenomena; glomerulonephritis, Osler’s nodes, Roth’s sp
Microbiological evidence: positive blood culture but does not meet a m
consistent with IE
Echocardiographic minor criteria eliminated
Modifications are shown in bold type. †Excludes single positive cultures for coagu
ermission from Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duk
IE indicates infective endocarditis; TEE, transesophageal echocardiography; and
able 23. Definition of Infective Endocarditis According to the P
efinite infective endocarditis
Pathological criteria
(1) Microorganisms demonstrated by culture or histological examinat
abscess specimen; or
(2) Pathological lesions; vegetation, or intracardiac abscess confirmed
Clinical criteria
(1) 2 major criteria, or
(2) 1 major criterion and 3 minor criteria; or
(3) 5 minor criteria
Possible infective endocarditis
(1) 1 major criterion and 1 minor criterion; or
(2) 3 minor criteria
Rejected
(1) Firm alternate diagnosis explaining evidence of infective endocard
(2) Resolution of infective endocarditis syndrome with antibiotic the
(3) No pathological evidence of infective endocarditis at surgery or a
(4) Does not meet criteria for possible infective endocarditis, as noteModifications are shown in bold type. Reprinted with permission from Li JS, Sexton DJ, M
ndocarditis. Clin Infect Dis 2000;30:633–8 (722)..2. Culture-Negative Endocarditis
ulture-negative endocarditis most frequently (62%) results
rom prior antibiotic treatment before blood cultures are
rawn (724,725). Other reasons for negative blood cultures
nclude infections due to Candida; Aspergillus; other fas-
idious, slow-growing organisms (726) such as Q-fever and
artonella organisms; and noninfective endocarditis such as
ibman-Sacks endocarditis in patients with systemic lupus
rythematosus. A proposed regimen for culture-negative,
resumed bacterial endocarditis (723) is shown in Table 30.
Criteria for the Diagnosis of Infective Endocarditis*
:
reus; or
es, defined as follows:
rt; or
first and last sample drawn at least 1 h apart)
antibody titer greater than 1:800
etic valves, rated at least “possible IE” by clinical criteria, or complicated
follows:
of regurgitant jets, or on implanted material in the absence of an
ot sufficient)
ic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and
d rheumatoid factor
riterion,† or serological evidence of active infection with organism
gative staphylococci and organisms that do not cause endocarditis. Reprinted with
ria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633–8 (722).
transthoracic echocardiography.
sed Modified Duke Criteria*
f a vegetation, a vegetation that has embolized, or an intracardiac
istological examination showing active endocarditis
r
or less than 4 days; or
y, with antibiotic therapy for less than 4 days; or
veuke
ltures
cus au
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IgG
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treptococcus bovis
Regimen Dosage and Route*
Duration,
wk Comments
queous crystalline penicillin G
sodium
12–18 million U per 24 h IV either
continuously or in 4 or 6 equally
divided doses
4 Preferred in most patients greater than 65 y
of age or patients with impairment of
8th cranial nerve function or renal
function
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose 4
Pediatric dose†: penicillin 200 000
U per kg per 24 h IV in 4–6
equally divided doses; ceftriaxone
100 mg per kg per 24 h IV/IM
in 1 dose
queous crystalline penicillin G
sodium
12–18 million U per 24 h IV either
continuously or in 6 equally
divided doses
2 Two-week regimen not intended for
patients with known cardiac or
extracardiac abscess or for those with
creatinine clearance of less than 20 ml
per min, impaired 8th cranial nerve
function, or Abiotrophia, Granulicatella, or
Gemella spp. infection. Gentamicin
dosage should be adjusted to achieve
peak serum concentration of 3–4 mcg per
ml and trough serum concentration of
less than 1 mcg per ml when 3 divided
doses are used; nomogram used for single
daily dosing.
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose 2
lus
entamicin sulfate‡ 3 mg per kg per 24 h IV/IM in
1 dose
2
Pediatric dose: penicillin 200 000 U
per kg per 24 h IV in 4–6
equally divided doses; ceftriaxone
100 mg per kg per 24 h IV/IM
in 1 dose; gentamicin 3 mg per
kg per 24 h IV/IM in 1 dose or
3 equally divided doses§
ancomycin hydrochloride 30 mg per kg per 24 h IV in 2
equally divided doses not to
exceed 2 g per 24 h unless
concentrations in serum are
inappropriately low
4 Vancomycin therapy recommended only for
patients unable to tolerate penicillin or
ceftriaxone; vancomycin dosage should be
adjusted to obtain peak (1 h after
infusion completed) serum concentration
of 30–45 mcg per ml and a trough
concentration range of 10–15 mcg per ml
Pediatric dose: 40 mg per kg per
24 h IV in 2–3 equally divided
doses
inimum inhibitory concentration less than or equal to 0.12 mcg per ml. *Dosages recommended are for patients with normal renal function. †Pediatric dose should not exceed
hat of a normal adult. ‡Other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy.
Data for once-daily dosing of aminoglycosides for children exist, but no data for treatment of infective endocarditis exist. Vancomycin dosages should be infused during course
f at least 1 h to reduce risk of histamine-release “red man” syndrome. Modified from Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial
herapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
ardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation
005;111:e394–434 (723).
IM indicates intramuscular; and IV, intravenous.
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ndocarditis in patients who are HIV (human immunode-
ciency virus) seropositive usually occurs as a complication
f injection drug use or long-term indwelling central cath-
ters. S aureus is the most frequent pathogen. When
ndocarditis is not related to intravenous drug use, right-
nd left-sided valves are equally involved. Intravenous drug
se is the most common cause of tricuspid valve endocar-
itis. Endocarditis-related mortality in patients with ac-
uired immune deficiency syndrome (AIDS) exceeds that of
IV-positive patients without AIDS. Thus, it is recom-
ended that endocarditis in patients with AIDS be treated
ith maximum-duration antibiotic regimens (723).
.4. Indications for Echocardiography in Suspected or
nown Endocarditis
chocardiography is useful for the detection and charac-
able 25. Therapy of Native Valve Endocarditis Caused by Strai
esistant to Penicillin
Regimen Dosage* and Route
queous crystalline penicillin
G sodium
24 million U per 24 h IV ei
continuously or in 4 to 6
equally divided doses
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 do
lus
entamicin sulfate† 3 mg per kg per 24 h IV/IM
1 dose
Pediatric dose‡: penicillin
300 000 U per 24 h IV in
4 to 6 equally divided dos
ceftriaxone 100 mg per kg
per 24 h IV/IM in 1 dose
gentamicin 3 mg per kg p
24 h IV/IM in 1 dose or
equally divided doses
ancomycin hydrochloride‡ 30 mg per kg per 24 h IV in
equally divided doses not
exceed 2 g per 24 h, unles
serum concentrations are
inappropriately low
Pediatric dose: 40 mg per kg
per 24 h in 2 or 3 equally
divided doses
inimum inhibitory concentration (MIC) greater than 0.12 mcg per ml to less tha
unction. †See Table 24 for appropriate dosage of gentamicin. ‡Pediatric dose shoul
odified from Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: dia
rofessionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasak
ardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart As
IM indicates intramuscular; IV, intravenous; and MIC, minimum inhibitory conerization of the hemodynamic and pathological conse- ruences of infection. These consequences include valvu-
ar vegetations; valvular regurgitation; ventricular
ysfunction; and associated lesions such as abscesses,
hunts, and ruptured chordae (727). The indications for
ransthoracic and transesophageal echocardiography are dis-
ussed in the “ACC/AHA/ASE 2004 Guidelines for the
linical Application of Echocardiography” (2) and the 2005
HA endocarditis guidelines (723). Transesophageal imaging
s more sensitive in detecting vegetations than transthoracic
maging (718,723,728), particularly in patients with prosthetic
alves, and in determining the presence and severity of impor-
ant complications such as abscesses and perforations. In
atients with prosthetic valves, it is reasonable to proceed
irectly to transesophageal imaging as the first-line diagnostic
est when endocarditis is suspected. Echocardiography can be
seful in the case of culture-negative endocarditis (729) or the
iagnosis of a persistent bacteremia the source of which
Viridans Group Streptococci and Streptococcus bovis Relatively
Duration,
wk Comments
4 Patients with endocarditis caused
by penicillin-resistant (MIC
greater than 0.5 mcg per ml)
strains should be treated with
regimen recommended for
enterococcal endocarditis
4 Recommended for enterococcal
endocarditis (see Table 26)
(723)
2
4 Vancomycin§ therapy is
recommended only for
patients unable to tolerate
penicillin or ceftriaxone
therapy
qual to 0.5 mcg per ml. *Dosages recommended are for patients with normal renal
xceed that of a normal adult. §See Table 24 for appropriate dosage of vancomycin.
, antimicrobial therapy, and management of complications: a statement for healthcare
se, Council on Cardiovascular Disease in the Young, and the Councils on Clinical
ion. Circulation 2005;111:e394–434 (723).
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August 1, 2006:e1–148 ACC/AHA Practice Guidelines.4.1. Transthoracic Echocardiography in Endocarditis
lass I
. Transthoracic echocardiography to detect valvular
vegetations with or without positive blood cultures is
recommended for the diagnosis of infective endocar-
ditis. (Level of Evidence: B)
. Transthoracic echocardiography is recommended to
characterize the hemodynamic severity of valvular
lesions in known infective endocarditis. (Level of
Evidence: B)
. Transthoracic echocardiography is recommended for
assessment of complications of infective endocarditis
(e.g., abscesses, perforation, and shunts). (Level of
Evidence: B)
. Transthoracic echocardiography is recommended for
reassessment of high-risk patients (e.g., those with a
able 26. Therapy for Native Valve or Prosthetic Valve Enteroco
entamicin, and Vancomycin
Regimen Dosage* and Route
mpicillin sodium 12 g per 24 h IV in 6 equally divi
doses
r
queous crystalline penicillin
G sodium
18–30 million U per 24 h IV eithe
continuously or in 6 equally
divided doses
lus
entamicin sulfate† 3 mg per kg per 24 h IV/IM in
3 equally divided doses
Pediatric dose‡: ampicillin 300 mg
per kg per 24 h IV in 4 to 6
equally divided doses; penicillin
300 000 U per kg per 24 h IV i
to 6 equally divided doses;
gentamicin 3 mg per kg per 24
IV/IM in 3 equally divided dose
ancomycin hydrochloride§ 30 mg per kg per 24 IV in 2 equa
divided doses
lus
entamicin sulfate 3 mg per kg per 24 h IV/IM in 3
equally divided doses
Pediatric dose: vancomycin 40 mg
per kg per 24 h IV in 2 or 3
equally divided doses; gentamici
mg per kg per 24 h IV/IM in 3
equally divided doses
Dosages recommended are for patients with normal renal function. †Dosage of gen
trough concentration of less than 1 mcg per ml. Patients with a creatinine clearanc
pecialist. ‡Pediatric dose should not exceed that of a normal adult. §See Table 24 fo
t al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of co
ever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the
nesthesia, American Heart Association. Circulation 2005;111:e394–434 (723). Se
IM indicates intramuscular; and IV, intravenous.virulent organism, clinical deterioration, persistentor recurrent fever, new murmur, or persistent bacte-
remia). (Level of Evidence: C)
lass IIa
Transthoracic echocardiography is reasonable to di-
agnose infective endocarditis of a prosthetic valve in
the presence of persistent fever without bacteremia or
a new murmur. (Level of Evidence: C)
lass IIb
Transthoracic echocardiography may be considered
for the re-evaluation of prosthetic valve endocarditis
during antibiotic therapy in the absence of clinical
deterioration. (Level of Evidence: C)
lass III
Transthoracic echocardiography is not indicated to
Endocarditis Caused by Strains Susceptible to Penicillin,
Duration,
wk Comments
4 to 6 Native valve: 4-wk therapy recommended for
patients with symptoms of illness less than
or equal to 3 mo; 6-wk therapy
recommended for patients with symptoms
greater than 3 mo
4 to 6 Prosthetic valve or other prosthetic cardiac
material: minimum of 6-wk therapy
recommended
4 to 6
6 Vancomycin therapy is recommended only
for patients unable to tolerate penicillin or
ampicillin
6 6 wk of vancomycin therapy recommended
because of decreased activity against
enterococci
n should be adjusted to achieve peak serum concentration of 3 to 4 mcg per ml and
ss than 50 ml per min should be treated in consultation with an infectious diseases
priate dosing of vancomycin. Modified from Baddour LM, Wilson WR, Bayer AS,
ations: a statement for healthcare professionals from the Committee on Rheumatic
g, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and
ocument for treatment regimens of resistant organisms.ccal
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ACC/AHA Practice Guidelines August 1, 2006:e1–148tion on baseline echocardiogram) native valve endo-
carditis during antibiotic treatment in the absence of
clinical deterioration, new physical findings or per-
sistent fever. (Level of Evidence: C)
.4.2. Transesophageal Echocardiography in Endocarditis
lass I
. Transesophageal echocardiography is recommended
to assess the severity of valvular lesions in symptom-
atic patients with infective endocarditis, if transtho-
racic echocardiography is nondiagnostic. (Level of
Evidence: C)
. Transesophageal echocardiography is recommended
able 27. Therapy for Endocarditis Caused by Staphylococci in t
Regimen Dosage* and Route
xacillin-susceptible strains
Nafcillin or oxacillin† 12 g per 24 h IV in 4–6 equally
divided doses
with
Optional addition of
gentamicin sulfate‡
3 mg per kg per 24 h IV/IM in
2 or 3 equally divided doses
Pediatric dose§: Nafcillin or
oxacillin 200 mg per kg per
24 h IV in 4–6 equally
divided doses; gentamicin 3
mg per kg per 24 h IV/IM in
3 equally divided doses
or penicillin-allergic
(nonanaphylactoid
type) patients:
Cefazolin 6g per 24 h IV in 3 equally
divided doses
with
Optional addition of
gentamicin sulfate
3 mg per kg per 24 h IV/IM in
2 or 3 equally divided doses
Pediatric dose: cefazolin 100
mg per kg per 24 h IV in 3
equally divided doses;
gentamicin 3 mg per kg per
24 h IV/IM in 3 equally
divided doses
xacillin-resistant strains
Vancomycin
30 mg per kg per 24 h IV in 2
equally divided doses
Pediatric dose: 40 mg/kg per 24
h IV in 2 or 3 equally
divided doses
Dosages recommended are for patients with normal renal function. †Penicillin G 24
xacillin if strain is penicillin susceptible (minimum inhibitory concentration less than
e administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosin
nd issues concerning vancomycin, see Table 24 footnotes. Modified from Baddour L
nd management of complications: a statement for healthcare professionals from
ardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stro
005;111:e394–434 (723).
IE indicates infective endocarditis; IM, intramuscular; and IV, intravenous.to diagnose infective endocarditis in patients withvalvular heart disease and positive blood cultures, if
transthoracic echocardiography is nondiagnostic.
(Level of Evidence: C)
. Transesophageal echocardiography is recommended
to diagnose complications of infective endocarditis
with potential impact on prognosis and management
(e.g., abscesses, perforation, and shunts). (Level of
Evidence: C)
. Transesophageal echocardiography is recommended
as first-line diagnostic study to diagnose prosthetic
valve endocarditis and assess for complications.
(Level of Evidence: C)
. Transesophageal echocardiography is recommended
for preoperative evaluation in patients with known
bsence of Prosthetic Materials
Duration Comments
6 wk For complicated right-sided IE and for left-sided
IE; for uncomplicated right-sided IE, 2 wk
(see text)
3–5 d Clinical benefit of aminoglycosides has not been
established
Consider skin testing for oxacillin-susceptible
staphylococci and questionable history of
immediate-type hypersensitivity to penicillin
6 wk Cephalosporins should be avoided in patients
with anaphylactoid-type hypersensitivity to
beta lactams; vancomycin should be used in
these cases§
3–5 d Clinical benefit of aminoglycosides has not been
established
6 wk Adjust vancomycin dosage to achieve 1-h serum
concentration of 30–45 mcg per ml and
trough concentration of 10–15 mcg per ml
n U per 24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or
al to 0.1 mcg per ml) and dose does not produce beta lactamase. ‡Gentamicin should
diatric dose should not exceed that of a normal adult. For specific dosing adjustment
ilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy,
ommittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
d Cardiovascular Surgery and Anesthesia, American Heart Association. Circulationhe A
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesevident on transthoracic imaging and unless preop-
erative imaging will delay surgery in urgent cases.
(Level of Evidence: C)
. Intraoperative transesophageal echocardiography is
recommended for patients undergoing valve surgery
able 28. Therapy for Prosthetic Valve Endocarditis Caused by S
Regimen Dosage* and Route
xacillin-susceptible strains
Nafcillin or oxacillin 12 g per 24 h IV in 6 equally divide
doses
plus
Rifampin 900 mg per 24 h IV/PO in 3 equally
divided doses
plus
Gentamicin† 3 mg per kg per 24 h IV/IM in 2 or
3 equally divided doses
Pediatric dose‡: nafcillin or oxacillin
200 mg per kg per 24 h IV in 4 t
6 equally divided doses; rifampin
20 mg per kg per 24 h IV/PO in
equally divided doses; gentamicin
mg per kg per 24 h IV/IM in 3
equally divided doses
xacillin-resistant strains
Vancomycin 30 mg per kg per 24 h in
2 equally divided doses
plus
Rifampin 900 mg per 24 h IV/PO in
3 equally divided doses
plus
Gentamicin 3 mg per kg per 24 h IV/IM in 2 or
3 equally divided doses
Pediatric dose: vancomycin 40 mg
per kg per 24 h IV in 2 or 3
equally divided doses; rifampin 20
mg per kg per 24 h IV/PO in 3
equally divided doses (up to adult
dose); gentamicin 3 mg per kg pe
24 h IV or IM in 3 equally divide
doses
Dosages recommended are for patients with normal renal function. †Gentamicin
Pediatric dose should not exceed that of a normal adult. Modified from Baddour L
nd management of complications: a statement for healthcare professionals from
ardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stro
005;111:e394–434 (723).
IM indicates intramuscular; IV, intravenous; and PO, by mouth.for infective endocarditis. (Level of Evidence: C)lass IIa
Transesophageal echocardiography is reasonable to
diagnose possible infective endocarditis in patients
with persistent staphylococcal bacteremia without a
ylococci
Duration,
wk Comments
At least 6 Penicillin G 24 million U per 24 h IV in 4 to 6
equally divided doses may be used in place of
nafcillin or oxacillin if strain is penicillin
susceptible (minimum inhibitory
concentration less than or equal to 0.1 mcg
per ml) and does not produce -lactamase;
vancomycin should be used in patients with
immediate-type hypersensitivity reactions to
-lactam antibiotics (see Table 24 for dosing
guidelines); cefazolin may be substituted for
nafcillin or oxacillin in patients with non–
immediate-type hypersensitivity reactions to
penicillins
At least 6
2
At least 6 Adjust vancomycin to achieve 1-h serum
concentration of 30 to 45 mcg per ml and
trough concentration of 10 to 15 mcg per ml
At least 6
2
be administered in close proximity to vancomycin, nafcillin, or oxacillin dosing.
ilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy,
ommittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
d Cardiovascular Surgery and Anesthesia, American Heart Association. Circulationtaph
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Transesophageal echocardiography might be consid-
ered to detect infective endocarditis in patients with
nosocomial staphylococcal bacteremia. (Level of Ev-
idence: C)
.5. Outpatient Treatment
atients with penicillin-susceptible S. viridans endocarditis
ho are hemodynamically stable, compliant, and capable of
anaging the technical aspects of outpatient therapy may be
andidates for a single daily-dose regimen of ceftriaxone
723). Clinical reports suggest that right-sided endocarditis
aused by S. aureus in intravenous drug users may be
menable to a short 2-week course of therapy (730,731).
onotherapy with ceftriaxone or combination therapy with
n aminoglycoside has been tried as an outpatient therapeu-
ic option (732); however, more data are needed to deter-
ine with more certainty whether such outpatient regimens
ave therapeutic effectiveness equivalent to the established
- to 6-week regimens.
.6. Indications for Surgery in Patients With Acute
nfective Endocarditis
urgery is indicated in patients with life-threatening con-
able 29. Therapy for Both Native and Prosthetic Valve Endoca
Regimen Dosage and Route
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose†
r
mpicillin-sulbactam‡ 12 g per 24 IV in 4 equally divided doses
r
iprofloxacin‡§ 1000 mg per 24 h PO or 800 mg per 24
in 2 equally divided doses
Pediatric dose: Ceftriaxone 100 mg per k
24 h IV/IM once daily; ampicillin-sulb
300 mg per kg per 24 h IV divided int
or 6 equally divided doses; ciprofloxacin
to 30 mg per kg per 24 h IV/PO in 2
equally divided doses
Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Card
hat intramuscular injection of ceftriaxone is painful. ‡Dosage recommended for patien
icroorganisms. Published data on use of fluoroquinolone therapy for endocarditis c
odified from Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: dia
rofessionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasak
ardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart As
IM indicates intramuscular; IV, intravenous; and PO, by mouth.estive heart failure or cardiogenic shock due to surgically vreatable valvular heart disease with or without proven
nfective endocarditis if the patient has reasonable prospects
f recovery with satisfactory quality of life after the opera-
ion (615,723,733–757). Surgery should not be delayed in
he setting of acute infective endocarditis when congestive
eart failure intervenes. Surgery is not indicated if compli-
ations (severe embolic cerebral damage) or comorbid con-
itions make the prospect of recovery remote.
The indications for surgery for infective endocarditis in
atients with stable hemodynamics are less clear. Consulta-
ion with a cardiovascular surgeon is recommended in a
atient with complicated endocarditis so that the surgical
eam is aware of the patient who may suddenly need
urgery. Surgery is recommended in patients with annular
r aortic abscesses, heart block, recurrent emboli on
ppropriate antibiotic therapy, infections resistant to
ntibiotic therapy, and fungal endocarditis. It is recog-
ized that the presence of valvular vegetations poses a
hreat of embolic events. Prosthetic valve endocarditis
nd native valve endocarditis caused by S. aureus are
lmost always surgical diseases. Early surgery in MV
ndocarditis caused by virulent organisms (such as S.
ureus or fungi) may make repair possible. Echocardiog-
aphy, especially with transesophageal imaging, identifies
Caused by HACEK* Microorganisms
Duration,
wk Comments
4 Cefotaxime or another third- or fourth-
generation cephalosporin may be
substituted
4
4 Fluoroquinolone therapy recommended only
for patients unable to tolerate
cephalosporin and ampicillin therapy;
levofloxacin, gatifloxacin, or moxifloxacin
may be substituted; fluoroquinolones
generally not recommended for patients
less than 18 y old Prosthetic valve:
patients with endocarditis involving
prosthetic cardiac valve or other
prosthetic cardiac material should be
treated for 6 wk
rium hominis, Eikenella corrodens, and Kingella kingae. †Patients should be informed
normal renal function. §Fluoroquinolones are highly active in vitro against HACEK
by HACEK are minimal. Pediatric dose should not exceed that of a normal adult.
, antimicrobial therapy, and management of complications: a statement for healthcare
se, Council on Cardiovascular Disease in the Young, and the Councils on Clinical
ion. Circulation 2005;111:e394–434 (723).rditis
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesable 30. Therapy for Culture-Negative Endocarditis Including Bartonella Endocarditis
Regimen Dosage* and Route
Duration,
wk Comments
ative valve
Ampicillin-sulbactam 12 g per 24 h IV in 4 equally divided doses 4–6 Patients with culture-negative endocarditis
should be treated with consultation
with an infectious diseases specialist
plus
Gentamicin sulfate† 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6
Vancomycin‡ 30 mg per kg per 24 h IV in 2 equally divided doses 4–6 Vancomycin recommended only for
patients unable to tolerate penicillins
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6
plus
Ciprofloxacin 1000 mg per 24 h PO or 800 mg per 24 h IV in 2
equally divided doses
4–6
Pediatric dose§: ampicillin-sulbactam 300 mg per kg per
24 h IV in 4–6 equally divided doses; gentamicin 3
mg per kg per 24 h IV/IM in 3 equally divided doses;
vancomycin 40 mg per kg per 24 h in 2 or 3 equally
divided doses; ciprofloxacin 20–30 mg per kg per 24 h
IV/PO in 2 equally divided doses
rosthetic valve (early—less
than or equal to 1 y)
Vancomycin 30 mg per kg per 24 h IV in 2 equally divided doses 6
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
plus
Cefepime 6 g per 24 h IV in 3 equally divided doses 6
plus
Rifampin 900 mg per 24 h PO/IV in 3 equally divided doses 6
Pediatric dose: vancomycin 40 mg per kg per 24 h IV in
2 or 3 equally divided doses; gentamicin 3 mg per kg
per 24 h IV/IM in 3 equally divided doses; cefepime
150 mg per kg per 24 h IV in 3 equally divided doses;
rifampin 20 mg per kg per 24 h PO/IV in 3 equally
divided doses
rosthetic valve (late—
greater than 1 y)
6 Same regimens as listed above for native
valve endocarditis
uspected Bartonella,
culture negative
Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose 6 Patients with Bartonella endocarditis
should be treated in consultation with
an infectious diseases specialist
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
with/without
Doxycycline 200 mg per kg per 24 h IV/PO in 2 equally divided doses 6
ocumented Bartonella,
culture positive
Doxycycline 200 mg per 24 h IV or PO in 2 equally divided doses 6 If gentamicin cannot be given, then
replace with rifampin, 600 mg per 24 h
PO/IV in 2 equally divided doses
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
Pediatric dose: ceftriaxone 100 mg per kg per 24 h IV/
IM once daily; gentamicin 3 mg per kg per 24 h IV/
IM in 3 equally divided doses; doxycycline 2–4 mg
per kg per 24 h IV/PO in 2 equally divided doses;
rifampin 20 mg per kg per 24 h PO/IV in 2 equally
divided doses
Continued on next page
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ACC/AHA Practice Guidelines August 1, 2006:e1–148tances. Patients with a vegetation diameter greater than
0 mm have a significantly higher incidence of emboli-
ation than those with a vegetation diameter less than or
qual to 10 mm (718), and this risk appears to be higher
n patients with MV endocarditis than in those with
ortic valve endocarditis. However, surgery on the basis
f vegetation size alone is controversial.
Patients with prosthetic valves who receive warfarin
nticoagulation and develop endocarditis should have
heir warfarin discontinued and replaced with heparin.
his recommendation is less related to the possibility of
emorrhagic complications of endocarditis (758) than the
ossibility of urgent surgery. If surgery is required, the
ffects of warfarin will have dissipated, and heparin can
asily be reversed. Likewise, aspirin, if part of the medical
egimen, should also be discontinued. If neurological
ymptoms develop, anticoagulation should be discontin-
ed until an intracranial hemorrhagic event is excluded by
agnetic resonance imaging or computed tomographic
canning.
.6.1. Surgery for Native Valve Endocarditis
lass I
. Surgery of the native valve is indicated in patients
with acute infective endocarditis who present with
valve stenosis or regurgitation resulting in heart
failure. (Level of Evidence: B)
. Surgery of the native valve is indicated in patients with
acute infective endocarditis who present with AR or
MR with hemodynamic evidence of elevated LV end-
diastolic or left atrial pressures (e.g., premature closure
of MV with AR, rapid decelerating MR signal by
continuous-wave Doppler (v-wave cutoff sign), or mod-
erate or severe pulmonary hypertension). (Level of Ev-
idence: B)
. Surgery of the native valve is indicated in patients
with infective endocarditis caused by fungal or other
highly resistant organisms. (Level of Evidence: B)
. Surgery of the native valve is indicated in pa-
tients with infective endocarditis complicated by
heart block, annular or aortic abscess, or destruc-
tive penetrating lesions (e.g., sinus of Valsalva to
right atrium, right ventricle, or left atrium fistula;
mitral leaflet perforation with aortic valve endocar-
ditis; or infection in annulus fibrosa). (Level of
able 30. Continued
Dosages recommended are for patients with normal renal function. †See Table 24 f
Pediatric dose should not exceed that of a normal adult. Modified from Baddour L
nd management of complications: a statement for healthcare professionals from
ardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stro
005;111:e394–434 (723).
IM indicates intramuscular; IV, intravenous; and PO, by mouth.Evidence: B)lass IIa
Surgery of the native valve is reasonable in patients
with infective endocarditis who present with recur-
rent emboli and persistent vegetations despite appro-
priate antibiotic therapy. (Level of Evidence: C)
lass IIb
Surgery of the native valve may be considered in
patients with infective endocarditis who present with
mobile vegetations in excess of 10 mm with or
without emboli. (Level of Evidence: C)
Patients with left-sided native valve endocarditis compli-
ated by congestive heart failure, systemic embolization to
ital organs, or presence of a large vegetation on echocar-
iography have poor outcomes on medical treatment alone.
large cohort study using a multivariate model reported
hat valve surgery was associated with improved 6-month
urvival (759). An additional benefit of early surgery is likely
o include successful valve repair as an outcome, especially
or the MV. When at all possible, MV repair should be
erformed instead of MV replacement in the setting of
ctive infection because of the risk of infection of prosthetic
aterials (760–762). Aortic valves may often be repaired as
ell if there are leaflet perforations, and this is preferable to
VR for the same reasons.
.6.2. Surgery for Prosthetic Valve Endocarditis
lass I
. Consultation with a cardiac surgeon is indicated for
patients with infective endocarditis of a prosthetic
valve. (Level of Evidence: C)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with heart
failure. (Level of Evidence: B)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with dehis-
cence evidenced by cine fluoroscopy or echocardiog-
raphy. (Level of Evidence: B)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with evi-
dence of increasing obstruction or worsening regur-
gitation. (Level of Evidence: C)
. Surgery is indicated for patients with infective endo-
ropriate dosing of gentamicin. ‡See Table 24 for appropriate dosing of vancomycin.
ilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy,
ommittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
d Cardiovascular Surgery and Anesthesia, American Heart Association. Circulationor app
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dence: C)
lass IIa
. Surgery is reasonable for patients with infective
endocarditis of a prosthetic valve who present with
evidence of persistent bacteremia or recurrent emboli
despite appropriate antibiotic treatment. (Level of
Evidence: C)
. Surgery is reasonable for patients with infective
endocarditis of a prosthetic valve who present with
relapsing infection. (Level of Evidence: C)
lass III
Routine surgery is not indicated for patients with
uncomplicated infective endocarditis of a prosthetic
valve caused by first infection with a sensitive organ-
ism. (Level of Evidence: C)
. MANAGEMENT OF VALVULAR DISEASE IN
REGNANCY
.1. Physiological Changes of Pregnancy
he evaluation and management of valvular heart disease in
he pregnant patient requires an understanding of the
ormal physiological changes associated with gestation,
abor, delivery, and the early postpartum period. On aver-
ge, there is a 50% increase in circulating blood volume
uring pregnancy that is accompanied by a commensurate
ncrease in cardiac output that usually peaks between the
idportion of the second and third trimesters. The aug-
ented cardiac output derives from an increase in the stroke
olume, although there is also a smaller increase in heart
ate, averaging 10 to 20 beats per minute. Because of the
ffects of uterine circulation and endogenous hormones,
ystemic vascular resistance falls with a disproportionately
reater lowering of diastolic blood pressure and a wide pulse
ressure. Inferior vena caval obstruction from a gravid uterus
n the supine position can result in an abrupt decrease in
ardiac preload, which leads to hypotension with weakness
nd lightheadedness. These symptoms resolve quickly with
change in position (763).
There is a further abrupt increase in cardiac output during
abor and delivery related in part to the associated anxiety
nd pain. Uterine contractions can lead to marked increases
n both systolic and diastolic blood pressure. After delivery,
here is an initial surge in preload related to the autotrans-
usion of uterine blood into the systemic circulation and to
aval decompression (763).
Pregnancy is also associated with a hypercoagulable state
ue to relative decreases in protein S activity, stasis, and
enous hypertension (764). Estrogens can interfere with
ollagen deposition within the media of the medium and
arge muscular arteries. Circulating elastase can break up the
lastic lamellae and weaken the aortic media during preg- fancy. Weakening of the vascular wall may in turn predis-
ose to dissection with or without an underlying connective
issue disorder (765). Relaxin, an insulin-like growth factor
ormone, is detectable in serum during pregnancy and
auses a decrease in collagen synthesis and may predispose
o aortic dissection during pregnancy (766).
.2. Physical Examination
he physical examination of the normal parturient is nota-
le for a slightly fast resting heart rate, bounding pulses, a
idened pulse pressure with a low normal peak systolic
ressure, and warm extremities. Venous pressure is usually
t or near the upper limits for nonpregnant women but
arely in a clearly abnormal range. The thyroid gland may be
nlarged in the absence of clinical hyperthyroidism. De-
ending on the stage of pregnancy, the lung volumes may be
ow because of the raised diaphragms. The precordial
mpulse is hyperkinetic, and the first heart sound may be
ouder than normal, with prominent splitting. The second
eart sound is usually physiologically split but may also
iden and appear fixed during the later stages of pregnancy.
hird heart sounds are present in most patients. A soft
rade 1 to 2 midsystolic murmur that is best heard along the
id to upper left sternal edge is a frequent finding (26). A
ontinuous murmur, which reflects either a venous hum or
mammary souffle, may sometimes be heard during auscul-
ation. The cervical venous hum is best appreciated in the
ight supraclavicular fossa and can be obliterated by move-
ent of the chin toward the stethoscope or digital pressure
ver the ipsilateral jugular vein. The mammary souffle is a
ystolic or continuous sound over the engorged breast that
an usually be obliterated with firm pressure applied to the
iaphragm of the stethoscope. It is heard in the supine
osition and attenuates or disappears when standing. It is
ppreciated in the late stages of pregnancy or early in the
uerperium. Diastolic heart murmurs are unusual. The
ncreased blood volume and enhanced cardiac output asso-
iated with normal pregnancy can accentuate the murmurs
ssociated with stenotic heart valve lesions (e.g., MS and
S). On the other hand, murmurs of AR, MR, and
entricular septal defect can actually attenuate or become
naudible as systemic vascular resistance is lowered (767).
.3. Echocardiography
ormal pregnancy is accompanied by echocardiographic
vidence of mild ventricular chamber enlargement. Pul-
onic and tricuspid valvular regurgitation, as assessed by
oppler interrogation, is the rule rather than the exception
768). Most women will demonstrate Doppler evidence of
physiological” MR in the absence of structural valve dis-
ase. Atrioventricular valve regurgitation may result from
he annular dilatation that accompanies ventricular enlarge-
ent. Appreciation of these echocardiographic and Doppler
ndings in normal individuals is an important foundation
or the noninvasive evaluation of subjects with suspected
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.4. General Management Guidelines
linical experience has shown that there are several cardiac
onditions in which the physiological changes of pregnancy
re poorly tolerated. For some conditions, such as cyanotic
eart disease, Eisenmenger syndrome, or severe pulmonary
ypertension, pregnancy should be discouraged. Valvular
eart lesions associated with high maternal and fetal risk
uring pregnancy are listed in Table 31. Lesions associated
ith low risk during pregnancy are listed in Table 32.
Reimold and Rutherford (769) and Elkayam and Bitar
770,771) have published excellent reviews for the clinical
ractitioner involved in managing pregnant patients who
ave either valvular or prosthetic heart disease. They delin-
ate the increased risk of adverse maternal, fetal, and
eonatal outcomes on the basis of valvular abnormality and
he NYHA functional class. Additionally, Siu et al. have
dentified predictors of adverse maternal and fetal outcomes
n a heterogeneous group of Canadian women with con-
enital or acquired heart disease (772,773). Abnormal
unctional capacity (NYHA class II or higher) and left-
ided heart obstruction were predictors of neonatal compli-
ations that included premature birth, intrauterine growth
etardation, respiratory distress syndrome, intraventricular
emorrhage, and death. However, outcomes data are lim-
ted for pregnant patients with valvular heart disease, except
or those with MS (769,770).
Individual counseling usually requires a multidisciplinary
pproach and should include information regarding contra-
Table 31. Valvular Heart Lesions Associated W
Pregnancy
1. Severe AS with or without symptoms
2. AR with NYHA functional class III-IV symptom
3. MS with NYHA functional class II-IV symptoms
4. MR with NYHA functional class III-IV symptom
5. Aortic and/or mitral valve disease resulting in seve
than 75% of systemic pressures)
6. Aortic and/or mitral valve disease with severe LV
7. Mechanical prosthetic valve requiring anticoagulat
8. Marfan syndrome with or without AR
AR indicates aortic regurgitation; AS, aortic stenosis; EF, eje
mitral stenosis; and NYHA, New York Heart Association.
Table 32. Valvular Heart Lesions Associated W
Pregnancy
1. Asymptomatic AS with low mean gradient (less t
cm2) in presence of normal LV systolic function (
2. NYHA functional class I or II AR with normal L
3. NYHA functional class I or II MR with normal L
4. MVP with no MR or with mild to moderate MR
5. Mild MS (MVA greater than 1.5 cm2, gradient le
hypertension
6. Mild to moderate pulmonary valve stenosisAR indicates aortic regurgitation; AS, aortic stenosis; EF, ejection
mitral stenosis; MVA, mitral valve area; MVP, mitral valve prolapeption, maternal and fetal risks of pregnancy, and expected
ong-term outcomes. However, many patients with valvular
eart disease can be successfully managed throughout preg-
ancy and during labor and delivery with conservative
edical measures designed to optimize intravascular volume
nd systemic loading conditions.
Simple interventions such as bed rest and avoidance of
he supine position should not be overlooked. Whenever
ossible, symptomatic or severe valvular lesions should be
ddressed and rectified before conception and pregnancy.
ontemporaneous management with a dedicated obstetric
eam accustomed to working with high-risk patients is
ncouraged. Drugs should generally be avoided whenever
ossible (Table 33) (763).
.5. Specific Lesions
.5.1. Mitral Stenosis
oung pregnant women with a previous history of acute
heumatic fever and carditis should continue to receive
enicillin prophylaxis as indicated in the nonpregnant
tate. Patients with mild to moderate MS can almost
lways be managed with judicious use of diuretics and
eta blockade. Diuretics are given to relieve pulmonary
nd excess systemic venous congestion, but care must be
aken to avoid vigorous volume depletion to protect
gainst uteroplacental hypoperfusion. Beta blockers are
hiefly indicated to treat or prevent tachycardia to opti-
ize diastolic filling. Although the nonselective beta
locker propranolol has been in use for decades, some
uthorities recommend a cardioselective beta blocker
uch as metoprolol or atenolol to prevent the potential
High Maternal and/or Fetal Risk During
lmonary hypertension (pulmonary pressure greater
nction (EF less than 0.40)
fraction; LV, left ventricular; MR, mitral regurgitation; MS,
Low Maternal and Fetal Risk During
5 mm Hg and aortic valve area greater than 1.5
eater than 0.50)
tolic function
stolic function
normal LV systolic function
an 5 mm Hg) without severe pulmonaryith
s
s
re pu
dysfu
ionith
han 2
EF gr
V sys
V sy
with
ss thfraction; LV, left ventricular; MR, mitral regurgitation; MS,
se; and NYHA, New York Heart Association.
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Drug Use in Pregnancy Potential Side Effects Breast Feeding Risk Factors
denosine Maternal and fetal arrhythmias No side effects reported; data on use during first
trimester are limited
Data NA C
miodarone Maternal arrhythmias IUGR, prematurity, congenital goiter,
hypothyroidism and hyperthyroidism,
transient bradycardia, and prolonged QT in
the newborn
Not recommended C
ngiotensin-converting
enzyme inhibitors
Hypertension Oligohydramnios, IUGR, prematurity, neonatal
hypotension, renal failure, anemia, death,
skull ossification defect, limb contractures,
patent ductus arteriosus
Compatible C
eta blockers Hypertension, maternal
arrhythmias, myocardial
ischemia, mitral stenosis,
hypertrophic
cardiomyopathy,
hyperthyroidism, Marfan
syndrome
Fetal bradycardia, low placental weight, possible
IUGR, hypoglycemia, no information on
carvedilol
Compatible,
monitoring of
infant’s heart
rate
recommended
Acebutolol: B
Labetalol: C
Matoprolol: C
Propranolol: C
Atenolol: D
igoxin Maternal and fetal
arrhythmias, heart failure
No evidence for unfavorable effects on the fetus Compatible C
iltiazem Myocardial ischemia, tocolysis Limited data; increased incidence of major birth
defects
Compatible C
isopyramide Maternal arrhythmias Limited data; may induce uterine contraction
and premature delivery
Compatible C
iuretics Hypertension, congestive heart
failure
Hypovolemia leads to reduced uteroplacental
perfusion, fetal hypoglycemia,
thrombocytopenia, hyponatremia,
hypokalemia; thiazide diuretics can inhibit
labor and suppress lactation
Compatible C
lecainide Maternal and fetal arrhythmias Limited data; 2 cases of fetal death after
successful treatment of fetal SVT reported,
but relation to flecainide uncertain
Compatible C
eparin Anticoagulation None reported Compatible C
ydralazine Hypertension None reported Compatible C
idocaine Local anesthesia, maternal
arrhythmias
No evidence for unfavorable fetal effects; high
serum levels may cause central nervous
depression at birth
Compatible C
ifedipine Hypertension, tocolysis Fetal distress related to maternal hypotension
reported
Compatible C
itrates Myocardial infarction and
ischemia, hypertension,
pulmonary edema, tocolysis
Limited data; use is generally safe, few cases of
fetal heart rate deceleration and bradycardia
have been reported
Data NA C
rocainamide Maternal and fetal arrhythmias Limited data; no fetal side effects reported Compatible C
ropafenone Fetal arrhythmias Limited data; fetal death reported after direct
intrauterine administration in fetuses with
fetal hydrops
Data NA CContinued on next page
d
a
c
b
n
t
w
d
v
m
t
w
fl
p
g
v
c
o
p
o
o
h
o
n
5
M
w
o
n
s
b
s
a
m
p
o
s
l
z
d
d
a
i
t
t
a
5
T
T
Q
S
S
V
W
F
r
t
r
i
c
A
o
a
e86 Bonow et al. JACC Vol. 48, No. 3, 2006
ACC/AHA Practice Guidelines August 1, 2006:e1–148eleterious effects of epinephrine blockade on myometrial
ctivity.
Patients with severe MS who are symptomatic before
onception will not predictably tolerate the hemodynamic
urden of pregnancy and should be considered for percuta-
eous balloon mitral valvotomy before conception, provided
he valve is anatomically suitable. Patients with severe MS
ho develop NYHA functional class III–IV symptoms
uring pregnancy should undergo percutaneous balloon
alvotomy (774).
For the rare patients with MS who fail medical
anagement during pregnancy with repetitive or persis-
ent heart failure, there is now a nearly 10-year experience
ith balloon mitral valvotomy, either with very limited
uoroscopy (less than 1 to 2 minutes’ exposure with both
elvic and abdominal shielding) or echocardiographic
uidance. The reported results with mitral balloon val-
otomy have been excellent, with few maternal or fetal
omplications, although caution is advised in interpreting
utcomes from individual centers reporting relatively few
atients (775–784). Percutaneous mitral balloon valvot-
my should only be performed in experienced centers and
nly after aggressive medical measures have been ex-
austed. In developing countries, there is a long history
f successful surgical closed commissurotomy for preg-
able 33. Continued
Drug Use in Pregnancy
uinidine Maternal and fetal arrhythmias Minimal ox
prematur
neonatal
eighth ne
odium nitroprusside Hypertension, aortic dissection Limited da
toxicity,
otalol Maternal arrhythmias,
hypertension, fetal
tachycardia
Limited da
of signifi
newborn
newborn
erapamil Maternal and fetal
arrhythmias, hypertension,
tocolysis
Limited da
death of
newborn
arfarin Anticoagulation Crosses pla
utero, em
abnorma
DA classification: Category B: Either animal reproduction studies have not dem
eproduction studies have shown an adverse effect that was not confirmed in controlle
he fetus and there are no controlled studies in women, or studies in women and ani
isk to the fetus. Category D: There is positive evidence of human fetal risk, but the be
n animals or human beings have demonstrated fetal abnormalities. The risk of the
ontraindicated in women who are or may become pregnant. Source: Drug Informatio
dapted and modified from Elkayam U. Pregnancy and cardiovascular disease. In: Zip
f Cardiovascular Medicine. 7th ed. Philadelphia, PA: Elsevier, Copyright 2005: 196
nd hydralazine to this list.
IUGR indicates intrauterine growth retardation; NA, not available; and SVT, suant women (785). c.5.2. Mitral Regurgitation
VP is the most common cause of MR in pregnant
omen. The physical findings pertinent to MVP may be
bscured or varied by the physiological changes of preg-
ancy, especially the increased blood volume and reduced
ystemic vascular resistance. Associated MR can usually
e managed medically, although on rare occasions, MV
urgery is required because of ruptured chordae and
cute, severe worsening of the regurgitant lesion. Medical
anagement includes diuretics for the rare patient with
ulmonary congestion. Vasodilator therapy is indicated
nly in the presence of concomitant systemic hyperten-
ion and should not be advised in the setting of normal or
ow systemic blood pressure. Angiotensin-converting en-
yme inhibitors are considered unsafe and are contrain-
icated because of their multiple adverse effects on fetal
evelopment. There is wide experience with hydralazine,
n agent generally considered safe. When MV surgery
s required, repair is always preferred, as would be
he case for any young patient but especially in relation
o the desirability of avoiding the potential need for
nticoagulation.
.5.3. Aortic Stenosis
he most common cause of AS in pregnant women is
ential Side Effects Breast Feeding Risk Factors
c effect, high doses may cause
r or abortion; transient
bocytopenia and damage to
eported
Compatible C
tential thiocyanate fetal
ortality reported in animals
Data NA C
ases of fetal death and 2 cases
eurological morbidity in
rted, as well as bradycardia in
Compatible,
monitoring of
infant’s heart
rate
recommended
B
er than a single case of fetal
tain cause, no adverse fetal or
s have been reported
Compatible C
l barrier; fetal hemorrhage in
athy, central nervous system
Compatible X
ed a fetal risk but there are no controlled studies in pregnant women, or animal
ies in women. Category C: Either studies in animals have revealed adverse effects on
re not available. Drugs should be given only if potential benefits justify the potential
from use in pregnant woman may be acceptable despite the risk. Category X: Studies
f the drug in pregnant women clearly outweighs any possible benefit. The drug is
e Health Care Professional (USDPI Vol 1); Micromedex; 23rd ed (January 1, 2003).
Libby P, Bonow RO, Braunwald E, editors. Braunwald’s Heart Disease: A Textbook
permission from Elsevier (763). The guidelines committee added warfarin, heparin,
tricular tachycardia.Pot
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesion and normal LV systolic function can be managed
onservatively throughout the pregnancy. Patients with
oderate to severe obstruction (Table 4) (27) or symptoms
hould be advised to delay conception until relief of AS can
e obtained. Women with severe AS who become pregnant
ut who remain asymptomatic or have mild symptoms may
ften be managed conservatively during pregnancy with bed
est, oxygen, and beta blockers. In women with severe AS
ho develop symptoms, consideration may have to be given
o either percutaneous aortic balloon valvotomy (786,787)
r surgery (depending on the anatomic findings) before
abor and delivery. These procedures are fraught with
anger to both the mother and fetus, although successful
utcomes have been reported. Neither is to be undertaken
ithout caution and forewarning. There is an association
etween the presence of a bicuspid aortic valve and aortic
oot dilatation, which may predispose to spontaneous aortic
issection, usually in the third trimester, especially if there is
n associated aortic coarctation.
.5.4. Aortic Regurgitation
solated AR, like MR, can usually be managed medically
ith a combination of diuretics and, if necessary, vasodilator
herapy (788). Angiotensin-converting enzyme inhibitors
re considered unsafe and are contraindicated because of
heir multiple adverse effects on fetal development. Women
ith symptoms or signs of LV failure should be monitored
hroughout labor and delivery with strict attention to
olume status and blood pressure. As is true for MR, surgery
uring pregnancy should be contemplated only for control
f refractory NYHA functional class III or IV symptoms.
onsideration regarding LV size or systolic function in less
ymptomatic patients should not apply. The recommenda-
ions for AVR based on LV size that apply to nonpregnant
atients should not be used for pregnant patients.
.5.5. Pulmonic Stenosis
ulmonic valve stenosis can exist in isolation but frequently
ccompanies other congenital heart lesions. In general,
atients with cyanotic congenital heart disease tolerate the
tresses of pregnancy far less well than those with acyanotic
esions. Isolated pulmonic stenosis is rarely a significant
mpediment to a successful pregnancy. This lesion can be
pproached with percutaneous valvotomy under echocardio-
raphic guidance when necessary.
.5.6. Tricuspid Valve Disease
ricuspid valve disease may be congenital (Ebstein’s anom-
ly, tricuspid atresia) or acquired (endocarditis, myxomatous
eplacement/proliferation, carcinoid). The approach to the
atient with tricuspid valve involvement as part of a more
omplex congenital heart disease syndrome is predicated on
he features of the associated lesions. Isolated TR should
ot pose a significant problem during pregnancy, although
reater care may be necessary to protect against diuretic-
nduced hypoperfusion. u.5.7. Marfan Syndrome
he Marfan syndrome is an inheritable disorder of connec-
ive tissue that often stems from abnormalities in the
brillin gene on chromosome 15. It is transmitted in an
utosomal dominant fashion and is recognized clinically by
ts ocular, skeletal, and cardiovascular expressions. Sponta-
eous aortic dissection or rupture is the most feared cardio-
ascular complications associated with pregnancy
765,789,790). Dissection can occur at any point along the
orta but most commonly originates in the ascending
ortion. Enlargement of the aortic root to greater than 4.0
m identifies a particularly high-risk group, although a
ormal dimension is by no means a guarantee against this
atastrophic complication. Aortic root enlargement may or
ay not be accompanied by regurgitation and an audible
eart murmur. MVP with regurgitation is also frequently
etected.
Any woman with Marfan syndrome should be counseled
gainst pregnancy, because aortic rupture or dissection can
ccur in any root size. All patients with Marfan syndrome
hould have a screening transthoracic echocardiogram with
areful assessment of aortic root dimensions. Enlargement
reater than 4.5 cm is generally considered an indication for
lective repair before conception, usually with a composite
alve-graft conduit and reimplantation of the coronary
rteries. If any degree of aortic root enlargement (greater
han 4.0 cm) is first detected during pregnancy, some
uthorities recommend termination of the pregnancy with
rompt aortic repair, although this is controversial. Less
ontroversial is prompt repair if serial imaging studies
emonstrate progressive dilatation over time. Dissection
nd rupture are most likely to occur during the third
rimester or near the time of delivery. Special care must be
aken to provide adequate analgesia to prevent wide surges
n blood pressure and its rate of rise (dP/dt) during labor
nd delivery. Obstetric techniques to shorten the second
tage of labor are appropriate. General anesthesia and
aesarean section may allow more optimal hemodynamic
ontrol. The use of prophylactic beta blockade throughout
he pregnancy is strongly recommended. Such treatment has
een shown to slow the rate of aortic dilatation and reduce
he cumulative incidence of cardiovascular complications in
onpregnant adolescents and adults (359). Successful sur-
ical correction does not confer a normal risk during
ubsequent pregnancy, because such patients remain at
ncreased for aortic dissection, albeit reduced compared with
atients with Marfan syndrome who have not undergone
urgical intervention.
.6. Endocarditis Prophylaxis
he Committee on Rheumatic Fever, Endocarditis, and Ka-
asaki Disease of the AHA does not recommend routine
ntibiotic prophylaxis in patients with valvular heart disease
ndergoing uncomplicated vaginal delivery or caesarean section
nless infection is suspected. Antibiotics are optional for
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ACC/AHA Practice Guidelines August 1, 2006:e1–148igh-risk patients with prosthetic heart valves, a previous
istory of endocarditis, complex congenital heart disease, or a
urgically constructed systemic-pulmonary conduit (28). Many
ractitioners routinely provide antibiotics.
.7. Cardiac Valve Surgery
he performance of cardiac valve surgery is a difficult and
omplex undertaking in the pregnant patient. Even under
deal conditions, including the use of cardiopulmonary
ypass techniques that promote high flow rates and warm
erfusion temperatures, there is a high incidence of fetal
istress, growth retardation, or wastage (791–795). If pos-
ible, it is always preferable to delay surgery until the time
he fetus is viable and a caesarean section can be performed
s part of a concomitant procedure (796,797). Surgery
hould be pursued only in the setting of medically refractory
ardiac symptoms (pulmonary congestion), especially if a
ow-output syndrome intervenes.
For suitable valve lesions, repair is always preferred
ver replacement. If valve replacement is necessary, the
hoice of a heart valve substitute can be problematic.
ioprosthetic valves degenerate more quickly in younger
atients, a process that can be further accelerated during
regnancy (798). Although such valves may not require
onger-term anticoagulation, they do expose the young
atient to an earlier risk of failure and need for reopera-
ion. Mechanical valve substitutes are more durable, but
he obligate need for anticoagulation may complicate
urrent and future pregnancies. For aortic valve disease,
omograft valves or pulmonary autografts should be
onsidered (799).
.8. Anticoagulation During Pregnancy
iven the paucity of data regarding the efficacy of antico-
gulants during pregnancy, recommendations concerning
heir use during pregnancy are based largely on extrapola-
ions from data from nonpregnant patients, from case
eports, and from case series of pregnant patients (771,799–
02).
.8.1. Warfarin
arfarin (vitamin K antagonist therapy) crosses the pla-
enta and has been associated with an increased incidence of
pontaneous abortion, prematurity, and stillbirth. Warfarin
an also cause bleeding in the fetus, and fetal cerebral
emorrhage can complicate labor and delivery, especially if
orceps evacuation is necessary. The manufacturer considers
he use of warfarin during pregnancy to be strictly contra-
ndicated because of its association with embryopathy,
onsisting of nasal hypoplasia and/or stippled epiphyses
fter in utero exposure during the first trimester of preg-
ancy, and central nervous system abnormalities after expo-
ure during any trimester. The true incidence of warfarin
mbryopathy has been difficult to ascertain. This has ranged
rom less than 5% to as high as 67% (801–804), and an
stimate of 4% to 10% seems reasonable (805,806). How- rver, the risk of clinically important embryopathy may be
ower if the dose of warfarin is less than or equal to 5 mg per
ay.
Warfarin is probably safe during the first 6 weeks of
estation, but there is a risk of embryopathy if warfarin is
aken between 6 and 12 weeks of gestation. For women
equiring long-term warfarin therapy who are attempting
regnancy, it seems wise to perform frequent pregnancy
ests with the substitution of unfractionated heparin (UFH)
r low-molecular-weight heparin (LMWH) for warfarin
hen pregnancy is achieved. Warfarin is also relatively safe
uring the second and third trimesters of pregnancy but
ust be discontinued and switched to a heparin compound
everal weeks before delivery.
.8.2. Unfractionated Heparin
everal studies suggest that UFH or LMWH therapy is safe
or the fetus (800–804). Heparin does not cross the
lacenta and does not have the potential to cause fetal
leeding or teratogenicity. Thus, heparin is generally con-
idered safer than warfarin during pregnancy in terms of the
evelopment of embryopathy (805,807). However, bleeding
t the uteroplacental junction is possible, and numerous case
eries and patient registries attest to a high incidence of
hromboembolic complications (12% to 24%), including
atal valve thrombosis, in high-risk pregnant women man-
ged with subcutaneous UFH or LMWH (805,808–810).
hen heparin is used during the first trimester, the risks of
aternal thromboembolism and maternal death are more
han doubled. These studies have been criticized because of
he inclusion of a predominant population of women with
lder-generation and more thrombogenic prostheses, inad-
quate heparin dosing, and/or the lack of meticulous mon-
toring strategies. Unfortunately, the efficacy of adjusted-
ose subcutaneous heparin has not been definitively
stablished.
During pregnancy, the activated partial thromboplastin
ime (aPTT) response to heparin is often attenuated because
f increased levels of factor VIII and fibrinogen. Adjusted-
ose subcutaneous UFH can cause a persistent anticoagu-
ant effect at the time of delivery, which can complicate its
se before labor. Bleeding complications appear to be very
ncommon with LMWH (811).
.8.3. Low-Molecular-Weight Heparins
MWHs have potential advantages over UFH during
regnancy because they 1) cause less heparin-induced
hrombocytopenia; 2) have a longer plasma half-life and a
ore predictable dose response than UFH; 3) have greater
ase of administration, with lack of need for laboratory
onitoring and the potential for once-daily dosing admin-
stration; 4) are likely associated with a lower risk of
eparin-induced osteoporosis; and 5) appear to have a low
isk of bleeding complications. They do not cross the
lacenta and are likely safe for the fetus (811). Allergic skin
eactions to both LMWH and UFH can occur.
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesAs the pregnancy progresses (and most women gain
eight), the potential volume of distribution for LMWH
hanges. It is thus necessary to measure plasma anti-Xa
evels 4 to 6 h after the morning dose and adjust the dose of
MWH to achieve an anti-Xa level of approximately 0.7 to
.2 units per ml.
Although LMWHs have been used successfully to treat
eep venous thrombosis in pregnant patients, there are no
ata to guide their use in the management of patients with
echanical heart valves (810). Reports of LMWH use in
regnant women with prosthetic heart valves are becoming
ore frequent, and many physicians now prescribe these
gents during pregnancy in women with mechanical valves,
ut treatment failures have been reported. The use of
MWH during pregnancy remains controversial because of
n early warning by the manufacturer and FDA in July 2001
egarding safety concerns in this situation. In 2004, labeling
pproved by the FDA indicated specifically that use of
MWH for thromboprophylaxis in pregnant women with
echanical prosthetic heart valves has not been studied
dequately.
In a clinical study of pregnant women with prosthetic
eart valves given subcutaneous enoxaparin (1 mg per kg
wice daily), 2 of 8 women developed prosthetic valve
hromboses that led to maternal and fetal death. Although
causal relationship has not been established, these deaths
ay have been due to therapeutic failure or inadequate
nticoagulation (811).
.8.4. Selection of Anticoagulation Regimen in Preg-
ant Patients With Mechanical Prosthetic Valves
lass I
. All pregnant patients with mechanical prosthetic
valves must receive continuous therapeutic anticoag-
ulation with frequent monitoring (see Section 9.2.).
(Level of Evidence: B)
. For women requiring long-term warfarin therapy
who are attempting pregnancy, pregnancy tests
should be monitored with discussions about subse-
quent anticoagulation therapy, so that anticoagula-
tion can be continued uninterrupted when pregnancy
is achieved. (Level of Evidence: C)
. Pregnant patients with mechanical prosthetic valves
who elect to stop warfarin between weeks 6 and 12 of
gestation should receive continuous intravenous
UFH, dose-adjusted UFH, or dose-adjusted subcu-
taneous LMWH. (Level of Evidence: C)
. For pregnant patients with mechanical prosthetic
valves, up to 36 weeks of gestation, the therapeutic
choice of continuous intravenous or dose-adjusted
subcutaneous UFH, dose-adjusted LMWH, or war-
farin should be discussed fully. If continuous intra-
venous UFH is used, the fetal risk is lower, but the
maternal risks of prosthetic valve thrombosis, sys- atemic embolization, infection, osteoporosis, and
heparin-induced thrombocytopenia are relatively
higher. (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic
valves who receive dose-adjusted LMWH, the
LMWH should be administered twice daily subcuta-
neously to maintain the anti-Xa level between 0.7
and 1.2 U per ml 4 h after administration. (Level of
Evidence: C)
. In pregnant patients with mechanical prosthetic
valves who receive dose-adjusted UFH, the aPTT
should be at least twice control. (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic
valves who receive warfarin, the INR goal should be
3.0 (range 2.5 to 3.5). (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic
valves, warfarin should be discontinued and contin-
uous intravenous UFH given starting 2 to 3 weeks
before planned delivery. (Level of Evidence: C)
lass IIa
. In patients with mechanical prosthetic valves, it is
reasonable to avoid warfarin between weeks 6 and 12
of gestation owing to the high risk of fetal defects.
(Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is
reasonable to resume UFH 4 to 6 h after delivery and
begin oral warfarin in the absence of significant
bleeding. (Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is
reasonable to give low-dose aspirin (75 to 100 mg per
day) in the second and third trimesters of pregnancy
in addition to anticoagulation with warfarin or hep-
arin. (Level of Evidence: C)
lass III
. LMWH should not be administered to pregnant
patients with mechanical prosthetic valves unless
anti-Xa levels are monitored 4 to 6 h after adminis-
tration. (Level of Evidence: C)
. Dipyridamole should not be used instead of aspirin as
an alternative antiplatelet agent in pregnant patients
with mechanical prosthetic valves because of its
harmful effects on the fetus. (Level of Evidence: B)
In April 2004, labeling approved by the FDA stated that
regnancy alone conferred an increased risk for thrombo-
mbolism and an even higher risk with thrombotic disease
nd certain high-risk pregnancy conditions. Although not
dequately studied, women with mechanical prosthetic
eart valves may be at higher risk for thromboembolism
uring pregnancy regardless of the anticoagulant used, and
hen pregnant, they have a higher rate of fetal loss from
tillbirth, spontaneous abortion, and premature delivery.
With both warfarin and UFH, monitoring is required tossess whether the antithrombotic effects of these drugs
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ACC/AHA Practice Guidelines August 1, 2006:e1–148hange during pregnancy because of alterations in intravas-
ular volume. Both European and North American guide-
ines emphasize that the use of oral coumarin derivatives
hroughout pregnancy targeted to an INR of 2.0 to 3.0
onfers the greatest maternal protection (5.7% risk of death
r thromboembolism) and that heparin used during the first
rimester confers a lesser degree of protection. Unfortu-
ately, these drugs are also associated with a great risk of
etal loss (up to 30%) (812).
To examine the validity of these conclusions and explore
ptimum antithrombotic regimens, Chan and colleagues
813) performed a systematic review of the literature exam-
ning fetal and maternal outcomes of pregnant women with
rosthetic heart valves. Because no randomized trials were
dentified, the overview consisted of prospective and retro-
pective cohort studies. This analysis suggests that warfarin
s more efficacious than UFH for thromboembolic prophy-
axis of women with mechanical heart valves in pregnancy,
ut with an increased risk of embryopathy (813). The use of
ow-dose UFH is inadequate; the use of adjusted-dose UFH
arrants aggressive monitoring and appropriate dose adjust-
ent. Contemporary aPTT reagents are more sensitive to
he anticoagulant effect of heparin. Therefore, a minimum
arget aPTT ratio of 1.5 times the control is likely to be
nadequate. A target aPTT ratio of at least twice the control
hould be attained.
Thus, there are still insufficient grounds to make
efinitive recommendations about optimal antithrom-
otic therapy in pregnant patients with mechanical heart
alves, because properly designed studies have not been
erformed. Substantial concern remains about the fetal
afety of warfarin, the efficacy of subcutaneous UFH and
f LMWH in preventing thromboembolic complications,
nd the risks of maternal bleeding with various regimens.
uropean experts have recommended warfarin therapy
hroughout pregnancy in view of the reports of poor
aternal outcomes with heparin and their impression
hat the risk of embryopathy with coumarin derivatives
as been overstated, especially if the dosage of warfarin is
ess than or equal to 5 mg per day.
The American College of Chest Physicians Conference
n Antithrombotic and Thrombolytic Therapy (814,815)
oncluded that it is reasonable to use 1 of the following 3
egimens: 1) either LMWH or UFH between 6 and 12
eeks and close to term only, with warfarin used at other
imes; 2) aggressive dose-adjusted UFH throughout preg-
ancy; or 3) aggressive adjusted-dose LMWH throughout
regnancy. Before any of these approaches is used, it is
rucial to explain the risks in detail to the patient. If warfarin
s used, the dose should be adjusted to attain a target INR
f 3.0 (range 2.5 to 3.5). If subcutaneous UFH is used, it
hould be initiated in high doses (17 500 to 20 000 U every
2 h) and adjusted to prolong a 6-h postinjection aPTT of
t least twice the control. Adjusted-dose LMWH appears to
e a reasonable substitute for UFH, but further information
s required about dosing during pregnancy. If LMWH is gsed during pregnancy, it has been recommended that it be
dministered twice daily and dosed to achieve anti-Xa levels
f 0.7 to 1.2 U per ml 4 to 6 h after injection (771,814). The
ddition of aspirin 75 to 100 mg can be considered in an
ttempt to reduce the risk of thrombosis, with the recogni-
ion that it can increase the risk of bleeding (808).
Dipyridamole should not be considered as an alternative
ntiplatelet agent because of its harmful effects on the fetus.
either warfarin nor heparin is contraindicated in postpar-
um mothers who breast-feed (807).
.9. Selection of Valve Prostheses in Young Women
major area of ongoing controversy concerns the use of
rosthetic heart valves in women likely to become preg-
ant (769,771). Bioprostheses are not as durable as
echanical prostheses, although they may eliminate the
eed for anticoagulation therapy associated with mechan-
cal prostheses. Also, MV repair is preferable to MV
eplacement whenever possible in women contemplating
regnancy, because it does not require anticoagulation.
urthermore, MV balloon commissurotomy is an alter-
ative to surgery in many patients with MS. The Ross
rocedure in patients requiring AVR is an attractive
ption for women who wish to become pregnant, but this
hould be performed only in institutions with established
xpertise in this procedure (799).
. MANAGEMENT OF CONGENITAL VALVULAR HEART
ISEASE IN ADOLESCENTS AND YOUNG ADULTS
lthough the majority of valvular heart disease in older
dults is acquired, the predominant cause is congenital in
dolescents and young adults. It has been estimated that the
revalence of moderate or complex congenital heart disease
n adults is approximately 419 000 in the United States
816). Many patients with congenital heart disease have
ome valvular involvement; frequently, it is part of a more
omplex congenital cardiac anomaly, that is, tricuspid ste-
osis in children with pulmonary atresia and an intact
entricular septum or AS as part of a series of left-sided
eart obstruction lesions (Shone’s syndrome). The manage-
ent of these complex diseases with multiple valve involve-
ent is beyond the scope of these guidelines. Rather, this
ection concerns isolated valve involvement when it is the
rimary anatomic abnormality.
In evaluating valvular stenosis in children, the severity
f valvular obstruction is usually reported as the peak
entricular–to–peak great artery systolic gradient at car-
iac catheterization or maximum instantaneous or mean
radient by Doppler echocardiography rather than valve
rea. In the catheterization laboratory, the variation in
ody size from the neonate to the adult, difficulties in
easuring cardiac output (especially in young children),
nd the relatively rare patient with low cardiac output
ave made peak ventricular–to–peak great artery pressure
radients for semilunar valves and atrial a-wave–to–RV
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesr LV end-diastolic or mean pressure gradients for
trioventricular valves the reference standards rather than
alve area. With the development of Doppler echocar-
iographic assessment of valvular obstruction, many pe-
iatric cardiologists have continued to rely on gradients
alculated from peak velocity for the semilunar valves
ather than on mean gradient or valve area. The peak
radient measured by Doppler velocity (based on maxi-
um instantaneous velocity) is almost always higher than
he peak ventricular–to–peak great vessel gradient mea-
ured at catheterization. The difference between Doppler
eak instantaneous and catheterization peak-to-peak gra-
ients is greater with AS than with pulmonic stenosis and
as resulted in most cardiologists using mean gradients,
specially in patients with AS. Significant valvular regur-
itation may exacerbate the differences. In contrast to
hildren and adolescents, valve area is used by many
enters in evaluation of the young adult.
Ventricular end-systolic or end-diastolic diameter or
olumes used in evaluating patients with valvular regur-
itation are frequently corrected for the large variations in
ody size among adolescents and young adults. Chamber
ize is corrected for body surface area (m2) or commonly
y the number of standard deviations (z score) above or
elow the mean with standard nomograms that correct
or body size (817).
The management of the neonate, infant, and young child
iffers significantly from that of the adolescent and young
dult. This section will deal exclusively with adolescents and
oung adults. Patients with these conditions are at risk of
nfective endocarditis and should have antibiotic prophylaxis
ccording to the established AHA guidelines (28) as dis-
ussed in Section 2.3.1.
.1. Aortic Stenosis
.1.1. Pathophysiology
lthough most adults with valvular AS have a degenerative-
alcific process that produces immobilization of the valve
usps, adolescents and young adults with isolated AS almost
lways have congenital fusion of 1 or more commissures that
esults in a bicuspid or unicuspid valve. Although the
revalence of bicuspid and unicuspid valves may be as high
s 1% to 2%, only 1 of 50 children born with these
bnormalities will actually have significant obstruction or
egurgitation by adolescence.
For purposes of these guidelines, adolescents and young
dults are defined as patients with minimally calcified valves
ho are less than 30 years old. Some adults with minimally
alcified valves who are more than 30 years old may also
enefit under these guidelines.
Much of what has been written in these guidelines for
dults with acquired AS may be transferred to the adoles-
ent or young adult (see Section 3.1.); however, certain
mportant differences must be emphasized. Throughout
hildhood, the aortic annulus and aortic valve must grow inarallel with somatic growth. If growth of either the annulus
r valve leaflets lags, increased obstruction may occur.
herefore, the rate of progression during childhood and
dolescent growth can be different from that in the adult
ith acquired heart disease. The report from the joint study
n the Natural History of Congenital Heart Defects (818)
ollowed 473 patients (before the advent of echocardiogra-
hy), 60% of whom were initially evaluated between 2 and
1 years of age and 34% between 11 and 21 years of age.
ne third of the children had an increase in the transaortic
radient measured by cardiac catheterization during the 4-
o 8-year follow-up period. However, the 54 patients greater
han 12 years of age showed very small increases. Those
ith higher initial gradients had a greater likelihood of
emonstrating an increase in the gradient.
Long-term results of the original cohort have been
eported (819), with a mean follow-up period of 20 years.
nly 20% of those with initial peak LV–to–peak aortic
ressure gradients less than 25 mm Hg at initial catheter-
zation had any intervention. However, in those with an
nitial catheter-derived LV–to–peak aortic gradient greater
han 50 mm Hg, arrhythmias, sudden death, or other
orbid events (including endocarditis, congestive heart
ailure, syncope, angina, myocardial infarction, stroke, and
acemaker insertion) occurred at a rate on average of 1.2%
er year. Sudden cardiac death occurred in 25 of the 370
atients followed up over an average of 8000 patient years,
or an average incidence of 0.3% per year. The severity of
bstruction in those who died could not be determined, and
higher-risk subgroup could not be excluded.
.1.2. Evaluation of Asymptomatic Adolescents or
oung Adults With Aortic Stenosis
lass I
. An ECG is recommended yearly in the asymptom-
atic adolescent or young adult with AS who has a
Doppler mean gradient greater than 30 mm Hg or
a peak velocity greater than 3.5 m per second (peak
gradient greater than 50 mm Hg) and every 2 years
if the echocardiographic Doppler mean gradient is
less than or equal to 30 mm Hg or the peak velocity
is less than or equal to 3.5 m per second (peak
gradient less than or equal to 50 mm Hg). (Level of
Evidence C)
. Doppler echocardiography is recommended yearly in
the asymptomatic adolescent or young adult with AS
who has a Doppler mean gradient greater than 30
mm Hg or a peak velocity greater than 3.5 m per
second (peak gradient greater than 50 mm Hg) and
every 2 years if the Doppler gradient is less than or
equal to 30 mm Hg or the peak jet velocity is less
than or equal to 3.5 m per second (peak gradient less
than or equal to 50 mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is an
effective diagnostic tool in the asymptomatic adoles-
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cardiography are equivocal regarding severity of AS
or when there is a discrepancy between clinical and
noninvasive findings regarding severity of AS. (Level
of Evidence: C)
. Cardiac catheterization is indicated in the adoles-
cent or young adult with AS who has symptoms of
angina, syncope, or dyspnea on exertion if the
Doppler mean gradient is greater than 30 mm Hg
or the peak velocity is greater than 3.5 m per
second (peak gradient greater than 50 mm Hg).
(Level of Evidence C)
. Cardiac catheterization is indicated in the asymp-
tomatic adolescent or young adult with AS who
develops T-wave inversion at rest over the left pre-
cordium if the Doppler mean gradient is greater than
30 mm Hg or the peak velocity is greater than 3.5 m
per second (peak gradient greater than 50 mm Hg).
(Level of Evidence C)
lass IIa
. Graded exercise testing is a reasonable diagnostic
evaluation in the adolescent or young adult with AS
who has a Doppler mean gradient greater than 30
mm Hg or a peak velocity greater than 3.5 m per
second (peak gradient greater than 50 mm Hg) if the
patient is interested in athletic participation, or if the
clinical findings and Doppler findings are disparate.
(Level of Evidence: C)
. Cardiac catheterization for the evaluation of AS is a
reasonable diagnostic tool in the asymptomatic ado-
lescent or young adult who has a Doppler mean
gradient greater than 40 mm Hg or a peak velocity
greater than 4 m per second (peak gradient greater
than 64 mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is
reasonable in the adolescent or young adult who has
a Doppler mean gradient greater than 30 mm Hg or
a peak velocity greater than 3.5 m per second (peak
gradient greater than 50 mm Hg) if the patient is
interested in athletic participation or becoming
pregnant, or if the clinical findings and Doppler
echocardiographic findings are disparate. (Level of
Evidence C)
The diagnosis of AS can usually be made clinically, with
everity estimated by ECG and Doppler echocardiographic
tudies. Diagnostic cardiac catheterization is occasionally
equired if there is a discrepancy among clinical evaluation,
CG, and/or Doppler echocardiographic findings. Exercise
esting may be useful, especially in those interested in
thletic participation. Diagnostic cardiac catheterization
ay be helpful if the clinical findings and the Dopplerchocardiographic assessment are disparate. w.1.3. Indications for Aortic Balloon Valvotomy in Ad-
lescents and Young Adults
lass I
. Aortic balloon valvotomy is indicated in the adoles-
cent or young adult patient with AS who has symp-
toms of angina, syncope, or dyspnea on exertion and
a catheterization peak LV–to–peak aortic gradient
greater than or equal to 50 mm Hg without a heavily
calcified valve. (Level of Evidence: C)*
. Aortic balloon valvotomy is indicated for the asymp-
tomatic adolescent or young adult patient with AS who
has a catheterization peak LV–to–peak aortic gradient
greater than 60 mm Hg. (Level of Evidence: C)*
. Aortic balloon valvotomy is indicated in the asymp-
tomatic adolescent or young adult patient with AS
who develops ST or T-wave changes over the left
precordium on ECG at rest or with exercise and who
has a catheterization peak LV–to–aortic gradient
greater than 50 mm Hg. (Level of Evidence: C)*
lass IIa
. Aortic balloon valvotomy is reasonable in the asymp-
tomatic adolescent or young adult patient with AS
when catheterization peak LV–to–peak aortic gradi-
ent is greater than 50 mm Hg and the patient wants
to play competitive sports or desires to become
pregnant. (Level of Evidence: C)*
. In the adolescent or young adult patient with AS,
aortic balloon valvotomy is probably recommended
over valve surgery when balloon valvotomy is possi-
ble. Patients should be referred to a center with
expertise in balloon valvotomy. (Level of Evidence: C)*
lass III
Aortic balloon valvotomy should not be performed
when the asymptomatic adolescent or young adult
patient with AS has a catheterization peak LV–to–
peak aortic gradient less than 40 mm Hg without
symptoms or ECG changes. (Level of Evidence: C)*
Gradients are usually obtained with patients sedated. If
eneral anesthesia is used, the gradients may be somewhat
ower.
Balloon valvotomy for calcific AS in older adults consti-
utes at best very short-term palliation. In contrast, balloon
alvotomy in children and adolescents with obstruction due
o fusion of commissures is considerably more efficacious.
here are insufficient published data to establish an age
utoff. Until more information becomes available, recom-
endations for balloon valvotomy should be limited to
dolescents and young adults. In a large collaborative
egistry involving 606 patients from 23 institutions, the peak
V–to–peak aortic pressure gradients at catheterization
ere reduced by a mean of 60% (820). In a single-institution
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinestudy of 148 patients dilated at age 1 month to 20 years
821), midterm results showed an 8-year actuarial survival of
5%, with 3 of the 4 deaths occurring in infants who were
ilated at less than 1 year of age. Seventy percent of patients
ere free from operation and 50% were free from interven-
ion 8 years after dilation, which was similar to results
eported with surgical valvuloplasty. Long-term follow-up
nformation is incomplete because balloon valvotomy was
ot introduced until the 1980s.
Although balloon dilation has become standard in chil-
ren and adolescents with AS, it is rarely recommended in
lder adults with calcific valves, because even short-term
alliation is uncommon. Because balloon valvotomy has
esulted in good midterm palliation with little morbidity
nd little or no short- or intermediate-term mortality in
hildren, adolescents, and young adults, the indications for
ntervention are considerably more liberal than those in
lder adults, in whom intervention usually involves valve
eplacement.
Surgical valvotomy is of historic interest but is now rarely
sed except in situations in which interventional cardiolo-
ists are not available. Children and young adults with peak
oppler gradients of 64 mm Hg or more or mean gradients
reater than 40 mm Hg and those with symptoms may be
onsidered for cardiac catheterization and possible balloon
ilation. Patients with lower gradients (50 mm Hg peak or
0 mm Hg mean) are sometimes referred for catheterization
f they are interested in participating in athletics, are
ontemplating pregnancy, or have developed ST–T-wave
hanges over the left precordium at rest or with exercise.
he gradient should be confirmed hemodynamically before
roceeding with dilation. Gradients are usually obtained
ith the patient sedated. If general anesthesia is used, the
radients may be lower. It is reasonable to perform valvot-
my in asymptomatic patients with catheterization gradi-
nts greater than 60 mm Hg and in some patients with a
atheterization peak LV–to–peak aortic pressure gradient of
0 to 60 mm Hg who have symptoms, have associated
schemic changes on rest or exercise ECG, are interested in
articipating in vigorous athletics, or are contemplating
regnancy. In those children who have had a balloon
alvuloplasty when younger, a repeat attempt is usually tried
efore surgical valve replacement using the above criteria if
ignificant AR is not present.
When balloon aortic valvotomy is ineffective or signifi-
ant AR is present, valve repair or replacement may be
ecessary. Long-term follow-up into adulthood is manda-
ory, because the long-term cumulative risks of endocarditis,
hromboembolism, and bleeding from anticoagulation over
0- to 40-year follow-up have been problematic, and
rogressive stenosis has been observed (153,822). Because
egeneration of homograft or bioprosthetic valves is usually
ccelerated in the young (see Sections 7.2 and 7.3), AVR is
sually performed with a mechanical valve. Recently, there
as been a renewed interest in valve repair or the Ross
peration (153,822), that is, moving the native pulmonaryalve to the aortic position using a homograft to replace the
ulmonary valve. Three studies from the Netherlands (343
atients; mean age 26 years) (823), Canada (155 patients;
ean age 35 years) (824), and the United States (328
atients) (825) have shown relatively low operative mortality
2.6%, 0.6%, and 4.6%, respectively) with actuarial survival
f 94% and 98% at 7 years in 2 of the studies and 89.9% at
years in the other. The most common complications were
R, usually secondary to neoaortic root dilation, and RV
utflow tract obstruction, with intervention necessary in
pproximately 10% of patients within 7 to 10 years.
Although the Ross operation, homograft, heterograft,
nd valve repair each appear to offer an attractive alternative
o a mechanical valve for those with a relative contraindi-
ation to warfarin for anticoagulation (e.g., athletes or
oman desiring pregnancy), in the absence of long-term
esults, it is not believed that the indications for surgery with
he Ross operation, heterograft, or homograft differ from
hose for mechanical valve replacement at this time.
.2. Aortic Regurgitation
lass I
. An adolescent or young adult with chronic severe
AR* with onset of symptoms of angina, syncope, or
dyspnea on exertion should receive aortic valve repair
or replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients
with chronic severe AR* with LV systolic dysfunction
(ejection fraction less than 0.50) on serial studies 1 to
3 months apart should receive aortic valve repair or
replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients
with chronic severe AR* with progressive LV enlarge-
ment (end-diastolic dimension greater than 4 stan-
dard deviations above normal) should receive aortic
valve repair or replacement. (Level of Evidence: C)
. Coronary angiography is recommended before AVR
in adolescent or young adult patients with AR in
whom a pulmonary autograft (Ross operation) is
contemplated when the origin of the coronary arter-
ies has not been identified by noninvasive techniques.
(Level of Evidence: C)
lass IIb
. An asymptomatic adolescent with chronic severe AR*
with moderate AS (peak LV–to–peak aortic gradient
greater than 40 mm Hg at cardiac catheterization)
may be considered for aortic valve repair or replace-
ment. (Level of Evidence: C)
. An asymptomatic adolescent with chronic severe AR*
with onset of ST depression or T-wave inversion over
the left precordium on ECG at rest may be consid-
ered for aortic valve repair or replacement. (Level of
Evidence: C)
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AR is an uncommon isolated congenital lesion, although
t may occasionally develop in adolescents and young adults
ith a bicuspid aortic valve, discrete subaortic obstruction,
r prolapse of 1 aortic cusp into a ventricular septal defect.
t is commonly the consequence of attempts to relieve
tenosis of the valve by either balloon dilation or surgical
alvulotomy, as part of a connective tissue disorder, or when
he pulmonary artery is relocated in the aortic position (Ross
rocedure or arterial switch repair of transposition). The
ndications for surgery with severe isolated AR or mixed
ortic valve disease are at present similar to those for adults,
hat is, symptoms, LV dysfunction (ejection fraction less
han 0.50), or very increased LV end-diastolic or end-
ystolic diameter, taking into account variations in body
ize. If the durability of pulmonary autograft and homograft
alves in the RV outflow tract is substantiated in long-term
tudies, the indications for autograft valve replacement are
ikely to become more liberal. Surgery has usually involved
echanical or biological valve replacement (see Sections
.2.3.8 and 7.2), but some have performed the Ross oper-
tion or aortic valve repair. Although not all valves are
menable to repair, some success has been reported for AR
fter balloon dilation (100% freedom from reoperation at 1
ear and 80% from reintervention at 3 years) (826) and with
prolapsing leaflet (freedom from reoperation of 95%, 87%,
nd 84% at 1, 5, and 7 years, respectively) (827). Aortic
alve repair is a viable alternative in some centers and may
e preferred in the future, but in view of the relative youth
f the patients and lack of long-term durability of valve
epair or replacement with biological valves, these alterna-
ives to mechanical valve replacement may be appropriate
nly for those with a contraindication to anticoagulation in
he majority of centers. Indications for surgery in patients
ith AR and dilated aortic roots or ascending aortas are the
ame as in older adult patients (see Sections 3.2.4 and 3.3).
.3. Mitral Regurgitation
lass I
. MV surgery is indicated in the symptomatic adoles-
cent or young adult with severe congenital MR* with
NYHA functional class III or IV symptoms. (Level of
Evidence: C)
. MV surgery is indicated in the asymptomatic adoles-
cent or young adult with severe congenital MR* and
LV systolic dysfunction (ejection fraction less than or
equal to 0.60). (Level of Evidence: C)
lass IIa
MV repair is reasonable in experienced surgical cen-
ters in the asymptomatic adolescent or young adult
with severe congenital MR* with preserved LV sys-
tolic function if the likelihood of successful repair mwithout residual MR is greater than 90%. (Level of
Evidence: B)
lass IIb
The effectiveness of MV surgery is not well estab-
lished in asymptomatic adolescent or young adult
patients with severe congenital MR* and preserved
LV systolic function in whom valve replacement is
highly likely. (Level of Evidence: C)
See Table 4 (27).
MR caused by myxomatous MV disease and MVP is a
ommon congenital lesion, but other forms of isolated
ongenital MR are extremely uncommon. MR can be
ssociated with MVP in adolescents or young adults with
onnective tissue, metabolic, or storage diseases. It can be
een with acquired inflammatory diseases such as rheumatic
ever, endocarditis, or Kawasaki disease or with certain
ollagen vascular disorders.
MR also develops commonly in children with primum
trioventricular septal defects. These defects are caused by a
eficiency of the atrioventricular septum in the embryonic
eart. There may be an isolated ostium primum atrial septal
efect; ventricular septal defect in the inlet (posterior)
eptum; abnormalities of the mitral or tricuspid valve,
ncluding clefts; or some combination of the above. In a
omplete atrioventricular septal defect, there is a combina-
ion of a large primum atrial septal defect, a large inlet
posterior) ventricular septal defect, and a common atrio-
entricular valve that failed to develop into separate mitral
nd tricuspid valves. Repair of the defects in early child-
ood, with low mortality and morbidity, is now common-
lace. The most common long-term sequela of surgery is
R, which can be mild, moderate, or severe.
The pathophysiology, diagnosis, and medical therapy of
esidual MR in atrioventricular septal defects, rheumatic
ever, or MVP are similar to those discussed for the adult
ith MR (Section 3.5). When MR is associated with
ymptoms or deteriorating LV systolic function on echocar-
iography or angiography, surgery should be performed. In
hildren with MR associated with atrioventricular septal
efects, the MR can usually be reduced or eliminated with
urgery. In patients with MR after atrioventricular septal
efect repair or MR secondary to MVP, rheumatic fever, or
nflammatory disease, it is usually possible to decrease the
R with MV repair and annular reduction. Rarely, MV
eplacement with a mechanical or biological valve is neces-
ary. When valve repair rather than replacement is likely,
urgery for severe MR is frequently performed in asymp-
omatic patients before the development of heart failure or
V dysfunction. On the other extreme, for symptomatic
atients with MR and severe LV dysfunction, cardiac
ransplantation may be the preferred option to MV replace-
ent or repair.
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lass I
MV surgery is indicated in adolescent or young adult
patients with congenital MS who have symptoms
(NYHA functional class III or IV) and mean MV
gradient greater than 10 mm Hg on Doppler echo-
cardiography.* (Level of Evidence: C)
lass IIa
. MV surgery is reasonable in adolescent or young
adult patients with congenital MS who have mild
symptoms (NYHA functional class II) and mean MV
gradient greater than 10 mm Hg on Doppler echo-
cardiography.* (Level of Evidence: C)
. MV surgery is reasonable in the asymptomatic ado-
lescent or young adult with congenital MS with
pulmonary artery systolic pressure 50 mm Hg or
greater and a meanMV gradient greater than or equal
to 10 mm Hg.* (Level of Evidence: C)
lass IIb
The effectiveness of MV surgery is not well estab-
lished in the asymptomatic adolescent or young adult
with congenital MS and new-onset atrial fibrillation
or multiple systemic emboli while receiving adequate
anticoagulation.* (Level of Evidence: C)
See Table 4 (27).
In developed countries, MS in adolescents and young
dults is often congenital in origin. In developing areas of
he world, MS is more likely to result from rheumatic fever.
ongenital MS is usually classified by the component of the
itral apparatus that is abnormal, that is, the leaflets,
nnulus, chordae, or papillary muscles. Frequently, multiple
alve components are involved, which results in rolled,
hickened leaflet margins; shortened and thickened chordae
endineae; obliteration of the interchordal spaces with
bnormal chordal insertions; papillary muscle hypoplasia;
nd fusion of the anterolateral and posteromedial papillary
uscles (828). This latter condition causes the mitral
pparatus to appear like a funnel or a parachute. MS results
rom the inability of blood to pass unobstructed from the
eft atrium to the LV through a very abnormal mitral
pparatus.
Congenital MS may be associated with a wide variety of
ther congenital cardiac malformations of the left side of the
eart, including bicuspid aortic valve and AS, supravalvar
itral ring, and/or coarctation of the aorta.
The clinical, electrocardiographic, and radiologic features
f congenital MS are similar to those of acquired MS in
dults. The echocardiogram is essential in evaluating the
V apparatus and papillary muscles and may provide
onsiderable insight into the feasibility of successful valve
epair. The information obtained from transthoracic imag- sng is usually sufficient, but in adolescents and young adults,
transesophageal echocardiogram is sometimes necessary.
Medical management including beta blockers and diuret-
cs may be of some utility with mild MS. It is important to
revent and treat common complications such as pulmonary
nfections, endocarditis, and atrial fibrillation. Surgical in-
ervention may be necessary in severe cases. The surgical
anagement of congenital MS has improved considerably
ith the improved appreciation of the mechanism of MV
unction and the improved ability to visualize the valve
fforded by transesophageal echocardiography. In those
atients with a parachute MV, creation of fenestrations
mong the fused chordae may increase effective orifice area
nd improve symptoms dramatically. MV replacement may
ccasionally be necessary but is especially problematic in
hose with a hypoplastic mitral annulus, in whom an
nnulus-enlarging operation may be necessary. Recently,
alloon dilation of congenital MS has been attempted
829), but its utility is limited in patients with significant
tenosis of the subvalvular apparatus. This is one of the most
ifficult and dangerous therapeutic catheterization proce-
ures and should be undertaken only in centers with
perators who have established experience and skill in this
nterventional procedure. In adolescent and young adult
atients with rheumatic MS, the results of balloon dilation
re similar to those in older adults (see Section 3.4.8).
ulmonary artery hypertension usually resolves with relief of
he MS.
.5. Tricuspid Valve Disease
.5.1. Pathophysiology
cquired disease of the tricuspid valve is very uncommon in
dolescents and young adults. Other than occasional cases of
R secondary to trauma, bacterial endocarditis in intrave-
ous drug abusers, and small ventricular septal defects in
dolescents in whom the jet through the ventricular septum
reates endothelial damage to the tricuspid valve, virtually
ll cases of acquired TR are limited to case reports.
Most cases of tricuspid valve disease are congenital, with
bstein’s anomaly of the tricuspid valve being the most
ommon. In Ebstein’s anomaly, there is inferior displace-
ent of the septal and posterior leaflets of the valve into the
ight ventricle. If there is significant adherence of the leaflets
o the RV wall, the normal or relatively normal anterior
eaflet fails to coapt with the abnormal posterior leaflet,
reating severe TR. If the valve leaflets are not adherent,
here is redundancy of valve tissue with severe prolapse
ssociated with varying degrees of TR.
There is wide variation in the severity of valve leaflet
bnormalities in Ebstein’s disease. Some children may have
evere TR, especially in the perinatal period, when pulmo-
ary vascular resistance and resulting RV pressures are high.
thers have very mild abnormalities that may not be
ecognized until a chest X-ray obtained for other reasons
hows cardiomegaly. An interatrial communication, usually
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ases. If TR elevates right atrial pressure above left atrial
ressure, right-to-left shunting can occur, with resulting
ypoxemia. One or more accessory conduction pathways are
uite common, with a risk of paroxysmal atrial tachycardia
f approximately 25%.
Patients with Ebstein’s anomaly may be asymptomatic
ith no cyanosis and no atrial arrhythmias. They often are
yanotic owing to right-to-left shunting (830), which is
ssociated with exercise intolerance. RV dysfunction may
ventually lead to right-sided congestive heart failure fre-
uently exacerbated by an atrial arrhythmia such as atrial
achycardia, atrial flutter, or atrial fibrillation. Exercise
esting may be useful in determining symptom status and
egree of exercise-induced arterial desaturation.
The natural history of Ebstein’s anomaly varies. In
atients who present in the perinatal period, the 10-year
ctuarial survival is 61% (831). In a study that included more
hildren who presented after the perinatal period, the
robability of survival was 50% at 47 years of age (832).
redictors of poor outcome include NYHA functional class
II or IV symptoms, cardiothoracic ratio greater than 65%,
trial fibrillation, severity of cyanosis, and magnitude of TR.
owever, patients with Ebstein’s anomaly who reach late
dolescence and adulthood often have an excellent outcome
832).
.5.2. Evaluation of Tricuspid Valve Disease in Adoles-
ents and Young Adults
lass I
. An ECG is indicated for the initial evaluation of
adolescent and young adult patients with TR, and
serially every 1 to 3 years, depending on severity.
(Level of Evidence: C)
. Chest X-ray is indicated for the initial evaluation of
adolescent and young adult patients with TR, and
serially every 1 to 3 years, depending on severity.
(Level of Evidence: C)
. Doppler echocardiography is indicated for the initial
evaluation of adolescent and young adult patients
with TR, and serially every 1 to 3 years, depending on
severity. (Level of Evidence: C)
. Pulse oximetry at rest and/or during exercise is
indicated for the initial evaluation of adolescent and
young adult patients with TR if an atrial communi-
cation is present, and serially every 1 to 3 years,
depending on severity. (Level of Evidence: C)
lass IIa
. If there is a symptomatic atrial arrhythmia, an elec-
trophysiology study can be useful for the initial
evaluation of adolescent and young adult patients
with TR. (Level of Evidence: C). Exercise testing is reasonable for the initial evalua-
tion of adolescent and young adult patients with TR,
and serially every 1 to 3 years. (Level of Evidence: C)
lass IIb
Holter monitoring may be considered for the initial
evaluation of asymptomatic adolescent and young
adult patients with TR, and serially every 1 to 3 years.
(Level of Evidence: C)
.5.3. Indications for Intervention in Tricuspid Regur-
itation
lass I
. Surgery for severe TR is recommended for adolescent
and young adult patients with deteriorating exercise
capacity (NYHA functional class III or IV). (Level of
Evidence: C)
. Surgery for severe TR is recommended for adolescent
and young adult patients with progressive cyanosis
and arterial saturation less than 80% at rest or with
exercise. (Level of Evidence: C)
. Interventional catheterization closure of the atrial
communication is recommended for the adolescent
or young adult with TR who is hypoxemic at rest and
with exercise intolerance due to increasing hypoxemia
with exercise, when the tricuspid valve appears diffi-
cult to repair surgically. (Level of Evidence: C)
lass IIa
. Surgery for severe TR is reasonable in adolescent and
young adult patients with NYHA functional class II
symptoms if the valve appears to be repairable. (Level
of Evidence: C)
. Surgery for severe TR is reasonable in adolescent and
young adult patients with atrial fibrillation. (Level of
Evidence: C)
lass IIb
. Surgery for severe TR may be considered in asymp-
tomatic adolescent and young adult patients with
increasing heart size and a cardiothoracic ratio of
more than 65%. (Level of Evidence: C)
. Surgery for severe TR may be considered in asymp-
tomatic adolescent and young adult patients with
stable heart size and an arterial saturation of less than
85% when the tricuspid valve appears repairable.
(Level of Evidence: C)
. In adolescent and young adult patients with TR who
are mildly cyanotic at rest but who become very
hypoxemic with exercise, closure of the atrial com-
munication by interventional catheterization may be
considered when the valve does not appear amenable
to repair. (Level of Evidence: C)
. If surgery for Ebstein’s anomaly is planned in ado-
lescents and young adult patients (tricuspid valve
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logical study may be considered to identify accessory
pathways. If present, these may be considered for
mapping and ablation either preoperatively or at the
time of surgery. (Level of Evidence: C)
Surgical management of Ebstein’s anomaly remains chal-
enging (833). A Glenn anastomosis between the superior
ena cava and right pulmonary artery is occasionally per-
ormed to reduce the volume load on the right ventricle. For
dolescents and young adults, tricuspid valve repair has been
ttempted. Reconstruction of the valve is possible, especially
hen there is a mobile anterior leaflet free of tethering to
he ventricular septum. Valvuloplasty may be performed
ith positioning of the displaced leaflet of the tricuspid
alve to the normal level, sometimes with placation of the
trialized portion of the right ventricle to reduce its size. If
R is mild and hypoxemia at rest or exercise is problematic,
losure of the atrial septal defect in the catheterization
aboratory has been successful in eliminating the hypoxemia.
Occasionally, the tricuspid valve is not reparable, and
alve replacement with a bioprosthesis or a mechanical valve
ay be necessary (834). When present, atrial communica-
ions should be closed unless significant postoperative TR or
V dysfunction is anticipated and the presence of an atrial
eptal defect may allow decompression of the right atrium.
f an accessory pathway is present, this should be mapped
nd ablated either preoperatively in the electrophysiology
aboratory or at the time of surgery.
.6. Pulmonic Stenosis
.6.1. Pathophysiology
ecause the pulmonary valve is the least likely valve to be
ffected by acquired heart disease, virtually all cases of
ulmonary valve stenosis are congenital in origin. Most
atients with stenosis have a conical or dome-shaped
ulmonary valve formed by fusion of the valve leaflets.
ccasionally, the valve may be thickened and dysplastic,
ith the stenosis caused by inability of the valve leaflets to
eparate sufficiently during ventricular systole (835).
Symptoms are unusual in children or adolescents with
ulmonary valve stenosis even when severe. Adults with
ong-standing severe obstruction may have dyspnea and
atigue secondary to an inability to increase cardiac output
dequately with exercise. Exertional syncope or light-
eadedness may occur in the presence of severe pulmonic
tenosis with systemic or suprasystemic RV pressures, with
ecreased preload or dehydration, or with a low systemic
ascular resistance state (such as pregnancy). However,
udden death is very unusual. Eventually, with long-
tanding untreated severe obstruction, TR and RV failure
ay occur.
At any age, if the foramen ovale is patent, RV compliance
ay be reduced sufficiently to elevate right atrial pressure,
hich allows right-to-left shunting and cyanosis. Thisncreases the risk of paradoxical emboli..6.2. Evaluation of Pulmonic Stenosis in Adolescents
nd Young Adults
lass I
. An ECG is recommended for the initial evaluation of
pulmonic stenosis in adolescent and young adult
patients, and serially every 5 to 10 years for follow-up
examinations. (Level of Evidence: C)
. Transthoracic Doppler echocardiography is recom-
mended for the initial evaluation of pulmonic steno-
sis in adolescent and young adult patients, and
serially every 5 to 10 years for follow-up examina-
tions. (Level of Evidence: C)
. Cardiac catheterization is recommended in the ado-
lescent or young adult with pulmonic stenosis for
evaluation of the valvular gradient if the Doppler
peak jet velocity is greater than 3 m per second
(estimated peak gradient greater than 36 mmHg) and
balloon dilation can be performed if indicated. (Level
of Evidence: C)
lass III
Diagnostic cardiac catheterization is not recom-
mended for the initial diagnostic evaluation of pul-
monic stenosis in adolescent and young adult pa-
tients. (Level of Evidence: C)
The clinical diagnosis of pulmonary valve stenosis is
traightforward, and the severity can usually be determined
ccurately by 2D and Doppler echocardiography. Diagnos-
ic catheterization is rarely required.
.6.3. Indications for Balloon Valvotomy in Pulmonic
tenosis
lass I
. Balloon valvotomy is recommended in adolescent
and young adult patients with pulmonic stenosis who
have exertional dyspnea, angina, syncope, or presyn-
cope and an RV–to–pulmonary artery peak-to-peak
gradient greater than 30 mm Hg at catheterization.
(Level of Evidence: C)
. Balloon valvotomy is recommended in asymptomatic
adolescent and young adult patients with pulmonic
stenosis and RV–to–pulmonary artery peak-to-peak
gradient greater than 40 mm Hg at catheterization.
(Level of Evidence: C)
lass IIb
Balloon valvotomy may be reasonable in asymptom-
atic adolescent and young adult patients with pul-
monic stenosis and an RV–to–pulmonary artery
peak-to-peak gradient 30 to 39 mm Hg at catheter-
ization. (Level of Evidence: C)
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Balloon valvotomy is not recommended in asymp-
tomatic adolescent and young adult patients with
pulmonic stenosis and RV–to–pulmonary artery
peak-to-peak gradient less than 30 mm Hg at cath-
eterization. (Level of Evidence: C)
The clinical course of children and young adults with
ulmonary valve stenosis has been well described. The
atural History of Congenital Heart Defects study (836) in
he mid 1960s and early 1970s followed 564 patients with
alvar pulmonary stenosis with cardiac catheterization at 4-
nd 8-year intervals. On admission to the study, an average
f 15% of patients were less than 2 years old; 20% were 12
o 21 years old; and the remainder were 2 to 11 years old. At
nitial cardiac catheterization, they were divided into 4
roups based on severity: less than 25 mm Hg peak-to-peak
radient between the right ventricle and the pulmonary
rtery, trivial; 25 to 49 mm Hg, mild; 50 to 79 mm Hg,
oderate; and greater than 80 mm Hg, severe.
Of the 261 patients (46% of the total) treated medically,
ost had trivial, mild, or moderate obstruction. None of
hese patients had cyanosis or congestive heart failure, and
nly 6% had symptoms. There were no deaths during the
tudy. The pressure gradients were stable in the majority,
ith 14% of patients manifesting a significant increase and
4% a significant decrease. Most of the increases were in
hildren less than 2 years old and/or those with initial
radients greater than 40 mm Hg. Those not in either
ategory had only a 4% chance of an increase in the gradient
reater than 20 mm Hg. There was little or no change in the
verall status of the medically treated patients. During the
eriod of observation, 304 patients, most with moderate or
evere disease, were treated surgically. Only 1 death oc-
urred among the 245 patients in this group who underwent
urgery beyond infancy. At postoperative follow-up, the
radient had been reduced to insignificant levels in more
han 90%, with no recurrence of pulmonary stenosis in those
ollowed up to 14 years.
In 1993, the second Natural History of Congenital Heart
efects study (837) reported on the 16- to 29-year (mean
2 years) follow-up of the same group of patients. The
robability of 25-year survival was 96%, not statistically
ifferent from the normal control group. Fewer than 20% of
atients managed medically during the first Natural History
tudy subsequently required a valvotomy, and only 4% of
he patients who had undergone surgery required a second
peration. Most patients, whether managed medically or
urgically, had mild obstruction by Doppler echocardiogra-
hy. For patients who had an initial transpulmonary gradi-
nt less than 25 mm Hg in the first Natural History Study,
6% were free of cardiac operation over a 25-year period.
Infective endocarditis was uncommon. Only 1 case de-
eloped in the 592 patients followed up for a median of 18
ears, an incidence of 0.94 per 10 000 patient years.
lthough endocarditis prophylaxis has been recommended eor patients with pulmonic stenosis, the incidence and
everity of infection are such that the morbidity from
naphylactic reactions to endocarditis prophylaxis may be as
roblematic as the disease itself.
Surgical relief of severe obstruction by valvotomy with a
ransventricular (838) or transpulmonary artery (839) ap-
roach predates the introduction of cardiopulmonary by-
ass. A nonsurgical approach with balloon valvotomy was
escribed in 1982 (840) and by the late 1980s had become
he procedure of choice in the United States for the typically
omed, thickened valve, both for children (841) and adults
842,843). Surgery is still usually required for the dysplastic
alve often seen in Noonan’s syndrome. Although long-
erm follow-up of pulmonary balloon valvotomy is not yet
vailable, the early and midterm results (up to 10 years)
844) suggest that the long-term results will be similar to
urgical valvotomy, that is, little or no recurrence over a 22-
o 30-year period. Some pulmonary regurgitation almost
nvariably occurs after valvuloplasty, but it is rarely clinically
mportant in this group.
In those with severe or long-standing valvular obstruc-
ion, infundibular hypertrophy may cause secondary ob-
truction when the pulmonary valve is successfully dilated.
his frequently regresses over time without treatment.
ome have advocated transient pharmacological beta block-
de, but there is insufficient information to determine
hether this is effective or necessary.
From the Natural History Study data, it appears that
ongenital mild pulmonary stenosis is a benign disease that
arely progresses, that moderate or severe pulmonary steno-
is can be improved with either surgery or balloon valvotomy
t very low risk, and that patients who undergo surgery or
alloon valvotomy have an excellent prognosis and a low
ate of recurrence. Thus, the goal of the clinician is to
scertain the severity of the disease, treat those in whom it
s moderate or severe, and infrequently follow up on those
ith mild disease (845).
.7. Pulmonary Regurgitation
ulmonary valve regurgitation is an uncommon congenital
esion seen occasionally with what has been described as
diopathic dilation of the pulmonary artery or with connec-
ive tissue disorders. In this condition, the annulus of the
ulmonary valve dilates, which causes failure of the leaflets
o coapt during diastole. Mild pulmonary regurgitation may
e a normal finding on Doppler echocardiography.
Although pulmonary regurgitation is unusual as an iso-
ated congenital defect, it is an almost unavoidable result of
ither surgical or balloon valvuloplasty of valvular pulmonic
tenosis or surgical repair of tetralogy of Fallot. Among
atients with pulmonic stenosis who underwent surgical
alvotomy in the first Natural History Study (836), 87% had
ulmonary regurgitation by Doppler echocardiography in
he second Natural History Study (837), although it was
udible in only 58%. The echocardiogram tended to over-
stimate severity compared with auscultation, with 20%
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesonsidered moderate to severe by Doppler but only 6% by
uscultation. In those with pulmonary regurgitation, the
ight ventricle tended to be larger, but RV systolic dysfunc-
ion was uncommon, being present in only 9%.
Pulmonary regurgitation also commonly occurs after
uccessful repair of tetralogy of Fallot. Several studies have
ocumented that the vast majority of children and young
dults who underwent surgery in the late 1950s and 1960s
ontinued to do well for up to 35 years after surgery (846).
owever, an increasing number of patients with long-
tanding pulmonary regurgitation have developed severe RV
ilatation and diminished RV systolic performance, which
an lead to an inadequate ability to augment cardiac output
ith exercise and, in some cases, congestive heart failure.
his group has also been shown to have a significant
ncidence of ventricular arrhythmias known to be associated
ith late sudden death. Increased pulmonary artery pressure
rom LV dysfunction or residual peripheral pulmonary
rtery stenosis will increase the amount of regurgitation, and
hese conditions should be treated when present. Cardiac
agnetic resonance has proven to be a useful tool for
valuating pulmonary regurgitant fraction, RV end-diastolic
nd end-systolic volumes, and RV ejection fraction. A wide
ariation has been observed, but many adolescents and
oung adults with repaired tetralogy of Fallot have regurgi-
ant fractions exceeding 40% to 50%, with RV end-diastolic
imensions of more than 150 ml per m2 (normal 75 ml per
2) and RV ejection fractions of less than 0.40. Gatzoulis et
l. have noted that QRS prolongation (greater than 180 m
er second) relates to RV size and predicts malignant
entricular arrhythmias and sudden death after tetralogy of
allot repair (847). Pulmonary valve replacement, usually
ith a homograft or xenograft, has been performed with low
isk (833), has been shown to stabilize QRS duration, and,
n conjunction with cryoablation, has decreased the inci-
ence of pre-existing atrial and ventricular tachyarrhythmias
848). Pulmonary valve replacement has also been found to
esult in reduction in regurgitant fraction and RV end-
iastolic volumes but little change in RV ejection fraction
849,850).
Most physicians would perform pulmonary valve replace-
ent in patients with NYHA class II or III symptoms and
evere pulmonary regurgitation, but for asymptomatic pa-
ients, the indications based on regurgitant fraction, RV
nd-diastolic or end-systolic volume, and RV ejection frac-
ion remain unclear. Many would share the concern that it
ay be unwise to wait until RV function deteriorates, and
hat with pulmonary regurgitation, as with AR, valve
eplacement (see Section 3.2.3.8) should be considered
efore irreversible damage to ventricular performance occurs
851). That point has yet to be determined, however.
. SURGICAL CONSIDERATIONS
ardiac valve surgery began with off-pump trans-LV and/or
rans-left atrial commissurotomy performed to treat rheu- 1atic MS in the early 1950s. Since this limited beginning,
alve surgery has flourished on the basis of advances in
urgical experience and technology, particularly the devel-
pment of cardiopulmonary bypass, effective prosthetic
alves, and consistent intraoperative myocardial protection.
The availability of cardiopulmonary bypass allowed iso-
ation of the heart from the circulation and the performance
f true open heart operations. Early valve operations were by
ecessity conservative in nature and included open commis-
urotomy of the MV, simple repair of some types of MR
nd AR, and decalcification of aortic valves.
The development of cardiac valve prostheses in the early
960s expanded the spectrum of pathologies in patients
ith valvular heart disease that could be treated surgically.
any different designs for prosthetic heart valves were
tudied experimentally and clinically during the 1970s, but
y 1980, the basic designs of the prostheses used today had
een established. Available heart valve prostheses can be
rouped into 2 major categories: mechanical valves and
ioprostheses. Mechanical valves have the advantage of
tructural stability but the disadvantage of requiring antico-
gulation with warfarin. Bioprostheses have the advantage
f not requiring anticoagulation with warfarin but the
isadvantage of being subject to time-related structural valve
ailure. All heart valve replacement strategies are imperfect.
n excellent review of long-term durability and complica-
ions of valve prostheses has been published by Grunk-
meier et al. (852) based on 265 clinical studies involving
ore than 61 000 prostheses and a cumulative experience of
19 749 valve-years (Table 34).
After the development of cardiopulmonary bypass and
alvular prostheses, the next important technological ad-
ance was development of cardioplegic myocardial protec-
ion, a strategy that allows intraoperative protection of
entricular function, even for patients with diffuse CAD,
nd at the same time provides a favorable surgical field for
omplex valve operations. As a result, abnormal preoperative
yocardial function is no longer the major predictor of risk
or patients undergoing valve surgery, and the overall
n-hospital mortality and morbidity have decreased. In
ddition, effective myocardial protection has made possible
he most recent technological trend in valve surgery, which
s in the direction of complex valve reparative procedures
nd the avoidance of valve replacement.
.1. American Association for Thoracic Surgery/Society of
horacic Surgeons Guidelines for Clinical Reporting of
eart Valve Complications
n 1988, standards for defining and reporting complications
fter heart valve operations were proposed by the Ad Hoc
iaison Committee for Standardizing Definitions of Pros-
hetic Heart Valve Morbidity, a joint committee of the
merican Association for Thoracic Surgery and the STS
853). These guidelines were revised in 1996 (854,855). The
omplications determined to be of critical importance in the
996 guidelines are summarized as follows:
••
•
•
•
•
aftel D
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ACC/AHA Practice Guidelines August 1, 2006:e1–148Structural valvular deterioration refers to any change in
function of an operated valve that results from an intrinsic
abnormality that causes stenosis or regurgitation.
Nonstructural dysfunction is a composite category that
includes any abnormality that results in stenosis or
regurgitation of the operated valve that is not intrinsic to
the valve itself, exclusive of thrombosis and infection.
This category includes inappropriate sizing, also called
“valve prosthesis-patient mismatch” (856), and tissue
ingrowth around the prosthesis that may cause a fixed
stenosis or inhibit valve motion, causing stenosis and/or
regurgitation.
Valve thrombosis is any thrombus, in the absence of
infection, attached to or near an operated valve that
occludes part of the blood flow path or interferes with
Table 34. Prosthetic Valve Clinical Studies
Type Model
Mechanical valves
Ball Starr-Edwards
Disc Björk-Shiley
Monostrut
Medtronic Hall
Omniscience
Omnicarbon
Ultracor
Bileaflet St. Jude
Carbomedics
Edwards Tekna
Duromedics
Sorin Bicarbon
Total mechanical
Biological valves
Porcine Hancock I
Hancock II
Intact
Carpentier-Edwards
Freestyle
Bicor
Pericardial C-E Perimount
Mitroflow
Homograft Homograft
Total biological
Total
Modified with permission from Grunkemeier GL, Li HH, N
Curr Probl Cardiol 2000;25:73–154 (852).function of the valve.Embolism is any embolic event that occurs in the absence
of infection after the immediate perioperative period
(when anesthesia-induced unconsciousness is completely
reversed). This includes any new, temporary or perma-
nent, focal or global neurological deficit and peripheral
embolic event; emboli proven to consist of nonthrom-
botic material are excluded.
Bleeding event (formerly anticoagulant hemorrhage) is
any episode of major internal or external bleeding that
causes death, hospitalization, or permanent injury or
requires transfusion. The complication “bleeding event”
applies to all patients, whether or not they are taking
anticoagulants or antiplatelet drugs.
Operated valvular endocarditis is any infection that
involves an operated valve. Morbidity associated with
tion Series Valves Valve-Years
tic 5 2339 19 069
ral 8 2524 20 928
tic 4 795 5954
ral 6 1330 8895
tic 4 4950 16 776
ral 3 4265 14 747
tic 8 1964 11 918
ral 4 638 3256
tic 2 185 1239
ral 1 103 716
tic 2 232 1280
ral 1 95 463
tic 1 225 751
ral 1 172 660
tic 14 6813 33 379
ral 15 5636 28 456
tic 5 2252 7928
ral 4 1094 3917
tic 4 1039 4586
ral 2 439 1903
tic 1 163 408
95 37 253 187 230
tic 10 4118 30 260
ral 6 2014 16 282
tic 2 858 5010
ral 3 551 3086
tic 3 1265 2779
ral 3 779 2066
tic 9 3069 15 962
ral 7 1977 12 632
tic 1 699 577
tic 1 856 2317
ral 1 137 510
tic 10 4865 23 027
ral 3 481 2179
tic 2 318 1800
ral 1 96 576
tic 8 2119 13 457
70 24 202 132 519
265 61 455 319 749
C, et al. Long-term performance of heart valve prostheses.Posi
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Mit
Aor
Aor
Mit
Aor
Mit
Aor
Mit
Aoractive infection, such as valve thrombosis, thrombotic
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesembolus, bleeding event, or paravalvular leak, is included
under this category and not in other categories of
morbidity.
The consequences of the above events include reopera-
ion; valve-related mortality; sudden unexpected, unex-
lained death; cardiac death; total deaths; and permanent
alve-related impairment (854,855) in addition to cardiac-
elated symptoms such as dyspnea, fatigue, and angina. In
ddition, valve prosthesis may produce hemolysis due either
o the valve itself or to associated perivalvular leak.
There is a wide range in the reported incidence of
omplications with the same prosthetic valve and between
ifferent valves (852). This is most likely due to variation
mong series rather than to valve type and model (857). It
as been emphasized (858) that these variations include
actors associated with patients (e.g., ventricular function,
omorbidities), medical center (e.g., surgical variables, def-
nitions of complications, thoroughness of follow-up), and
ata analysis (e.g., influences of patient-related factors)
857). In addition, published data represent only a small
raction of valves implanted (852,858).
Many types of bias affect reported results (859), which
ight be overcome with randomized trials; however, ran-
omized trials also have difficulties (860,861). The number
f randomized studies of prosthetic heart valves is small, and
he majority of those that have been reported are of
nsufficient size to add importantly to the knowledge already
btained from careful observational studies.
.2. Aortic Valve Surgery
he types of operations available to treat aortic valve
ysfunction include AVR with a mechanical or a biopros-
hetic valve, AVR with an allograft (homograft) valve,
ulmonic valve autotransplantation (Ross operation)
153,822–825,862), aortic valve repair, and left ventricle–
o–descending aorta shunt. Each has specific advantages
nd disadvantages. Cardiopulmonary bypass is used in aortic
alve operations, and these procedures are usually performed
hrough a median sternotomy incision, although partial
ternotomy (minimally invasive incisions) is gaining accep-
ance. See Sections 3.1.7 and 3.2.3.8 for indications for
VR or repair in patients with AS and AR.
.2.1. Risks and Strategies in Aortic Valve Surgery
he voluntary STS database (165) received reports regard-
ng 9108 to 11 665 isolated AVRs per year during the years
999 through 2004 (total of 62 834 operations). This
oluntary registry is not inclusive of national practice, but it
epresents the best approximation currently available. Se-
ected patient-related descriptors were mean age 66 years,
emale gender 42%, and previous cardiac surgery 16.5%.
pproximately 76% of patients had AS, and the mean LV
jection fraction was 0.53. In-hospital mortality by year
anged from 2.9% to 3.6%, and the risk of permanent stroke
as 1.5% to 1.8%. Experienced centers have reported iortality rates for primary isolated AVR of less than 1% to
%, although the national average in the STS database is 3%
o 4% (165) and is higher in low-volume centers (166).
uring the 1999 to 2002 time frame, the implantation of
echanical valves declined from 41% to 33% of total cases,
ith a corresponding increase in the implantation of bio-
rostheses from 50% to 65%, whereas the use of homografts
as steady at approximately 2%.
The majority of patients undergoing AVR have other
ardiac lesions, most commonly CAD, and more complex
athology has been associated with increased risk. Experi-
nced centers have reported very little incremental risk
ssociated with combined pathology, but the mortality rates
or a combined AVR and CABG is 6% to 7% (165). Even
echnical expertise does not negate the influence of cardiac
nd noncardiac comorbidity associated with diffuse athero-
clerosis or aneurysmal disease.
.2.2. Mechanical Aortic Valve Prostheses
esigns of mechanical aortic valve prostheses currently avail-
ble in the United States include ball-and-cage valves, single
ilting disc prostheses, and bileaflet prostheses. Ball-and-cage
alves have the disadvantage of noise and hemodynamic
nefficiency and today are rarely used, although the mechanical
tability of ball-and-cage prostheses has been excellent at
ollow-up intervals of more than 30 years. Single-tilting disc
alves currently available in the United States are the
edtronic-Hall valve and the Omnicarbon valve. These valves
ave superior hemodynamic efficiency to ball-and-cage valves
nd have been structurally stable. The most severe disadvantage
f the single-disc design is severe hemodynamic compromise if
isc thrombosis or immobility occurs.
The most common mechanical valve design used in the
ortic position is the bileaflet valve, with versions available
n the United States being manufactured by St. Jude,
arboMedics, ATS Medical, and On-X. The bileaflet
alves are relatively quiet, appear to be mechanically stable,
nd are relatively hemodynamically efficient. The operation
or implantation of mechanical prostheses is standard, as is
he surgery for reoperation when that is needed. The
isadvantages of mechanical valves are the need to take
arfarin for anticoagulation to prevent thromboembolism,
he risk of bleeding complications, the risk of thromboem-
olism despite warfarin therapy, endocarditis, and hemody-
amic inefficiency in smaller sizes. Also, the structural
tability of mechanical valves does not eliminate the possi-
ility of reoperation for other indications such as valve
hrombosis, tissue ingrowth and valve dysfunction,
eriprosthetic leak, endocarditis, symptomatic patient-
rosthesis mismatch, and multiple bleeding episodes sec-
ndary to warfarin therapy.
.2.2.1. Antithrombotic Therapy for Patients With Aortic
echanical Heart Valves
fter mechanical AVR, the goal of antithrombotic therapy
s usually to achieve an INR of 2.5 to 3.5 for the first 3
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ACC/AHA Practice Guidelines August 1, 2006:e1–148onths after surgery and 2.0 to 3.0 beyond that time (see
ection 9.2). Low-dose aspirin (75 to 100 mg per day) is
lso indicated in addition to warfarin (808), as discussed in
ection 9.2.1. At that level of anticoagulation, the risk of
ignificant hemorrhage appears to be 1% to 2% per year.
lthough the goal of mechanical and materials engineering
as been to produce a mechanical valve that does not require
nticoagulation with warfarin, that goal has not yet been
chieved. Trials diminishing or eliminating anticoagulation
ith warfarin or substituting platelet inhibitors for warfarin
ave so far noted a high rate of thromboembolism.
.2.3. Stented and Nonstented Heterografts
.2.3.1. Aortic Valve Replacement With Stented Heterografts
he most commonly used aortic valve prostheses in the
nited States today are stented heterografts that are con-
tructed with bovine pericardial tissue or porcine aortic valve
issue arranged on a cloth and metal frame. These valves
ave the advantages of a low thromboembolism rate without
arfarin, a simple and standard implantation technique, a
tandard reoperation risk, a low risk of catastrophic valve
ailure, and widespread availability in many valve sizes. The
isadvantages of stented heterografts are structural valve
eterioration, imperfect hemodynamic efficiency, a standard
isk of prosthetic valve endocarditis, and a low (0.7% per
ear) but present risk of thromboembolism without warfarin
nticoagulation. Stented pericardial heterografts have better
emodynamic performance than porcine heterografts, espe-
ially in smaller sizes (less than 21 mm) (863–866). In a
andomized trial comparing stented porcine xenografts and
tented pericardial valves (866), the reduced pressure gradi-
nts with the pericardial valve translated into greater reduc-
ion in LV mass at a mean 1.2-year follow-up period after
VR.
The first-generation stented heterografts (porcine hetero-
rafts) exhibited a freedom from structural valve deteriora-
ion of approximately 40% by 18 postoperative years. How-
ver, the rate of structural valve deterioration is age-related
168,867–880), being increased for younger patients, and in
atients less than 40 years of age, approximately half of
orcine valves fail by 10 years (Table 35). Bovine pericardial
alves appear to have a lower rate of structural valve
eterioration, with 15-year data indicating that 77% of
alves in surviving patients of all ages are functioning
ithout explantation, and among patients undergoing pri-
ary AVR at an age greater than 65 years, fewer than 10%
nderwent valve explantation by 15 postoperative years
168,876). The reported rate of structural valve deteriora-
ion for second-generation porcine valves appears so far to
e equivalent to that of stented bovine valves.
.2.3.2. Aortic Valve Replacement With Stentless Heterografts
tentless heterografts are valves constructed from porcine
ortic valves that use a smaller amount of cloth for stabili-
ation, sewing, and tissue ingrowth than a full cloth-metal wtent. The major goal of stentless heterografts is to achieve
nhanced hemodynamic efficiency relative to stented valves
881–886). The long-term importance of hemodynamic
fficiency of prosthetic heart valves is currently a subject of
nvestigation and disagreement. The argument favoring the
se of stentless valves is that stented valves of any kind are
t least partially stenotic (particularly in small sizes) and that
ven small postoperative gradients may lead to incomplete
V mass regression postoperatively (883,885–887), which
ill, in turn, lead to impaired long-term survival and
ymptom status. Some randomized and nonrandomized but
omparative studies (885–887) have reported lower trans-
alvular gradients and more consistent regression of LV
ass after AVR when stentless valves are used than with
tented prostheses, whereas other studies show no differ-
nces (888,889). In addition, the long-term importance of
V mass regression is not clear.
One nonrandomized study reported improved postoper-
tive survival with stentless than with stented porcine
ioprostheses (890). However, in the several randomized
rials comparing stented and stentless valves, there has been
o difference in patient outcomes at 1 to 3 years after
urgery (886–889). It is clear that the combination of large
nd active patients and small aortic valve prostheses can lead
o high transprosthetic gradients (particularly with exercise)
nd symptoms related to patient-prosthesis mismatch (856).
owever, the importance of small transvalvular gradients is
s yet unclear. Stentless heterografts have the disadvantage
hat their implantation is more complex than that for
tented valves, and their long-term outcomes are unknown.
here is a low incidence (7% to 10%) of early mild AR in
ome series (883,884,886), which may progress with time,
ut it is uncertain whether this differs from the experience
ith some stented bioprostheses (856,883,884). Observa-
ional studies with 8- to 10-year follow-up (891) appear to
how a low risk of structural valve deterioration with
tentless heterografts, and the hope is that improved hemo-
ynamic design will lead to improved longevity. Time will
ell. Stentless valves are implanted with techniques similar
o those used for aortic valve homografts, but they have the
dvantage of increased availability compared with aortic
alve homografts.
.2.4. Aortic Valve Homografts
ortic valve allografts (homografts) have been used for
VR since early in the cardiac surgical era (892), but the
apid failure rate of early homografts (30% structural valve
eterioration by 10 years) and the complex implantation
echniques required limited their use. The use of ho-
ografts has been revived by cryopreservation techniques
hat appear to diminish the rate of structural valve deterio-
ation (169,171). Homografts may be implanted as a “free
and” valve in the subcoronary position; as a “mini-root”
eplacement, during which the valve is implanted within the
ative root cylinder; and as a full root replacement, during
hich the native aortic root is removed and entirely replaced
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesith the homograft aortic root, the coronary arteries being
eimplanted into the homograft. All these operations are
ore complex than the implantation of standard mechanical
alves or stented heterografts. Total aortic root replacement
s currently the most common homograft implantation
trategy.
It had been hoped that aortic valve homografts would
utlast heterografts, particularly in young patients, but to
able 35. Structural Valve Deterioration of Bioprosthetic Valves
Author, Year
Mean
Follow-
Up, y
Number of
Valves Time of
SVD
Estimate, y AAVR MVR
amieson et al.,
1988 (867)
5.6 572 509 10 30–59
Greate
ohn et al.,
1989 (868)
6.0 971 708 15 40 or l
41–69
70 or g
ones et al.,
1990 (869)
8.3 610 528 10 Less th
40–49
50–59
60–69
urdon et al.,
1992 (872)
7.3 857 793 15 16–39
40–49
50–59
60–69
Greate
urr et al.,
1992 (873)
— 574 500 7 Less th
65–69
70–79
80 or g
13–15 Less th
65–69
70–79
80 or g
elletier et al.,
1992 (874)
7.0 451 547 10 Less th
45–54
55–64
65 or g
osgrove et al.,
1995 (875)
7.8 310 — 10 Less th
65 or g
elletier et al.,
1995 (876)
4.5 416 — 10 Less th
60–69
70 or g
ohn et al.,
1998 (877)
6.1 843 — 10 50 or l
51–69
70 or g
15 50 or l
51–69
70 or g
anbury et al.,
2001 (168)
12 267 — 15 45
55
65
75
amieson et al.,
2001 (879)
6.2 836 332 12 51–60
61–70
Greate
VR indicates aortic valve replacement; MVR, mitral valve replacement; SVD, struate, long-term data do not support this view. One possible tdvantage of homografts is in the avoidance of early endo-
arditis and in the treatment of aortic valve endocarditis
893–896), particularly complex aortic root endocarditis,
lthough the literature does not demonstrate the superiority
f any single prosthesis in these situations (852,897–900).
he risk of thromboembolism is very low after homograft
mplantation, and hemodynamic efficiency is excellent even
n small sizes. The biggest disadvantage of homografts is
Freedom From
SVD, %
CommentsAVR MVR
60
81  4
91  3
78  5
71  9
Carpentier-Edwards standard porcine
bioprosthesis
r
68  9
86  2
94  3
68  10
84  13
84  10
Hancock porcine bioprosthesis (includes
146 combined AVR  MVR
procedures)
46  7
60
79
92  2
47  8
48  8
61
80  6
Hancock or Carpentier-Edwards
porcine bioprosthesis (includes 88
combined AVR  MVR procedures)
33  7
54  10
37  6
38  12
Hancock I and Hancock modified
orifice porcine bioprosthesis
57  6 38  5
73  6 61  15
70 93  3 62  6
r
94  1
98  1
100
100
88  2
90  4
95  3
100
Carpentier-Edwards standard porcine
bioprosthesis (similar results were
obtained with Carpentier-Edwards
supra-annular porcine bioprosthesis)
62  8 37  7
98  3 63  8
95  5 74  19
r 100 —
r
70
84
84
93
55
64
69
95
Carpentier-Edwards standard (302
AVR, 324 MVR) improved annulus
(97 AVR, 135 MVR), supra-annular
(52 AVR, 88 MVR) porcine
bioprostheses (includes 121 combined
AVR  MVR and 5 combined
MVR  TVR procedures)
r
88.6
95.5
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
86.3
95.3
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
r 100 —
57
77
—
—
Hancock modified orifice porcine aortic
valve
r 96 —
16 —
54 —
r 87 —
58
70
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
82 —
91 —
92  3
96  2
90  3 Medtronic Intact porcine bioprosthesis
70 98  1 97  3
valve deterioration; and TVR, tricuspid valve replacement.ge, y
r than
ess
reate
an 40
r than
an 65
reate
an 65
reate
an 45
reate
an 65
reate
an 60
reate
ess
reate
ess
reate
r thanhat reoperation after homograft AVR is more difficult than
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he entire homograft may become severely calcified. In a
andomized trial comparing homografts and stentless bio-
rosthetic valves, there was no difference in hemodynamics
r patient outcomes at 1 year after operation (901,902). As
ith stentless bioprostheses, AR may develop, and there is
n increased likelihood of need for reoperation in patients
nder the age of 40 years (903).
.2.5. Pulmonic Valve Autotransplantation
ulmonic valve autotransplantation (Ross operation) is an
peration developed in an attempt to provide a permanent
iological aortic valve prosthesis using the pulmonic valve
153,822,823,825,862) In this operation, the pulmonic valve
s excised and used to replace the aortic valve either as a
ubcoronary implantation or as a full aortic root replace-
ent, while the pulmonic valve is then replaced with an
lternative prosthesis, usually a pulmonic homograft. This
peration has been performed in small numbers, and long-
erm follow-up studies have been inconsistent, which makes
nalysis of long-term advantages and disadvantages difficult.
he known advantages of the procedure are that the
utograft may grow in children, warfarin is not required,
here is a low incidence of thromboembolism, the autograft
s a hemodynamically efficient valve, and the incidence of
ndocarditis is low (904). The disadvantage of pulmonic
utotransplantation is that the operation is much more
omplex than standard AVR and in most series has been
ssociated with at least some increase in in-hospital mor-
ality. There is also an incidence of early aortic valve failure
ased on technical considerations or dilatation of the aortic
oot, and the homograft used to replace the pulmonic valve
s also subject to failure, sometimes early, within a few years
f operation (862). Small, short-term randomized and
onrandomized comparisons of pulmonary autografts and
ortic homografts have demonstrated no definite advantage
f either in adults in terms of hemodynamics and patient
utcome (905–907). Deterioration of the pulmonary ho-
ograft also offsets potential advantages of the autograft.
.2.6. Aortic Valve Repair
ultiple strategies for aortic valve repair have been ex-
lored, some successfully. Aortic valve repair by decalcifying
tenotic calcific aortic valves was used in the preprosthesis
ra but abandoned because of recalcification and restenosis.
evival of its use with modern myocardial protection and
ecalcification techniques still is associated with a high rate
f restenosis. Repair of rheumatic aortic valves has, in
eneral, not been successful over time. In contrast, repair of
nsufficient bicuspid aortic valves in the adult has been
ncreasingly successful at limited numbers of centers
827,908,909). Among the advantages of this strategy are
he lack of need for anticoagulation, a low thromboembolic
isk, a low endocarditis risk, a hemodynamically efficient
alve, and a straightforward reoperation, if needed. The
isadvantages are lack of uniform applicability, lack of aidespread experience with surgical techniques, and the
eed for reoperation. Long-term data are limited, but the
isk of reoperation appears to be about 15% by 10 postop-
rative years. Although late calcification of these repaired
alves has to be considered likely given enough time,
alcification may be delayed in some patients with repaired
icuspid valves, who may avoid reoperation for decades.
Much progress has been made in the repair of aortic
alves rendered insufficient by aortic root pathology
364,910–915). When an aortic root aneurysm exists, the
peration to restore competence to the aortic valve involves
esecting the aorta and resuspending the valve in association
ith a Dacron graft that is used to replace the aorta.
dvantages of this strategy include avoidance of warfarin, a
ow thromboembolic risk, a very efficient valve, and what
ppears to be a low risk of prosthetic valve endocarditis. The
isadvantages are, again, limited applicability in the setting
f intrinsic leaflet pathology and the high level of surgical
xpertise and experience required.
.2.7. Left Ventricle–to–Descending Aorta Shunt
n situations involving pathologies that make standard AVR
perations particularly risky, such as multiple previous
perations, severe aortic calcification, and previous radiation
herapy, a left ventricle–to–descending thoracic aortic shunt
sing a Dacron graft containing a valve can be an effective
lternative treatment (916). This procedure is performed
hrough a left thoracotomy with or without cardiopulmo-
ary bypass. A valved conduit is connected to the LV apex
ia a metal connector and then anastomosed to the descend-
ng intrathoracic aorta. Favorable short-term outcomes have
een reported, but the long-term hemodynamics results and
omplication rate associated with this strategy are currently
nknown.
.2.8. Comparative Trials and Selection of Aortic Valve
rostheses
wo randomized trials have compared outcomes for pa-
ients receiving mechanical and bioprosthetic valves in the
ortic position, the Edinburgh Heart Valve Trial (1975–
979) (917) and the Veterans Affairs Cooperative Study on
alvular Heart Disease (1979–1982) (174,918). Both com-
ared the Bjork-Shiley tilting-disc valve with first-
eneration porcine heterografts. In the Veterans Affairs
rial, 15-year survival rates were superior for patients with
echanical valves (34%) compared with those with biopros-
heses (21%) in the aortic position (p  0.02), but 20-year
urvival rates were no different in the Edinburgh trial. As
xpected, bleeding rates were significantly higher for pa-
ients with mechanical valves, and structural valve deterio-
ation and reoperation rates were higher for patients with
ioprostheses in both trials (174,917,918). The long-term
esults of the Veterans Affairs Cooperative Study (174) are
hown in Table 36.
Despite the randomized design of these trials and the
pparent slight advantage for patients receiving mechanical
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesrostheses, the trend in the United States has been away
rom mechanical prostheses and towards biological valves
or multiple reasons.
Current bioprostheses appear to have lower rates of
structural valve deterioration than those used during the
randomized trials that involved first-generation biopros-
theses. Reoperation rates for patients over 65 years of age
are particularly low with modern stented bioprostheses
(Table 35).
The risks of reoperation have continued to decrease since
these trials were completed, particularly the risk of a first
reoperation.
Patients undergoing AVR today represent an older pop-
ulation than those studied in the randomized trials.
Young patients undergoing aortic valve surgery are often
reluctant to accept warfarin therapy and the activity
constraints associated with anticoagulants.
There are some nonrandomized but relatively large com-
parative trials that have shown apparent survival benefit
for patients receiving bioprostheses, particularly for those
over the age of 65 years (919).
On the basis of these considerations, most patients over
5 years of age receive a bioprosthesis. There are no data
nvolving large patient numbers that clearly show long-term
dvantages for one type of aortic valve operation over
nother or for any individual prosthesis over another.
At many major valve surgery centers, the age threshold
or the use of bioprosthetic valves in the aortic position has
ecreased to well below 65 years in those patients who do
ot wish to take anticoagulation. The decision requires full
iscussion with the patient, with the understanding that
here is a higher chance of the need for reoperation with a
ioprosthesis.
In the previous 1998 ACC/AHA Guidelines for the
anagement of Patients with Valvular Heart Disease,
echanical valves were recommended (Class IIa) in patients
ith end-stage renal failure, especially those undergoing
able 36. Probability of Death Due to Any Cause, Any Valve-R
5 Years After Randomization in the Veterans Affairs Cooperativ
Event
Aortic Valve
Mechanical
(n  198)
Porcine
(n  196)
eath due to any cause 66  3 79  3
ny valve-related
complications
65  4 66  5
ystemic embolism 18  4 18  4
leeding 51  4 30  4
ndocarditis 7  2 15  5
alve thrombosis 2  1 1  1
erivalvular regurgitation 8  2 2  1
eoperation 10  3 29  5
tructural valve failure 0  0 23  5
alues are actuarial percentages plus/minus standard error. Note: p values are for differ
enderson WG, et al. Outcomes 15 years after valve replacement with a mechanical v
ardiol 2000;36:1152–8 (174). Reprinted with permission.hronic dialysis, because of the concern of acceleratedalcification of bioprosthetic valves. Subsequent retropsec-
ive studies (919a) have demonstrated no significant differ-
nce in outcome of such patients treated with mechanical
rostheses versus bioprostheses. The current writing com-
ittee has made no specific recommendations for valve
election in dialysis patients, but notes the difficulties in
aintaining anticoagulation in these patients.
Selection among biological valve operations is based on
ogic and opinion rather than consistently defined differ-
nces and outcomes. Surgeon experience is important,
ecause there are no long-term data justifying the use of
perations that increase perioperative risk. The most com-
on biological valve used is a stented heterograft because of
ts easy implantation, the ease of reoperation, the extensive
ata defining its late outcomes, and the lack of data
upporting the use of more complex strategies. Although it
ad been hoped that homografts would have an improved
ailure rate relative to stented heterografts, at this point, data
o not support that view. A stentless allograft or homografts
re a good choice for patients with small aortic root sizes at
isk for patient-prosthesis mismatch (856,863–865). Stent-
ess heterografts have been effective in the short term, but
he extent of their advantage is unclear in regard to valve
fficiency, and long-term failure rates are not known
886,889,920). Current data noting a 20% failure rate by 10
ostoperative years do not indicate improved long-term
utcomes compared with stented bioprostheses. Pulmonic
alve autotransplantation is used by some to allow growth of
he autograft in children. Its use in adults has been limited
y some increase in operative risk and data indicating a
eoperation rate of approximately 20% by 10 postoperative
ears.
.2.9. Major Criteria for Aortic Valve Selection
lass I
. A mechanical prosthesis is recommended for AVR in
patients with a mechanical valve in the mitral or
Complications, and Individual Valve-Related Complications
dy on Valvular Heart Disease
Mitral Valve
p
Mechanical
(n  88)
Porcine
(n  93) p
0.02 81  4 79  4 0.30
0.26 73  6 81  5 0.56
0.66 18  5 22  5 0.96
0.001 53  7 31  6 0.01
0.45 11  4 17  5 0.37
0.33 1  1 1  1 0.95
0.09 17  5 7  4 0.05
0.004 25  6 50  8 0.15
0.001 5  4 44  8 0.001
between mechanical and porcine valves. Data are from Hammermeister K, Sethi GK,
a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Collelated
e Stu
encestricuspid position. (Level of Evidence: C)
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ACC/AHA Practice Guidelines August 1, 2006:e1–148. A bioprosthesis is recommended for AVR in patients
of any age who will not take warfarin or who have
major medical contraindications to warfarin therapy.
(Level of Evidence: C)
lass IIa
. Patient preference is a reasonable consideration in
the selection of aortic valve operation and valve
prosthesis. A mechanical prosthesis is reasonable for
AVR in patients under 65 years of age who do not
have a contraindication to anticoagulation. A bio-
prosthesis is reasonable for AVR in patients under 65
years of age who elect to receive this valve for lifestyle
considerations after detailed discussions of the risks
of anticoagulation versus the likelihood that a second
AVR may be necessary in the future. (Level of Evi-
dence: C)
. A bioprosthesis is reasonable for AVR in patients
aged 65 years or older without risk factors for throm-
boembolism. (Level of Evidence: C)
. Aortic valve re-replacement with a homograft is
reasonable for patients with active prosthetic valve
endocarditis. (Level of Evidence: C)
lass IIb
A bioprosthesis might be considered for AVR in a
woman of childbearing age (see Sections 5.7 and 5.8).
(Level of Evidence: C)
.3. Mitral Valve Surgery
V surgery began with valve-conserving operations for
heumatic MS and expanded to treat a variety of pathologies
nce prosthetic valve replacement became available. Today,
alve-conserving operations have become more common
nd are used to treat a variety of pathologies. Analysis of the
utcomes after MV surgery is complex. Those outcomes are
ffected not only by the valve-coronary pathology treated
ut also by LV function, cardiac rhythm, and surgeon
xperience. Operations currently available to treat MV
ysfunction include closed mitral commissurotomy, replace-
ent with a mechanical prosthesis, replacement with a
ioprosthesis, replacement with an MV homograft or Ross-
ype autograft, and a variety of reparative MV procedures.
The surgical approaches to MV surgery are varied. Closed
r “off-pump” mitral commissurotomy can be performed
ither percutaneously with a balloon catheter or surgically
hrough a left thoracotomy (see Sections 3.4.8 and 3.4.9).
he standard approach for MV replacement or complex
epair is use of a median sternotomy with cardiopulmonary
ypass; however, many alternative incisions are now used,
ncluding partial sternotomy and small right thoracotomy
ccess, strategies described as “minimally invasive.” Video-
ssisted and robotic-assisted MV surgery are becoming
ore feasible, and standard outcomes have been described
or small numbers of selected patients undergoing surgery at
enters that specialize in these alternative surgical strategies.When the MV is replaced, an attempt is made to preserve
t least part of the subvalvular apparatus, that is, the chordae
endineae connecting the papillary muscles with the valve
nnulus. Experimental and clinical data show that long-
erm LV function may benefit by this strategy.
.3.1. Mitral Valve Repair
V surgery began with conservative operations for rheu-
atic MS; within the last 20 years, conservative operations
o treat MR have been developed and popularized to treat
egenerative and functional MV disease, as well as some
atients with MV endocarditis. The outcomes of MV repair
ust be analyzed according to the pathologies treated rather
han the operation alone.
.3.1.1. Myxomatous Mitral Valve
lass I
. MV repair is recommended when anatomically pos-
sible for patients with severe degenerative MR who
fulfill clinical indications, and patients should be
referred to surgeons who are expert in repair. (Level of
Evidence: B)
. Patients who have undergone successful MV repair
should continue to receive antibiotics as indicated for
endocarditis prophylaxis. (Level of Evidence: C)
. Patients who have undergone successful MV repair
and have chronic or paroxysmal atrial fibrillation
should continue to receive long-term anticoagulation
with warfarin. (Level of Evidence: B)
. Patients who have undergone successful MV repair
should undergo 2D and Doppler echocardiography
before discharge or at the first postoperative outpa-
tient visit. (Level of Evidence: C)
. Tricuspid valve repair is beneficial for severe TR in
patients with MV disease that requires MV surgery.
(Level of Evidence: B)
lass IIa
. Oral anticoagulation is reasonable for the first 3
months after MV repair. (Level of Evidence: C)
. Long-term treatment with low-dose aspirin (75 to
100 mg per day) is reasonable in patients who have
undergone successful MV repair and remain in sinus
rhythm. (Level of Evidence: C)
. Tricuspid annuloplasty is reasonable for mild TR in
patients undergoing MV repair when there is pulmo-
nary hypertension or tricuspid annular dilatation.
(Level of Evidence: C)
lass IIb
In patients with MR and a history of atrial fibrilla-
tion, a Maze procedure may be considered at the time
of MV repair. (Level of Evidence: B)
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesMyxomatous MV disease produces MR based on
upture or elongation of chordae tendineae, valve leaflet
nstability, annulus dilatation, or multiple causes that
esult in excessive MV leaflet motion. In the majority of
hese conditions, experienced surgeons can repair the MV
sing strategies that involve removal of unsupported
eaflet structures, transfer of chordae (467,468), or the
se of artificial chordae to support unstable areas of the
eaflet, the sliding of supported areas of the leaflet to
over the MV orifice, and stabilization of the size and
hape of the MV annulus with an artificial ring
529,530,545,568 –573). When possible, MV repair is
he treatment of choice for degenerative valve disease,
ecause patients in sinus rhythm do not need warfarin,
he thromboembolism rate is low, valve efficiency and
emodynamics are good, there is little adverse effect on
V function, the risk of endocarditis is low, and the
ong-term survival rate is favorable compared with MV
eplacement (see Section 3.6.4). Concomitant tricuspid
alve repair should be performed when there is severe TR
r mild-to-moderate TR and tricuspid annular dilatation
see Section 3.7.4.3 and Section 3.8.3). In patients
resenting for MV repair with chronic atrial fibrillation,
concomitant surgical procedure to eliminate atrial
brillation may prevent future embolic events by restor-
ng normal sinus rhythm (608 – 614). The decision to
roceed with a surgical procedure to eliminate atrial
brillation should be made based on the age and health of
he patient, as well as the surgical expertise, because this
rocedure may add to the morbidity of the operation (see
ection 3.6.4.2.4).
The likelihood of a successful MV repair is related to the
xtent of the MV dysfunction (with isolated posterior leaflet
ysfunction being the most favorable condition); the pres-
nce and extent of calcification; the amount of pliable,
oncalcified valve tissue; and surgeon experience. Recurrent
R after repair may occur with time, but in favorable
ituations, more than 90% of valves are still functioning well
fter 10 years (529,530).
.3.1.2. Rheumatic Heart Disease
lass I
Percutaneous or surgical MV commissurotomy is
indicated when anatomically possible for treatment
of severe MS, when clinically indicated. (Level of
Evidence: C)
Rheumatic MR is inconsistently reparable, and the long-
erm outcomes after repair are not as good as for valve repair
or degenerative MV disease. Rheumatic pathology often
eads to leaflet and chordal scarring, which restricts the
eaflet motion, and leaflet scarring may be progressive after
epair. Rheumatic MS that is not associated with severe
hordal fusion or shortening or with calcification may be
reated with either percutaneous or open mitral commissur- Itomy with a high degree of long-term success. Clinical
ndications for these procedures are discussed in Section
.4.8.
.3.1.3. Ischemic Mitral Valve Disease
y definition, all patients with ischemic MR have signifi-
ant CAD that usually has a significant effect on long-term
urvival. The pathology of ischemic MR has multiple
ubgroups, with the most common situation being func-
ional MR, in which the valve leaflets are structurally
ormal, but LV chamber enlargement and papillary muscle
isplacement tether the MV via the chordal attachments
nd prevent leaflet coaptation (616–623). When functional
R is severe, it may be corrected by placement of an
nnuloplasty ring that decreases the annular circumference,
hortens the intertrigonal distance, reduces the septal-lateral
anterior-posterior) annular diameter, and restores the ge-
metry of the annulus, thereby allowing the MV leaflets to
oapt (624–627,633–642). This strategy acutely decreases
r eliminates MR, but because the fundamental abnormality
s related to LV function, the late survival rate of these
atients is relatively low compared with patients with other
V pathologies, and the recurrence rate of mitral dysfunc-
ion is higher. For patients with moderate functional MR, it
s not yet clear whether MV repair improves outcomes.
Patients with ischemic MV disease who have anatomic
R based on infarction or rupture of the papillary muscles
enefit from either mitral repair or MV replacement.
apillary muscle rupture often produces severe MR and
emodynamic decompensation, which is an indication for
mergency surgery.
.3.1.4. Mitral Valve Endocarditis
ith increased surgical experience in mitral reparative
echniques, MV endocarditis has become more consistently
reatable with repair (760–762). There appears to be a low
isk of recurrent infection, and in experienced hands, it is
ften possible to avoid the need for an MV prosthesis (see
ection 4.6.1). Surgery, however, must not be delayed until
xtensive valve disruption has occurred.
.3.2. Mitral Valve Prostheses (Mechanical or Bioprostheses)
echanical Prostheses
all-and-cage valves, single-tilting disc valves, and bileaflet
rostheses are available MV prostheses. Ball-and-cage
alves have been effective but can cause some degree of
utflow tract obstruction by projecting into the LV outflow
ract, a problem not present with bileaflet or disc valves.
ost studies have shown that the thromboembolism risk is
reater for patients with mechanical MV prostheses than for
atients with aortic valves, even when adjusted for the
resence of atrial fibrillation. Thus, anticoagulation for
atients with mechanical MV prostheses is maintained at an
NR of 2.5 to 3.5 indefinitely.
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oth porcine heterografts and bovine pericardial hetero-
rafts are available in the United States for MV replace-
ent. Porcine heterografts have been followed up for longer
ntervals, but limited data appear to show a slower rate of
tructural valve deterioration for second-generation porcine
eterografts and bovine pericardial valves (921,922). The
ailure rate of mitral heterografts appears to be higher than
hat for aortic heterografts (Table 35). For example, in the
A Cooperative Study, 29% of aortic valve and 50% of
itral porcine heterografts needed reoperation by 15 post-
perative years (Table 36) (174).
.3.2.1. Selection of an Mitral Valve Prosthesis
lass I
A bioprosthesis is indicated for MV replacement in a
patient who will not take warfarin, is incapable of
taking warfarin, or has a clear contraindication to
warfarin therapy. (Level of Evidence: C)
lass IIa
. A mechanical prosthesis is reasonable for MV re-
placement in patients under 65 years of age with
long-standing atrial fibrillation. (Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in
patients 65 years of age or older. (Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in
patients under 65 years of age in sinus rhythm who
elect to receive this valve for lifestyle considerations
after detailed discussions of the risks of anticoagula-
tion versus the likelihood that a second MV replace-
ment may be necessary in the future. (Level of
Evidence: C)
The STS National Cardiac Surgery Database (165)
ndicates that the numbers of MV reparative procedures are
ncreasing relative to MV replacement. For isolated MV
perations during the years 2000 through 2004, valve repairs
umbered 2335, 2755, 3779, 3978, and 3712, respectively,
ompared with 4215, 4141, 4517, 4145, and 3579 MV
eplacement operations, respectively. Mortality rates were
.5% to 2.0% for repair versus 5.4% to 6.4% for MV
eplacement. Among patients receiving a MV replacement,
ore patients received mechanical valves than bioprosthe-
es. Medicare data indicate that the mortality for isolated
V replacement in patients older than 65 years is 14.1%,
hich increases to 20.5% in low-volume centers
167).When MV pathology is combined with CAD, the
isks of surgery increase. For the same 5 years noted above,
n average of 3637 patients per year underwent MV repair
ombined with CABG (165), with mortality rates ranging
rom 7% to 8.7%, and 2814 patients per year underwent MV
eplacement plus CABG, with mortality rates in excess of
1%. The majority of patients in this group received tioprostheses. The selection of a valve is a multifactorial
ecision.
hoice of Mitral Valve Operation
V repair should be able to be achieved by experienced
urgeons for the majority of patients with degenerative MV
isease and ischemic valve disease, and patients should be
eferred to surgeons expert in repair. For patients with
heumatic MV disease and endocarditis, repair may be more
ifficult.
For patients undergoing MV replacement, preservation
f the chordal apparatus preserves LV function and en-
ances postoperative survival compared with MV replace-
ent in which the apparatus is disrupted (570,579–582), as
iscussed in Section 3.6.4.1. In the randomized trials, there
as no difference in survival rate based on valve type;
owever, the failure rate of bioprostheses has been higher in
he mitral than in the aortic position (Table 35), which adds
mpetus to the use of mechanical prostheses in younger
atients.
The availability of surgical ablation procedures for atrial
brillation offers the possibility of converting the patient to
inus rhythm and avoiding anticoagulation after MV repair
r replacement with a bioprosthesis (608–614). If patients
an be maintained in sinus rhythm, the advantage of a
ioprosthesis is enhanced. For patients with a history of
trial fibrillation who are undergoing MV repair, a Maze-
ype procedure results in sinus rhythm in 75% to 90% of
ases by 6 postoperative months, with long-term data
ndicating sustained results up to 8 years and reduced risk of
troke (611,614). The effect of ablation of atrial fibrillation
or patients with multivalve disease or valve disease com-
ined with CAD is not known.
.4. Tricuspid Valve Surgery
lass I
Severe TR in the setting of surgery for multivalvular
disease should be corrected. (Level of Evidence: C)
lass IIa
Tricuspid annuloplasty is reasonable for mild TR in
patients undergoing MV surgery when there is pul-
monary hypertension or tricuspid annular dilatation.
(Level of Evidence: C)
The most common cause of TR is dilatation of the
ricuspid valve annulus caused by pulmonary hypertension.
he tricuspid leaflets are usually normal, and tricuspid valve
nnuloplasty usually corrects or improves the situation.
evere TR should be treated with annuloplasty during
perations for multivalvular disease (see Sections 3.7.4.3
nd 3.8.3). Other causes of TR include rheumatic valvular
isease, endocarditis, leaflet scarring due to inflammatory
onditions, and adherence of tricuspid valve structures to
ranstricuspid pacing wires. When leaflet anatomy is se-
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August 1, 2006:e1–148 ACC/AHA Practice Guidelineserely abnormal, tricuspid valve replacement may be needed,
ut this situation is not common. There are no data clearly
howing the advantage of one type of tricuspid prosthesis
ver another.
.5. Valve Selection for Women of Childbearing Age
here is no ideal valve prosthesis for women of childbearing
ge who might wish to become pregnant (see detailed
iscussion in Section 5.8). Bioprostheses may be subject to
remature heterograft or homograft failure. Because me-
hanical valves require anticoagulation, there is an increased
isk of fetal abnormalities and mortality, and there may be
n increased risk of maternal complications, including
hromboembolism. Discussion with the patient concerning
he risk of the prosthesis is important (see Section 5.8.4).
. INTRAOPERATIVE ASSESSMENT
lass I
. Intraoperative transesophageal echocardiography is
recommended for valve repair surgery. (Level of Ev-
idence: B)
. Intraoperative transesophageal echocardiography is
recommended for valve replacement surgery with a
stentless xenograft, homograft, or autograft valve.
(Level of Evidence: B)
. Intraoperative transesophageal echocardiography is
recommended for valve surgery for infective endocar-
ditis. (Level of Evidence: B)
lass IIa
Intraoperative transesophageal echocardiography is
reasonable for all patients undergoing cardiac valve
surgery. (Level of Evidence: C)
Detailed and comprehensive evaluation of valve lesions
uring cardiac surgery has become possible and common
ince the development of transesophageal echocardiography.
his includes confirmation of the preoperative diagnosis
nd associated pathology, provision of additional detail and
epth about the severity and mechanism of valve dysfunc-
ion, detection of previously undiagnosed conditions, and
valuation of the surgical result in the operating room,
hich makes possible the immediate correction of detected
roblems. Studies have documented the impact of intraop-
rative transesophageal echocardiography on valve surgery,
ith changes in the operative plan based on transesophageal
chocardiography findings reported in 11% to 14% of cases
nd detection of problems with surgical procedure and
ubsequent need to return to cardiopulmonary bypass re-
orted in 2% to 6% (923–926). Other important aspects of
ransesophageal echocardiography during valve surgery in-
lude assessment of ventricular function and detection of
ntracardiac air and aortic dissection.
Currently, the application of transesophageal echocardi-
graphy during valve surgery varies a great deal from enstitution to institution. Availability of equipment and
xpertise are important factors in determining this applica-
ion, and the committee recognizes that such resources may
ary. Although controlled, randomized trials substantiating
he benefit of intraoperative transesophageal echocardiogra-
hy during valve surgery have not been performed, there are
any nonrandomized studies, case series, and significant
xpert experience that support its utility in this setting.
Intraoperative transesophageal echocardiography is espe-
ially important during valve repair surgery. Examination
efore cardiopulmonary bypass provides insight into the
echanism of valve dysfunction and therefore facilitates
urgical planning. More importantly, intraoperative trans-
sophageal echocardiography allows immediate assessment
f the repair after cardiopulmonary bypass. Intraoperative
ransesophageal echocardiography during valve replacement
urgery with a stented prosthetic valve is also useful,
lthough there will be a lower rate of problems detected
fter cardiopulmonary bypass. Valve replacement with a
tentless xenograft, homograft, or autograft valve will have a
igher likelihood of technical problems during surgery, and
herefore, transesophageal echocardiography is virtually es-
ential in this setting because it is currently the best way to
ssess valve function intraoperatively. Because of the poten-
ial for multiple valve involvement and associated lesions
uch as abscesses and fistulas, transesophageal echocardiog-
aphy should also be performed during valve surgery for
cute infective endocarditis. Patients undergoing valve sur-
ery may have other indications for intraoperative trans-
sophageal echocardiography, such as severely decreased LV
unction or hemodynamic instability. The committee rec-
mmends that institutions performing valve surgery estab-
ish consistent and credible intraoperative echocardiography
rograms with knowledgeable echocardiographers commit-
ed to and capable of providing accurate anatomic and
unctional information relevant to valve operations. Such
ervices should be available during surgery to facilitate
valuation of unexpected difficulties. Although transesoph-
geal echocardiography is generally a safe procedure when
roperly performed in appropriate patients, there are risks to
ts performance (927). Thus, preoperative screening for risk
actors and the obtainment of informed consent should be a
outine part of every intraoperative transesophageal study.
A physician trained in transesophageal echocardiography, be
t a cardiologist, cardiac anesthesiologist, or cardiac surgeon,
ust perform the intraoperative transesophageal echocardio-
ram (928). Intraoperative transesophageal echocardiography
tudies may vary considerably in duration depending on com-
lexity of the information being sought. For instance, evalua-
ion of complex MV repair before cardiopulmonary bypass
ften requires a detailed, time-consuming study, whereas
valuation of severe calcific AS tends to be more limited and
ess time consuming. The physician must have sufficient time
o obtain comprehensive images as needed to ensure an
ccurate diagnosis, facilitate perioperative decision making, and
nhance patient outcome. Echocardiography technicians or
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ACC/AHA Practice Guidelines August 1, 2006:e1–148onographers should not manipulate an intraoperative trans-
sophageal echocardiography probe, nor should they be put in
position to provide patient outcome-related interpretations or
dvice.
Several means of evaluating patients during valve surgery
ther than transesophageal echocardiography are available,
ut they are not a substitute for the direct anatomic
nformation provided by transesophageal echocardiography.
easurements of intracardiac pressures and flows may be
ade with central venous and pulmonary artery catheters or
y direct transmyocardial needle insertion after exposure of
he heart. A surface echocardiographic transducer may be
laced in a sterile sheath and passed onto the surgical field
or application directly to the heart or the ascending aorta,
technique called epicardial and epiaortic echocardiogra-
hy, as a useful alternative in patients in whom transesoph-
geal probe insertion cannot be performed or is contraindi-
ated (929). Information gained from all these techniques
ay be complementary and may be combined to obtain a
ore comprehensive characterization of the lesion.
In general, whenever possible, the decision to treat a valve
esion surgically should be made before the patient is in the
perating room. Specifically, in cases of MR, intraoperative
ssessment of the degree of MR can be misleading owing to
he unloading effects of general anesthesia. In a patient
aving surgery for another reason (e.g., CABG or another
alve), intraoperative transesophageal echocardiography oc-
asionally might provide the basis for this decision, but it
hould not replace preoperative assessment of the valve
esion with transthoracic echocardiography or catheteriza-
ion. Intraoperative transesophageal echocardiography can
onfirm the preoperative diagnosis, provide additional de-
ails that may guide the surgical procedure, and help to
uide management of hemodynamics. It remains the best
eans of immediately assessing the technical results of the
urgical procedure in the operating room.
.1. Specific Valve Lesions
.1.1. Aortic Stenosis
he surgical treatment for AS is almost always replacement
ith a prosthetic valve. Intraoperative transesophageal
chocardiography (926) can be used to measure the size of
he aortic annulus to facilitate selection of the proper size
rosthesis and also, in patients with bicuspid valves, to
rovide information regarding aortic root dilatation and
eed for repair (see Section 3.3). After implantation of the
rosthesis, transesophageal echocardiography can detect
echnical problems such as paravalvular regurgitation or
bnormal leaflet motion. Stentless prostheses and ho-
ografts are more prone to distortion, with resulting
egurgitation, and should be assessed in the operating room
y transesophageal echocardiography. Excessive cardiac
ent return or arterial pulsatility during cardiopulmonary
ypass may be indications of significant AR after AVR.
ransesophageal echocardiography can be used to confirm phe diagnosis. Transesophageal imaging can also determine
he adequacy of coronary reimplantation by both direct
maging of the coronaries and assessment of LV function.
.1.2. Aortic Regurgitation
lthough the severity and significance of AR is partially
ependent on afterload and may be difficult to quantify with
ransesophageal echocardiography during surgery, trans-
sophageal echocardiography usually provides high-
esolution images of the aortic valve and is quite helpful in
etermining the mechanism and cause of regurgitation. The
mount of cardiac vent return and arterial pulsatility during
ardiopulmonary bypass may provide some indication of
everity as well. The surgical treatment for AR is usually
eplacement with a prosthetic valve, but valve repair is
ometimes attempted. Measurements of the size of the
ortic root may direct the surgeon toward root replacement
ather than simple replacement of the regurgitant valve.
ntraoperative transesophageal echocardiography should be
sed to evaluate the results of an aortic valve repair imme-
iately after cardiopulmonary bypass. Considerations of the
ransesophageal echocardiography evaluation of a prosthetic
ortic valve after cardiopulmonary bypass are similar to
hose for AS.
.1.3. Mitral Stenosis
ost adult patients presenting for surgery for MS have
heumatic heart disease, although extremely severe mitral
nnular calcification on occasion may cause significant
tenosis. Intraoperative transesophageal echocardiogra-
hy can provide anatomic information, especially about
he subvalvar structures, that is difficult to directly visu-
lize through the left atriotomy and is critical in deciding
hether to replace or repair a rheumatic valve. The
resence of thrombus in the left atrium may be detected
ith transesophageal echocardiography as well. Intraop-
rative transesophageal echocardiography should be used
o evaluate the results of a mitral commissurotomy
mmediately after cardiopulmonary bypass, primarily to
etect significant MR. Residual stenosis may be difficult
o quantify by echocardiography. For example, the pres-
ure half-time method to measure MV area is probably
ot accurate immediately after a commissurotomy and
hould not be relied on solely to assess adequacy of the
ommissurotomy (403). Although the Doppler-derived
ransmitral pressure gradient is easily obtained and may
elp in this situation, this may underestimate MS severity
n the presence of a low cardiac output. The transmitral
radient can be measured by direct transduction of LV
nd left atrial pressures if there is concern about residual
tenosis. If a prosthetic MV is implanted, transesopha-
eal echocardiography can detect technical problems such
s paravalvular regurgitation or abnormal leaflet motion.
mall, insignificant central and paravalvular leaks are
ommonly seen immediately after cardiopulmonary by-
ass and should not be a cause for concern (930).
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atients undergoing surgery for MR usually have either
yxomatous degeneration (MVP) or ischemic heart dis-
ase. Other less common causes of MR that requires
urgery are infective endocarditis and rheumatic heart disease.
ecause the change in hemodynamic loading conditions
aused by general anesthesia during surgery may lead to
nderestimation of the severity of MR by intraoperative
ransesophageal echocardiography (632,633,931,932), the de-
ision to operate is best made before surgery based on the
ymptoms and preoperative testing. If intraoperative evalu-
tion is required as a precursor to MV repair or replacement,
he operator must attempt to reproduce both preoperative
fterload and preload conditions. Intraoperative transesoph-
geal echocardiography may provide additional information
bout the mechanism of regurgitation and may be helpful to
irect the decision whether to repair or replace the valve
923,924,933). Thus, intraoperative transesophageal imag-
ng should be used whenever a repair is contemplated.
ntraoperative transesophageal echocardiography should
lso be used to evaluate the results of an MV repair
mmediately after cardiopulmonary bypass to assess for
esidual MR, systolic anterior motion of the valve leaflets,
nd restriction of mitral opening with stenosis. Represen-
ative loading conditions may need to be created with
olume or vasopressors to fully assess the adequacy of the
V repair immediately after the patient is weaned from
ardiopulmonary bypass. If a prosthetic MV is implanted,
ransesophageal echocardiography can detect technical
roblems such as paravalvular regurgitation or abnormal
eaflet motion. Small, insignificant central or paravalvular
eaks are commonly observed immediately after cardiopul-
onary bypass, and should not be a cause for concern (930).
t is possible to injure the left circumflex coronary artery or
ether a cusp of the aortic valve with a suture placed in the
itral annulus. Therefore, assessment of LV function and
xamination of the aortic valve and adjacent structures
hould always be performed with transesophageal echocar-
iography after MV surgery.
.1.5. Tricuspid Regurgitation
R that requires surgery is most often secondary to
nnular dilation with right-sided heart enlargement,
hich is usually corrected with tricuspid valve repair.
econdary TR can change with the hemodynamic loading
onditions. Therefore, the decision to address TR surgi-
ally is best made before induction of general anesthesia
nd surgery whenever possible (see Sections 3.7.4 and
.8). Intraoperative transesophageal echocardiography
an provide detailed information about the mechanism of
R that is useful in deciding whether to repair or replace
valve and should be used when a repair is contemplated.
ntraoperative transesophageal echocardiography should
e used to evaluate the results of a tricuspid valve repair
mmediately after cardiopulmonary bypass to assess for uesidual regurgitation and restriction of the tricuspid
alve opening with stenosis. If a prosthetic tricuspid valve
s implanted, transesophageal echocardiography can de-
ect technical problems such as paravalvular regurgitation
r abnormal leaflet motion.
.1.6. Tricuspid Stenosis
ricuspid stenosis that requires surgery is most commonly
ue to rheumatic heart disease and is treated by replacement
f the valve with a prosthesis. As with other prosthetic valve
eplacements, transesophageal echocardiography can detect
echnical problems such as paravalvular leaks or immobile
eaflets after cardiopulmonary bypass and allow correction of
he problem during the same operation.
.1.7. Pulmonic Valve Lesions
n adults, the pulmonic valve is much less commonly
perated on than the aortic, mitral, and tricuspid valves.
t is often difficult to image with transesophageal echo-
ardiography, and decisions to operate on the pulmonic
alve should be made based on preoperative studies such
s transthoracic echocardiography or cardiac magnetic
esonance whenever possible. Pulmonic valve lesions are
reated surgically by prosthetic valve replacement in
dults, and transesophageal echocardiography may be
ble to detect technical problems such as paravalvular
eaks or immobile leaflets in the operating room after
ardiopulmonary bypass. When the issue of pulmonic
tenosis is raised during heart surgery, direct measure-
ent of RV and pulmonary artery pressures with cathe-
ers or needles can be very helpful.
.2. Specific Clinical Scenarios
.2.1. Previously Undetected Aortic Stenosis During
ABG
AD and AS are commonly present in the same patient. On
ccasion, intraoperative transesophageal echocardiography de-
ects previously undiagnosed AS in a patient undergoing
ABG surgery. Indications for AVR in this situation are the
ame as described in Section 10.4. If the AS is moderate or
evere, AVR is indicated. Controversy persists as to whether
VR should be performed during CABG surgery when mild
S is present. There may be difficulty in accurately assessing
he severity of AS with intraoperative transesophageal echo-
ardiography by Doppler techniques in some patients. Confir-
ation of the severity of the gradient may be obtained after the
eart is exposed by direct transduction of the LV and aortic
ressures. Epicardial echocardiography may also provide addi-
ional, helpful information.
.2.2. Previously Undetected Mitral Regurgitation Dur-
ng CABG
n occasion, intraoperative transesophageal echocardiography
ay detect previously undiagnosed, significant MR in a patientndergoing CABG surgery (see Sections 3.6.5, 7.3.1.3, and
10.5). An examination of the valve with transesophageal
echocardiography should be performed to determine the
mechanism of the MR. If there is a structural abnormality such
as prolapse or flail, the valve should be repaired or replaced.
Ischemic MR due to LV remodeling and apical tenting of the
leaflets can be very dynamic and may respond to acute
hemodynamic management in the operating room by increas-
ing or decreasing in severity according to changes in afterload
and LV size. Patients with severe ischemic MR should
undergo MV repair or MV replacement (see Sections 3.6.5 and
7.3.1.3). Controversy exists as to whether patients having
CABG surgery with moderate or mild MR should undergo
MV repair as well. However, the hemodynamic effects of drugs
received during surgery often lessen the severity of the MR,
and mild intraoperative MR may increase postoperatively.
Hence, it is reasonable to perform MV repair when there is
moderate and, in many cases, mild MR detected on intraop-
erative transesophageal echocardiography.
9. MANAGEMENT OF PATIENTS WITH PROSTHETIC
HEART VALVES
The results of valve surgery with regard to survival, func-
tional class, valve function, and complications are dependent
on patient related factors, cardiac function, type of surgery,
type of prosthesis, and medical comorbidities (857).
9.1. Antibiotic Prophylaxis
9.1.1. Infective Endocarditis
All patients with prosthetic valves need appropriate antibi-
otics for prophylaxis against infective endocarditis (see
Section 2.3.1).
9.1.2. Recurrence of Rheumatic Carditis
Patients with rheumatic heart disease continue to need
antibiotics as prophylaxis against recurrence of rheumatic
carditis (see Section 2.3.2).
9.2. Antithrombotic Therapy
Class I
1. After AVR with bileaflet mechanical or Medtronic
Hall prostheses, in patients with no risk factors,*
warfarin is indicated to achieve an INR of 2.0 to
3.0. If the patient has risk factors, warfarin is
indicated to achieve an INR of 2.5 to 3.5. (Level of
Evidence: B)
2. After AVR with Starr-Edwards valves or mechanical
disc valves (other than Medtronic Hall prostheses),
in patients with no risk factors,* warfarin is indicated
to achieve an INR of 2.5 to 3.5. (Level of Evidence: B)
3. After MV replacement with any mechanical valve,
warfarin is indicated to achieve an INR of 2.5 to 3.5.
(Level of Evidence: C)
4. After AVR or MV replacement with a bioprosthesis
and no risk factors,* aspirin is indicated at 75 to 100
mg per day. (Level of Evidence: C)
5. After AVR with a bioprosthesis and risk factors,*
warfarin is indicated to achieve an INR of 2.0 to 3.0.
(Level of Evidence: C)
6. After MV replacement with a bioprosthesis and risk
factors,* warfarin is indicated to achieve an INR of
2.0 to 3.0. (Level of Evidence: C)
7. For those patients who are unable to take warfarin
after MV replacement or AVR, aspirin is indicated in
a dose of 75 to 325 mg per day. (Level of Evidence: B)
8. The addition of aspirin 75 to 100 mg once daily to
therapeutic warfarin is recommended for all patients
with mechanical heart valves and those patients with
biological valves who have risk factors.* (Level of
Evidence: B)
Class IIa
1. During the first 3 months after AVR with a mechan-
ical prosthesis, it is reasonable to give warfarin to
achieve an INR of 2.5 to 3.5. (Level of Evidence: C)
2. During the first 3 months after AVR or MV replace-
ment with a bioprosthesis, in patients with no risk
factors,* it is reasonable to give warfarin to achieve an
INR of 2.0 to 3.0. (Level of Evidence: C)
Class IIb
In high-risk patients with prosthetic heart valves in
whom aspirin cannot be used, it may be reasonable to
give clopidogrel (75 mg per day) or warfarin to
achieve an INR of 3.5 to 4.5. (Level of Evidence: C)
*Risk factors include atrial fibrillation, previous thromboem-
bolism, LV dysfunction, and hypercoagulable condition.
All patients with mechanical valves require warfarin therapy,
as indicated in Table 37 (934). Aspirin is recommended for all
patients with prosthetic heart valves: aspirin alone in patients
with bioprostheses and no risk factors, and aspirin combined
with warfarin in patients with mechanical heart valves and
high-risk patients with bioprostheses. In high-risk patients
who cannot take aspirin, the addition of clopidogrel to warfarin
therapy should be considered. Even with the use of warfarin,
risk of thromboemboli is 1% to 2% per year (171,172,174,
214,852,935), but the risk is considerably higher without
treatment with warfarin (936). The risk of a clinical thrombo-
embolism is on average 0.7% per year in patients with biolog-
ical valves in sinus rhythm; this figure is derived from several
studies in which the majority of patients were not undergoing
therapy with warfarin (171,172, 74,214,937). Almost all stud-
ies have shown that the risk of embolism is greater with a valve
in the mitral position (mechanical or biological) than with one
in the aortic position (172,178,852,936,938). With either type
of prosthesis or valve location, the risk of emboli is probably
higher in the first few days and months after valve insertion
(937), before the valve is fully endothelialized (804).
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesIt is frequently difficult to maintain a patient at a fixed or
elatively fixed level of anticoagulation owing to changes in
bsorption of medication, the effects of various foods and
edications, and changes in liver function. Therefore, in
linical practice, the patient’s anticoagulation level is main-
ained within a certain therapeutic range. This can be
ptimized through a program of patient education and close
urveillance by an experienced healthcare professional.
.2.1. Mechanical Valves
ll patients with mechanical valves require anticoagulation.
or mechanical prostheses in the aortic position, the INR with
arfarin therapy should be maintained between 2.0 and 3.0 for
ileaflet valves and Medtronic Hall valves and between 2.5 and
.5 for other disc valves and Starr-Edwards valves; for pros-
heses in the mitral position, the INR should be maintained
etween 2.5 and 3.5 for all mechanical valves (172,174,852,
38–947). There is a difference of opinion regarding the
tarr-Edwards valve in the aortic position, with the minority
pinion recommending that INR be maintained between 2.0
nd 3.0. The recommendation for higher INR values in the
itral position is based on the greater risk of thromboembolic
omplications with mechanical valves in the mitral position
171,852,936,938,942,943,946,947) and the greater risk of
leeding at higher INRs (946). In patients with aortic
echanical prosthesis who are at higher risk of throm-
oembolic complications, INR should be maintained at 2.5 to
.5, and the addition of aspirin should be considered (see
elow). These include patients with atrial fibrillation, previous
hromboembolism, and a hypercoagulable state. Many would
lso include patients with severe LV dysfunction in this
igher-risk group (948). Some prostheses are thought to be
ore thrombogenic than others (particularly the tilting-disc
alves), and a case could be made for increasing the INR to
etween 3 and 4.5; however, this level of anticoagulation is
able 37. Recommendations for Antithrombotic Therapy in Pati
Aspirin (75–100 mg) War
echanical prosthetic valves
AVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR—high risk Class I
MVR Class I
iological prosthetic valves
AVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR—high risk Class I
MVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
MVR—high risk Class I
epending on patients’ clinical status, antithrombotic therapy must be individualized (see
ituations. Risk factors: atrial fibrillation, left ventricular dysfunction, previous thromb
aintained between 2.5 and 3.5 for aortic disc valves and Starr-Edwards valves. Modifi
chlant R, Alexander RW, editors. Hurst’s The Heart. New York, NY: McGraw-Hill,
AVR indicates aortic valve replacement; and MVR, mitral valve replacement.ssociated with a considerably increased risk of bleeding (938,949). mThe addition of low-dose aspirin (75 to 100 mg per day) to
arfarin therapy (INR 2.0 to 3.5) not only further decreases
he risk of thromboembolism (808,946,950–953) but also
ecreases mortality due to other cardiovascular diseases. A
light increase in the risk of bleeding with this combination
hould be kept in mind (950,954). The risk of gastrointestinal
rritation and hemorrhage with aspirin is dose dependent over
he range of 100 to 1000 mg per day, and the antiplatelet
ffects are independent of dose over this range (955,956).
here are no data in patients with prosthetic heart valves
eceiving warfarin and aspirin in doses of 100 to 325 mg per
ay. Doses of 500 to 1000 mg per day clearly increase the risk
f bleeding (957–959). The addition of aspirin (75 to 100 mg
er day) to warfarin should be strongly considered unless there
s a contraindication to the use of aspirin (i.e., bleeding or
spirin intolerance). This combination is particularly appropri-
te in patients who have had an embolus while undergoing
arfarin therapy, those with known vascular disease, and those
ho are known to be particularly hypercoagulable. As an
xample, such combination therapy is recommended by a
ommittee concerning the use of antithrombotic therapy in
omen during pregnancy (807). The method of anticoagula-
ion in pregnant patients is controversial and is discussed in
ection 5.8.
Thromboembolic risk is increased early after insertion of
he prosthetic heart valve. The use of UFH early after
rosthetic valve replacement, before warfarin achieves ther-
peutic levels, is controversial. Many centers start UFH as
oon as the risk of increased surgical bleeding is reduced
usually within 24 to 48 h), with maintenance of aPTT
etween 55 and 70 s. After an overlap of UFH and warfarin
or 3 to 5 days, UFH is discontinued when an INR of 2.0 to
.0 is achieved. In some patients, achievement of therapeu-
ic INR must be delayed several days after surgery because of
With Prosthetic Heart Valves
(INR 2.0–3.0) Warfarin (INR 2.5–3.5) No Warfarin
Class I Class IIa
Class I
Class I
Class I
Class IIa Class IIb
Class IIa
Class I
Class IIa
Class IIa
Class I
l situations in text). In patients receiving warfarin, aspirin is recommended in virtually all
lism, and hypercoagulable condition. International normalized ratio (INR) should be
McAnulty JH, Rahimtoola SH. Antithrombotic therapy in valvular heart disease. In:
867–74 (934). Reprinted with permission from the McGraw-Hill Companies.ents
farin
specia
oembo
ed fromitigating complications.
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ecause of an increased risk of thromboemboli during the
rst 3 months after implantation of a biological prosthetic
alve, anticoagulation with warfarin is often used, especially
hen the valve is in the mitral position (937), although most
enters use only aspirin for biological valves in the aortic
osition. The risk is particularly high in the first few days
fter surgery, and many centers start UFH as soon as the
isk of increased surgical bleeding is reduced (usually within
4 to 48 h), with maintenance of aPPT between 55 and 70
econds. After an overlap of UFH and warfarin for 3 to 5
ays, UFH may be discontinued when an INR of 2.0 to 3.0
s achieved. After 3 months, the tissue valve can be treated
ike native valve disease, and warfarin can be discontinued in
ore than two thirds of patients with biological valves
174,937,960). In the remaining patients with associated
isk factors for thromboembolism, such as atrial fibrillation,
revious thromboembolism, or hypercoagulable condition,
ifelong warfarin therapy is indicated to achieve an INR of
.0 to 3.0. Many would also recommend continuing anti-
oagulation in patients with severe LV dysfunction (ejection
raction less than 0.30) (948).
.2.3. Embolic Events During Adequate Antithrom-
otic Therapy
n the patient who has a definite embolic episode while
ndergoing adequate antithrombotic therapy, the dosage of
ntithrombotic therapy should be increased, when clinically
afe, as follows:
Warfarin, INR 2.0 to 3.0: warfarin dose increased to
achieve INR of 2.5 to 3.5
Warfarin, INR 2.5 to 3.5: warfarin dose may need to be
increased to achieve INR of 3.5 to 4.5
Not taking aspirin: aspirin 75 to 100 mg per day should
be initiated
Warfarin plus aspirin 75 to 100 mg per day: aspirin dose
may also need to be increased to 325 mg per day if the
higher dose of warfarin is not achieving the desired
clinical result
Aspirin alone: aspirin dose may need to be increased to
325 mg per day, clopidogrel 75 mg per day per day
added, and/or warfarin added.
.2.4. Excessive Anticoagulation
n most patients with INR above the therapeutic range,
xcessive anticoagulation can be managed by withholding
arfarin and monitoring the level of anticoagulation with serial
NR determinations (804). Excessive anticoagulation (INR
reater than 5) greatly increases the risk of hemorrhage.
owever, rapid decreases in INR that lead to INR falling
elow the therapeutic level increase the risk of thromboembo-
ism. Patients with prosthetic heart valves with an INR of 5 to
0 who are not bleeding can be treated by withholding
arfarin and administering 1 to 2.5 mg of oral vitamin K1phytonadione) (804,961). The INR should be determined tfter 24 h and subsequently as needed. Warfarin therapy is
estarted and adjusted dose appropriately to ensure that the
NR is in the therapeutic range. In emergency situations, the
se of fresh frozen plasma is preferable to high-dose vitamin
1 (962), especially parenteral vitamin K1, because use of the
atter increases the risk of overcorrection to a hypercoagulable
tate. Low-dose intravenous vitamin K (1 mg) appears safe in
his situation (963).
.2.5. Bridging Therapy in Patients With Mechanical
alves Who Require Interruption of Warfarin Therapy for
oncardiac Surgery, Invasive Procedures, or Dental Care
lass I
. In patients at low risk of thrombosis, defined as those
with a bileaflet mechanical AVR with no risk factors,*
it is recommended that warfarin be stopped 48 to 72
h before the procedure (so the INR falls to less than
1.5) and restarted within 24 h after the procedure.
Heparin is usually unnecessary. (Level of Evidence: B)
. In patients at high risk of thrombosis, defined as
those with any mechanical MV replacement or a
mechanical AVR with any risk factor, therapeutic
doses of intravenous UFH should be started when the
INR falls below 2.0 (typically 48 h before surgery),
stopped 4 to 6 h before the procedure, restarted as
early after surgery as bleeding stability allows, and
continued until the INR is again therapeutic with
warfarin therapy. (Level of Evidence: B)
lass IIa
It is reasonable to give fresh frozen plasma to pa-
tients with mechanical valves who require interrup-
tion of warfarin therapy for emergency noncardiac
surgery, invasive procedures, or dental care. Fresh
frozen plasma is preferable to high-dose vitamin K1.
(Level of Evidence: B)
lass IIb
In patients at high risk of thrombosis (see above),
therapeutic doses of subcutaneous UFH (15 000 U
every 12 h) or LMWH (100 U per kg every 12 h) may
be considered during the period of a subtherapeutic
INR. (Level of Evidence: B)
lass III
In patients with mechanical valves who require in-
terruption of warfarin therapy for noncardiac surgery,
invasive procedures, or dental care, high-dose vita-
min K1 should not be given routinely, because this
may create a hypercoagulable condition. (Level of
Evidence: B)
Risk factors: atrial fibrillation, previous thromboembolism,
V dysfunction, hypercoagulable conditions, older-generation
hrombogenic valves, mechanical tricuspid valves, or more
han 1 mechanical valve.
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August 1, 2006:e1–148 ACC/AHA Practice GuidelinesThe risk of increased bleeding during a procedure per-
ormed with a patient receiving antithrombotic therapy has
o be weighed against the increased risk of a thromboem-
olism caused by stopping the therapy. The risk of stopping
arfarin can be estimated and is relatively slight if the drug
s withheld for only a few days. As an example, in a
orst-case scenario (e.g., a patient with a mechanical
rosthesis with previous thromboemboli), the risk of a
hromboembolism when the patient is not taking warfarin is
0% to 20% per year. Thus, if therapy were stopped for 3
ays, the risk of an embolus would be 0.08% to 0.16%.
here are theoretical concerns that stopping the drug and
hen reinstituting it might result in hypercoagulability or
hat there might be a thrombotic “rebound.” An increase in
arkers for activation of thrombosis with abrupt discontin-
ation of warfarin therapy has been observed (964), but it is
ot clear whether the clinical risk of thromboembolism
ncreases (965). In addition, when warfarin therapy is
einstituted, there are theoretical concerns about a hyperco-
gulable state caused by suppression of protein C and
rotein S before the drug affects the thrombotic factors.
lthough these risks are only hypothetical, individuals at
ery high risk should be treated with heparin until INR
eturns to the desired range.
Management of antithrombotic therapy must be individu-
lized, but some generalizations apply (934). Antithrombotic
herapy should not be stopped for procedures in which bleed-
ng is unlikely or would be inconsequential if it occurred, for
xample, surgery on the skin, dental cleaning, or simple
reatment for dental caries. Eye surgery, particularly for cata-
acts or glaucoma, is usually associated with very little bleeding
nd thus is frequently performed without alterations to anti-
hrombotic treatment. When bleeding is likely or its potential
onsequences are severe, antithrombotic treatment should be
ltered. If a patient is taking aspirin, it should be discontinued
week before the procedure and restarted as soon as it is
onsidered safe by the surgeon or dentist. Clopidogrel should
e stopped at least 5 days before the procedure.
Spyropoulos et al. performed a retrospective analysis of
osts and clinical outcomes associated with LMWH for
erioperative bridging in patients receiving long-term
ral anticoagulant therapy (966). The mean total health-
are costs in the perioperative period were significantly
ower (by $13 114) in patients receiving long-term oral
nticoagulant therapy with LMWH than in those receiv-
ng it with UFH for an elective surgical procedure. The
ost savings associated with LMWH use were accom-
lished through the avoidance or minimization of inpa-
ient stays and no increase in the overall rate of clinical
dverse events in the postoperative period (966).
For patients with a bileaflet mechanical aortic valve and no
isk factors, warfarin should be stopped before the procedure so
hat the INR is less than 1.5 (which is often 48 to 72 h after
arfarin is discontinued) (934,967) and restarted within 24 h
fter a procedure. Admission to the hospital or a delay in
ischarge to give heparin is usually unnecessary (965,968–70).atients at high risk of thrombosis include all patients with
echanical mitral or tricuspid valve replacements and patients
ith an AVR and any risk factors. Such risk factors include
trial fibrillation, previous thromboembolism, hypercoagulable
ondition, older-generation mechanical valves, LV dysfunction
ejection fraction less than 0.30), or more than 1 mechanical
alve (971–973). When UFH is used, it should be started when
NR falls below 2.0 (i.e., 48 h before surgery) and stopped 4 to
h before the procedure. UFH should be restarted as early
fter surgery as bleeding stability allows, and the aPTT should
e maintained at 55 to 70 s until warfarin is therapeutic.
MWH is attractive because it is more easily used outside the
ospital. One study of bridging therapy for interruption of
arfarin included 215 patients with mechanical valves. In the
otal group of 650 patients, the risk of thromboembolism
including possible events) was 0.62%, with 95% confidence
ntervals of 0.17% to 1.57%. Major bleeding occurred in 0.95%
0.34% to 2.00%) (974). However, concerns about the use of
MWH for mechanical valves persists, and package inserts
ontinue to list a warning for this use of these medications (815).
High-dose vitamin K1 should not be given routinely,
ecause this may create a hypercoagulable condition. For
mergency situations, fresh frozen plasma is preferable to
igh-dose vitamin K1 (see Section 9.2.4).
.2.6. Antithrombotic Therapy in Patients Who Need
ardiac Catheterization/Angiography
n an emergency or semiurgent situation, cardiac catheter-
zation can be performed in a patient taking warfarin, but
referably, the drug should be stopped, on average, 72 h
efore the procedure so that INR is less than 1.5 (see
bove). The drug should be restarted as soon as the
rocedure is completed. This is true for patients with
iological valves who are receiving antithrombotic therapy
nd for those with mechanical valves. If a patient has more
han 1 risk factor that predisposes to thromboembolism,
eparin should be started when INR falls below 2.0 and
hould be continued when warfarin is restarted. After an
verlap of 3 to 5 days, heparin may be discontinued when
he desired INR is achieved. If the catheterization procedure
s to include a transseptal puncture (especially in a patient
ho has not had previous opening of the pericardium),
atients should be removed from all antithrombotic therapy,
nd INR should be less than 1.2; the same is true if an LV
uncture is to be performed (975). In patients who are to
ndergo transseptal or LV puncture and are receiving
eparin therapy, heparin should be discontinued 4 to 6 h
efore the procedure(s) and can be restarted without a bolus
ore than 4 h after the sheath in the peripheral vessel has
een removed.
.2.7. Thrombosis of Prosthetic Heart Valves
lass I
. Transthoracic and Doppler echocardiography is in-
dicated in patients with suspected prosthetic valve
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Evidence: B)
. Transesophageal echocardiography and/or fluoros-
copy is indicated in patients with suspected valve
thrombosis to assess valve motion and clot burden.
(Level of Evidence: B)
lass IIa
. Emergency operation is reasonable for patients with a
thrombosed left-sided prosthetic valve and NYHA
functional class III–IV symptoms. (Level of Evi-
dence: C)
. Emergency operation is reasonable for patients with a
thrombosed left-sided prosthetic valve and a large
clot burden. (Level of Evidence: C)
. Fibrinolytic therapy is reasonable for thrombosed
right-sided prosthetic heart valves with NYHA class
III–IV symptoms or a large clot burden. (Level of
Evidence C)
lass IIb
. Fibrinolytic therapy may be considered as a first-line
therapy for patients with a thrombosed left-sided
prosthetic valve, NYHA functional class I–II symp-
toms, and a small clot burden. (Level of Evidence: B)
. Fibrinolytic therapy may be considered as a first-line
therapy for patients with a thrombosed left-sided
prosthetic valve, NYHA functional class III–IV
symptoms, and a small clot burden if surgery is high
risk or not available. (Level of Evidence: B)
. Fibrinolytic therapy may be considered for patients
with an obstructed, thrombosed left-sided prosthetic
valve who have NYHA functional class II–IV symp-
toms and a large clot burden if emergency surgery is
high risk or not available. (Level of Evidence: C)
. Intravenous UFH as an alternative to fibrinolytic
therapy may be considered for patients with a throm-
bosed valve who are in NYHA functional class I–II
and have a small clot burden. (Level of Evidence: C)
Obstruction of prosthetic heart valves may be caused by
hrombus formation, pannus ingrowth, or a combination of
oth. The cause may be difficult to determine and requires
nowledge of the clinical presentation and findings on echo-
ardiography, including transesophageal echocardiography
976–981). If the prosthesis is obstructed by pannus, fibrino-
ytic therapy will be ineffective, and the valve needs to be
eplaced. Fibrinolytic therapy for a left-sided prosthetic valve
bstructed by thrombus is associated with significant risks
cerebral emboli in 12% to 15% of cases) and is often
neffective. Fibrinolytic therapy in such patients is reserved for
hose in whom surgical intervention carries a high risk and
hose with contraindications to surgery (976–980,982–986).
In patients with a “small clot” who are in NYHA
unctional class I or II, treatment with short-term intrave-
ous UFH therapy or continuous infusion of fibrinolyticherapy may be considered (976–980,982–986). The size
hreshold for this recommendation is difficult to define
ecause of the lack of large cohort studies and differing
hresholds from small studies (ranging from 5 to 10 mm, as
etermined by transesophageal echocardiography), below
hich intravenous UFH or fibrinolytic therapy is safe and
ffective (976–978,984). The risk associated with clot size is
continuous function, with 1 study showing an odds ratio of
.41 per 1-cm2 increment (978). Data support the use of
rokinase, streptokinase, or recombinant tissue plasminogen
ctivator as the fibrinolytic agents in this situation. Factors
hat identify patients at risk for adverse outcomes of
brinolytic therapy include active internal bleeding, history
f hemorrhagic stroke, recent cranial trauma of neoplasm,
iabetic hemorrhagic retinopathy, large thrombi, mobile
hrombi, hypertension (greater than 200 over 120 mm Hg),
ypotension or shock, and NYHA functional class III–IV
ymptoms. If fibrinolytic therapy is successful, it should be
ollowed by intravenous UFH until warfarin achieves an
NR of 3.0 to 4.0 for aortic prosthetic valves and 3.5 to 4.5
or mitral prosthetic valves. If partially successful, fibrino-
ytic therapy may be followed by a combination of subcu-
aneous UFH twice daily (to achieve an aPTT of 55 to 80 s)
lus warfarin (INR 2.5 to 3.5) for a 3-month period (985).
Patients with small thrombi who receive intravenous
FH as first-line therapy and who do not respond success-
ully may receive a trial of continuous-infusion fibrinolytic
herapy. If fibrinolytic therapy is unsuccessful or there is an
ncreased risk associated with fibrinolytic therapy, reopera-
ion should be considered. An alternative in patients who
emain hemodynamically stable is to convert intravenous
FH to combined therapy with subcutaneous UFH (twice
aily to an aPTT of 55 to 80 s) and warfarin (INR 2.5 to
.5) for 1 to 3 months on an outpatient basis to allow for
ndogenous fibrinolysis (985). If intravenous UFH, fibrino-
ytic therapy, combined UFH/fibrinolytic therapy, or com-
ined UFH/warfarin is successful, warfarin doses should be
ncreased so that INR is between 3.0 and 4.0 (approximately
.5) for prosthetic aortic valves and between 3.5 and 4.5
approximately 4.0) for prosthetic MVs. These patients
hould also receive low-dose aspirin.
Thrombosis of mechanical tricuspid valve prostheses may
e treated with fibrinolytic therapy, although experience
ith this is limited (987,988).
.3. Follow-Up Visits
lass I
. For patients with prosthetic heart valves, a history,
physical examination, and appropriate tests should be
performed at the first postoperative outpatient eval-
uation, 2 to 4 weeks after hospital discharge. This
should include a transthoracic Doppler echocardio-
gram if a baseline echocardiogram was not obtained
before hospital discharge. (Level of Evidence: C)
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follow-up visits should be conducted annually, with
earlier re-evaluations (with echocardiography) if there is
a change in clinical status. (Level of Evidence: C)
lass IIb
Patients with bioprosthetic valves may be considered
for annual echocardiograms after the first 5 years in
the absence of a change in clinical status. (Level of
Evidence: C)
lass III
Routine annual echocardiograms are not indicated in
the absence of a change in clinical status in patients
with mechanical heart valves or during the first 5
years after valve replacement with a bioprosthetic
valve. (Level of Evidence: C)
.3.1. First Outpatient Postoperative Visit
he first outpatient evaluation after valve surgery usually
ccurs 3 to 4 weeks after hospital discharge. By this time,
he patient’s physical capabilities and expected improvement
n functional capacity can be assessed.
The workup on this visit should include an interval or
omplete history and physical examination, ECG, chest X-ray,
D and Doppler echocardiography, complete blood count,
lood urea nitrogen/creatinine, electrolytes, lactate dehydroge-
ase, and INR, if indicated. The main focus of the examination
s on signs that relate to function of the prosthesis or that might
uggest the presence of infection or a myocardial infarction,
onduction, or valvular disorder. Severe perivalvular MR may
e inaudible on physical examination, a fact to remember when
ne considers the possible causes of functional deterioration in
patient. In patients who undergo surgery in the setting of
cute valvular infection, the first postoperative visit may occur at
he end of a postoperative course of antibiotics. Surveillance blood
ultures may be indicated at this visit if 1 or more weeks have
assed since cessation of antibiotics to confirm bacteriologic cure.
Echocardiography is the most useful noninvasive test. It
rovides information about prosthesis stenosis/regurgitation,
alve area, assessment of other valve disease(s), pulmonary
ypertension, atrial size, LV and RV hypertrophy, LV and RV
ize and function, and pericardial effusion/thickening. It is an
ssential component of the first postoperative visit because it
llows an assessment of the effects and results of surgery, as well
s serving as a baseline for comparison should complications or
eterioration occur later.
Every prosthetic heart valve has an intrinsic degree of
bstruction (857,989–992); one reason for obtaining a baseline
oppler echocardiogram early after valve replacement is so that
his intrinsic gradient can be measured and compared with
ubsequent measurements if necessary. The gradient varies
mong different types of prosthetic valves. Doppler echocardi-
graphy also detects the prosthetic valve regurgitation that is
ormal for various types of mechanical valve. rMultiple other noninvasive tests (e.g., cardiac magnetic
esonance) have emerged for the assessment of valvular and
entricular function, but these should be performed only in
elected patients for specific indications. Fluoroscopy can reveal
bnormal rocking of a dehiscing prosthesis, limitation of the
ccluder if the latter is opaque, and strut fracture of the
onvexoconcave Björk-Shiley valve. Radionuclide angiography
r cardiac magnetic resonance is useful to determine whether
unctional deterioration is the result of reduced ventricular
unction and is performed if the same data cannot be obtained
y echocardiography. Cardiac magnetic resonance is safe for all
ommercially available prosthetic heart valves.
.3.2. Follow-Up Visits in Patients Without Complications
atients who have undergone valve replacement are not cured
ut still have serious heart disease. They have exchanged native
alve disease for prosthetic valve disease and must be followed
ith the same care as patients with native valve disease (993).
he clinical course of patients with prosthetic heart valves is
nfluenced by several factors (857), including LV dysfunction,
rogression of other valve disease, pulmonary hypertension,
ther cardiac diseases, complications of prosthetic heart valves,
nd clinical heart failure. The interval between routine follow-up
isits depends on the patient’s needs. Anticoagulant regulation
oes not require visits to the physician’s office but should be closely
upervised by an experienced healthcare professional.
The asymptomatic uncomplicated patient needs to be seen
nly at 1-year intervals, at which time a complete history and
horough physical examination should be performed. ECG
nd chest X-ray examinations are not routinely indicated but
re valuable in individual patients. Additional tests that are
ften performed include hemoglobin, hematocrit, and lactate
ehydrogenase. No further echocardiographic testing is re-
uired after the initial postoperative evaluation in patients with
echanical valves who are stable and who have no symptoms
r clinical evidence of LV dysfunction, prosthetic valve dys-
unction, or dysfunction of other heart valves, in keeping with
he ACC/AHA/ASE 2003 Guidelines for the Clinical Ap-
lication of Echocardiography (2). Once regurgitation is de-
ected, close follow-up with 2D and Doppler echocardiogra-
hy every 3 to 6 months is indicated. Echocardiography is
ndicated in any patient with a prosthetic heart valve whenever
here is evidence of a new murmur or change in clinical status,
hen there are questions about prosthetic valve integrity and
unction, and when there are concerns about ventricular function.
.3.3. Follow-Up Visits in Patients With Complications
lass I
Patients with LV systolic dysfunction after valve
surgery should receive standard medical therapy for
systolic heart failure. This therapy should be contin-
ued even if there is improvement of LV dysfunction.
(Level of Evidence: B)
LV dysfunction and clinical heart failure after valve
eplacement may be the result of
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only partially
perioperative myocardial damage
other valve disease that has progressed
complications of prosthetic heart valves
associated heart disease such as CAD and systemic
hypertension.
Any patient with a prosthetic heart valve who does not
mprove after surgery or who later shows deterioration of
unctional capacity should undergo appropriate testing,
ncluding 2D and Doppler echocardiography and, if neces-
ary, transesophageal echocardiography and cardiac cathe-
erization with angiography to determine the cause. Patients
ith postoperative LV systolic dysfunction, even if asymp-
omatic, should receive standard medical therapy for systolic
eart failure, and this therapy should be continued indefi-
itely even if there is improvement in systolic function
nd/or symptoms. All patients should also receive primary
nd secondary prevention measures to reduce the risk of
uture cardiovascular events.
.4. Reoperation to Replace a Prosthetic Valve
eoperation to replace a prosthetic heart valve is a serious
linical event. It is usually required for moderate to severe
rosthetic dysfunction (structural and nonstructural), dehis-
ence, and prosthetic endocarditis. Reoperation may also be
eeded for recurrent thromboembolism, severe intravascular
emolysis, severe recurrent bleeding from anticoagulant
herapy, and thrombosed prosthetic valves In a patient with
small aortic annulus, valve prosthesis-patient mismatch
ay occur after AVR (856,989–992,994,995), especially if a
tented bioprosthesis is used. If a patient with AS does not
mprove clinically after AVR, prosthetic valve function
hould be evaluated. In selected situations, repeat AVR to
eplace a malfunctioning prosthesis may be necessary.
The patient who is in stable condition without prosthetic
alve endocarditis under many circumstances undergoes
eoperation with only slightly greater risk than that accom-
anying the initial surgery. For the patient with catastrophic
rosthetic valvular dysfunction, surgery is clearly indicated
nd urgent. The patient without endocarditis or severe
rosthetic valve dysfunction requires careful hemodynamic
valuation, and the decision about reoperation should then
e based on hemodynamic abnormalities, symptoms, ven-
ricular function, and current knowledge of the natural
istory of the particular prosthesis.
0. EVALUATION AND TREATMENT OF CORONARY
RTERY DISEASE IN PATIENTS WITH VALVULAR
EART DISEASE
any patients with valvular heart disease have concomitant
AD, but there are only limited data regarding the optimal
trategies for diagnosis and treatment of CAD in such patients.
hus, management decisions are usually developed by blend- ing information from the randomized studies of treatment of
AD and the smaller published series of patients undergoing
urgical treatment of valvular heart disease.
0.1. Probability of Coronary Artery Disease in Patients
ith Valvular Heart Disease
he probability of developing CAD in the general
opulation (996) and the prevalence of CAD in patients
ho come to medical attention (997) can be estimated on
he basis of age, sex, and clinical risk factors. The
revalence of CAD in patients with valvular heart disease
s determined by these same variables (998). Risk factors
or coronary atherosclerosis in patients with valvular
isease should be approached with the prevention and
isk reduction strategies that have been recommended for
he general population (999).
Ischemic symptoms are important markers of CAD in
he general population. Thus, the prevalence of CAD
average) has been estimated at 90% in middle-aged men
ith typical angina , 50% in those with atypical angina,
6% in those with nonanginal chest pain, and 4% in
symptomatic subjects (997). On the basis of data from
he Framingham Study, the rate of CAD increases with
ge, and in asymptomatic individuals who are low risk, it
anges from 1% to 6%. In those aged less than 45 years,
he risk is 1% to 2% (1000). In contrast, ischemic
ymptoms in patients with valvular heart disease may
ave multiple causes, such as LV chamber enlargement,
ncreased wall stress or wall thickening with subendocar-
ial ischemia (1001), and RV hypertrophy (1002). An-
ina is thus a less specific indicator of CAD in patients
ith valvular heart disease than in the general population.
Among patients with severe AS, angina is a common
ymptom in young patients with normal coronary arteries and
ongenital or rheumatic AS. On the other hand, CAD is a
ommon finding in older symptomatic men with AS. Among
atients with AS, the prevalence of CAD is 40% to 50% in
hose with typical angina, an average 25% in those with
typical chest pain, and an average 20% in those without chest
ain (1003–1010). Even in patients less than 40 years old with
o chest pain and no coronary risk factors, the prevalence of
AD is 0% to 5% (998,1005,1011). In elderly patients (greater
han 70 years old), angina is a strong determinant of CAD
sensitivity 78%, specificity 82%) (1012). Calcification of the
ortic valve is also associated with a high presence of CAD
90%) (1013). In general, because angina is a poor marker of
AD in patients with AS, coronary angiography is recom-
ended in symptomatic patients before AVR in men older
han 35 years; premenopausal women older than 35 years with
oronary risk factors, as well as asymptomatic men older than
5 years; women older than 55 years; and those with 2 or more
oronary risk factors.
CAD is less prevalent in patients with AR than in those
ith AS (1003–1010,1014–1020), which is related in part to
he younger age of patients with AR. The prevalence of CAD
n patients with MS (an average of 20%) is lower than in
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August 1, 2006:e1–148 ACC/AHA Practice Guidelinesatients with aortic valve disease (1015,1017,1018,1021,1022),
n observation explained principally on the basis of differences
n age and gender. Nonetheless, because of the impact of
ntreated CAD on perioperative and long-term postoperative
urvival, preoperative identification of CAD is of great impor-
ance in patients with AR or MS and those with AS. Thus, in
ymptomatic patients and/or those with LV dysfunction,
reoperative coronary angiography is recommended in men
ged greater than 35 years, premenopausal women aged greater
han 35 years with coronary risk factors, and postmenopausal
omen.
The relation between MR and CAD is unique in that
AD is frequently the cause of this valve lesion. The
anagement of these patients is discussed in Section 3.6.5.
either angina nor heart failure symptoms are reliable
arkers of CAD in these patients. In patients undergoing
atheterization to evaluate the cause and severity of MR,
AD is present in an average of 33% (1023,1024). In
atients undergoing catheterization for acute ischemic syn-
romes, an average of 20% have associated MR (1025).
hose with chronic CAD and MR usually have lower LV
jection fractions and more extensive CAD than those
ithout MR (1023,1026). However, CAD is infrequent in
atients with degenerative MV disease undergoing surgery.
n a large series, only 1.3% of such patients had CAD, and
hey only had single-vessel disease. Thus, routine coronary
ngiography is not indicated in patients undergoing MV
urgery for MR due to MV degeneration in the absence of
ymptoms and without risk factors when they are less than
5 years of age (1027).
0.2. Diagnosis of Coronary Artery Disease
lass I
. Coronary angiography is indicated before valve surgery
(including infective endocarditis) or mitral balloon
commissurotomy in patients with chest pain, other
objective evidence of ischemia, decreased LV systolic
function, history of CAD, or coronary risk factors
(including age). Patients undergoing mitral balloon
valvotomy need not undergo coronary angiography
solely on the basis of coronary risk factors. (Level of
Evidence: C)
. Coronary angiography is indicated in patients with
apparently mild to moderate valvular heart disease but
with progressive angina (Canadian Heart Association
functional class II or greater), objective evidence of
ischemia, decreased LV systolic function, or overt con-
gestive heart failure. (Level of Evidence: C)
. Coronary angiography should be performed before
valve surgery in men aged 35 years or older, premeno-
pausal women aged 35 years or older who have coronary
risk factors, and postmenopausal women. (Level of
Evidence: C) olass IIa
Surgery without coronary angiography is reasonable
for patients having emergency valve surgery for acute
valve regurgitation, aortic root disease, or infective
endocarditis. (Level of Evidence: C)
lass IIb
Coronary angiography may be considered for patients
undergoing catheterization to confirm the severity of
valve lesions before valve surgery without pre-
existing evidence of CAD, multiple coronary risk
factors, or advanced age. (Level of Evidence: C)
lass III
. Coronary angiography is not indicated in young
patients undergoing nonemergency valve surgery
when no further hemodynamic assessment by cathe-
terization is deemed necessary and there are no
coronary risk factors, no history of CAD, and no
evidence of ischemia. (Level of Evidence: C)
. Patients should not undergo coronary angiography
before valve surgery if they are severely hemodynam-
ically unstable. (Level of Evidence: C)
The resting ECG in patients with valvular heart disease
requently shows ST-segment changes due to LV hypertrophy,
V dilatation, or bundle-branch block, which reduces the
ccuracy of the ECG at rest and during exercise for the
iagnosis of concomitant CAD.
Similarly, resting or exercise-induced regional wall-motion
bnormalities are nonspecific markers for CAD in patients
ith underlying valvular heart disease who have LV hypertro-
hy and/or chamber dilatation (1028–1030), as are myocardial
erfusion abnormalities induced by exercise or pharmacological
tress (1029,1031–1034). Limited data are available on the use
f myocardial perfusion imaging with thallium-201 or
echnetium-99m perfusion agents in patients with severe
alvular disease. Although some studies of perfusion imaging
n AS have demonstrated a sensitivity of 87% and a specificity
f 77%, the presence of CAD is missed in 13% of patients with
AD (1035). Given the importance of determining the
resence of CAD, coronary angiography remains the most
ppropriate method for the definitive diagnosis of CAD
1004). Noninvasive imaging is useful when CAD is suspected
n patients with mild valve stenosis or regurgitation and normal
V cavity size and wall thickness.
In patients undergoing emergency valve surgery for acute
R, aortic dissection, or endocarditis with hemodynamic
nstability, cardiac catheterization, aortography, and coronary
ngiography are rarely required, are associated with increased
isk, and might delay urgent surgery unnecessarily (221,224–
27). Angiography should be considered only when the valve
iagnosis cannot be determined by noninvasive imaging and
hen patients have known CAD, especially those with previ-
us CABG (see Section 3.2.2.3).
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f Aortic Valve Replacement
lass I
Patients undergoing AVR with significant stenoses
(greater than or equal to 70% reduction in luminal
diameter) in major coronary arteries should be
treated with bypass grafting. (Level of Evidence: C)
lass IIa
. In patients undergoing AVR and coronary bypass
grafting, use of the left internal thoracic artery is
reasonable for bypass of stenoses of the left anterior
descending coronary artery greater than or equal to
50% to 70%. (Level of Evidence: C)
. For patients undergoing AVR with moderate stenosis
(50% to 70% reduction in luminal diameter), it is
reasonable to perform coronary bypass grafting in
major coronary arteries. (Level of Evidence: C)
As noted previously, more than 33% of patients with AS
ho are undergoing AVR have concomitant CAD. More than
0% of patients older than 70 years have CAD. Several studies
ave reported the outcomes of patients undergoing combined
ABG and AVR. Although combined myocardial revascular-
zation and AVR increases cross-clamp time (1036) and has
he potential to increase perioperative myocardial infarction
nd early postoperative mortality compared with patients
ithout CAD undergoing isolated AVR (1037–1040), in
everal series, combined CABG has had little or no adverse
ffect on operative mortality (1041–1047). Moreover, com-
ined CABG and AVR reduces the rates of perioperative
yocardial infarction, operative mortality, and late mortality
nd morbidity compared with patients with significant CAD
ho do not undergo revascularization at the time of AVR
1045,1046,1048,1049). In addition to severity of CAD, the
ultivariate factors for late postoperative mortality include
everity of AS, severity of LV dysfunction, age greater than 70
ears (especially in women), and presence of NYHA functional
lass IV symptoms (1046,1050,1051). Incomplete revascular-
zation is associated with greater postoperative systolic dysfunc-
ion (1052,1053) and reduced survival rates (1054) after surgery
ompared with patients who receive complete revascularization.
or more than a decade, improved myocardial preservation tech-
iques have been associated with reduced overall operative
ortality (1055), and it has become standard practice to bypass
ll significant coronary artery stenoses when possible in patients
ndergoing AVR. The committee recommends this approach.
0.4. Aortic Valve Replacement in Patients Undergoing
oronary Artery Bypass Surgery
lass I
AVR is indicated in patients undergoing CABG who
have severe AS who meet the criteria for valve
replacement (see Section 3.1.7). (Level of Evidence: C) ilass IIa
AVR is reasonable in patients undergoing CABG
who have moderate AS (mean gradient 30 to 50 mm
Hg or Doppler velocity 3 to 4 m per second). (Level
of Evidence: B)
lass IIb
AVR may be considered in patients undergoing
CABG who have mild AS (mean gradient less than
30 mm Hg or Doppler velocity less than 3 m per
second) when there is evidence, such as moderate-
severe valve calcification, that progression may be
rapid. (Level of Evidence: C)
Patients undergoing CABG who have severe AS should
ndergo AVR at the time of revascularization. Decision
aking is less clear in patients who have CAD that requires
ABG when these patients have mild to moderate AS. Contro-
ersy persists regarding the indications for “prophylactic” AVR at
he time of CABG in such patients. This decision should be made
nly after the severity of AS is determined by Doppler echocar-
iography and cardiac catheterization.
Confirmation by cardiac catheterization is especially impor-
ant in patients with reduced stroke volumes, mixed valve
esions, or intermediate mean aortic valve gradients (between
0 and 50 mm Hg) by Doppler echocardiography, because
any such patients may actually have severe AS (as discussed
n Section 3.1.6). The more complex and controversial issue is
he decision to replace the aortic valve for only mild AS at the
ime of CABG, because the degree of AS may become more
evere within a few years, necessitating a second, more difficult
VR operation in a patient with patent bypass grafts.
It is difficult to predict whether a given patient with CAD
nd mild AS is likely to develop significant AS in the years
fter CABG. As noted previously (see Section 3.1.3), the
atural history of mild AS is variable, with some patients
anifesting a relatively rapid progression of AS with a decrease
n valve area of up to 0.3 cm2 per year and an increase in
ressure gradient of up to 15 to 19 mm Hg per year; however,
he majority may show little or no change (61,86 –
5,107,1056). The average rate of reduction in valve area is
.12 cm2 per year (61), but the rate of change in an individual
atient is difficult to predict.
Retrospective studies of patients who have come to AVR
fter previous CABG have been reported in which the mean
ime to reoperation was 5 to 8 years (1057–1062). The aortic
alve gradient at the primary operation was small, less than 20
m Hg, but the mean gradient increased significantly to
reater than 50 mm Hg at the time of the second operation.
hese reports represent selected patients in whom AS pro-
ressed to the point that AVR was warranted. The number of
atients in these surgical series who had similar gradients at the
ime of the primary operation but who did not have significant
rogression of AS is unknown.
Although definitive data are not yet available, patients withntermediate aortic valve gradients (mean gradient 30 to 50
m
p
C
(
d
c
p
e
m
d
a
1
a
M
M
1
r
u
p
t
c
i
p
a
w
u
a
S
A
T
K
M
B
E
K
l
P
A
M
R
e
A
M
R
B
K
A
D
M
W
B
R
P
R
C
P
J
e121JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:e1–148 ACC/AHA Practice Guidelinesm Hg at catheterization or transvalvular velocity of 3 to 4 m
er second by Doppler echocardiography) who are undergoing
ABG may warrant AVR at the time of revascularization
181–185), whereas patients with gradients below 10 mm Hg
o not need valve replacement. The degree of mobility and
alcification are also important factors predicting more rapid
rogression of aortic disease and should be taken into consid-
ration, particularly in those with gradients between 10 and 25
m Hg (98,181,185–187,1063–1066). Because of the lack of
ata, controversy exists regarding AVR at the time of CABG,
nd the strength of these recommendations is reduced.
0.5. Management of Concomitant Mitral Valve Disease
nd Coronary Artery Disease
ost patients with both MV disease and CAD have ischemic
R, as discussed in Sections 3.6.5 and 7.3.1.3. In patients with
to 2 MR, ischemic symptoms usually dictate the need for
evascularization. Patients with more severe ischemic MR
sually have significant LV dysfunction, and the decision to
erform revascularization and MV repair is based on symp-
oms, severity of CAD, LV dysfunction, and inducible myo-In patients with MV disease due to diseases other than
schemia, significantly obstructed coronary arteries identified at
reoperative cardiac catheterization are generally revascularized
t the time of MV surgery. There are no data to indicate the
isdom of this general policy, but because revascularization
sually adds little morbidity or mortality to the operation, the
dditional revascularization surgery is usually recommended.
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APPENDIX 3. Abbreviation List
ACC  American College of Cardiology
ACCF  American College of Cardiology Foundation
ACE  angiotensin converting enzyme
AHA  American Heart Association
aPTT  activated partial thromboplastin time
AR  aortic regurgitation
AS  aortic stenosis
AVR  aortic valve replacement
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
ECG  electrocardiogram
FDA  Food and Drug Administration
HIV  human immunodeficiency virus
INR  international normalized ratio
LMWH  low-molecular-weight heparin
LV  left ventricular
MR  mitral regurgitation
MS  mitral stenosis
MV  mitral valve
MVP  mitral valve prolapse
NYHA  New York Heart Association
RV  right ventricular
STS  Society of Thoracic Surgeons
TR  tricuspid regurgitation
2D  two-dimensional
UFH  unfractionated heparinEFERENCES
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